doi	section	n_itc	study_number	questions	answer
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Medical Condition of Interest Name	thyroid eye disease
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of first author affiliations	usa
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Countries of last author affiliations	canada
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 1	teprotumumab
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Treatment name 2	intravenous methylprednisolone
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Anchored comparison?	No
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in proptosis in mm
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1001/jamaophthalmol.2021.6284	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	419
10.1001/jamaophthalmol.2021.6284	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	79
10.1001/jamaophthalmol.2021.6284	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56
10.1001/jamaophthalmol.2021.6284	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1001/jamaophthalmol.2021.6284	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1001/jamaophthalmol.2021.6284	results	1	NA	Number of covariates adjusted for/matched on	3
10.1001/jamaophthalmol.2021.6284	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Other(s)
10.1001/jamaophthalmol.2021.6284	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1001/jamaophthalmol.2021.6284	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1001/jamaophthalmol.2021.6284	results	1	NA	Primary outcome: unadjusted treatment effect	-2.38
10.1001/jamaophthalmol.2021.6284	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.49;-1.27]
10.1001/jamaophthalmol.2021.6284	results	1	NA	Primary outcome: adjusted treatment effect	-2.31
10.1001/jamaophthalmol.2021.6284	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.45;-1.17]
10.1001/jamaophthalmol.2021.6284	results	1	NA	geographical region	No
10.1001/jamaophthalmol.2021.6284	results	1	NA	lb_ci	-3.49
10.1001/jamaophthalmol.2021.6284	results	1	NA	ub_ci	-1.27
10.1001/jamaophthalmol.2021.6284	results	1	NA	pval	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	num_pval	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ci_cutoff	0
10.1001/jamaophthalmol.2021.6284	results	1	NA	significant	FALSE
10.1001/jamaophthalmol.2021.6284	results	1	NA	lb_ci	-3.45
10.1001/jamaophthalmol.2021.6284	results	1	NA	ub_ci	-1.17
10.1001/jamaophthalmol.2021.6284	results	1	NA	pval	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	num_pval	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ci_cutoff	0
10.1001/jamaophthalmol.2021.6284	results	1	NA	significant	FALSE
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Patient-level data used	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Clinical Trial	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01868997
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Patient-level data used	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Clinical Trial	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03298867
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Patient-level data used	No
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Clinical Trial	No
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	meta-analysis of clinical trials from 12 articles
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1002/edm2.259	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes
10.1002/edm2.259	general_information	NA	NA	Countries of first author affiliations	uk
10.1002/edm2.259	general_information	NA	NA	Countries of last author affiliations	denmark
10.1002/edm2.259	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1002/edm2.259	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1002/edm2.259	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1002/edm2.259	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1002/edm2.259	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1002/edm2.259	methodology	1	NA	Treatment name 1	semaglutide 0.5  +  1 mg
10.1002/edm2.259	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1002/edm2.259	methodology	1	NA	Treatment name 2	dulaglutide 1.5 mg
10.1002/edm2.259	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1002/edm2.259	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1002/edm2.259	methodology	1	NA	Anchored comparison?	Yes
10.1002/edm2.259	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1002/edm2.259	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1002/edm2.259	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	3 point mace (cardiovascular death, non-fatal myocardial infraction, non-fatal stroke)
10.1002/edm2.259	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1002/edm2.259	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1002/edm2.259	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1002/edm2.259	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1002/edm2.259	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1002/edm2.259	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1002/edm2.259	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1002/edm2.259	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1002/edm2.259	results	1	NA	Number of covariates adjusted for/matched on	6
10.1002/edm2.259	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1002/edm2.259	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1002/edm2.259	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1002/edm2.259	results	1	NA	Primary outcome: adjusted treatment effect	0.74
10.1002/edm2.259	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.06
10.1002/edm2.259	results	1	NA	If anchored, total initial sample size IPD	3297
10.1002/edm2.259	results	1	NA	If anchored, total ESS IPD	2633
10.1002/edm2.259	results	1	NA	If anchored, total sample size non IPD	9901
10.1002/edm2.259	results	1	NA	lb_ci	NA
10.1002/edm2.259	results	1	NA	ub_ci	NA
10.1002/edm2.259	results	1	NA	pval	0.06
10.1002/edm2.259	results	1	NA	num_pval	0.06
10.1002/edm2.259	results	1	NA	ci_cutoff	1
10.1002/edm2.259	results	1	NA	significant	FALSE
10.1002/edm2.259	study_information	NA	1	Patient-level data used	Yes
10.1002/edm2.259	study_information	NA	1	Clinical Trial	Yes
10.1002/edm2.259	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01720446
10.1002/edm2.259	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1002/edm2.259	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1002/edm2.259	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1002/edm2.259	study_information	NA	2	Patient-level data used	No
10.1002/edm2.259	study_information	NA	2	Clinical Trial	Yes
10.1002/edm2.259	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01394952
10.1002/edm2.259	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1002/edm2.259	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1002/edm2.259	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/bf03261873	general_information	NA	NA	Medical Condition of Interest Name	attention-deficit/hyperactivity disorder
10.1007/bf03261873	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/bf03261873	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/bf03261873	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/bf03261873	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/bf03261873	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/bf03261873	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/bf03261873	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/bf03261873	methodology	1	NA	Treatment name 1	guanfacine extended-release low dose
10.1007/bf03261873	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/bf03261873	methodology	1	NA	Treatment name 2	atomoxetine
10.1007/bf03261873	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1007/bf03261873	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/bf03261873	methodology	1	NA	Anchored comparison?	No
10.1007/bf03261873	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/bf03261873	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/bf03261873	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/bf03261873	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/bf03261873	methodology	2	NA	Treatment name 1	guanfacine extended-release mid dose
10.1007/bf03261873	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1007/bf03261873	methodology	2	NA	Treatment name 2	atomoxetine
10.1007/bf03261873	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1007/bf03261873	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/bf03261873	methodology	2	NA	Anchored comparison?	No
10.1007/bf03261873	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/bf03261873	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/bf03261873	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/bf03261873	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/bf03261873	methodology	3	NA	Treatment name 1	guanfacine extended-release high dose
10.1007/bf03261873	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.1007/bf03261873	methodology	3	NA	Treatment name 2	atomoxetine
10.1007/bf03261873	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.1007/bf03261873	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/bf03261873	methodology	3	NA	Anchored comparison?	No
10.1007/bf03261873	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/bf03261873	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/bf03261873	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/bf03261873	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/bf03261873	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	84
10.1007/bf03261873	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	147
10.1007/bf03261873	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	49
10.1007/bf03261873	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/bf03261873	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/bf03261873	results	1	NA	Number of covariates adjusted for/matched on	6
10.1007/bf03261873	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/bf03261873	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.07
10.1007/bf03261873	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	1	NA	Primary outcome: adjusted treatment effect	-3,7
10.1007/bf03261873	results	1	NA	geographical region	No
10.1007/bf03261873	results	1	NA	lb_ci	NA
10.1007/bf03261873	results	1	NA	ub_ci	NA
10.1007/bf03261873	results	1	NA	pval	0.07
10.1007/bf03261873	results	1	NA	num_pval	0.07
10.1007/bf03261873	results	1	NA	ci_cutoff	0
10.1007/bf03261873	results	1	NA	significant	FALSE
10.1007/bf03261873	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	84
10.1007/bf03261873	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	46
10.1007/bf03261873	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	16
10.1007/bf03261873	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/bf03261873	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/bf03261873	results	2	NA	Number of covariates adjusted for/matched on	6
10.1007/bf03261873	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/bf03261873	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.02
10.1007/bf03261873	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	2	NA	Primary outcome: adjusted treatment effect	-6
10.1007/bf03261873	results	2	NA	geographical region	No
10.1007/bf03261873	results	2	NA	lb_ci	NA
10.1007/bf03261873	results	2	NA	ub_ci	NA
10.1007/bf03261873	results	2	NA	pval	0.02
10.1007/bf03261873	results	2	NA	num_pval	0.02
10.1007/bf03261873	results	2	NA	ci_cutoff	0
10.1007/bf03261873	results	2	NA	significant	TRUE
10.1007/bf03261873	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	84
10.1007/bf03261873	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	82
10.1007/bf03261873	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	38
10.1007/bf03261873	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/bf03261873	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/bf03261873	results	3	NA	Number of covariates adjusted for/matched on	6
10.1007/bf03261873	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/bf03261873	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.01
10.1007/bf03261873	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	3	NA	Primary outcome: adjusted treatment effect	-7
10.1007/bf03261873	results	3	NA	geographical region	No
10.1007/bf03261873	results	3	NA	lb_ci	NA
10.1007/bf03261873	results	3	NA	ub_ci	NA
10.1007/bf03261873	results	3	NA	pval	<0.01
10.1007/bf03261873	results	3	NA	num_pval	NA
10.1007/bf03261873	results	3	NA	ci_cutoff	0
10.1007/bf03261873	results	3	NA	significant	TRUE
10.1007/bf03261873	study_information	NA	1	Patient-level data used	Yes
10.1007/bf03261873	study_information	NA	1	Clinical Trial	Yes
10.1007/bf03261873	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00152009
10.1007/bf03261873	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/bf03261873	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/bf03261873	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/bf03261873	study_information	NA	2	Patient-level data used	Yes
10.1007/bf03261873	study_information	NA	2	Clinical Trial	Yes
10.1007/bf03261873	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00150618
10.1007/bf03261873	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/bf03261873	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/bf03261873	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	sallee et al. (2009)
10.1007/bf03261873	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/bf03261873	study_information	NA	3	Patient-level data used	No
10.1007/bf03261873	study_information	NA	3	Clinical Trial	Yes
10.1007/bf03261873	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	michelson et al. (2001)
10.1007/bf03261873	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/bf03261873	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s00432-021-03602-w	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of first author affiliations	italy
10.1007/s00432-021-03602-w	general_information	NA	NA	Countries of last author affiliations	italy
10.1007/s00432-021-03602-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.1007/s00432-021-03602-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s00432-021-03602-w	general_information	NA	NA	Mentioned sources of funding	No fundings
10.1007/s00432-021-03602-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s00432-021-03602-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 1	regorafenib
10.1007/s00432-021-03602-w	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s00432-021-03602-w	methodology	1	NA	Treatment name 2	cabozantinib
10.1007/s00432-021-03602-w	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s00432-021-03602-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s00432-021-03602-w	methodology	1	NA	Anchored comparison?	No
10.1007/s00432-021-03602-w	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s00432-021-03602-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s00432-021-03602-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s00432-021-03602-w	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s00432-021-03602-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s00432-021-03602-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s00432-021-03602-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s00432-021-03602-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s00432-021-03602-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s00432-021-03602-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	331
10.1007/s00432-021-03602-w	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	278
10.1007/s00432-021-03602-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s00432-021-03602-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.1007/s00432-021-03602-w	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s00432-021-03602-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1007/s00432-021-03602-w	results	1	NA	Primary outcome: unadjusted treatment effect	0.8
10.1007/s00432-021-03602-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.66;0.97]
10.1007/s00432-021-03602-w	results	1	NA	Primary outcome: adjusted treatment effect	0.83
10.1007/s00432-021-03602-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.62;1.09]
10.1007/s00432-021-03602-w	results	1	NA	lb_ci	0.66
10.1007/s00432-021-03602-w	results	1	NA	ub_ci	0.97
10.1007/s00432-021-03602-w	results	1	NA	pval	NA
10.1007/s00432-021-03602-w	results	1	NA	num_pval	NA
10.1007/s00432-021-03602-w	results	1	NA	ci_cutoff	1
10.1007/s00432-021-03602-w	results	1	NA	significant	FALSE
10.1007/s00432-021-03602-w	results	1	NA	lb_ci	0.62
10.1007/s00432-021-03602-w	results	1	NA	ub_ci	1.09
10.1007/s00432-021-03602-w	results	1	NA	pval	NA
10.1007/s00432-021-03602-w	results	1	NA	num_pval	NA
10.1007/s00432-021-03602-w	results	1	NA	ci_cutoff	1
10.1007/s00432-021-03602-w	results	1	NA	significant	TRUE
10.1007/s00432-021-03602-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s00432-021-03602-w	study_information	NA	1	Clinical Trial	No
10.1007/s00432-021-03602-w	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	real-world data from unknown origin
10.1007/s00432-021-03602-w	study_information	NA	2	Patient-level data used	No
10.1007/s00432-021-03602-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s00432-021-03602-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.1007/s00432-021-03602-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s00432-021-03602-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s00432-021-03602-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s11523-021-00803-8	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of first author affiliations	italy
10.1007/s11523-021-00803-8	general_information	NA	NA	Countries of last author affiliations	italy
10.1007/s11523-021-00803-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.1007/s11523-021-00803-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s11523-021-00803-8	general_information	NA	NA	Mentioned sources of funding	No fundings
10.1007/s11523-021-00803-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s11523-021-00803-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 1	lenvatinib
10.1007/s11523-021-00803-8	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s11523-021-00803-8	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab
10.1007/s11523-021-00803-8	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s11523-021-00803-8	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s11523-021-00803-8	methodology	1	NA	Anchored comparison?	No
10.1007/s11523-021-00803-8	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s11523-021-00803-8	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s11523-021-00803-8	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s11523-021-00803-8	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s11523-021-00803-8	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s11523-021-00803-8	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s11523-021-00803-8	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s11523-021-00803-8	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s11523-021-00803-8	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s11523-021-00803-8	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	336
10.1007/s11523-021-00803-8	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	455
10.1007/s11523-021-00803-8	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s11523-021-00803-8	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s11523-021-00803-8	results	1	NA	Number of covariates adjusted for/matched on	12
10.1007/s11523-021-00803-8	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s11523-021-00803-8	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s11523-021-00803-8	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1007/s11523-021-00803-8	results	1	NA	Primary outcome: adjusted treatment effect	0.59
10.1007/s11523-021-00803-8	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;0.75]
10.1007/s11523-021-00803-8	results	1	NA	lb_ci	0.46
10.1007/s11523-021-00803-8	results	1	NA	ub_ci	0.75
10.1007/s11523-021-00803-8	results	1	NA	pval	NA
10.1007/s11523-021-00803-8	results	1	NA	num_pval	NA
10.1007/s11523-021-00803-8	results	1	NA	ci_cutoff	1
10.1007/s11523-021-00803-8	results	1	NA	significant	FALSE
10.1007/s11523-021-00803-8	study_information	NA	1	Patient-level data used	Yes
10.1007/s11523-021-00803-8	study_information	NA	1	Clinical Trial	No
10.1007/s11523-021-00803-8	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	real-world data from 12 japanese centers from march 2018 to may 2020
10.1007/s11523-021-00803-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.1007/s11523-021-00803-8	study_information	NA	2	Patient-level data used	No
10.1007/s11523-021-00803-8	study_information	NA	2	Clinical Trial	Yes
10.1007/s11523-021-00803-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379
10.1007/s11523-021-00803-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s11523-021-00803-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s11523-021-00803-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	general_information	NA	NA	Medical Condition of Interest Name	relapsing-remitting multiple sclerosis
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of first author affiliations	switzerland
10.1007/s12325-014-0167-z	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-014-0167-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-014-0167-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-014-0167-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-014-0167-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-014-0167-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 1	fingolimod
10.1007/s12325-014-0167-z	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s12325-014-0167-z	methodology	1	NA	Treatment name 2	dimethyl fumarate
10.1007/s12325-014-0167-z	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1007/s12325-014-0167-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.1007/s12325-014-0167-z	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-014-0167-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 1	fingolimod
10.1007/s12325-014-0167-z	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s12325-014-0167-z	methodology	2	NA	Treatment name 2	teriflunomide 7 mg
10.1007/s12325-014-0167-z	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.1007/s12325-014-0167-z	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.1007/s12325-014-0167-z	methodology	2	NA	Anchored comparison?	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-014-0167-z	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 1	fingolimod
10.1007/s12325-014-0167-z	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s12325-014-0167-z	methodology	3	NA	Treatment name 2	teriflunomide 14 mg
10.1007/s12325-014-0167-z	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.1007/s12325-014-0167-z	methodology	3	NA	Type of population-adjusted indirect comparisons performed	STC
10.1007/s12325-014-0167-z	methodology	3	NA	Anchored comparison?	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-014-0167-z	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-014-0167-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	769
10.1007/s12325-014-0167-z	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	771
10.1007/s12325-014-0167-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	783
10.1007/s12325-014-0167-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	783
10.1007/s12325-014-0167-z	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	773
10.1007/s12325-014-0167-z	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	773
10.1007/s12325-014-0167-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-014-0167-z	results	1	NA	Number of covariates adjusted for/matched on	2
10.1007/s12325-014-0167-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Past treatments for the disease of interest
10.1007/s12325-014-0167-z	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-014-0167-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	1	NA	Primary outcome: unadjusted treatment effect	1.58
10.1007/s12325-014-0167-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.00;2.50]
10.1007/s12325-014-0167-z	results	1	NA	Primary outcome: adjusted treatment effect	1.67
10.1007/s12325-014-0167-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.08;2.57]
10.1007/s12325-014-0167-z	results	1	NA	lb_ci	1
10.1007/s12325-014-0167-z	results	1	NA	ub_ci	2.5
10.1007/s12325-014-0167-z	results	1	NA	pval	NA
10.1007/s12325-014-0167-z	results	1	NA	num_pval	NA
10.1007/s12325-014-0167-z	results	1	NA	ci_cutoff	1
10.1007/s12325-014-0167-z	results	1	NA	significant	FALSE
10.1007/s12325-014-0167-z	results	1	NA	lb_ci	1.08
10.1007/s12325-014-0167-z	results	1	NA	ub_ci	2.57
10.1007/s12325-014-0167-z	results	1	NA	pval	NA
10.1007/s12325-014-0167-z	results	1	NA	num_pval	NA
10.1007/s12325-014-0167-z	results	1	NA	ci_cutoff	1
10.1007/s12325-014-0167-z	results	1	NA	significant	FALSE
10.1007/s12325-014-0167-z	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	365
10.1007/s12325-014-0167-z	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	363
10.1007/s12325-014-0167-z	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	783
10.1007/s12325-014-0167-z	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	783
10.1007/s12325-014-0167-z	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	773
10.1007/s12325-014-0167-z	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	773
10.1007/s12325-014-0167-z	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-014-0167-z	results	2	NA	Number of covariates adjusted for/matched on	1
10.1007/s12325-014-0167-z	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age
10.1007/s12325-014-0167-z	results	2	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-014-0167-z	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	2	NA	Primary outcome: unadjusted treatment effect	2.18
10.1007/s12325-014-0167-z	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.46;3.25]
10.1007/s12325-014-0167-z	results	2	NA	Primary outcome: adjusted treatment effect	2.01
10.1007/s12325-014-0167-z	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.38;2.93]
10.1007/s12325-014-0167-z	results	2	NA	lb_ci	1.46
10.1007/s12325-014-0167-z	results	2	NA	ub_ci	3.25
10.1007/s12325-014-0167-z	results	2	NA	pval	NA
10.1007/s12325-014-0167-z	results	2	NA	num_pval	NA
10.1007/s12325-014-0167-z	results	2	NA	ci_cutoff	1
10.1007/s12325-014-0167-z	results	2	NA	significant	FALSE
10.1007/s12325-014-0167-z	results	2	NA	lb_ci	1.38
10.1007/s12325-014-0167-z	results	2	NA	ub_ci	2.93
10.1007/s12325-014-0167-z	results	2	NA	pval	NA
10.1007/s12325-014-0167-z	results	2	NA	num_pval	NA
10.1007/s12325-014-0167-z	results	2	NA	ci_cutoff	1
10.1007/s12325-014-0167-z	results	2	NA	significant	FALSE
10.1007/s12325-014-0167-z	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	358
10.1007/s12325-014-0167-z	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	363
10.1007/s12325-014-0167-z	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	783
10.1007/s12325-014-0167-z	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	783
10.1007/s12325-014-0167-z	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	773
10.1007/s12325-014-0167-z	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	773
10.1007/s12325-014-0167-z	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-014-0167-z	results	3	NA	Number of covariates adjusted for/matched on	1
10.1007/s12325-014-0167-z	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age
10.1007/s12325-014-0167-z	results	3	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-014-0167-z	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	3	NA	Primary outcome: unadjusted treatment effect	1.75
10.1007/s12325-014-0167-z	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.18;2.57]
10.1007/s12325-014-0167-z	results	3	NA	Primary outcome: adjusted treatment effect	1.61
10.1007/s12325-014-0167-z	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.12;2.31]
10.1007/s12325-014-0167-z	results	3	NA	lb_ci	1.18
10.1007/s12325-014-0167-z	results	3	NA	ub_ci	2.57
10.1007/s12325-014-0167-z	results	3	NA	pval	NA
10.1007/s12325-014-0167-z	results	3	NA	num_pval	NA
10.1007/s12325-014-0167-z	results	3	NA	ci_cutoff	1
10.1007/s12325-014-0167-z	results	3	NA	significant	FALSE
10.1007/s12325-014-0167-z	results	3	NA	lb_ci	1.12
10.1007/s12325-014-0167-z	results	3	NA	ub_ci	2.31
10.1007/s12325-014-0167-z	results	3	NA	pval	NA
10.1007/s12325-014-0167-z	results	3	NA	num_pval	NA
10.1007/s12325-014-0167-z	results	3	NA	ci_cutoff	1
10.1007/s12325-014-0167-z	results	3	NA	significant	FALSE
10.1007/s12325-014-0167-z	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-014-0167-z	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978
10.1007/s12325-014-0167-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	2	Patient-level data used	Yes
10.1007/s12325-014-0167-z	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134
10.1007/s12325-014-0167-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	3	Patient-level data used	No
10.1007/s12325-014-0167-z	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.1007/s12325-014-0167-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	4	Patient-level data used	No
10.1007/s12325-014-0167-z	study_information	NA	4	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.1007/s12325-014-0167-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-014-0167-z	study_information	NA	5	Patient-level data used	No
10.1007/s12325-014-0167-z	study_information	NA	5	Clinical Trial	Yes
10.1007/s12325-014-0167-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563
10.1007/s12325-014-0167-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-014-0167-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-014-0167-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-017-0564-1	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia
10.1007/s12325-017-0564-1	general_information	NA	NA	Countries of first author affiliations	belgium
10.1007/s12325-017-0564-1	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-017-0564-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry
10.1007/s12325-017-0564-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s12325-017-0564-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-017-0564-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-017-0564-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 1	ibrutinib
10.1007/s12325-017-0564-1	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-017-0564-1	methodology	1	NA	Treatment name 2	obinutuzumab + chlorambucil
10.1007/s12325-017-0564-1	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-017-0564-1	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-017-0564-1	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-017-0564-1	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-017-0564-1	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1007/s12325-017-0564-1	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-017-0564-1	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-017-0564-1	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-017-0564-1	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-017-0564-1	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-017-0564-1	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-017-0564-1	results	1	NA	Number of covariates adjusted for/matched on	9
10.1007/s12325-017-0564-1	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-017-0564-1	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-017-0564-1	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-017-0564-1	results	1	NA	Primary outcome: unadjusted treatment effect	0.5
10.1007/s12325-017-0564-1	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.22;1.15]
10.1007/s12325-017-0564-1	results	1	NA	Primary outcome: adjusted treatment effect	0.24
10.1007/s12325-017-0564-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.04;1.35]
10.1007/s12325-017-0564-1	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	589
10.1007/s12325-017-0564-1	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	115
10.1007/s12325-017-0564-1	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	35
10.1007/s12325-017-0564-1	results	1	NA	If anchored, total initial sample size IPD	115
10.1007/s12325-017-0564-1	results	1	NA	If anchored, total ESS IPD	35
10.1007/s12325-017-0564-1	results	1	NA	If anchored, total sample size non IPD	589
10.1007/s12325-017-0564-1	results	1	NA	lb_ci	0.22
10.1007/s12325-017-0564-1	results	1	NA	ub_ci	1.15
10.1007/s12325-017-0564-1	results	1	NA	pval	NA
10.1007/s12325-017-0564-1	results	1	NA	num_pval	NA
10.1007/s12325-017-0564-1	results	1	NA	ci_cutoff	1
10.1007/s12325-017-0564-1	results	1	NA	significant	TRUE
10.1007/s12325-017-0564-1	results	1	NA	lb_ci	0.04
10.1007/s12325-017-0564-1	results	1	NA	ub_ci	1.35
10.1007/s12325-017-0564-1	results	1	NA	pval	NA
10.1007/s12325-017-0564-1	results	1	NA	num_pval	NA
10.1007/s12325-017-0564-1	results	1	NA	ci_cutoff	1
10.1007/s12325-017-0564-1	results	1	NA	significant	TRUE
10.1007/s12325-017-0564-1	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-017-0564-1	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-017-0564-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487
10.1007/s12325-017-0564-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-017-0564-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-017-0564-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-017-0564-1	study_information	NA	2	Patient-level data used	No
10.1007/s12325-017-0564-1	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-017-0564-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01010061
10.1007/s12325-017-0564-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-017-0564-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-017-0564-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-018-0734-9	general_information	NA	NA	Medical Condition of Interest Name	advanced or metastatic non-small-cell lung cancer
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-018-0734-9	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s12325-018-0734-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-018-0734-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-018-0734-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-018-0734-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-018-0734-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 1	dabrafenib + trametinib
10.1007/s12325-018-0734-9	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-018-0734-9	methodology	1	NA	Treatment name 2	nivolumab
10.1007/s12325-018-0734-9	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-018-0734-9	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-018-0734-9	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-018-0734-9	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-018-0734-9	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1007/s12325-018-0734-9	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-018-0734-9	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-018-0734-9	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-018-0734-9	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-018-0734-9	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-018-0734-9	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	290
10.1007/s12325-018-0734-9	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	57
10.1007/s12325-018-0734-9	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-018-0734-9	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-018-0734-9	results	1	NA	Number of covariates adjusted for/matched on	10
10.1007/s12325-018-0734-9	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-018-0734-9	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	34
10.1007/s12325-018-0734-9	results	1	NA	geographical region	No
10.1007/s12325-018-0734-9	results	1	NA	If anchored, total initial sample size IPD	57
10.1007/s12325-018-0734-9	results	1	NA	If anchored, total ESS IPD	34
10.1007/s12325-018-0734-9	results	1	NA	If anchored, total sample size non IPD	290
10.1007/s12325-018-0734-9	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-018-0734-9	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-018-0734-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01336634
10.1007/s12325-018-0734-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-018-0734-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-018-0734-9	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-018-0734-9	study_information	NA	2	Patient-level data used	No
10.1007/s12325-018-0734-9	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-018-0734-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01673867
10.1007/s12325-018-0734-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-018-0734-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-018-0734-9	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-00991-w	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of first author affiliations	canada
10.1007/s12325-019-00991-w	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-019-00991-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-00991-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-00991-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-00991-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-00991-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 1	inotuzumab ozogamicin
10.1007/s12325-019-00991-w	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-00991-w	methodology	1	NA	Treatment name 2	blinatumomab
10.1007/s12325-019-00991-w	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-00991-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-019-00991-w	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-019-00991-w	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-00991-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-00991-w	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-019-00991-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-019-00991-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-019-00991-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-00991-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-00991-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 1	inotuzumab ozogamicin
10.1007/s12325-019-00991-w	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-00991-w	methodology	2	NA	Treatment name 2	blinatumomab
10.1007/s12325-019-00991-w	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-00991-w	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.1007/s12325-019-00991-w	methodology	2	NA	Anchored comparison?	Yes
10.1007/s12325-019-00991-w	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-00991-w	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-00991-w	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	complete response rate
10.1007/s12325-019-00991-w	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-019-00991-w	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-019-00991-w	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-019-00991-w	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-00991-w	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-00991-w	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-019-00991-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	271
10.1007/s12325-019-00991-w	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	134
10.1007/s12325-019-00991-w	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	164
10.1007/s12325-019-00991-w	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70
10.1007/s12325-019-00991-w	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	162
10.1007/s12325-019-00991-w	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	53
10.1007/s12325-019-00991-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-019-00991-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-00991-w	results	1	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-019-00991-w	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s12325-019-00991-w	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1007/s12325-019-00991-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-00991-w	results	1	NA	Primary outcome: unadjusted treatment effect	2.63
10.1007/s12325-019-00991-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.35;5.12]
10.1007/s12325-019-00991-w	results	1	NA	Primary outcome: adjusted treatment effect	2.81
10.1007/s12325-019-00991-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.12;7.05]
10.1007/s12325-019-00991-w	results	1	NA	geographical region	No
10.1007/s12325-019-00991-w	results	1	NA	lb_ci	1.35
10.1007/s12325-019-00991-w	results	1	NA	ub_ci	5.12
10.1007/s12325-019-00991-w	results	1	NA	pval	NA
10.1007/s12325-019-00991-w	results	1	NA	num_pval	NA
10.1007/s12325-019-00991-w	results	1	NA	ci_cutoff	1
10.1007/s12325-019-00991-w	results	1	NA	significant	FALSE
10.1007/s12325-019-00991-w	results	1	NA	lb_ci	1.12
10.1007/s12325-019-00991-w	results	1	NA	ub_ci	7.05
10.1007/s12325-019-00991-w	results	1	NA	pval	NA
10.1007/s12325-019-00991-w	results	1	NA	num_pval	NA
10.1007/s12325-019-00991-w	results	1	NA	ci_cutoff	1
10.1007/s12325-019-00991-w	results	1	NA	significant	FALSE
10.1007/s12325-019-00991-w	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	271
10.1007/s12325-019-00991-w	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	134
10.1007/s12325-019-00991-w	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	164
10.1007/s12325-019-00991-w	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	138
10.1007/s12325-019-00991-w	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	162
10.1007/s12325-019-00991-w	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	133
10.1007/s12325-019-00991-w	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-00991-w	results	2	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-019-00991-w	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s12325-019-00991-w	results	2	NA	Primary outcome: treatment effect contrast	OR
10.1007/s12325-019-00991-w	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-00991-w	results	2	NA	Primary outcome: unadjusted treatment effect	2.63
10.1007/s12325-019-00991-w	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.35;5.12]
10.1007/s12325-019-00991-w	results	2	NA	Primary outcome: adjusted treatment effect	3.91
10.1007/s12325-019-00991-w	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.53;9.99]
10.1007/s12325-019-00991-w	results	2	NA	geographical region	No
10.1007/s12325-019-00991-w	results	2	NA	lb_ci	1.35
10.1007/s12325-019-00991-w	results	2	NA	ub_ci	5.12
10.1007/s12325-019-00991-w	results	2	NA	pval	NA
10.1007/s12325-019-00991-w	results	2	NA	num_pval	NA
10.1007/s12325-019-00991-w	results	2	NA	ci_cutoff	1
10.1007/s12325-019-00991-w	results	2	NA	significant	FALSE
10.1007/s12325-019-00991-w	results	2	NA	lb_ci	1.53
10.1007/s12325-019-00991-w	results	2	NA	ub_ci	9.99
10.1007/s12325-019-00991-w	results	2	NA	pval	NA
10.1007/s12325-019-00991-w	results	2	NA	num_pval	NA
10.1007/s12325-019-00991-w	results	2	NA	ci_cutoff	1
10.1007/s12325-019-00991-w	results	2	NA	significant	FALSE
10.1007/s12325-019-00991-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-00991-w	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-00991-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784
10.1007/s12325-019-00991-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-00991-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-00991-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-00991-w	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-00991-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-00991-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167
10.1007/s12325-019-00991-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-00991-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-00991-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01156-5	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-019-01156-5	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s12325-019-01156-5	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-019-01156-5	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01156-5	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-01156-5	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-01156-5	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-01156-5	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 1	apalutamide
10.1007/s12325-019-01156-5	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-01156-5	methodology	1	NA	Treatment name 2	enzalutamide
10.1007/s12325-019-01156-5	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-01156-5	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-019-01156-5	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-019-01156-5	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-01156-5	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-01156-5	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	metastasis-free survival
10.1007/s12325-019-01156-5	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-019-01156-5	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01156-5	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-019-01156-5	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-01156-5	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-01156-5	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-019-01156-5	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	933
10.1007/s12325-019-01156-5	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	468
10.1007/s12325-019-01156-5	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	806
10.1007/s12325-019-01156-5	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	401
10.1007/s12325-019-01156-5	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-019-01156-5	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-01156-5	results	1	NA	Number of covariates adjusted for/matched on	7
10.1007/s12325-019-01156-5	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-01156-5	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-019-01156-5	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-01156-5	results	1	NA	Primary outcome: adjusted treatment effect	0.91
10.1007/s12325-019-01156-5	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.736
10.1007/s12325-019-01156-5	results	1	NA	If anchored, total initial sample size IPD	1207
10.1007/s12325-019-01156-5	results	1	NA	If anchored, total ESS IPD	1171
10.1007/s12325-019-01156-5	results	1	NA	If anchored, total sample size non IPD	1401
10.1007/s12325-019-01156-5	results	1	NA	lb_ci	NA
10.1007/s12325-019-01156-5	results	1	NA	ub_ci	NA
10.1007/s12325-019-01156-5	results	1	NA	pval	0.736
10.1007/s12325-019-01156-5	results	1	NA	num_pval	0.736
10.1007/s12325-019-01156-5	results	1	NA	ci_cutoff	1
10.1007/s12325-019-01156-5	results	1	NA	significant	FALSE
10.1007/s12325-019-01156-5	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-01156-5	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-01156-5	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1007/s12325-019-01156-5	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01156-5	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01156-5	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01156-5	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-01156-5	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-01156-5	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924
10.1007/s12325-019-01156-5	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01156-5	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01156-5	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01157-4	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s12325-019-01157-4	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-019-01157-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01157-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-01157-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-01157-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-01157-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 1	apalutamide
10.1007/s12325-019-01157-4	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-01157-4	methodology	1	NA	Treatment name 2	enzalutamide
10.1007/s12325-019-01157-4	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-01157-4	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-019-01157-4	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-019-01157-4	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-01157-4	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-01157-4	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	fatigue occurrence
10.1007/s12325-019-01157-4	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-019-01157-4	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01157-4	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-019-01157-4	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-01157-4	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-01157-4	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-019-01157-4	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	933
10.1007/s12325-019-01157-4	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	468
10.1007/s12325-019-01157-4	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	806
10.1007/s12325-019-01157-4	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	401
10.1007/s12325-019-01157-4	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-019-01157-4	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-01157-4	results	1	NA	Number of covariates adjusted for/matched on	7
10.1007/s12325-019-01157-4	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-01157-4	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1007/s12325-019-01157-4	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-01157-4	results	1	NA	Primary outcome: adjusted treatment effect	0.57
10.1007/s12325-019-01157-4	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.37;0.88]
10.1007/s12325-019-01157-4	results	1	NA	If anchored, total initial sample size IPD	1207
10.1007/s12325-019-01157-4	results	1	NA	If anchored, total ESS IPD	1171
10.1007/s12325-019-01157-4	results	1	NA	If anchored, total sample size non IPD	1401
10.1007/s12325-019-01157-4	results	1	NA	lb_ci	0.37
10.1007/s12325-019-01157-4	results	1	NA	ub_ci	0.88
10.1007/s12325-019-01157-4	results	1	NA	pval	NA
10.1007/s12325-019-01157-4	results	1	NA	num_pval	NA
10.1007/s12325-019-01157-4	results	1	NA	ci_cutoff	1
10.1007/s12325-019-01157-4	results	1	NA	significant	FALSE
10.1007/s12325-019-01157-4	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-01157-4	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-01157-4	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1007/s12325-019-01157-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01157-4	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01157-4	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01157-4	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-01157-4	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-01157-4	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924
10.1007/s12325-019-01157-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-01157-4	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-01157-4	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-01173-4	general_information	NA	NA	Medical Condition of Interest Name	atrial fibrillation
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-019-01173-4	general_information	NA	NA	Countries of last author affiliations	italy
10.1007/s12325-019-01173-4	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01173-4	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-01173-4	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-01173-4	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-01173-4	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 1	ratiofrequency catheter ablation with ablation index
10.1007/s12325-019-01173-4	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-01173-4	methodology	1	NA	Treatment name 2	ratiofrequency catheter ablation with cryoballoon
10.1007/s12325-019-01173-4	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4
10.1007/s12325-019-01173-4	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-019-01173-4	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-019-01173-4	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-019-01173-4	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	arrhythmia recurrence
10.1007/s12325-019-01173-4	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-019-01173-4	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01173-4	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-01173-4	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-019-01173-4	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	155
10.1007/s12325-019-01173-4	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	132
10.1007/s12325-019-01173-4	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	125
10.1007/s12325-019-01173-4	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-019-01173-4	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-01173-4	results	1	NA	Number of covariates adjusted for/matched on	1
10.1007/s12325-019-01173-4	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age
10.1007/s12325-019-01173-4	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-019-01173-4	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-01173-4	results	1	NA	Primary outcome: unadjusted treatment effect	0.42
10.1007/s12325-019-01173-4	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.21;0.86]
10.1007/s12325-019-01173-4	results	1	NA	Primary outcome: adjusted treatment effect	0.41
10.1007/s12325-019-01173-4	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.85]
10.1007/s12325-019-01173-4	results	1	NA	lb_ci	0.21
10.1007/s12325-019-01173-4	results	1	NA	ub_ci	0.86
10.1007/s12325-019-01173-4	results	1	NA	pval	NA
10.1007/s12325-019-01173-4	results	1	NA	num_pval	NA
10.1007/s12325-019-01173-4	results	1	NA	ci_cutoff	1
10.1007/s12325-019-01173-4	results	1	NA	significant	FALSE
10.1007/s12325-019-01173-4	results	1	NA	lb_ci	0.2
10.1007/s12325-019-01173-4	results	1	NA	ub_ci	0.85
10.1007/s12325-019-01173-4	results	1	NA	pval	NA
10.1007/s12325-019-01173-4	results	1	NA	num_pval	NA
10.1007/s12325-019-01173-4	results	1	NA	ci_cutoff	1
10.1007/s12325-019-01173-4	results	1	NA	significant	FALSE
10.1007/s12325-019-01173-4	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-01173-4	study_information	NA	1	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	solimene et al. doi: 10.1007/s10840-018-0420-5
10.1007/s12325-019-01173-4	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s12325-019-01173-4	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-01173-4	study_information	NA	2	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	jourda et al.
10.1007/s12325-019-01173-4	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1007/s12325-019-01173-4	study_information	NA	3	Patient-level data used	No
10.1007/s12325-019-01173-4	study_information	NA	3	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	giovanni et al. 10.1111/jce.12409
10.1007/s12325-019-01173-4	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	belgium
10.1007/s12325-019-01173-4	study_information	NA	4	Patient-level data used	No
10.1007/s12325-019-01173-4	study_information	NA	4	Clinical Trial	No
10.1007/s12325-019-01173-4	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	zhao et al. doi: 10.1016/j.acvd.2017.01.015
10.1007/s12325-019-01173-4	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1007/s12325-019-0873-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory acute lymphoblastic leukemia
10.1007/s12325-019-0873-7	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-019-0873-7	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-019-0873-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-0873-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-019-0873-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-019-0873-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-019-0873-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 1	blinatumomab
10.1007/s12325-019-0873-7	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-0873-7	methodology	1	NA	Treatment name 2	inotuzumab ozogamicin
10.1007/s12325-019-0873-7	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-0873-7	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-019-0873-7	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-019-0873-7	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-0873-7	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-0873-7	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s12325-019-0873-7	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-019-0873-7	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1007/s12325-019-0873-7	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-019-0873-7	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-0873-7	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 1	blinatumomab
10.1007/s12325-019-0873-7	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-019-0873-7	methodology	2	NA	Treatment name 2	inotuzumab ozogamicin
10.1007/s12325-019-0873-7	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-019-0873-7	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-019-0873-7	methodology	2	NA	Anchored comparison?	No
10.1007/s12325-019-0873-7	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-0873-7	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-0873-7	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s12325-019-0873-7	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-019-0873-7	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1007/s12325-019-0873-7	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-019-0873-7	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-019-0873-7	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-019-0873-7	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-019-0873-7	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	164
10.1007/s12325-019-0873-7	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	162
10.1007/s12325-019-0873-7	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	203
10.1007/s12325-019-0873-7	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	107
10.1007/s12325-019-0873-7	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-019-0873-7	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-0873-7	results	1	NA	Number of covariates adjusted for/matched on	9
10.1007/s12325-019-0873-7	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-0873-7	results	1	NA	Primary outcome: treatment effect contrast	RMST difference at 12 months
10.1007/s12325-019-0873-7	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-0873-7	results	1	NA	Primary outcome: unadjusted treatment effect	1.02
10.1007/s12325-019-0873-7	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.16
10.1007/s12325-019-0873-7	results	1	NA	Primary outcome: adjusted treatment effect	1.62
10.1007/s12325-019-0873-7	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.04
10.1007/s12325-019-0873-7	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	107
10.1007/s12325-019-0873-7	results	1	NA	lb_ci	NA
10.1007/s12325-019-0873-7	results	1	NA	ub_ci	NA
10.1007/s12325-019-0873-7	results	1	NA	pval	0.16
10.1007/s12325-019-0873-7	results	1	NA	num_pval	0.16
10.1007/s12325-019-0873-7	results	1	NA	ci_cutoff	0
10.1007/s12325-019-0873-7	results	1	NA	significant	FALSE
10.1007/s12325-019-0873-7	results	1	NA	lb_ci	NA
10.1007/s12325-019-0873-7	results	1	NA	ub_ci	NA
10.1007/s12325-019-0873-7	results	1	NA	pval	0.04
10.1007/s12325-019-0873-7	results	1	NA	num_pval	0.04
10.1007/s12325-019-0873-7	results	1	NA	ci_cutoff	0
10.1007/s12325-019-0873-7	results	1	NA	significant	TRUE
10.1007/s12325-019-0873-7	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	164
10.1007/s12325-019-0873-7	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	203
10.1007/s12325-019-0873-7	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-019-0873-7	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-019-0873-7	results	2	NA	Number of covariates adjusted for/matched on	9
10.1007/s12325-019-0873-7	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-0873-7	results	2	NA	Primary outcome: treatment effect contrast	RMST difference at 12 months
10.1007/s12325-019-0873-7	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-019-0873-7	results	2	NA	Primary outcome: unadjusted treatment effect	-0.18
10.1007/s12325-019-0873-7	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.69
10.1007/s12325-019-0873-7	results	2	NA	Primary outcome: adjusted treatment effect	0.15
10.1007/s12325-019-0873-7	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.76
10.1007/s12325-019-0873-7	results	2	NA	lb_ci	NA
10.1007/s12325-019-0873-7	results	2	NA	ub_ci	NA
10.1007/s12325-019-0873-7	results	2	NA	pval	0.69
10.1007/s12325-019-0873-7	results	2	NA	num_pval	0.69
10.1007/s12325-019-0873-7	results	2	NA	ci_cutoff	0
10.1007/s12325-019-0873-7	results	2	NA	significant	FALSE
10.1007/s12325-019-0873-7	results	2	NA	lb_ci	NA
10.1007/s12325-019-0873-7	results	2	NA	ub_ci	NA
10.1007/s12325-019-0873-7	results	2	NA	pval	0.76
10.1007/s12325-019-0873-7	results	2	NA	num_pval	0.76
10.1007/s12325-019-0873-7	results	2	NA	ci_cutoff	0
10.1007/s12325-019-0873-7	results	2	NA	significant	FALSE
10.1007/s12325-019-0873-7	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-019-0873-7	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-019-0873-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02013167
10.1007/s12325-019-0873-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-0873-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-0873-7	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-019-0873-7	study_information	NA	2	Patient-level data used	No
10.1007/s12325-019-0873-7	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-019-0873-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01564784
10.1007/s12325-019-0873-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-019-0873-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-019-0873-7	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01298-x	general_information	NA	NA	Medical Condition of Interest Name	age-related macular degeneration
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of first author affiliations	japan
10.1007/s12325-020-01298-x	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-020-01298-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-020-01298-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-020-01298-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-020-01298-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-020-01298-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 1	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment
10.1007/s12325-020-01298-x	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01298-x	methodology	1	NA	Treatment name 2	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year
10.1007/s12325-020-01298-x	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s12325-020-01298-x	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-020-01298-x	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-020-01298-x	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-020-01298-x	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01298-x	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	number of etdrs (early treatment diabetic retinopathy study) letters gained vs baseline after 2 years
10.1007/s12325-020-01298-x	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s12325-020-01298-x	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s12325-020-01298-x	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01298-x	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01298-x	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-020-01298-x	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-020-01298-x	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	607
10.1007/s12325-020-01298-x	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	124
10.1007/s12325-020-01298-x	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-020-01298-x	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-020-01298-x	results	1	NA	Number of covariates adjusted for/matched on	3
10.1007/s12325-020-01298-x	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1007/s12325-020-01298-x	results	1	NA	Primary outcome: treatment effect contrast	Median difference
10.1007/s12325-020-01298-x	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1007/s12325-020-01298-x	results	1	NA	Primary outcome: adjusted treatment effect	-0.99
10.1007/s12325-020-01298-x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.90;1.93]
10.1007/s12325-020-01298-x	results	1	NA	lb_ci	-3.9
10.1007/s12325-020-01298-x	results	1	NA	ub_ci	1.93
10.1007/s12325-020-01298-x	results	1	NA	pval	NA
10.1007/s12325-020-01298-x	results	1	NA	num_pval	NA
10.1007/s12325-020-01298-x	results	1	NA	ci_cutoff	0
10.1007/s12325-020-01298-x	results	1	NA	significant	TRUE
10.1007/s12325-020-01298-x	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-020-01298-x	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-020-01298-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02305238
10.1007/s12325-020-01298-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.1007/s12325-020-01298-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	4
10.1007/s12325-020-01298-x	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-020-01298-x	study_information	NA	2	Patient-level data used	No
10.1007/s12325-020-01298-x	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-020-01298-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00509795
10.1007/s12325-020-01298-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01298-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01298-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01298-x	study_information	NA	3	Patient-level data used	No
10.1007/s12325-020-01298-x	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-020-01298-x	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00637377
10.1007/s12325-020-01298-x	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01298-x	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01298-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01378-y	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma
10.1007/s12325-020-01378-y	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-020-01378-y	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s12325-020-01378-y	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-020-01378-y	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-020-01378-y	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-020-01378-y	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-020-01378-y	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 1	cabozantinib
10.1007/s12325-020-01378-y	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01378-y	methodology	1	NA	Treatment name 2	regorafenib
10.1007/s12325-020-01378-y	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01378-y	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-020-01378-y	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-020-01378-y	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01378-y	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01378-y	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s12325-020-01378-y	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-020-01378-y	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-020-01378-y	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-020-01378-y	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-020-01378-y	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-020-01378-y	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-020-01378-y	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	379
10.1007/s12325-020-01378-y	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	326
10.1007/s12325-020-01378-y	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	187
10.1007/s12325-020-01378-y	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-020-01378-y	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-020-01378-y	results	1	NA	Number of covariates adjusted for/matched on	11
10.1007/s12325-020-01378-y	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-020-01378-y	results	1	NA	Primary outcome: treatment effect contrast	Median difference
10.1007/s12325-020-01378-y	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-020-01378-y	results	1	NA	Primary outcome: adjusted treatment effect	0.8
10.1007/s12325-020-01378-y	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.3474
10.1007/s12325-020-01378-y	results	1	NA	geographical region	Yes
10.1007/s12325-020-01378-y	results	1	NA	lb_ci	NA
10.1007/s12325-020-01378-y	results	1	NA	ub_ci	NA
10.1007/s12325-020-01378-y	results	1	NA	pval	0.3474
10.1007/s12325-020-01378-y	results	1	NA	num_pval	0.3474
10.1007/s12325-020-01378-y	results	1	NA	ci_cutoff	0
10.1007/s12325-020-01378-y	results	1	NA	significant	FALSE
10.1007/s12325-020-01378-y	results	2	NA	geographical region	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.1007/s12325-020-01378-y	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01378-y	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01378-y	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01378-y	study_information	NA	2	Patient-level data used	No
10.1007/s12325-020-01378-y	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-020-01378-y	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01774344
10.1007/s12325-020-01378-y	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01378-y	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01378-y	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-020-01599-1	general_information	NA	NA	Medical Condition of Interest Name	haemophilia a
10.1007/s12325-020-01599-1	general_information	NA	NA	Countries of first author affiliations	sweden
10.1007/s12325-020-01599-1	general_information	NA	NA	Countries of last author affiliations	sweden
10.1007/s12325-020-01599-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-020-01599-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s12325-020-01599-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-020-01599-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-020-01599-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	1	NA	Treatment name 2	damoctocog alfa pegol (pooled prophylaxis)
10.1007/s12325-020-01599-1	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-020-01599-1	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-020-01599-1	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualized bleeding rates
10.1007/s12325-020-01599-1	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-020-01599-1	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	2	NA	Treatment name 2	damoctocog alfa pegol twice weekly
10.1007/s12325-020-01599-1	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-020-01599-1	methodology	2	NA	Anchored comparison?	No
10.1007/s12325-020-01599-1	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-020-01599-1	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	3	NA	Treatment name 2	damoctocog alfa pegol q5d
10.1007/s12325-020-01599-1	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-020-01599-1	methodology	3	NA	Anchored comparison?	No
10.1007/s12325-020-01599-1	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-020-01599-1	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 1	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-020-01599-1	methodology	4	NA	Treatment name 2	damoctocog alfa pegol q7d
10.1007/s12325-020-01599-1	methodology	4	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-020-01599-1	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-020-01599-1	methodology	4	NA	Anchored comparison?	No
10.1007/s12325-020-01599-1	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	4	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s12325-020-01599-1	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-020-01599-1	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	110
10.1007/s12325-020-01599-1	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.1007/s12325-020-01599-1	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	81
10.1007/s12325-020-01599-1	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-020-01599-1	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-020-01599-1	results	1	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-020-01599-1	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s12325-020-01599-1	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	1	NA	Primary outcome: unadjusted treatment effect	-2
10.1007/s12325-020-01599-1	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.5;-0.4]
10.1007/s12325-020-01599-1	results	1	NA	Primary outcome: adjusted treatment effect	-1.9
10.1007/s12325-020-01599-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.5;-0.4]
10.1007/s12325-020-01599-1	results	1	NA	geographical region	No
10.1007/s12325-020-01599-1	results	1	NA	lb_ci	-3.5
10.1007/s12325-020-01599-1	results	1	NA	ub_ci	-0.4
10.1007/s12325-020-01599-1	results	1	NA	pval	NA
10.1007/s12325-020-01599-1	results	1	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	1	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	1	NA	significant	FALSE
10.1007/s12325-020-01599-1	results	1	NA	lb_ci	-3.5
10.1007/s12325-020-01599-1	results	1	NA	ub_ci	-0.4
10.1007/s12325-020-01599-1	results	1	NA	pval	NA
10.1007/s12325-020-01599-1	results	1	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	1	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	1	NA	significant	FALSE
10.1007/s12325-020-01599-1	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	24
10.1007/s12325-020-01599-1	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.1007/s12325-020-01599-1	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	62
10.1007/s12325-020-01599-1	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-020-01599-1	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-020-01599-1	results	2	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-020-01599-1	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s12325-020-01599-1	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	2	NA	Primary outcome: unadjusted treatment effect	-2
10.1007/s12325-020-01599-1	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-4.6;0.6]
10.1007/s12325-020-01599-1	results	2	NA	Primary outcome: adjusted treatment effect	-1.6
10.1007/s12325-020-01599-1	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-4.2;1.1]
10.1007/s12325-020-01599-1	results	2	NA	geographical region	No
10.1007/s12325-020-01599-1	results	2	NA	lb_ci	-4.6
10.1007/s12325-020-01599-1	results	2	NA	ub_ci	0.6
10.1007/s12325-020-01599-1	results	2	NA	pval	NA
10.1007/s12325-020-01599-1	results	2	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	2	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	2	NA	significant	TRUE
10.1007/s12325-020-01599-1	results	2	NA	lb_ci	-4.2
10.1007/s12325-020-01599-1	results	2	NA	ub_ci	1.1
10.1007/s12325-020-01599-1	results	2	NA	pval	NA
10.1007/s12325-020-01599-1	results	2	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	2	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	2	NA	significant	TRUE
10.1007/s12325-020-01599-1	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	43
10.1007/s12325-020-01599-1	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.1007/s12325-020-01599-1	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	79
10.1007/s12325-020-01599-1	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-020-01599-1	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-020-01599-1	results	3	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-020-01599-1	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s12325-020-01599-1	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	3	NA	Primary outcome: unadjusted treatment effect	-0.4
10.1007/s12325-020-01599-1	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-1.9;1.1]
10.1007/s12325-020-01599-1	results	3	NA	Primary outcome: adjusted treatment effect	-0.6
10.1007/s12325-020-01599-1	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-2.0;0.8]
10.1007/s12325-020-01599-1	results	3	NA	geographical region	No
10.1007/s12325-020-01599-1	results	3	NA	lb_ci	-1.9
10.1007/s12325-020-01599-1	results	3	NA	ub_ci	1.1
10.1007/s12325-020-01599-1	results	3	NA	pval	NA
10.1007/s12325-020-01599-1	results	3	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	3	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	3	NA	significant	TRUE
10.1007/s12325-020-01599-1	results	3	NA	lb_ci	-2
10.1007/s12325-020-01599-1	results	3	NA	ub_ci	0.8
10.1007/s12325-020-01599-1	results	3	NA	pval	NA
10.1007/s12325-020-01599-1	results	3	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	3	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	3	NA	significant	TRUE
10.1007/s12325-020-01599-1	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	43
10.1007/s12325-020-01599-1	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.1007/s12325-020-01599-1	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	45
10.1007/s12325-020-01599-1	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-020-01599-1	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-020-01599-1	results	4	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-020-01599-1	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	4	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s12325-020-01599-1	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	4	NA	Primary outcome: unadjusted treatment effect	-3.5
10.1007/s12325-020-01599-1	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-6.6;-0.4]
10.1007/s12325-020-01599-1	results	4	NA	Primary outcome: adjusted treatment effect	-3.3
10.1007/s12325-020-01599-1	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-6.4;-0.2]
10.1007/s12325-020-01599-1	results	4	NA	geographical region	No
10.1007/s12325-020-01599-1	results	4	NA	lb_ci	-6.6
10.1007/s12325-020-01599-1	results	4	NA	ub_ci	-0.4
10.1007/s12325-020-01599-1	results	4	NA	pval	NA
10.1007/s12325-020-01599-1	results	4	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	4	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	4	NA	significant	FALSE
10.1007/s12325-020-01599-1	results	4	NA	lb_ci	-6.4
10.1007/s12325-020-01599-1	results	4	NA	ub_ci	-0.2
10.1007/s12325-020-01599-1	results	4	NA	pval	NA
10.1007/s12325-020-01599-1	results	4	NA	num_pval	NA
10.1007/s12325-020-01599-1	results	4	NA	ci_cutoff	0
10.1007/s12325-020-01599-1	results	4	NA	significant	FALSE
10.1007/s12325-020-01599-1	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-020-01599-1	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-020-01599-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.1007/s12325-020-01599-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01599-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-020-01599-1	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-020-01599-1	study_information	NA	2	Patient-level data used	No
10.1007/s12325-020-01599-1	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-020-01599-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293
10.1007/s12325-020-01599-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-020-01599-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.1007/s12325-020-01599-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01700-2	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma
10.1007/s12325-021-01700-2	general_information	NA	NA	Countries of first author affiliations	germany
10.1007/s12325-021-01700-2	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-021-01700-2	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01700-2	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01700-2	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01700-2	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01700-2	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 1	cabozantinib
10.1007/s12325-021-01700-2	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01700-2	methodology	1	NA	Treatment name 2	ramucirumab
10.1007/s12325-021-01700-2	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01700-2	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01700-2	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-021-01700-2	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01700-2	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01700-2	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s12325-021-01700-2	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-021-01700-2	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01700-2	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-021-01700-2	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-021-01700-2	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01700-2	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1007/s12325-021-01700-2	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	197
10.1007/s12325-021-01700-2	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	114
10.1007/s12325-021-01700-2	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	63
10.1007/s12325-021-01700-2	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-021-01700-2	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01700-2	results	1	NA	Number of covariates adjusted for/matched on	9
10.1007/s12325-021-01700-2	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s12325-021-01700-2	results	1	NA	Primary outcome: treatment effect contrast	Median difference
10.1007/s12325-021-01700-2	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01700-2	results	1	NA	Primary outcome: adjusted treatment effect	1.9
10.1007/s12325-021-01700-2	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.104
10.1007/s12325-021-01700-2	results	1	NA	lb_ci	NA
10.1007/s12325-021-01700-2	results	1	NA	ub_ci	NA
10.1007/s12325-021-01700-2	results	1	NA	pval	0.104
10.1007/s12325-021-01700-2	results	1	NA	num_pval	0.104
10.1007/s12325-021-01700-2	results	1	NA	ci_cutoff	0
10.1007/s12325-021-01700-2	results	1	NA	significant	FALSE
10.1007/s12325-021-01700-2	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01700-2	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01700-2	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.1007/s12325-021-01700-2	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01700-2	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01700-2	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01700-2	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01700-2	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01700-2	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02435433
10.1007/s12325-021-01700-2	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01700-2	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01700-2	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01756-0	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory diffuse large b-cell lymphoma
10.1007/s12325-021-01756-0	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-021-01756-0	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1007/s12325-021-01756-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01756-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01756-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01756-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01756-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel
10.1007/s12325-021-01756-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01756-0	methodology	1	NA	Treatment name 2	salvage chemotherapy
10.1007/s12325-021-01756-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01756-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01756-0	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-021-01756-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01756-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01756-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate (orr)
10.1007/s12325-021-01756-0	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-021-01756-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s12325-021-01756-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01756-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01756-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01756-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01756-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	523
10.1007/s12325-021-01756-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	248
10.1007/s12325-021-01756-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	142
10.1007/s12325-021-01756-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-021-01756-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01756-0	results	1	NA	Number of covariates adjusted for/matched on	7
10.1007/s12325-021-01756-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s12325-021-01756-0	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1007/s12325-021-01756-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01756-0	results	1	NA	Primary outcome: unadjusted treatment effect	7.7
10.1007/s12325-021-01756-0	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1007/s12325-021-01756-0	results	1	NA	Primary outcome: adjusted treatment effect	7
10.1007/s12325-021-01756-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1007/s12325-021-01756-0	results	1	NA	lb_ci	NA
10.1007/s12325-021-01756-0	results	1	NA	ub_ci	NA
10.1007/s12325-021-01756-0	results	1	NA	pval	<0.001
10.1007/s12325-021-01756-0	results	1	NA	num_pval	NA
10.1007/s12325-021-01756-0	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01756-0	results	1	NA	significant	TRUE
10.1007/s12325-021-01756-0	results	1	NA	lb_ci	NA
10.1007/s12325-021-01756-0	results	1	NA	ub_ci	NA
10.1007/s12325-021-01756-0	results	1	NA	pval	<0.001
10.1007/s12325-021-01756-0	results	1	NA	num_pval	NA
10.1007/s12325-021-01756-0	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01756-0	results	1	NA	significant	TRUE
10.1007/s12325-021-01756-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01756-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01756-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1007/s12325-021-01756-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s12325-021-01756-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1007/s12325-021-01756-0	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01756-0	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01756-0	study_information	NA	2	Clinical Trial	No
10.1007/s12325-021-01756-0	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	scholar-1
10.1007/s12325-021-01756-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	general_information	NA	NA	Medical Condition of Interest Name	persistent atrial fibrillation
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-021-01846-z	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-021-01846-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01846-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01846-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01846-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01846-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 1	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)
10.1007/s12325-021-01846-z	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1007/s12325-021-01846-z	methodology	1	NA	Treatment name 2	second-generation cryoballoon (cb)
10.1007/s12325-021-01846-z	methodology	1	NA	Study 'number(s)' for treatment 2	5;6;7;8
10.1007/s12325-021-01846-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01846-z	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-021-01846-z	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-021-01846-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	arrhythmia recurrence
10.1007/s12325-021-01846-z	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-021-01846-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01846-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01846-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01846-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	389
10.1007/s12325-021-01846-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	191
10.1007/s12325-021-01846-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	156
10.1007/s12325-021-01846-z	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-021-01846-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01846-z	results	1	NA	Number of covariates adjusted for/matched on	4
10.1007/s12325-021-01846-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-021-01846-z	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-021-01846-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01846-z	results	1	NA	Primary outcome: unadjusted treatment effect	0.39
10.1007/s12325-021-01846-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.27;0.56]
10.1007/s12325-021-01846-z	results	1	NA	Primary outcome: adjusted treatment effect	0.35
10.1007/s12325-021-01846-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.23;0.52]
10.1007/s12325-021-01846-z	results	1	NA	lb_ci	0.27
10.1007/s12325-021-01846-z	results	1	NA	ub_ci	0.56
10.1007/s12325-021-01846-z	results	1	NA	pval	NA
10.1007/s12325-021-01846-z	results	1	NA	num_pval	NA
10.1007/s12325-021-01846-z	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01846-z	results	1	NA	significant	FALSE
10.1007/s12325-021-01846-z	results	1	NA	lb_ci	0.23
10.1007/s12325-021-01846-z	results	1	NA	ub_ci	0.52
10.1007/s12325-021-01846-z	results	1	NA	pval	NA
10.1007/s12325-021-01846-z	results	1	NA	num_pval	NA
10.1007/s12325-021-01846-z	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01846-z	results	1	NA	significant	FALSE
10.1007/s12325-021-01846-z	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	1	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	hussein et al. (2017)
10.1007/s12325-021-01846-z	study_information	NA	2	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01846-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02628730
10.1007/s12325-021-01846-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01846-z	study_information	NA	3	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	3	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	solimene et al. (2019)
10.1007/s12325-021-01846-z	study_information	NA	4	Patient-level data used	Yes
10.1007/s12325-021-01846-z	study_information	NA	4	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03277976
10.1007/s12325-021-01846-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1007/s12325-021-01846-z	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	stabile et al. (2020)
10.1007/s12325-021-01846-z	study_information	NA	5	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	5	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	gramlich et al. (2019)
10.1007/s12325-021-01846-z	study_information	NA	6	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	6	Clinical Trial	Yes
10.1007/s12325-021-01846-z	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213731
10.1007/s12325-021-01846-z	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01846-z	study_information	NA	7	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	7	Clinical Trial	No
10.1007/s12325-021-01846-z	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	circonte et al. (2015)
10.1007/s12325-021-01846-z	study_information	NA	8	Patient-level data used	No
10.1007/s12325-021-01846-z	study_information	NA	8	Clinical Trial	Yes
10.1007/s12325-021-01846-z	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03012841
10.1007/s12325-021-01846-z	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01846-z	study_information	NA	8	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01853-0	general_information	NA	NA	Medical Condition of Interest Name	severe haemophilia a
10.1007/s12325-021-01853-0	general_information	NA	NA	Countries of first author affiliations	spain
10.1007/s12325-021-01853-0	general_information	NA	NA	Countries of last author affiliations	portugal
10.1007/s12325-021-01853-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01853-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01853-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01853-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01853-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 1	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01853-0	methodology	1	NA	Treatment name 2	rahf-pfm
10.1007/s12325-021-01853-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01853-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01853-0	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-021-01853-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr),
10.1007/s12325-021-01853-0	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-021-01853-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01853-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 1	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01853-0	methodology	2	NA	Treatment name 2	rahf-pfm
10.1007/s12325-021-01853-0	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1007/s12325-021-01853-0	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01853-0	methodology	2	NA	Anchored comparison?	No
10.1007/s12325-021-01853-0	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr)
10.1007/s12325-021-01853-0	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-021-01853-0	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01853-0	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 1	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01853-0	methodology	3	NA	Treatment name 2	rfviiifc
10.1007/s12325-021-01853-0	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1007/s12325-021-01853-0	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01853-0	methodology	3	NA	Anchored comparison?	No
10.1007/s12325-021-01853-0	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr)
10.1007/s12325-021-01853-0	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-021-01853-0	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01853-0	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01853-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	111
10.1007/s12325-021-01853-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	146
10.1007/s12325-021-01853-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	25.1
10.1007/s12325-021-01853-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-021-01853-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01853-0	results	1	NA	Number of covariates adjusted for/matched on	4
10.1007/s12325-021-01853-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Other(s)
10.1007/s12325-021-01853-0	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-021-01853-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	1	NA	Primary outcome: unadjusted treatment effect	0.55
10.1007/s12325-021-01853-0	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.17;3.12]
10.1007/s12325-021-01853-0	results	1	NA	Primary outcome: adjusted treatment effect	0.74
10.1007/s12325-021-01853-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.16;3.48]
10.1007/s12325-021-01853-0	results	1	NA	geographical region	No
10.1007/s12325-021-01853-0	results	1	NA	lb_ci	0.17
10.1007/s12325-021-01853-0	results	1	NA	ub_ci	3.12
10.1007/s12325-021-01853-0	results	1	NA	pval	NA
10.1007/s12325-021-01853-0	results	1	NA	num_pval	NA
10.1007/s12325-021-01853-0	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01853-0	results	1	NA	significant	TRUE
10.1007/s12325-021-01853-0	results	1	NA	lb_ci	0.16
10.1007/s12325-021-01853-0	results	1	NA	ub_ci	3.48
10.1007/s12325-021-01853-0	results	1	NA	pval	NA
10.1007/s12325-021-01853-0	results	1	NA	num_pval	NA
10.1007/s12325-021-01853-0	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01853-0	results	1	NA	significant	TRUE
10.1007/s12325-021-01853-0	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	32
10.1007/s12325-021-01853-0	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	146
10.1007/s12325-021-01853-0	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	79
10.1007/s12325-021-01853-0	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-021-01853-0	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01853-0	results	2	NA	Number of covariates adjusted for/matched on	2
10.1007/s12325-021-01853-0	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity
10.1007/s12325-021-01853-0	results	2	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-021-01853-0	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	2	NA	Primary outcome: unadjusted treatment effect	0.07
10.1007/s12325-021-01853-0	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.09;3.23]
10.1007/s12325-021-01853-0	results	2	NA	Primary outcome: adjusted treatment effect	0.01
10.1007/s12325-021-01853-0	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-2.36;2.37]
10.1007/s12325-021-01853-0	results	2	NA	lb_ci	-3.09
10.1007/s12325-021-01853-0	results	2	NA	ub_ci	3.23
10.1007/s12325-021-01853-0	results	2	NA	pval	NA
10.1007/s12325-021-01853-0	results	2	NA	num_pval	NA
10.1007/s12325-021-01853-0	results	2	NA	ci_cutoff	1
10.1007/s12325-021-01853-0	results	2	NA	significant	TRUE
10.1007/s12325-021-01853-0	results	2	NA	lb_ci	-2.36
10.1007/s12325-021-01853-0	results	2	NA	ub_ci	2.37
10.1007/s12325-021-01853-0	results	2	NA	pval	NA
10.1007/s12325-021-01853-0	results	2	NA	num_pval	NA
10.1007/s12325-021-01853-0	results	2	NA	ci_cutoff	1
10.1007/s12325-021-01853-0	results	2	NA	significant	TRUE
10.1007/s12325-021-01853-0	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	118
10.1007/s12325-021-01853-0	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	146
10.1007/s12325-021-01853-0	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	123.6
10.1007/s12325-021-01853-0	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-021-01853-0	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01853-0	results	3	NA	Number of covariates adjusted for/matched on	4
10.1007/s12325-021-01853-0	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Other(s)
10.1007/s12325-021-01853-0	results	3	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-021-01853-0	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	3	NA	Primary outcome: unadjusted treatment effect	1.14
10.1007/s12325-021-01853-0	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.82;1.57]
10.1007/s12325-021-01853-0	results	3	NA	Primary outcome: adjusted treatment effect	1.18
10.1007/s12325-021-01853-0	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.85;1.65]
10.1007/s12325-021-01853-0	results	3	NA	geographical region	Yes
10.1007/s12325-021-01853-0	results	3	NA	lb_ci	0.82
10.1007/s12325-021-01853-0	results	3	NA	ub_ci	1.57
10.1007/s12325-021-01853-0	results	3	NA	pval	NA
10.1007/s12325-021-01853-0	results	3	NA	num_pval	NA
10.1007/s12325-021-01853-0	results	3	NA	ci_cutoff	1
10.1007/s12325-021-01853-0	results	3	NA	significant	TRUE
10.1007/s12325-021-01853-0	results	3	NA	lb_ci	0.85
10.1007/s12325-021-01853-0	results	3	NA	ub_ci	1.65
10.1007/s12325-021-01853-0	results	3	NA	pval	NA
10.1007/s12325-021-01853-0	results	3	NA	num_pval	NA
10.1007/s12325-021-01853-0	results	3	NA	ci_cutoff	1
10.1007/s12325-021-01853-0	results	3	NA	significant	TRUE
10.1007/s12325-021-01853-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01853-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01486927
10.1007/s12325-021-01853-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 3
10.1007/s12325-021-01853-0	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01853-0	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01853-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	rahf-pfm-2004 - part 2 10.1111/j.1365-2516.2004.00932.x
10.1007/s12325-021-01853-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	2	Number of treatment arms (clinical trial only)	??
10.1007/s12325-021-01853-0	study_information	NA	3	Patient-level data used	No
10.1007/s12325-021-01853-0	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386
10.1007/s12325-021-01853-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	4
10.1007/s12325-021-01853-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01853-0	study_information	NA	4	Patient-level data used	No
10.1007/s12325-021-01853-0	study_information	NA	4	Clinical Trial	Yes
10.1007/s12325-021-01853-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.1007/s12325-021-01853-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01853-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01853-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01884-7	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of first author affiliations	france
10.1007/s12325-021-01884-7	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s12325-021-01884-7	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01884-7	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-021-01884-7	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01884-7	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01884-7	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 1	belantamab mafodotin
10.1007/s12325-021-01884-7	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01884-7	methodology	1	NA	Treatment name 2	selinexor + dexamethasone
10.1007/s12325-021-01884-7	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01884-7	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01884-7	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-021-01884-7	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01884-7	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01884-7	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s12325-021-01884-7	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-021-01884-7	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01884-7	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01884-7	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01884-7	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	122
10.1007/s12325-021-01884-7	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	95
10.1007/s12325-021-01884-7	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	63.46
10.1007/s12325-021-01884-7	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1007/s12325-021-01884-7	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01884-7	results	1	NA	Number of covariates adjusted for/matched on	8
10.1007/s12325-021-01884-7	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-021-01884-7	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-021-01884-7	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01884-7	results	1	NA	Primary outcome: unadjusted treatment effect	0.6
10.1007/s12325-021-01884-7	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.01
10.1007/s12325-021-01884-7	results	1	NA	Primary outcome: adjusted treatment effect	0.53
10.1007/s12325-021-01884-7	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.005
10.1007/s12325-021-01884-7	results	1	NA	lb_ci	NA
10.1007/s12325-021-01884-7	results	1	NA	ub_ci	NA
10.1007/s12325-021-01884-7	results	1	NA	pval	0.01
10.1007/s12325-021-01884-7	results	1	NA	num_pval	0.01
10.1007/s12325-021-01884-7	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01884-7	results	1	NA	significant	TRUE
10.1007/s12325-021-01884-7	results	1	NA	lb_ci	NA
10.1007/s12325-021-01884-7	results	1	NA	ub_ci	NA
10.1007/s12325-021-01884-7	results	1	NA	pval	0.005
10.1007/s12325-021-01884-7	results	1	NA	num_pval	0.005
10.1007/s12325-021-01884-7	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01884-7	results	1	NA	significant	TRUE
10.1007/s12325-021-01884-7	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01884-7	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01884-7	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678
10.1007/s12325-021-01884-7	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01884-7	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-021-01884-7	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01884-7	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01884-7	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01884-7	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815
10.1007/s12325-021-01884-7	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01884-7	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-021-01884-7	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1007/s12325-021-01885-6	general_information	NA	NA	Medical Condition of Interest Name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-021-01885-6	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s12325-021-01885-6	general_information	NA	NA	Countries of last author affiliations	germany
10.1007/s12325-021-01885-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-021-01885-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1007/s12325-021-01885-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-021-01885-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-021-01885-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 1	apalutamide + adt
10.1007/s12325-021-01885-6	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-021-01885-6	methodology	1	NA	Treatment name 2	darolutamide + adt
10.1007/s12325-021-01885-6	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-021-01885-6	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-021-01885-6	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01885-6	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	metastasis-free survival
10.1007/s12325-021-01885-6	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-021-01885-6	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s12325-021-01885-6	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-021-01885-6	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-021-01885-6	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-021-01885-6	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-021-01885-6	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-021-01885-6	results	1	NA	Number of covariates adjusted for/matched on	9
10.1007/s12325-021-01885-6	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-021-01885-6	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-021-01885-6	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-021-01885-6	results	1	NA	Primary outcome: adjusted treatment effect	0.7
10.1007/s12325-021-01885-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.51;0.98]
10.1007/s12325-021-01885-6	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	955
10.1007/s12325-021-01885-6	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	554
10.1007/s12325-021-01885-6	results	1	NA	geographical region	Yes
10.1007/s12325-021-01885-6	results	1	NA	If anchored, total initial sample size IPD	1150
10.1007/s12325-021-01885-6	results	1	NA	If anchored, total ESS IPD	455
10.1007/s12325-021-01885-6	results	1	NA	If anchored, total sample size non IPD	1509
10.1007/s12325-021-01885-6	results	1	NA	lb_ci	0.51
10.1007/s12325-021-01885-6	results	1	NA	ub_ci	0.98
10.1007/s12325-021-01885-6	results	1	NA	pval	NA
10.1007/s12325-021-01885-6	results	1	NA	num_pval	NA
10.1007/s12325-021-01885-6	results	1	NA	ci_cutoff	1
10.1007/s12325-021-01885-6	results	1	NA	significant	FALSE
10.1007/s12325-021-01885-6	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-021-01885-6	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-021-01885-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1007/s12325-021-01885-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01885-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01885-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-021-01885-6	study_information	NA	2	Patient-level data used	No
10.1007/s12325-021-01885-6	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-021-01885-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614
10.1007/s12325-021-01885-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-021-01885-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-021-01885-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-022-02054-z	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory follicular lymphoma
10.1007/s12325-022-02054-z	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s12325-022-02054-z	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s12325-022-02054-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-022-02054-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-022-02054-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-022-02054-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-022-02054-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	1	NA	Treatment name 2	idelalisib
10.1007/s12325-022-02054-z	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-022-02054-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-022-02054-z	methodology	1	NA	Anchored comparison?	No
10.1007/s12325-022-02054-z	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-022-02054-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	2	NA	Treatment name 2	duvelisib
10.1007/s12325-022-02054-z	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1007/s12325-022-02054-z	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-022-02054-z	methodology	2	NA	Anchored comparison?	No
10.1007/s12325-022-02054-z	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-022-02054-z	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	3	NA	Treatment name 2	copanlisib
10.1007/s12325-022-02054-z	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1007/s12325-022-02054-z	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-022-02054-z	methodology	3	NA	Anchored comparison?	No
10.1007/s12325-022-02054-z	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-022-02054-z	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 1	tazemetostat
10.1007/s12325-022-02054-z	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02054-z	methodology	4	NA	Treatment name 2	umbralisib
10.1007/s12325-022-02054-z	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.1007/s12325-022-02054-z	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-022-02054-z	methodology	4	NA	Anchored comparison?	No
10.1007/s12325-022-02054-z	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-022-02054-z	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-022-02054-z	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s12325-022-02054-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	72
10.1007/s12325-022-02054-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	99
10.1007/s12325-022-02054-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36
10.1007/s12325-022-02054-z	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-022-02054-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-022-02054-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-022-02054-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	1	NA	Primary outcome: unadjusted treatment effect	0.59
10.1007/s12325-022-02054-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1007/s12325-022-02054-z	results	1	NA	Primary outcome: adjusted treatment effect	0.45
10.1007/s12325-022-02054-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1007/s12325-022-02054-z	results	1	NA	Number of covariates adjusted for/matched on	8
10.1007/s12325-022-02054-z	results	1	NA	geographical region	No
10.1007/s12325-022-02054-z	results	1	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	1	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	1	NA	pval	<0.001
10.1007/s12325-022-02054-z	results	1	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	1	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	1	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	1	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	1	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	1	NA	pval	<0.001
10.1007/s12325-022-02054-z	results	1	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	1	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	1	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	129
10.1007/s12325-022-02054-z	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	99
10.1007/s12325-022-02054-z	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24
10.1007/s12325-022-02054-z	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-022-02054-z	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-022-02054-z	results	2	NA	Number of covariates adjusted for/matched on	8
10.1007/s12325-022-02054-z	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	2	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-022-02054-z	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	2	NA	Primary outcome: unadjusted treatment effect	0.45
10.1007/s12325-022-02054-z	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1007/s12325-022-02054-z	results	2	NA	Primary outcome: adjusted treatment effect	0.35
10.1007/s12325-022-02054-z	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1007/s12325-022-02054-z	results	2	NA	geographical region	No
10.1007/s12325-022-02054-z	results	2	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	2	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	2	NA	pval	<0.001
10.1007/s12325-022-02054-z	results	2	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	2	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	2	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	2	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	2	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	2	NA	pval	<0.001
10.1007/s12325-022-02054-z	results	2	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	2	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	2	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	142
10.1007/s12325-022-02054-z	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	99
10.1007/s12325-022-02054-z	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	66
10.1007/s12325-022-02054-z	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-022-02054-z	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-022-02054-z	results	3	NA	Number of covariates adjusted for/matched on	7
10.1007/s12325-022-02054-z	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	3	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-022-02054-z	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	3	NA	Primary outcome: unadjusted treatment effect	0.47
10.1007/s12325-022-02054-z	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1007/s12325-022-02054-z	results	3	NA	Primary outcome: adjusted treatment effect	0.37
10.1007/s12325-022-02054-z	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1007/s12325-022-02054-z	results	3	NA	geographical region	No
10.1007/s12325-022-02054-z	results	3	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	3	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	3	NA	pval	<0.001
10.1007/s12325-022-02054-z	results	3	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	3	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	3	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	3	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	3	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	3	NA	pval	<0.001
10.1007/s12325-022-02054-z	results	3	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	3	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	3	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	208
10.1007/s12325-022-02054-z	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	99
10.1007/s12325-022-02054-z	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	60
10.1007/s12325-022-02054-z	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-022-02054-z	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-022-02054-z	results	4	NA	Number of covariates adjusted for/matched on	6
10.1007/s12325-022-02054-z	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	4	NA	Primary outcome: treatment effect contrast	RR
10.1007/s12325-022-02054-z	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	4	NA	Primary outcome: unadjusted treatment effect	0.74
10.1007/s12325-022-02054-z	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.05
10.1007/s12325-022-02054-z	results	4	NA	Primary outcome: adjusted treatment effect	0.65
10.1007/s12325-022-02054-z	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.01
10.1007/s12325-022-02054-z	results	4	NA	geographical region	No
10.1007/s12325-022-02054-z	results	4	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	4	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	4	NA	pval	<0.05
10.1007/s12325-022-02054-z	results	4	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	4	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	4	NA	significant	TRUE
10.1007/s12325-022-02054-z	results	4	NA	lb_ci	NA
10.1007/s12325-022-02054-z	results	4	NA	ub_ci	NA
10.1007/s12325-022-02054-z	results	4	NA	pval	<0.01
10.1007/s12325-022-02054-z	results	4	NA	num_pval	NA
10.1007/s12325-022-02054-z	results	4	NA	ci_cutoff	1
10.1007/s12325-022-02054-z	results	4	NA	significant	TRUE
10.1007/s12325-022-02054-z	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-022-02054-z	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01897571
10.1007/s12325-022-02054-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1007/s12325-022-02054-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	2	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01282424
10.1007/s12325-022-02054-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	3	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	3	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01882803
10.1007/s12325-022-02054-z	study_information	NA	4	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	4	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01660451
10.1007/s12325-022-02054-z	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1007/s12325-022-02054-z	study_information	NA	5	Patient-level data used	No
10.1007/s12325-022-02054-z	study_information	NA	5	Clinical Trial	Yes
10.1007/s12325-022-02054-z	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02793583
10.1007/s12325-022-02054-z	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02054-z	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1007/s12325-022-02054-z	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-022-02099-0	general_information	NA	NA	Medical Condition of Interest Name	unresectable hepatocellular carcinoma
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of first author affiliations	germany
10.1007/s12325-022-02099-0	general_information	NA	NA	Countries of last author affiliations	france
10.1007/s12325-022-02099-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1007/s12325-022-02099-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s12325-022-02099-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s12325-022-02099-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s12325-022-02099-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 1	transarterial radioembolization
10.1007/s12325-022-02099-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s12325-022-02099-0	methodology	1	NA	Treatment name 2	atezolizumab + bevacizumab
10.1007/s12325-022-02099-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s12325-022-02099-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s12325-022-02099-0	methodology	1	NA	Anchored comparison?	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02099-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to deterioration in quality of life
10.1007/s12325-022-02099-0	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s12325-022-02099-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-022-02099-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1007/s12325-022-02099-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s12325-022-02099-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1007/s12325-022-02099-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	336
10.1007/s12325-022-02099-0	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	165
10.1007/s12325-022-02099-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	94
10.1007/s12325-022-02099-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53
10.1007/s12325-022-02099-0	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	123
10.1007/s12325-022-02099-0	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	78
10.1007/s12325-022-02099-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s12325-022-02099-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s12325-022-02099-0	results	1	NA	Number of covariates adjusted for/matched on	4
10.1007/s12325-022-02099-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score
10.1007/s12325-022-02099-0	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s12325-022-02099-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s12325-022-02099-0	results	1	NA	Primary outcome: adjusted treatment effect	1.06
10.1007/s12325-022-02099-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.725
10.1007/s12325-022-02099-0	results	1	NA	lb_ci	NA
10.1007/s12325-022-02099-0	results	1	NA	ub_ci	NA
10.1007/s12325-022-02099-0	results	1	NA	pval	0.725
10.1007/s12325-022-02099-0	results	1	NA	num_pval	0.725
10.1007/s12325-022-02099-0	results	1	NA	ci_cutoff	1
10.1007/s12325-022-02099-0	results	1	NA	significant	FALSE
10.1007/s12325-022-02099-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s12325-022-02099-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s12325-022-02099-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01482442
10.1007/s12325-022-02099-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1007/s12325-022-02099-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-022-02099-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s12325-022-02099-0	study_information	NA	2	Patient-level data used	No
10.1007/s12325-022-02099-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s12325-022-02099-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03434379
10.1007/s12325-022-02099-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s12325-022-02099-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s12325-022-02099-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	general_information	NA	NA	Medical Condition of Interest Name	mild-to-moderate atopic dermatitis
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s13555-021-00646-1	general_information	NA	NA	Countries of last author affiliations	denmark
10.1007/s13555-021-00646-1	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s13555-021-00646-1	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s13555-021-00646-1	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s13555-021-00646-1	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s13555-021-00646-1	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 1	crisaborole ointment 2
10.1007/s13555-021-00646-1	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s13555-021-00646-1	methodology	1	NA	Treatment name 2	pimecrolimus 1
10.1007/s13555-021-00646-1	methodology	1	NA	Study 'number(s)' for treatment 2	4;5;6;7
10.1007/s13555-021-00646-1	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s13555-021-00646-1	methodology	1	NA	Anchored comparison?	No
10.1007/s13555-021-00646-1	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s13555-021-00646-1	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	investigators static global assessment improvement score of 01
10.1007/s13555-021-00646-1	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s13555-021-00646-1	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s13555-021-00646-1	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 1	crisaborole
10.1007/s13555-021-00646-1	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s13555-021-00646-1	methodology	2	NA	Treatment name 2	tacrolimus 0.03
10.1007/s13555-021-00646-1	methodology	2	NA	Study 'number(s)' for treatment 2	3;4;5;8;9
10.1007/s13555-021-00646-1	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s13555-021-00646-1	methodology	2	NA	Anchored comparison?	No
10.1007/s13555-021-00646-1	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s13555-021-00646-1	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	investigators static global assessment improvement score of 01
10.1007/s13555-021-00646-1	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s13555-021-00646-1	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s13555-021-00646-1	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s13555-021-00646-1	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1021
10.1007/s13555-021-00646-1	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	627
10.1007/s13555-021-00646-1	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s13555-021-00646-1	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s13555-021-00646-1	results	1	NA	Number of covariates adjusted for/matched on	7
10.1007/s13555-021-00646-1	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.1007/s13555-021-00646-1	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1007/s13555-021-00646-1	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s13555-021-00646-1	results	1	NA	Primary outcome: unadjusted treatment effect	2.04
10.1007/s13555-021-00646-1	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.47;2.82]
10.1007/s13555-021-00646-1	results	1	NA	Primary outcome: adjusted treatment effect	2.03
10.1007/s13555-021-00646-1	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.45;2.85]
10.1007/s13555-021-00646-1	results	1	NA	lb_ci	1.47
10.1007/s13555-021-00646-1	results	1	NA	ub_ci	2.82
10.1007/s13555-021-00646-1	results	1	NA	pval	NA
10.1007/s13555-021-00646-1	results	1	NA	num_pval	NA
10.1007/s13555-021-00646-1	results	1	NA	ci_cutoff	1
10.1007/s13555-021-00646-1	results	1	NA	significant	FALSE
10.1007/s13555-021-00646-1	results	1	NA	lb_ci	1.45
10.1007/s13555-021-00646-1	results	1	NA	ub_ci	2.85
10.1007/s13555-021-00646-1	results	1	NA	pval	NA
10.1007/s13555-021-00646-1	results	1	NA	num_pval	NA
10.1007/s13555-021-00646-1	results	1	NA	ci_cutoff	1
10.1007/s13555-021-00646-1	results	1	NA	significant	FALSE
10.1007/s13555-021-00646-1	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	1021
10.1007/s13555-021-00646-1	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	311
10.1007/s13555-021-00646-1	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s13555-021-00646-1	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s13555-021-00646-1	results	2	NA	Number of covariates adjusted for/matched on	7
10.1007/s13555-021-00646-1	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.1007/s13555-021-00646-1	results	2	NA	Primary outcome: treatment effect contrast	OR
10.1007/s13555-021-00646-1	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s13555-021-00646-1	results	2	NA	Primary outcome: unadjusted treatment effect	1.31
10.1007/s13555-021-00646-1	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.02;1.69]
10.1007/s13555-021-00646-1	results	2	NA	Primary outcome: adjusted treatment effect	1.5
10.1007/s13555-021-00646-1	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.09;2.05]
10.1007/s13555-021-00646-1	results	2	NA	lb_ci	1.02
10.1007/s13555-021-00646-1	results	2	NA	ub_ci	1.69
10.1007/s13555-021-00646-1	results	2	NA	pval	NA
10.1007/s13555-021-00646-1	results	2	NA	num_pval	NA
10.1007/s13555-021-00646-1	results	2	NA	ci_cutoff	1
10.1007/s13555-021-00646-1	results	2	NA	significant	FALSE
10.1007/s13555-021-00646-1	results	2	NA	lb_ci	1.09
10.1007/s13555-021-00646-1	results	2	NA	ub_ci	2.05
10.1007/s13555-021-00646-1	results	2	NA	pval	NA
10.1007/s13555-021-00646-1	results	2	NA	num_pval	NA
10.1007/s13555-021-00646-1	results	2	NA	ci_cutoff	1
10.1007/s13555-021-00646-1	results	2	NA	significant	FALSE
10.1007/s13555-021-00646-1	study_information	NA	1	Patient-level data used	Yes
10.1007/s13555-021-00646-1	study_information	NA	1	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118766
10.1007/s13555-021-00646-1	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s13555-021-00646-1	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	2	Patient-level data used	Yes
10.1007/s13555-021-00646-1	study_information	NA	2	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02118792
10.1007/s13555-021-00646-1	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s13555-021-00646-1	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	3	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	3	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	schachner et al. (2005)
10.1007/s13555-021-00646-1	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	4	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	4	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	kempers et al. (2004)
10.1007/s13555-021-00646-1	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	5	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	5	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00667160
10.1007/s13555-021-00646-1	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4
10.1007/s13555-021-00646-1	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	6	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	6	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s13555-021-00646-1	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	abramovits et al. (2008)
10.1007/s13555-021-00646-1	study_information	NA	7	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	7	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	eichenfield et al. (2002)
10.1007/s13555-021-00646-1	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s13555-021-00646-1	study_information	NA	8	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	8	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	chapman et al. (2005)
10.1007/s13555-021-00646-1	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s13555-021-00646-1	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	9	Patient-level data used	No
10.1007/s13555-021-00646-1	study_information	NA	9	Clinical Trial	Yes
10.1007/s13555-021-00646-1	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1007/s13555-021-00646-1	study_information	NA	9	Data source name (only if observational study or clinical trial without NCT)	levy et al. (2005)
10.1007/s40258-016-0271-0	general_information	NA	NA	Medical Condition of Interest Name	relapsed and/or refractory multiple myeloma
10.1007/s40258-016-0271-0	general_information	NA	NA	Countries of first author affiliations	the netherlands
10.1007/s40258-016-0271-0	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40258-016-0271-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40258-016-0271-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40258-016-0271-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40258-016-0271-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40258-016-0271-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 1	panobinostat + bortezomib + dexamethasone
10.1007/s40258-016-0271-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40258-016-0271-0	methodology	1	NA	Treatment name 2	lenalidomide + dexamethasone
10.1007/s40258-016-0271-0	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40258-016-0271-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40258-016-0271-0	methodology	1	NA	Anchored comparison?	No
10.1007/s40258-016-0271-0	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40258-016-0271-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40258-016-0271-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1007/s40258-016-0271-0	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s40258-016-0271-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40258-016-0271-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40258-016-0271-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40258-016-0271-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40258-016-0271-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40258-016-0271-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	220
10.1007/s40258-016-0271-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	142
10.1007/s40258-016-0271-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	138
10.1007/s40258-016-0271-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40258-016-0271-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40258-016-0271-0	results	1	NA	Number of covariates adjusted for/matched on	4
10.1007/s40258-016-0271-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s40258-016-0271-0	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s40258-016-0271-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40258-016-0271-0	results	1	NA	Primary outcome: adjusted treatment effect	0.96
10.1007/s40258-016-0271-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.72;1.28]
10.1007/s40258-016-0271-0	results	1	NA	lb_ci	0.72
10.1007/s40258-016-0271-0	results	1	NA	ub_ci	1.28
10.1007/s40258-016-0271-0	results	1	NA	pval	NA
10.1007/s40258-016-0271-0	results	1	NA	num_pval	NA
10.1007/s40258-016-0271-0	results	1	NA	ci_cutoff	1
10.1007/s40258-016-0271-0	results	1	NA	significant	TRUE
10.1007/s40258-016-0271-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s40258-016-0271-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s40258-016-0271-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01023308
10.1007/s40258-016-0271-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40258-016-0271-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40258-016-0271-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40258-016-0271-0	study_information	NA	2	Patient-level data used	No
10.1007/s40258-016-0271-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s40258-016-0271-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00056160
10.1007/s40258-016-0271-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40258-016-0271-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40258-016-0271-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40258-016-0271-0	study_information	NA	3	Patient-level data used	No
10.1007/s40258-016-0271-0	study_information	NA	3	Clinical Trial	Yes
10.1007/s40258-016-0271-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00424047
10.1007/s40258-016-0271-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40258-016-0271-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40258-016-0271-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-013-0102-x	general_information	NA	NA	Medical Condition of Interest Name	attention-deficit/hyperactivity disorder in children and adolescents
10.1007/s40263-013-0102-x	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s40263-013-0102-x	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40263-013-0102-x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-013-0102-x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40263-013-0102-x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40263-013-0102-x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40263-013-0102-x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 1	guanfacine extended release
10.1007/s40263-013-0102-x	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s40263-013-0102-x	methodology	1	NA	Treatment name 2	atomoxetine
10.1007/s40263-013-0102-x	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1007/s40263-013-0102-x	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40263-013-0102-x	methodology	1	NA	Anchored comparison?	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40263-013-0102-x	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	the mean change from baseline in the adhd-rs-iv total score at the final on-treatment assessment prior to down-titration
10.1007/s40263-013-0102-x	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s40263-013-0102-x	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s40263-013-0102-x	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40263-013-0102-x	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40263-013-0102-x	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40263-013-0102-x	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	84
10.1007/s40263-013-0102-x	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	82
10.1007/s40263-013-0102-x	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40263-013-0102-x	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40263-013-0102-x	results	1	NA	Number of covariates adjusted for/matched on	8
10.1007/s40263-013-0102-x	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s40263-013-0102-x	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s40263-013-0102-x	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40263-013-0102-x	results	1	NA	Primary outcome: unadjusted treatment effect	-9.2
10.1007/s40263-013-0102-x	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.01
10.1007/s40263-013-0102-x	results	1	NA	Primary outcome: adjusted treatment effect	-7
10.1007/s40263-013-0102-x	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.01
10.1007/s40263-013-0102-x	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	83
10.1007/s40263-013-0102-x	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	136
10.1007/s40263-013-0102-x	results	1	NA	geographical region	No
10.1007/s40263-013-0102-x	results	1	NA	lb_ci	NA
10.1007/s40263-013-0102-x	results	1	NA	ub_ci	NA
10.1007/s40263-013-0102-x	results	1	NA	pval	<0.01
10.1007/s40263-013-0102-x	results	1	NA	num_pval	NA
10.1007/s40263-013-0102-x	results	1	NA	ci_cutoff	0
10.1007/s40263-013-0102-x	results	1	NA	significant	TRUE
10.1007/s40263-013-0102-x	results	1	NA	lb_ci	NA
10.1007/s40263-013-0102-x	results	1	NA	ub_ci	NA
10.1007/s40263-013-0102-x	results	1	NA	pval	<0.01
10.1007/s40263-013-0102-x	results	1	NA	num_pval	NA
10.1007/s40263-013-0102-x	results	1	NA	ci_cutoff	0
10.1007/s40263-013-0102-x	results	1	NA	significant	TRUE
10.1007/s40263-013-0102-x	study_information	NA	1	Patient-level data used	Yes
10.1007/s40263-013-0102-x	study_information	NA	1	Clinical Trial	Yes
10.1007/s40263-013-0102-x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00152009
10.1007/s40263-013-0102-x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-013-0102-x	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-013-0102-x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1007/s40263-013-0102-x	study_information	NA	2	Patient-level data used	Yes
10.1007/s40263-013-0102-x	study_information	NA	2	Clinical Trial	Yes
10.1007/s40263-013-0102-x	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00150618
10.1007/s40263-013-0102-x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-013-0102-x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-013-0102-x	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	sallee et al. (2009)
10.1007/s40263-013-0102-x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-013-0102-x	study_information	NA	3	Patient-level data used	No
10.1007/s40263-013-0102-x	study_information	NA	3	Clinical Trial	Yes
10.1007/s40263-013-0102-x	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	spencer et al. (2002)
10.1007/s40263-013-0102-x	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	general_information	NA	NA	Medical Condition of Interest Name	postpartum depression
10.1007/s40263-019-00672-w	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s40263-019-00672-w	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40263-019-00672-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-019-00672-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40263-019-00672-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40263-019-00672-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40263-019-00672-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 1	brexanolone
10.1007/s40263-019-00672-w	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1007/s40263-019-00672-w	methodology	1	NA	Treatment name 2	placebo
10.1007/s40263-019-00672-w	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.1007/s40263-019-00672-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40263-019-00672-w	methodology	1	NA	Anchored comparison?	No
10.1007/s40263-019-00672-w	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40263-019-00672-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40263-019-00672-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline for the hamilton rating scale for depression
10.1007/s40263-019-00672-w	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s40263-019-00672-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s40263-019-00672-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40263-019-00672-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40263-019-00672-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40263-019-00672-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40263-019-00672-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	30
10.1007/s40263-019-00672-w	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	63.2
10.1007/s40263-019-00672-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40263-019-00672-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40263-019-00672-w	results	1	NA	Number of covariates adjusted for/matched on	3
10.1007/s40263-019-00672-w	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Past treatments for the disease of interest
10.1007/s40263-019-00672-w	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s40263-019-00672-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40263-019-00672-w	results	1	NA	Primary outcome: unadjusted treatment effect	3.8
10.1007/s40263-019-00672-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.86;5.74]
10.1007/s40263-019-00672-w	results	1	NA	Primary outcome: adjusted treatment effect	13.9
10.1007/s40263-019-00672-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[9.84;17.10]
10.1007/s40263-019-00672-w	results	1	NA	lb_ci	1.86
10.1007/s40263-019-00672-w	results	1	NA	ub_ci	5.74
10.1007/s40263-019-00672-w	results	1	NA	pval	NA
10.1007/s40263-019-00672-w	results	1	NA	num_pval	NA
10.1007/s40263-019-00672-w	results	1	NA	ci_cutoff	0
10.1007/s40263-019-00672-w	results	1	NA	significant	FALSE
10.1007/s40263-019-00672-w	results	1	NA	lb_ci	9.84
10.1007/s40263-019-00672-w	results	1	NA	ub_ci	17.1
10.1007/s40263-019-00672-w	results	1	NA	pval	NA
10.1007/s40263-019-00672-w	results	1	NA	num_pval	NA
10.1007/s40263-019-00672-w	results	1	NA	ci_cutoff	0
10.1007/s40263-019-00672-w	results	1	NA	significant	FALSE
10.1007/s40263-019-00672-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s40263-019-00672-w	study_information	NA	1	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614547
10.1007/s40263-019-00672-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1007/s40263-019-00672-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	study_information	NA	2	Patient-level data used	Yes
10.1007/s40263-019-00672-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02942004
10.1007/s40263-019-00672-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-019-00672-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	study_information	NA	3	Patient-level data used	Yes
10.1007/s40263-019-00672-w	study_information	NA	3	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02942017
10.1007/s40263-019-00672-w	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-019-00672-w	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-019-00672-w	study_information	NA	4	Patient-level data used	No
10.1007/s40263-019-00672-w	study_information	NA	4	Clinical Trial	Yes
10.1007/s40263-019-00672-w	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	yonkers et al. (2008)
10.1007/s40263-019-00672-w	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40263-019-00672-w	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	general_information	NA	NA	Medical Condition of Interest Name	relapsing-remitting multiple sclerosis
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s40263-021-00805-0	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40263-021-00805-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-021-00805-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40263-021-00805-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40263-021-00805-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40263-021-00805-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 1	ozanimod
10.1007/s40263-021-00805-0	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1007/s40263-021-00805-0	methodology	1	NA	Treatment name 2	dimethyl fumarate
10.1007/s40263-021-00805-0	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1007/s40263-021-00805-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40263-021-00805-0	methodology	1	NA	Anchored comparison?	No
10.1007/s40263-021-00805-0	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40263-021-00805-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40263-021-00805-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate
10.1007/s40263-021-00805-0	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1007/s40263-021-00805-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40263-021-00805-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40263-021-00805-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	769
10.1007/s40263-021-00805-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	880
10.1007/s40263-021-00805-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	744
10.1007/s40263-021-00805-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1007/s40263-021-00805-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40263-021-00805-0	results	1	NA	Number of covariates adjusted for/matched on	7
10.1007/s40263-021-00805-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s40263-021-00805-0	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1007/s40263-021-00805-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40263-021-00805-0	results	1	NA	Primary outcome: adjusted treatment effect	0.8
10.1007/s40263-021-00805-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.67;0.97]
10.1007/s40263-021-00805-0	results	1	NA	lb_ci	0.67
10.1007/s40263-021-00805-0	results	1	NA	ub_ci	0.97
10.1007/s40263-021-00805-0	results	1	NA	pval	NA
10.1007/s40263-021-00805-0	results	1	NA	num_pval	NA
10.1007/s40263-021-00805-0	results	1	NA	ci_cutoff	1
10.1007/s40263-021-00805-0	results	1	NA	significant	FALSE
10.1007/s40263-021-00805-0	study_information	NA	1	Patient-level data used	Yes
10.1007/s40263-021-00805-0	study_information	NA	1	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058
10.1007/s40263-021-00805-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	study_information	NA	2	Patient-level data used	Yes
10.1007/s40263-021-00805-0	study_information	NA	2	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734
10.1007/s40263-021-00805-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	study_information	NA	3	Patient-level data used	No
10.1007/s40263-021-00805-0	study_information	NA	3	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.1007/s40263-021-00805-0	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40263-021-00805-0	study_information	NA	4	Patient-level data used	No
10.1007/s40263-021-00805-0	study_information	NA	4	Clinical Trial	Yes
10.1007/s40263-021-00805-0	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.1007/s40263-021-00805-0	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40263-021-00805-0	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1007/s40263-021-00805-0	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40273-021-01015-8	general_information	NA	NA	Medical Condition of Interest Name	anaplastic lymphoma kinase (alk)-positive non-small-cell lung cancer
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of first author affiliations	sweden
10.1007/s40273-021-01015-8	general_information	NA	NA	Countries of last author affiliations	uk
10.1007/s40273-021-01015-8	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40273-021-01015-8	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40273-021-01015-8	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40273-021-01015-8	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40273-021-01015-8	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 1	lorlatinib
10.1007/s40273-021-01015-8	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40273-021-01015-8	methodology	1	NA	Treatment name 2	pemetrexed or docetaxel
10.1007/s40273-021-01015-8	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40273-021-01015-8	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40273-021-01015-8	methodology	1	NA	Anchored comparison?	No
10.1007/s40273-021-01015-8	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40273-021-01015-8	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40273-021-01015-8	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1007/s40273-021-01015-8	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1007/s40273-021-01015-8	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40273-021-01015-8	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40273-021-01015-8	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 1	lorlatinib
10.1007/s40273-021-01015-8	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s40273-021-01015-8	methodology	2	NA	Treatment name 2	systemic therapy
10.1007/s40273-021-01015-8	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40273-021-01015-8	methodology	2	NA	Anchored comparison?	No
10.1007/s40273-021-01015-8	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40273-021-01015-8	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1007/s40273-021-01015-8	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1007/s40273-021-01015-8	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1007/s40273-021-01015-8	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1007/s40273-021-01015-8	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40273-021-01015-8	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40273-021-01015-8	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40273-021-01015-8	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40273-021-01015-8	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	151
10.1007/s40273-021-01015-8	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	59
10.1007/s40273-021-01015-8	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53.4
10.1007/s40273-021-01015-8	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40273-021-01015-8	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40273-021-01015-8	results	1	NA	Number of covariates adjusted for/matched on	4
10.1007/s40273-021-01015-8	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1007/s40273-021-01015-8	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1007/s40273-021-01015-8	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40273-021-01015-8	results	1	NA	Primary outcome: adjusted treatment effect	0.224
10.1007/s40273-021-01015-8	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.154;0.312]
10.1007/s40273-021-01015-8	results	1	NA	lb_ci	0.154
10.1007/s40273-021-01015-8	results	1	NA	ub_ci	0.312
10.1007/s40273-021-01015-8	results	1	NA	pval	NA
10.1007/s40273-021-01015-8	results	1	NA	num_pval	NA
10.1007/s40273-021-01015-8	results	1	NA	ci_cutoff	1
10.1007/s40273-021-01015-8	results	1	NA	significant	FALSE
10.1007/s40273-021-01015-8	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	37
10.1007/s40273-021-01015-8	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	59
10.1007/s40273-021-01015-8	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24.5
10.1007/s40273-021-01015-8	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40273-021-01015-8	results	2	NA	Number of covariates adjusted for/matched on	4
10.1007/s40273-021-01015-8	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1007/s40273-021-01015-8	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1007/s40273-021-01015-8	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40273-021-01015-8	results	2	NA	Primary outcome: adjusted treatment effect	0.159
10.1007/s40273-021-01015-8	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.052;0.356]
10.1007/s40273-021-01015-8	results	2	NA	lb_ci	0.052
10.1007/s40273-021-01015-8	results	2	NA	ub_ci	0.356
10.1007/s40273-021-01015-8	results	2	NA	pval	NA
10.1007/s40273-021-01015-8	results	2	NA	num_pval	NA
10.1007/s40273-021-01015-8	results	2	NA	ci_cutoff	1
10.1007/s40273-021-01015-8	results	2	NA	significant	FALSE
10.1007/s40273-021-01015-8	study_information	NA	1	Patient-level data used	Yes
10.1007/s40273-021-01015-8	study_information	NA	1	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01970865
10.1007/s40273-021-01015-8	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1007/s40273-021-01015-8	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1007/s40273-021-01015-8	study_information	NA	2	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	2	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02604342
10.1007/s40273-021-01015-8	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40273-021-01015-8	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40273-021-01015-8	study_information	NA	3	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	3	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828112
10.1007/s40273-021-01015-8	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40273-021-01015-8	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40273-021-01015-8	study_information	NA	4	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	4	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.1007/s40273-021-01015-8	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1
10.1007/s40273-021-01015-8	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1007/s40273-021-01015-8	study_information	NA	5	Patient-level data used	No
10.1007/s40273-021-01015-8	study_information	NA	5	Clinical Trial	Yes
10.1007/s40273-021-01015-8	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451
10.1007/s40273-021-01015-8	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40273-021-01015-8	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1007/s40273-021-01015-8	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1007/s40744-017-0070-6	general_information	NA	NA	Medical Condition of Interest Name	active psoriatic arthritis
10.1007/s40744-017-0070-6	general_information	NA	NA	Countries of first author affiliations	usa
10.1007/s40744-017-0070-6	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40744-017-0070-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-017-0070-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40744-017-0070-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40744-017-0070-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40744-017-0070-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 1	adalimumab
10.1007/s40744-017-0070-6	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-017-0070-6	methodology	1	NA	Treatment name 2	secukinumab 150 mg
10.1007/s40744-017-0070-6	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40744-017-0070-6	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-017-0070-6	methodology	1	NA	Anchored comparison?	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40744-017-0070-6	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-017-0070-6	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	response rates for acr 20 (american college of rheumatology) at week 24
10.1007/s40744-017-0070-6	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-017-0070-6	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-017-0070-6	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40744-017-0070-6	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 1	adalimumab
10.1007/s40744-017-0070-6	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-017-0070-6	methodology	2	NA	Treatment name 2	secukinumab 300 mg
10.1007/s40744-017-0070-6	methodology	2	NA	Study 'number(s)' for treatment 2	2;3
10.1007/s40744-017-0070-6	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-017-0070-6	methodology	2	NA	Anchored comparison?	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40744-017-0070-6	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-017-0070-6	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	response rates for acr 20 (american college of rheumatology) at week 24
10.1007/s40744-017-0070-6	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-017-0070-6	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-017-0070-6	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40744-017-0070-6	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-017-0070-6	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	302
10.1007/s40744-017-0070-6	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	300
10.1007/s40744-017-0070-6	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	134
10.1007/s40744-017-0070-6	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	49
10.1007/s40744-017-0070-6	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	147
10.1007/s40744-017-0070-6	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	79
10.1007/s40744-017-0070-6	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-017-0070-6	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-017-0070-6	results	1	NA	Number of covariates adjusted for/matched on	10
10.1007/s40744-017-0070-6	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-017-0070-6	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1007/s40744-017-0070-6	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-017-0070-6	results	1	NA	Primary outcome: adjusted treatment effect	9.50
10.1007/s40744-017-0070-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.176
10.1007/s40744-017-0070-6	results	1	NA	geographical region	No
10.1007/s40744-017-0070-6	results	1	NA	lb_ci	NA
10.1007/s40744-017-0070-6	results	1	NA	ub_ci	NA
10.1007/s40744-017-0070-6	results	1	NA	pval	0.176
10.1007/s40744-017-0070-6	results	1	NA	num_pval	0.176
10.1007/s40744-017-0070-6	results	1	NA	ci_cutoff	0
10.1007/s40744-017-0070-6	results	1	NA	significant	FALSE
10.1007/s40744-017-0070-6	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	100
10.1007/s40744-017-0070-6	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	300
10.1007/s40744-017-0070-6	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	134
10.1007/s40744-017-0070-6	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	76
10.1007/s40744-017-0070-6	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	147
10.1007/s40744-017-0070-6	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	79
10.1007/s40744-017-0070-6	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-017-0070-6	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-017-0070-6	results	2	NA	Number of covariates adjusted for/matched on	10
10.1007/s40744-017-0070-6	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-017-0070-6	results	2	NA	Primary outcome: treatment effect contrast	Rate difference
10.1007/s40744-017-0070-6	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-017-0070-6	results	2	NA	Primary outcome: adjusted treatment effect	5.30
10.1007/s40744-017-0070-6	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.507
10.1007/s40744-017-0070-6	results	2	NA	geographical region	No
10.1007/s40744-017-0070-6	results	2	NA	lb_ci	NA
10.1007/s40744-017-0070-6	results	2	NA	ub_ci	NA
10.1007/s40744-017-0070-6	results	2	NA	pval	0.507
10.1007/s40744-017-0070-6	results	2	NA	num_pval	0.507
10.1007/s40744-017-0070-6	results	2	NA	ci_cutoff	0
10.1007/s40744-017-0070-6	results	2	NA	significant	FALSE
10.1007/s40744-017-0070-6	study_information	NA	1	Patient-level data used	Yes
10.1007/s40744-017-0070-6	study_information	NA	1	Clinical Trial	Yes
10.1007/s40744-017-0070-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689
10.1007/s40744-017-0070-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40744-017-0070-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-017-0070-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-017-0070-6	study_information	NA	2	Patient-level data used	No
10.1007/s40744-017-0070-6	study_information	NA	2	Clinical Trial	Yes
10.1007/s40744-017-0070-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01392326
10.1007/s40744-017-0070-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-017-0070-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-017-0070-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-017-0070-6	study_information	NA	3	Patient-level data used	No
10.1007/s40744-017-0070-6	study_information	NA	3	Clinical Trial	Yes
10.1007/s40744-017-0070-6	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.1007/s40744-017-0070-6	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-017-0070-6	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-017-0070-6	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-018-0106-6	general_information	NA	NA	Medical Condition of Interest Name	active psoriatic arthritis
10.1007/s40744-018-0106-6	general_information	NA	NA	Countries of first author affiliations	australia
10.1007/s40744-018-0106-6	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1007/s40744-018-0106-6	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-018-0106-6	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40744-018-0106-6	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40744-018-0106-6	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40744-018-0106-6	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 1	secukinumab 150 mg
10.1007/s40744-018-0106-6	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	1	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-018-0106-6	methodology	1	NA	Anchored comparison?	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 response rate at week 12
10.1007/s40744-018-0106-6	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 1	secukinumab 300 mg
10.1007/s40744-018-0106-6	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	2	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-018-0106-6	methodology	2	NA	Anchored comparison?	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 response rate at week 12
10.1007/s40744-018-0106-6	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 1	secukinumab 150 mg
10.1007/s40744-018-0106-6	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	3	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-018-0106-6	methodology	3	NA	Anchored comparison?	No
10.1007/s40744-018-0106-6	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 response rate at week 16
10.1007/s40744-018-0106-6	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 1	secukinumab 300 mg
10.1007/s40744-018-0106-6	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-018-0106-6	methodology	4	NA	Treatment name 2	adalimumab
10.1007/s40744-018-0106-6	methodology	4	NA	Study 'number(s)' for treatment 2	2
10.1007/s40744-018-0106-6	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-018-0106-6	methodology	4	NA	Anchored comparison?	No
10.1007/s40744-018-0106-6	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 response rate at week 16
10.1007/s40744-018-0106-6	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-018-0106-6	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	151
10.1007/s40744-018-0106-6	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	162
10.1007/s40744-018-0106-6	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	100
10.1007/s40744-018-0106-6	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36
10.1007/s40744-018-0106-6	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	98
10.1007/s40744-018-0106-6	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	27
10.1007/s40744-018-0106-6	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-018-0106-6	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-018-0106-6	results	1	NA	Number of covariates adjusted for/matched on	11
10.1007/s40744-018-0106-6	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1007/s40744-018-0106-6	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	1	NA	Primary outcome: adjusted treatment effect	0.69
10.1007/s40744-018-0106-6	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.34;1.43]
10.1007/s40744-018-0106-6	results	1	NA	geographical region	No
10.1007/s40744-018-0106-6	results	1	NA	lb_ci	0.34
10.1007/s40744-018-0106-6	results	1	NA	ub_ci	1.43
10.1007/s40744-018-0106-6	results	1	NA	pval	NA
10.1007/s40744-018-0106-6	results	1	NA	num_pval	NA
10.1007/s40744-018-0106-6	results	1	NA	ci_cutoff	1
10.1007/s40744-018-0106-6	results	1	NA	significant	TRUE
10.1007/s40744-018-0106-6	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	151
10.1007/s40744-018-0106-6	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	162
10.1007/s40744-018-0106-6	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	100
10.1007/s40744-018-0106-6	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	38
10.1007/s40744-018-0106-6	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	98
10.1007/s40744-018-0106-6	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	27
10.1007/s40744-018-0106-6	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-018-0106-6	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-018-0106-6	results	2	NA	Number of covariates adjusted for/matched on	11
10.1007/s40744-018-0106-6	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	2	NA	Primary outcome: treatment effect contrast	RR
10.1007/s40744-018-0106-6	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	2	NA	Primary outcome: adjusted treatment effect	0.61
10.1007/s40744-018-0106-6	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.29;1.27]
10.1007/s40744-018-0106-6	results	2	NA	geographical region	No
10.1007/s40744-018-0106-6	results	2	NA	lb_ci	0.29
10.1007/s40744-018-0106-6	results	2	NA	ub_ci	1.27
10.1007/s40744-018-0106-6	results	2	NA	pval	NA
10.1007/s40744-018-0106-6	results	2	NA	num_pval	NA
10.1007/s40744-018-0106-6	results	2	NA	ci_cutoff	1
10.1007/s40744-018-0106-6	results	2	NA	significant	TRUE
10.1007/s40744-018-0106-6	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	151
10.1007/s40744-018-0106-6	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	100
10.1007/s40744-018-0106-6	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36
10.1007/s40744-018-0106-6	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-018-0106-6	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-018-0106-6	results	3	NA	Number of covariates adjusted for/matched on	11
10.1007/s40744-018-0106-6	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	3	NA	Primary outcome: treatment effect contrast	RR
10.1007/s40744-018-0106-6	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	3	NA	Primary outcome: adjusted treatment effect	1.34
10.1007/s40744-018-0106-6	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.05;1.70]
10.1007/s40744-018-0106-6	results	3	NA	geographical region	No
10.1007/s40744-018-0106-6	results	3	NA	lb_ci	1.05
10.1007/s40744-018-0106-6	results	3	NA	ub_ci	1.7
10.1007/s40744-018-0106-6	results	3	NA	pval	NA
10.1007/s40744-018-0106-6	results	3	NA	num_pval	NA
10.1007/s40744-018-0106-6	results	3	NA	ci_cutoff	1
10.1007/s40744-018-0106-6	results	3	NA	significant	FALSE
10.1007/s40744-018-0106-6	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	151
10.1007/s40744-018-0106-6	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	100
10.1007/s40744-018-0106-6	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	38
10.1007/s40744-018-0106-6	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-018-0106-6	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-018-0106-6	results	4	NA	Primary outcome: treatment effect contrast	RR
10.1007/s40744-018-0106-6	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	4	NA	Primary outcome: adjusted treatment effect	1.18
10.1007/s40744-018-0106-6	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.90;1.54]
10.1007/s40744-018-0106-6	results	4	NA	lb_ci	0.9
10.1007/s40744-018-0106-6	results	4	NA	ub_ci	1.54
10.1007/s40744-018-0106-6	results	4	NA	pval	NA
10.1007/s40744-018-0106-6	results	4	NA	num_pval	NA
10.1007/s40744-018-0106-6	results	4	NA	ci_cutoff	1
10.1007/s40744-018-0106-6	results	4	NA	significant	TRUE
10.1007/s40744-018-0106-6	study_information	NA	1	Patient-level data used	Yes
10.1007/s40744-018-0106-6	study_information	NA	1	Clinical Trial	Yes
10.1007/s40744-018-0106-6	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.1007/s40744-018-0106-6	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-018-0106-6	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-018-0106-6	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-018-0106-6	study_information	NA	2	Patient-level data used	No
10.1007/s40744-018-0106-6	study_information	NA	2	Clinical Trial	Yes
10.1007/s40744-018-0106-6	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689
10.1007/s40744-018-0106-6	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1007/s40744-018-0106-6	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-018-0106-6	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe rheumatoid arthritis
10.1007/s40744-020-00257-w	general_information	NA	NA	Countries of first author affiliations	uk
10.1007/s40744-020-00257-w	general_information	NA	NA	Countries of last author affiliations	usa
10.1007/s40744-020-00257-w	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-020-00257-w	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1007/s40744-020-00257-w	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1007/s40744-020-00257-w	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1007/s40744-020-00257-w	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 1	upadacitinib monotherapy
10.1007/s40744-020-00257-w	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1007/s40744-020-00257-w	methodology	1	NA	Treatment name 2	tofacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1007/s40744-020-00257-w	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-020-00257-w	methodology	1	NA	Anchored comparison?	Yes
10.1007/s40744-020-00257-w	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-020-00257-w	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-020-00257-w	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	proportions of patients achieving 70 improvement in the acr criteria (acr70) at month 3
10.1007/s40744-020-00257-w	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-020-00257-w	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-020-00257-w	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40744-020-00257-w	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40744-020-00257-w	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40744-020-00257-w	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 1	upadacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	2	NA	Study 'number(s)' for treatment 1	2
10.1007/s40744-020-00257-w	methodology	2	NA	Treatment name 2	tofacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1007/s40744-020-00257-w	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1007/s40744-020-00257-w	methodology	2	NA	Anchored comparison?	Yes
10.1007/s40744-020-00257-w	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-020-00257-w	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-020-00257-w	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	proportions of patients achieving 50 improvement in the acr criteria (acr50)at month 3,
10.1007/s40744-020-00257-w	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1007/s40744-020-00257-w	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-020-00257-w	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40744-020-00257-w	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40744-020-00257-w	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1007/s40744-020-00257-w	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1007/s40744-020-00257-w	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	204
10.1007/s40744-020-00257-w	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	108
10.1007/s40744-020-00257-w	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	217
10.1007/s40744-020-00257-w	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	173
10.1007/s40744-020-00257-w	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	216
10.1007/s40744-020-00257-w	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	158
10.1007/s40744-020-00257-w	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-020-00257-w	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-020-00257-w	results	1	NA	Number of covariates adjusted for/matched on	7
10.1007/s40744-020-00257-w	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1007/s40744-020-00257-w	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s40744-020-00257-w	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-020-00257-w	results	1	NA	Primary outcome: unadjusted treatment effect	9.60
10.1007/s40744-020-00257-w	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.018
10.1007/s40744-020-00257-w	results	1	NA	Primary outcome: adjusted treatment effect	9.90
10.1007/s40744-020-00257-w	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.019
10.1007/s40744-020-00257-w	results	1	NA	lb_ci	NA
10.1007/s40744-020-00257-w	results	1	NA	ub_ci	NA
10.1007/s40744-020-00257-w	results	1	NA	pval	0.018
10.1007/s40744-020-00257-w	results	1	NA	num_pval	0.018
10.1007/s40744-020-00257-w	results	1	NA	ci_cutoff	0
10.1007/s40744-020-00257-w	results	1	NA	significant	TRUE
10.1007/s40744-020-00257-w	results	1	NA	lb_ci	NA
10.1007/s40744-020-00257-w	results	1	NA	ub_ci	NA
10.1007/s40744-020-00257-w	results	1	NA	pval	0.019
10.1007/s40744-020-00257-w	results	1	NA	num_pval	0.019
10.1007/s40744-020-00257-w	results	1	NA	ci_cutoff	0
10.1007/s40744-020-00257-w	results	1	NA	significant	TRUE
10.1007/s40744-020-00257-w	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	376
10.1007/s40744-020-00257-w	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	386
10.1007/s40744-020-00257-w	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	647
10.1007/s40744-020-00257-w	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	480
10.1007/s40744-020-00257-w	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	324
10.1007/s40744-020-00257-w	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	228
10.1007/s40744-020-00257-w	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1007/s40744-020-00257-w	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1007/s40744-020-00257-w	results	2	NA	Number of covariates adjusted for/matched on	7
10.1007/s40744-020-00257-w	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1007/s40744-020-00257-w	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1007/s40744-020-00257-w	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1007/s40744-020-00257-w	results	2	NA	Primary outcome: unadjusted treatment effect	12.70
10.1007/s40744-020-00257-w	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.008
10.1007/s40744-020-00257-w	results	2	NA	Primary outcome: adjusted treatment effect	12.90
10.1007/s40744-020-00257-w	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.011
10.1007/s40744-020-00257-w	results	2	NA	lb_ci	NA
10.1007/s40744-020-00257-w	results	2	NA	ub_ci	NA
10.1007/s40744-020-00257-w	results	2	NA	pval	0.008
10.1007/s40744-020-00257-w	results	2	NA	num_pval	0.008
10.1007/s40744-020-00257-w	results	2	NA	ci_cutoff	0
10.1007/s40744-020-00257-w	results	2	NA	significant	TRUE
10.1007/s40744-020-00257-w	results	2	NA	lb_ci	NA
10.1007/s40744-020-00257-w	results	2	NA	ub_ci	NA
10.1007/s40744-020-00257-w	results	2	NA	pval	0.011
10.1007/s40744-020-00257-w	results	2	NA	num_pval	0.011
10.1007/s40744-020-00257-w	results	2	NA	ci_cutoff	0
10.1007/s40744-020-00257-w	results	2	NA	significant	TRUE
10.1007/s40744-020-00257-w	study_information	NA	1	Patient-level data used	Yes
10.1007/s40744-020-00257-w	study_information	NA	1	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02706951
10.1007/s40744-020-00257-w	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-020-00257-w	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	study_information	NA	2	Patient-level data used	Yes
10.1007/s40744-020-00257-w	study_information	NA	2	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02629159
10.1007/s40744-020-00257-w	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-020-00257-w	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	study_information	NA	3	Patient-level data used	No
10.1007/s40744-020-00257-w	study_information	NA	3	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00853385
10.1007/s40744-020-00257-w	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1007/s40744-020-00257-w	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1007/s40744-020-00257-w	study_information	NA	4	Patient-level data used	No
10.1007/s40744-020-00257-w	study_information	NA	4	Clinical Trial	Yes
10.1007/s40744-020-00257-w	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02187055
10.1007/s40744-020-00257-w	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1007/s40744-020-00257-w	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3, 4
10.1007/s40744-020-00257-w	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory large b cell lymphoma
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 1	axicabtagene ciloleucel
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Treatment name 2	tisagenlecleucel
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Anchored comparison?	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	Overall Survival
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.bbmt.2020.06.008	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	115
10.1016/j.bbmt.2020.06.008	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	101
10.1016/j.bbmt.2020.06.008	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	39.59
10.1016/j.bbmt.2020.06.008	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.bbmt.2020.06.008	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.bbmt.2020.06.008	results	1	NA	Number of covariates adjusted for/matched on	7
10.1016/j.bbmt.2020.06.008	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.bbmt.2020.06.008	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.bbmt.2020.06.008	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.bbmt.2020.06.008	results	1	NA	Primary outcome: unadjusted treatment effect	0.68
10.1016/j.bbmt.2020.06.008	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.47;0.98]
10.1016/j.bbmt.2020.06.008	results	1	NA	Primary outcome: adjusted treatment effect	0.51
10.1016/j.bbmt.2020.06.008	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.31;0.83]
10.1016/j.bbmt.2020.06.008	results	1	NA	lb_ci	0.47
10.1016/j.bbmt.2020.06.008	results	1	NA	ub_ci	0.98
10.1016/j.bbmt.2020.06.008	results	1	NA	pval	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	num_pval	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ci_cutoff	1
10.1016/j.bbmt.2020.06.008	results	1	NA	significant	FALSE
10.1016/j.bbmt.2020.06.008	results	1	NA	lb_ci	0.31
10.1016/j.bbmt.2020.06.008	results	1	NA	ub_ci	0.83
10.1016/j.bbmt.2020.06.008	results	1	NA	pval	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	num_pval	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ci_cutoff	1
10.1016/j.bbmt.2020.06.008	results	1	NA	significant	FALSE
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Patient-level data used	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Clinical Trial	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.bbmt.2020.06.008	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Patient-level data used	No
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Clinical Trial	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1016/j.bbmt.2020.06.008	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Medical Condition of Interest Name	locally advanced or metastatic urothelial carcinoma
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clgc.2020.07.006	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clgc.2020.07.006	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 1	pembrolizumab
10.1016/j.clgc.2020.07.006	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clgc.2020.07.006	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine
10.1016/j.clgc.2020.07.006	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4;5
10.1016/j.clgc.2020.07.006	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.1016/j.clgc.2020.07.006	methodology	1	NA	Anchored comparison?	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clgc.2020.07.006	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clgc.2020.07.006	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.clgc.2020.07.006	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.clgc.2020.07.006	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.clgc.2020.07.006	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clgc.2020.07.006	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clgc.2020.07.006	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clgc.2020.07.006	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.1016/j.clgc.2020.07.006	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.clgc.2020.07.006	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1016/j.clgc.2020.07.006	results	1	NA	Primary outcome: adjusted treatment effect	2.34
10.1016/j.clgc.2020.07.006	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.92;2.85]
10.1016/j.clgc.2020.07.006	results	1	NA	lb_ci	1.92
10.1016/j.clgc.2020.07.006	results	1	NA	ub_ci	2.85
10.1016/j.clgc.2020.07.006	results	1	NA	pval	NA
10.1016/j.clgc.2020.07.006	results	1	NA	num_pval	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ci_cutoff	1
10.1016/j.clgc.2020.07.006	results	1	NA	significant	FALSE
10.1016/j.clgc.2020.07.006	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424
10.1016/j.clgc.2020.07.006	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clgc.2020.07.006	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clgc.2020.07.006	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.clgc.2020.07.006	study_information	NA	2	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)
10.1016/j.clgc.2020.07.006	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.clgc.2020.07.006	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clgc.2020.07.006	study_information	NA	3	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	3	Clinical Trial	No
10.1016/j.clgc.2020.07.006	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)
10.1016/j.clgc.2020.07.006	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	spain
10.1016/j.clgc.2020.07.006	study_information	NA	4	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	4	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274
10.1016/j.clgc.2020.07.006	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clgc.2020.07.006	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2, 3
10.1016/j.clgc.2020.07.006	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clgc.2020.07.006	study_information	NA	5	Patient-level data used	No
10.1016/j.clgc.2020.07.006	study_information	NA	5	Clinical Trial	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2004)
10.1016/j.clgc.2020.07.006	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	greece
10.1016/j.clgc.2020.07.006	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clgc.2020.07.006	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Medical Condition of Interest Name	metastatic advanced renal cell carcinoma
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 1	everolimus
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Treatment name 2	axitinib
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Anchored comparison?	No
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2015.09.013	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	194
10.1016/j.clinthera.2015.09.013	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	43
10.1016/j.clinthera.2015.09.013	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43
10.1016/j.clinthera.2015.09.013	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.clinthera.2015.09.013	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2015.09.013	results	1	NA	Number of covariates adjusted for/matched on	3
10.1016/j.clinthera.2015.09.013	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00410124
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.09.013	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.09.013	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Medical Condition of Interest Name	chronic hepatitis c coinfected with hiv
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 1	daclatasvir + sofosbuvir
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Treatment name 2	sofosbuvir + ribavirin
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Anchored comparison?	No
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response at week 12 post-treatment
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2015.12.017	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2015.12.017	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	455
10.1016/j.clinthera.2015.12.017	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	91
10.1016/j.clinthera.2015.12.017	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2015.12.017	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2015.12.017	results	1	NA	Number of covariates adjusted for/matched on	11
10.1016/j.clinthera.2015.12.017	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1016/j.clinthera.2015.12.017	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2015.12.017	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2015.12.017	results	1	NA	Primary outcome: unadjusted treatment effect	0.12
10.1016/j.clinthera.2015.12.017	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	Primary outcome: adjusted treatment effect	0.15
10.1016/j.clinthera.2015.12.017	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1016/j.clinthera.2015.12.017	results	1	NA	geographical region	No
10.1016/j.clinthera.2015.12.017	results	1	NA	lb_ci	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ub_ci	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	pval	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	num_pval	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	ci_cutoff	0
10.1016/j.clinthera.2015.12.017	results	1	NA	significant	TRUE
10.1016/j.clinthera.2015.12.017	results	1	NA	lb_ci	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ub_ci	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	pval	<0.001
10.1016/j.clinthera.2015.12.017	results	1	NA	num_pval	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ci_cutoff	0
10.1016/j.clinthera.2015.12.017	results	1	NA	significant	TRUE
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032888
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.12.017	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01667731
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.12.017	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Patient-level data used	No
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Clinical Trial	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01783678
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2015.12.017	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Medical Condition of Interest Name	relapsed-refractory multiple myeloma
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 1	pomalidomide + dexamethasone
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Treatment name 2	daratumumab
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Anchored comparison?	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 1	pomalidomide + dexamethasone
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Treatment name 2	carfilzomib
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Anchored comparison?	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2017.08.010	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2017.08.010	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2017.08.010	results	1	NA	Number of covariates adjusted for/matched on	8
10.1016/j.clinthera.2017.08.010	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.clinthera.2017.08.010	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.clinthera.2017.08.010	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2017.08.010	results	1	NA	Primary outcome: adjusted treatment effect	0.945
10.1016/j.clinthera.2017.08.010	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	lb_ci	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ub_ci	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	pval	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	num_pval	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	ci_cutoff	1
10.1016/j.clinthera.2017.08.010	results	1	NA	significant	FALSE
10.1016/j.clinthera.2017.08.010	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2017.08.010	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2017.08.010	results	2	NA	Number of covariates adjusted for/matched on	8
10.1016/j.clinthera.2017.08.010	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.clinthera.2017.08.010	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.clinthera.2017.08.010	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2017.08.010	results	2	NA	Primary outcome: adjusted treatment effect	0.833
10.1016/j.clinthera.2017.08.010	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	lb_ci	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ub_ci	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	pval	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	num_pval	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	ci_cutoff	1
10.1016/j.clinthera.2017.08.010	results	2	NA	significant	FALSE
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833833
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.clinthera.2017.08.010	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2017.08.010	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Patient-level data used	No
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Clinical Trial	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00511238
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2017.08.010	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory mantle cell lymphoma
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Treatment name 2	ibrutinib
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Treatment name 2	bortezomib
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Treatment name 2	lenalidomide
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Study 'number(s)' for treatment 2	6;7
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Treatment name 2	temsirolimus
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Study 'number(s)' for treatment 2	2;8;9
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Treatment name 2	ibrutinib + rituximab
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Study 'number(s)' for treatment 2	10
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Treatment name 2	bendamustine + rituximab
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Study 'number(s)' for treatment 2	11
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 1	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Study 'number(s)' for treatment 1	1
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Treatment name 2	lenalidomide + rituximab
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Study 'number(s)' for treatment 2	12
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Anchored comparison?	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.clinthera.2019.09.012	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	370
10.1016/j.clinthera.2019.09.012	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	123
10.1016/j.clinthera.2019.09.012	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	45
10.1016/j.clinthera.2019.09.012	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	1	NA	Number of covariates adjusted for/matched on	10
10.1016/j.clinthera.2019.09.012	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	1	NA	Primary outcome: unadjusted treatment effect	10.2
10.1016/j.clinthera.2019.09.012	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	Primary outcome: adjusted treatment effect	9.3
10.1016/j.clinthera.2019.09.012	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	pval	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	1	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	1	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	pval	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	1	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	155
10.1016/j.clinthera.2019.09.012	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	124
10.1016/j.clinthera.2019.09.012	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	61
10.1016/j.clinthera.2019.09.012	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	2	NA	Number of covariates adjusted for/matched on	9
10.1016/j.clinthera.2019.09.012	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	2	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	2	NA	Primary outcome: unadjusted treatment effect	46
10.1016/j.clinthera.2019.09.012	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	Primary outcome: adjusted treatment effect	50.6
10.1016/j.clinthera.2019.09.012	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	pval	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	2	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	2	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	pval	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	2	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	304
10.1016/j.clinthera.2019.09.012	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	122
10.1016/j.clinthera.2019.09.012	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	28
10.1016/j.clinthera.2019.09.012	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	3	NA	Number of covariates adjusted for/matched on	12
10.1016/j.clinthera.2019.09.012	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	3	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	3	NA	Primary outcome: unadjusted treatment effect	39.7
10.1016/j.clinthera.2019.09.012	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	Primary outcome: adjusted treatment effect	38.1
10.1016/j.clinthera.2019.09.012	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	pval	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	3	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	3	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	pval	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	3	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	242
10.1016/j.clinthera.2019.09.012	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	123
10.1016/j.clinthera.2019.09.012	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	120
10.1016/j.clinthera.2019.09.012	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	4	NA	Number of covariates adjusted for/matched on	3
10.1016/j.clinthera.2019.09.012	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.clinthera.2019.09.012	results	4	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	4	NA	Primary outcome: unadjusted treatment effect	40.9
10.1016/j.clinthera.2019.09.012	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	Primary outcome: adjusted treatment effect	40.7
10.1016/j.clinthera.2019.09.012	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	pval	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	4	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	4	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	pval	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	4	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	50
10.1016/j.clinthera.2019.09.012	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	84
10.1016/j.clinthera.2019.09.012	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	16
10.1016/j.clinthera.2019.09.012	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	5	NA	Number of covariates adjusted for/matched on	8
10.1016/j.clinthera.2019.09.012	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	5	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	5	NA	Primary outcome: unadjusted treatment effect	-14.2
10.1016/j.clinthera.2019.09.012	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.05
10.1016/j.clinthera.2019.09.012	results	5	NA	Primary outcome: adjusted treatment effect	-10.6
10.1016/j.clinthera.2019.09.012	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	pval	<0.05
10.1016/j.clinthera.2019.09.012	results	5	NA	num_pval	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	5	NA	significant	TRUE
10.1016/j.clinthera.2019.09.012	results	5	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	pval	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	num_pval	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	5	NA	significant	FALSE
10.1016/j.clinthera.2019.09.012	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	45
10.1016/j.clinthera.2019.09.012	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	121
10.1016/j.clinthera.2019.09.012	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56
10.1016/j.clinthera.2019.09.012	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	6	NA	Number of covariates adjusted for/matched on	5
10.1016/j.clinthera.2019.09.012	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.clinthera.2019.09.012	results	6	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	6	NA	Primary outcome: unadjusted treatment effect	-7
10.1016/j.clinthera.2019.09.012	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	Primary outcome: adjusted treatment effect	-9.8
10.1016/j.clinthera.2019.09.012	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	pval	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	num_pval	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	6	NA	significant	FALSE
10.1016/j.clinthera.2019.09.012	results	6	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	pval	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	num_pval	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	6	NA	significant	FALSE
10.1016/j.clinthera.2019.09.012	results	7	NA	Sample size of the population of interest in the non IPD treatment arm	44
10.1016/j.clinthera.2019.09.012	results	7	NA	Initial sample size of the population of interest in the IPD treatment arm	93
10.1016/j.clinthera.2019.09.012	results	7	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	64
10.1016/j.clinthera.2019.09.012	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.clinthera.2019.09.012	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.clinthera.2019.09.012	results	7	NA	Number of covariates adjusted for/matched on	7
10.1016/j.clinthera.2019.09.012	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	7	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.clinthera.2019.09.012	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	7	NA	Primary outcome: unadjusted treatment effect	16.3
10.1016/j.clinthera.2019.09.012	results	7	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	Primary outcome: adjusted treatment effect	14.1
10.1016/j.clinthera.2019.09.012	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	pval	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	num_pval	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	7	NA	significant	FALSE
10.1016/j.clinthera.2019.09.012	results	7	NA	lb_ci	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ub_ci	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	pval	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	num_pval	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	ci_cutoff	0
10.1016/j.clinthera.2019.09.012	results	7	NA	significant	FALSE
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Patient-level data used	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02213926
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01880567
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	10	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Patient-level data used	no
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Clinical Trial	yes
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Data source name (only if observational study or clinical trial without NCT)	czuczman 2015
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	11	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Patient-level data used	no
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Clinical Trial	yes
10.1016/j.clinthera.2019.09.012	study_information	NA	12	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00294632
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.clinthera.2019.09.012	study_information	NA	12	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646021
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2019.09.012	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01236391
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01599949
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	pinnacle
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00875667
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00737529
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Phase of the clinical trial (clinical trial only)	2
10.1016/j.clinthera.2019.09.012	study_information	NA	7	Number of treatment arms (clinical trial only)	1
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00117598
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1016/j.clinthera.2019.09.012	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Patient-level data used	No
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Clinical Trial	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01180049
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Phase of the clinical trial (clinical trial only)	4
10.1016/j.clinthera.2019.09.012	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable gastroenteropancreatic neuroendocrine tumours
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Countries of last author affiliations	germany
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Treatment name 2	everolimus
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Anchored comparison?	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Treatment name 2	best supportive care (bsc)
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Anchored comparison?	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Treatment name 2	sunitinib
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Anchored comparison?	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Treatment name 2	best supportive care
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Study 'number(s)' for treatment 2	4
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Anchored comparison?	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Primary outcome: variable type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Treatment name 2	everolimus
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Study 'number(s)' for treatment 2	3
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Anchored comparison?	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Primary outcome: variable type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 1	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Treatment name 2	best supportive care
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Study 'number(s)' for treatment 2	3
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Anchored comparison?	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Primary outcome: variable type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.ejcsup.2021.06.002	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	118
10.1016/j.ejcsup.2021.06.002	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	111
10.1016/j.ejcsup.2021.06.002	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	105
10.1016/j.ejcsup.2021.06.002	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.ejcsup.2021.06.002	results	1	NA	Number of covariates adjusted for/matched on	1
10.1016/j.ejcsup.2021.06.002	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.ejcsup.2021.06.002	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.ejcsup.2021.06.002	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	1	NA	Primary outcome: adjusted treatment effect	0.38
10.1016/j.ejcsup.2021.06.002	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.25;0.58]
10.1016/j.ejcsup.2021.06.002	results	1	NA	lb_ci	0.25
10.1016/j.ejcsup.2021.06.002	results	1	NA	ub_ci	0.58
10.1016/j.ejcsup.2021.06.002	results	1	NA	pval	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	num_pval	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ci_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	1	NA	significant	FALSE
10.1016/j.ejcsup.2021.06.002	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	57
10.1016/j.ejcsup.2021.06.002	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	111
10.1016/j.ejcsup.2021.06.002	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	95
10.1016/j.ejcsup.2021.06.002	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.ejcsup.2021.06.002	results	2	NA	Number of covariates adjusted for/matched on	1
10.1016/j.ejcsup.2021.06.002	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.ejcsup.2021.06.002	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.ejcsup.2021.06.002	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	2	NA	Primary outcome: adjusted treatment effect	0.35
10.1016/j.ejcsup.2021.06.002	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.21;0.59]
10.1016/j.ejcsup.2021.06.002	results	2	NA	lb_ci	0.21
10.1016/j.ejcsup.2021.06.002	results	2	NA	ub_ci	0.59
10.1016/j.ejcsup.2021.06.002	results	2	NA	pval	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	num_pval	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ci_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	2	NA	significant	FALSE
10.1016/j.ejcsup.2021.06.002	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	86
10.1016/j.ejcsup.2021.06.002	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	62
10.1016/j.ejcsup.2021.06.002	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	48
10.1016/j.ejcsup.2021.06.002	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.ejcsup.2021.06.002	results	3	NA	Number of covariates adjusted for/matched on	4
10.1016/j.ejcsup.2021.06.002	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	3	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.ejcsup.2021.06.002	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	3	NA	Primary outcome: adjusted treatment effect	0.36
10.1016/j.ejcsup.2021.06.002	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.18;0.70]
10.1016/j.ejcsup.2021.06.002	results	3	NA	lb_ci	0.18
10.1016/j.ejcsup.2021.06.002	results	3	NA	ub_ci	0.7
10.1016/j.ejcsup.2021.06.002	results	3	NA	pval	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	num_pval	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ci_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	3	NA	significant	FALSE
10.1016/j.ejcsup.2021.06.002	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	85
10.1016/j.ejcsup.2021.06.002	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	62
10.1016/j.ejcsup.2021.06.002	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	35
10.1016/j.ejcsup.2021.06.002	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.ejcsup.2021.06.002	results	4	NA	Number of covariates adjusted for/matched on	4
10.1016/j.ejcsup.2021.06.002	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	4	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.ejcsup.2021.06.002	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	4	NA	Primary outcome: adjusted treatment effect	0.13
10.1016/j.ejcsup.2021.06.002	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.08;0.22]
10.1016/j.ejcsup.2021.06.002	results	4	NA	lb_ci	0.08
10.1016/j.ejcsup.2021.06.002	results	4	NA	ub_ci	0.22
10.1016/j.ejcsup.2021.06.002	results	4	NA	pval	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	num_pval	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ci_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	4	NA	significant	FALSE
10.1016/j.ejcsup.2021.06.002	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	207
10.1016/j.ejcsup.2021.06.002	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	62
10.1016/j.ejcsup.2021.06.002	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	22
10.1016/j.ejcsup.2021.06.002	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.ejcsup.2021.06.002	results	5	NA	Number of covariates adjusted for/matched on	4
10.1016/j.ejcsup.2021.06.002	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	5	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.ejcsup.2021.06.002	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	5	NA	Primary outcome: adjusted treatment effect	0.46
10.1016/j.ejcsup.2021.06.002	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.30;0.71]
10.1016/j.ejcsup.2021.06.002	results	5	NA	lb_ci	0.3
10.1016/j.ejcsup.2021.06.002	results	5	NA	ub_ci	0.71
10.1016/j.ejcsup.2021.06.002	results	5	NA	pval	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	num_pval	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ci_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	5	NA	significant	FALSE
10.1016/j.ejcsup.2021.06.002	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	203
10.1016/j.ejcsup.2021.06.002	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	62
10.1016/j.ejcsup.2021.06.002	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	18
10.1016/j.ejcsup.2021.06.002	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.ejcsup.2021.06.002	results	6	NA	Number of covariates adjusted for/matched on	4
10.1016/j.ejcsup.2021.06.002	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	6	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.ejcsup.2021.06.002	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	6	NA	Primary outcome: adjusted treatment effect	0.21
10.1016/j.ejcsup.2021.06.002	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.13;0.32]
10.1016/j.ejcsup.2021.06.002	results	6	NA	lb_ci	0.13
10.1016/j.ejcsup.2021.06.002	results	6	NA	ub_ci	0.32
10.1016/j.ejcsup.2021.06.002	results	6	NA	pval	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	num_pval	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ci_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	6	NA	significant	FALSE
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Patient-level data used	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	erasmus study
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	the netherlands
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Patient-level data used	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01524783
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Patient-level data used	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Patient-level data used	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Clinical Trial	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Medical Condition of Interest Name	braf-mutant advanced melanoma
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.esmoop.2021.100050	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.esmoop.2021.100050	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.esmoop.2021.100050	methodology	1	NA	Treatment name 2	dabrafenib + trametinib
10.1016/j.esmoop.2021.100050	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1016/j.esmoop.2021.100050	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.esmoop.2021.100050	methodology	1	NA	Anchored comparison?	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.esmoop.2021.100050	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.esmoop.2021.100050	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.esmoop.2021.100050	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 1	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.esmoop.2021.100050	methodology	2	NA	Treatment name 2	encorafenib + binimetinib
10.1016/j.esmoop.2021.100050	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1016/j.esmoop.2021.100050	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.esmoop.2021.100050	methodology	2	NA	Anchored comparison?	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.esmoop.2021.100050	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.esmoop.2021.100050	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.esmoop.2021.100050	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 1	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1016/j.esmoop.2021.100050	methodology	3	NA	Treatment name 2	vemurafenib + cobimetinib
10.1016/j.esmoop.2021.100050	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.1016/j.esmoop.2021.100050	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.esmoop.2021.100050	methodology	3	NA	Anchored comparison?	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.esmoop.2021.100050	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.esmoop.2021.100050	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.esmoop.2021.100050	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.esmoop.2021.100050	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	563
10.1016/j.esmoop.2021.100050	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	103
10.1016/j.esmoop.2021.100050	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	91.68
10.1016/j.esmoop.2021.100050	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.esmoop.2021.100050	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.esmoop.2021.100050	results	1	NA	Number of covariates adjusted for/matched on	5
10.1016/j.esmoop.2021.100050	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.esmoop.2021.100050	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	1	NA	Primary outcome: adjusted treatment effect	0.53
10.1016/j.esmoop.2021.100050	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.39;0.73]
10.1016/j.esmoop.2021.100050	results	1	NA	lb_ci	0.39
10.1016/j.esmoop.2021.100050	results	1	NA	ub_ci	0.73
10.1016/j.esmoop.2021.100050	results	1	NA	pval	NA
10.1016/j.esmoop.2021.100050	results	1	NA	num_pval	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ci_cutoff	1
10.1016/j.esmoop.2021.100050	results	1	NA	significant	FALSE
10.1016/j.esmoop.2021.100050	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	192
10.1016/j.esmoop.2021.100050	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	103
10.1016/j.esmoop.2021.100050	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	93.81
10.1016/j.esmoop.2021.100050	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.esmoop.2021.100050	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.esmoop.2021.100050	results	2	NA	Number of covariates adjusted for/matched on	5
10.1016/j.esmoop.2021.100050	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.esmoop.2021.100050	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	2	NA	Primary outcome: adjusted treatment effect	0.6
10.1016/j.esmoop.2021.100050	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.42;0.85]
10.1016/j.esmoop.2021.100050	results	2	NA	lb_ci	0.42
10.1016/j.esmoop.2021.100050	results	2	NA	ub_ci	0.85
10.1016/j.esmoop.2021.100050	results	2	NA	pval	NA
10.1016/j.esmoop.2021.100050	results	2	NA	num_pval	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ci_cutoff	1
10.1016/j.esmoop.2021.100050	results	2	NA	significant	FALSE
10.1016/j.esmoop.2021.100050	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	247
10.1016/j.esmoop.2021.100050	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	103
10.1016/j.esmoop.2021.100050	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	91.69
10.1016/j.esmoop.2021.100050	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.esmoop.2021.100050	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.esmoop.2021.100050	results	3	NA	Number of covariates adjusted for/matched on	5
10.1016/j.esmoop.2021.100050	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	3	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.esmoop.2021.100050	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	3	NA	Primary outcome: adjusted treatment effect	0.5
10.1016/j.esmoop.2021.100050	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.36;0.70]
10.1016/j.esmoop.2021.100050	results	3	NA	lb_ci	0.36
10.1016/j.esmoop.2021.100050	results	3	NA	ub_ci	0.7
10.1016/j.esmoop.2021.100050	results	3	NA	pval	NA
10.1016/j.esmoop.2021.100050	results	3	NA	num_pval	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ci_cutoff	1
10.1016/j.esmoop.2021.100050	results	3	NA	significant	FALSE
10.1016/j.esmoop.2021.100050	study_information	NA	1	Patient-level data used	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	1	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505
10.1016/j.esmoop.2021.100050	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	2	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	2	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648
10.1016/j.esmoop.2021.100050	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	3	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	3	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908
10.1016/j.esmoop.2021.100050	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	4	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	4	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01909453
10.1016/j.esmoop.2021.100050	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	5	Patient-level data used	No
10.1016/j.esmoop.2021.100050	study_information	NA	5	Clinical Trial	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519
10.1016/j.esmoop.2021.100050	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.esmoop.2021.100050	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1016/j.esmoop.2021.100050	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.euo.2018.09.009	general_information	NA	NA	Medical Condition of Interest Name	advanced, unresectable, or metastatic urothelial cancer
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.euo.2018.09.009	general_information	NA	NA	Countries of last author affiliations	the netherlands
10.1016/j.euo.2018.09.009	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.euo.2018.09.009	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.euo.2018.09.009	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.euo.2018.09.009	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 1	pembrolizumab
10.1016/j.euo.2018.09.009	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.euo.2018.09.009	methodology	1	NA	Treatment name 2	carboplatin + gemcitabine
10.1016/j.euo.2018.09.009	methodology	1	NA	Study 'number(s)' for treatment 2	2;4;5;6
10.1016/j.euo.2018.09.009	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.1016/j.euo.2018.09.009	methodology	1	NA	Anchored comparison?	No
10.1016/j.euo.2018.09.009	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.euo.2018.09.009	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.euo.2018.09.009	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.euo.2018.09.009	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.euo.2018.09.009	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.euo.2018.09.009	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.euo.2018.09.009	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.euo.2018.09.009	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.euo.2018.09.009	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 1	pembrolizumab
10.1016/j.euo.2018.09.009	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.euo.2018.09.009	methodology	2	NA	Treatment name 2	gemcitabine
10.1016/j.euo.2018.09.009	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1016/j.euo.2018.09.009	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.1016/j.euo.2018.09.009	methodology	2	NA	Anchored comparison?	No
10.1016/j.euo.2018.09.009	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.euo.2018.09.009	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.euo.2018.09.009	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.euo.2018.09.009	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1016/j.euo.2018.09.009	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1016/j.euo.2018.09.009	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.euo.2018.09.009	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.euo.2018.09.009	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.euo.2018.09.009	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.euo.2018.09.009	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.euo.2018.09.009	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.euo.2018.09.009	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1016/j.euo.2018.09.009	results	1	NA	Primary outcome: adjusted treatment effect	2.78
10.1016/j.euo.2018.09.009	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.29;3.38]
10.1016/j.euo.2018.09.009	results	1	NA	Number of covariates adjusted for/matched on	3
10.1016/j.euo.2018.09.009	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.euo.2018.09.009	results	1	NA	lb_ci	2.29
10.1016/j.euo.2018.09.009	results	1	NA	ub_ci	3.38
10.1016/j.euo.2018.09.009	results	1	NA	pval	NA
10.1016/j.euo.2018.09.009	results	1	NA	num_pval	NA
10.1016/j.euo.2018.09.009	results	1	NA	ci_cutoff	1
10.1016/j.euo.2018.09.009	results	1	NA	significant	FALSE
10.1016/j.euo.2018.09.009	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.euo.2018.09.009	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.euo.2018.09.009	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1016/j.euo.2018.09.009	results	2	NA	Primary outcome: adjusted treatment effect	2.94
10.1016/j.euo.2018.09.009	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.42;3.57]
10.1016/j.euo.2018.09.009	results	2	NA	Number of covariates adjusted for/matched on	3
10.1016/j.euo.2018.09.009	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.euo.2018.09.009	results	2	NA	lb_ci	2.42
10.1016/j.euo.2018.09.009	results	2	NA	ub_ci	3.57
10.1016/j.euo.2018.09.009	results	2	NA	pval	NA
10.1016/j.euo.2018.09.009	results	2	NA	num_pval	NA
10.1016/j.euo.2018.09.009	results	2	NA	ci_cutoff	1
10.1016/j.euo.2018.09.009	results	2	NA	significant	FALSE
10.1016/j.euo.2018.09.009	study_information	NA	1	Patient-level data used	Yes
10.1016/j.euo.2018.09.009	study_information	NA	1	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02335424
10.1016/j.euo.2018.09.009	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.euo.2018.09.009	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1016/j.euo.2018.09.009	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.euo.2018.09.009	study_information	NA	2	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	2	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00014274
10.1016/j.euo.2018.09.009	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.euo.2018.09.009	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.1016/j.euo.2018.09.009	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.euo.2018.09.009	study_information	NA	3	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	3	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	getug v01
10.1016/j.euo.2018.09.009	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1016/j.euo.2018.09.009	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.euo.2018.09.009	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.euo.2018.09.009	study_information	NA	4	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	4	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	bamias et al. (2007)
10.1016/j.euo.2018.09.009	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	greece
10.1016/j.euo.2018.09.009	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1016/j.euo.2018.09.009	study_information	NA	5	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	5	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	carles et al. (2000)
10.1016/j.euo.2018.09.009	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	spain
10.1016/j.euo.2018.09.009	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1016/j.euo.2018.09.009	study_information	NA	6	Patient-level data used	No
10.1016/j.euo.2018.09.009	study_information	NA	6	Clinical Trial	Yes
10.1016/j.euo.2018.09.009	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	linardou et al. (2003)
10.1016/j.euo.2018.09.009	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	greece
10.1016/j.euo.2018.09.009	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2
10.1016/j.euo.2018.09.009	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Medical Condition of Interest Name	advanced or metastatic non-small cell lung cancer
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Countries of first author affiliations	singapore
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Countries of last author affiliations	canada
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.jtho.2016.05.029	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.jtho.2016.05.029	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 1	ceritinib
10.1016/j.jtho.2016.05.029	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.jtho.2016.05.029	methodology	1	NA	Treatment name 2	crizotinib
10.1016/j.jtho.2016.05.029	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5
10.1016/j.jtho.2016.05.029	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.jtho.2016.05.029	methodology	1	NA	Anchored comparison?	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.jtho.2016.05.029	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jtho.2016.05.029	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.jtho.2016.05.029	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.jtho.2016.05.029	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.jtho.2016.05.029	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.jtho.2016.05.029	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.jtho.2016.05.029	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.jtho.2016.05.029	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	557
10.1016/j.jtho.2016.05.029	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	189
10.1016/j.jtho.2016.05.029	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	143
10.1016/j.jtho.2016.05.029	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.jtho.2016.05.029	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.jtho.2016.05.029	results	1	NA	Number of covariates adjusted for/matched on	6
10.1016/j.jtho.2016.05.029	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.jtho.2016.05.029	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.jtho.2016.05.029	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.jtho.2016.05.029	results	1	NA	Primary outcome: unadjusted treatment effect	0.49
10.1016/j.jtho.2016.05.029	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.33;0.74]
10.1016/j.jtho.2016.05.029	results	1	NA	Primary outcome: adjusted treatment effect	0.59
10.1016/j.jtho.2016.05.029	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;0.75]
10.1016/j.jtho.2016.05.029	results	1	NA	lb_ci	0.33
10.1016/j.jtho.2016.05.029	results	1	NA	ub_ci	0.74
10.1016/j.jtho.2016.05.029	results	1	NA	pval	NA
10.1016/j.jtho.2016.05.029	results	1	NA	num_pval	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ci_cutoff	1
10.1016/j.jtho.2016.05.029	results	1	NA	significant	FALSE
10.1016/j.jtho.2016.05.029	results	1	NA	lb_ci	0.46
10.1016/j.jtho.2016.05.029	results	1	NA	ub_ci	0.75
10.1016/j.jtho.2016.05.029	results	1	NA	pval	NA
10.1016/j.jtho.2016.05.029	results	1	NA	num_pval	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ci_cutoff	1
10.1016/j.jtho.2016.05.029	results	1	NA	significant	FALSE
10.1016/j.jtho.2016.05.029	study_information	NA	1	Patient-level data used	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	1	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516
10.1016/j.jtho.2016.05.029	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	2	Patient-level data used	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	2	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685138
10.1016/j.jtho.2016.05.029	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1016/j.jtho.2016.05.029	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	3	Patient-level data used	No
10.1016/j.jtho.2016.05.029	study_information	NA	3	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.1016/j.jtho.2016.05.029	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	4	Patient-level data used	No
10.1016/j.jtho.2016.05.029	study_information	NA	4	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932451
10.1016/j.jtho.2016.05.029	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1016/j.jtho.2016.05.029	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1016/j.jtho.2016.05.029	study_information	NA	5	Patient-level data used	No
10.1016/j.jtho.2016.05.029	study_information	NA	5	Clinical Trial	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893
10.1016/j.jtho.2016.05.029	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jtho.2016.05.029	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1016/j.jtho.2016.05.029	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.jval.2018.03.015	general_information	NA	NA	Medical Condition of Interest Name	tremor
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of first author affiliations	uk
10.1016/j.jval.2018.03.015	general_information	NA	NA	Countries of last author affiliations	israel
10.1016/j.jval.2018.03.015	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.jval.2018.03.015	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.jval.2018.03.015	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.jval.2018.03.015	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 1	magnetic resonance-guided focused ultrasound
10.1016/j.jval.2018.03.015	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1016/j.jval.2018.03.015	methodology	1	NA	Treatment name 2	unilateral deep brain stimulation
10.1016/j.jval.2018.03.015	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1016/j.jval.2018.03.015	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.jval.2018.03.015	methodology	1	NA	Anchored comparison?	No
10.1016/j.jval.2018.03.015	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.jval.2018.03.015	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jval.2018.03.015	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	clinical rating scale for tremor part c at 1 month
10.1016/j.jval.2018.03.015	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1016/j.jval.2018.03.015	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.jval.2018.03.015	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.jval.2018.03.015	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.jval.2018.03.015	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.jval.2018.03.015	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 1	magnetic resonance-guided focused ultrasound
10.1016/j.jval.2018.03.015	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1016/j.jval.2018.03.015	methodology	2	NA	Treatment name 2	unilateral deep brain stimulation (dbs)
10.1016/j.jval.2018.03.015	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1016/j.jval.2018.03.015	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.1016/j.jval.2018.03.015	methodology	2	NA	Anchored comparison?	No
10.1016/j.jval.2018.03.015	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1016/j.jval.2018.03.015	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jval.2018.03.015	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	clinical rating scale for tremor part c at 1 month
10.1016/j.jval.2018.03.015	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1016/j.jval.2018.03.015	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.jval.2018.03.015	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.jval.2018.03.015	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.jval.2018.03.015	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1016/j.jval.2018.03.015	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.jval.2018.03.015	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	22
10.1016/j.jval.2018.03.015	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	56
10.1016/j.jval.2018.03.015	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	35.8
10.1016/j.jval.2018.03.015	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.jval.2018.03.015	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.jval.2018.03.015	results	1	NA	Number of covariates adjusted for/matched on	3
10.1016/j.jval.2018.03.015	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.jval.2018.03.015	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1016/j.jval.2018.03.015	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.jval.2018.03.015	results	1	NA	Primary outcome: unadjusted treatment effect	0.35
10.1016/j.jval.2018.03.015	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-2.17;2.87]
10.1016/j.jval.2018.03.015	results	1	NA	Primary outcome: adjusted treatment effect	1.92
10.1016/j.jval.2018.03.015	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.94;4.79]
10.1016/j.jval.2018.03.015	results	1	NA	lb_ci	-2.17
10.1016/j.jval.2018.03.015	results	1	NA	ub_ci	2.87
10.1016/j.jval.2018.03.015	results	1	NA	pval	NA
10.1016/j.jval.2018.03.015	results	1	NA	num_pval	NA
10.1016/j.jval.2018.03.015	results	1	NA	ci_cutoff	0
10.1016/j.jval.2018.03.015	results	1	NA	significant	TRUE
10.1016/j.jval.2018.03.015	results	1	NA	lb_ci	-0.94
10.1016/j.jval.2018.03.015	results	1	NA	ub_ci	4.79
10.1016/j.jval.2018.03.015	results	1	NA	pval	NA
10.1016/j.jval.2018.03.015	results	1	NA	num_pval	NA
10.1016/j.jval.2018.03.015	results	1	NA	ci_cutoff	0
10.1016/j.jval.2018.03.015	results	1	NA	significant	TRUE
10.1016/j.jval.2018.03.015	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	22
10.1016/j.jval.2018.03.015	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	56
10.1016/j.jval.2018.03.015	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	56
10.1016/j.jval.2018.03.015	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.jval.2018.03.015	results	2	NA	Number of covariates adjusted for/matched on	3
10.1016/j.jval.2018.03.015	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.jval.2018.03.015	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1016/j.jval.2018.03.015	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.jval.2018.03.015	results	2	NA	Primary outcome: unadjusted treatment effect	0.35
10.1016/j.jval.2018.03.015	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-2.17;2.87]
10.1016/j.jval.2018.03.015	results	2	NA	Primary outcome: adjusted treatment effect	1.67
10.1016/j.jval.2018.03.015	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.74;4.08]
10.1016/j.jval.2018.03.015	results	2	NA	lb_ci	-2.17
10.1016/j.jval.2018.03.015	results	2	NA	ub_ci	2.87
10.1016/j.jval.2018.03.015	results	2	NA	pval	NA
10.1016/j.jval.2018.03.015	results	2	NA	num_pval	NA
10.1016/j.jval.2018.03.015	results	2	NA	ci_cutoff	0
10.1016/j.jval.2018.03.015	results	2	NA	significant	TRUE
10.1016/j.jval.2018.03.015	results	2	NA	lb_ci	-0.74
10.1016/j.jval.2018.03.015	results	2	NA	ub_ci	4.08
10.1016/j.jval.2018.03.015	results	2	NA	pval	NA
10.1016/j.jval.2018.03.015	results	2	NA	num_pval	NA
10.1016/j.jval.2018.03.015	results	2	NA	ci_cutoff	0
10.1016/j.jval.2018.03.015	results	2	NA	significant	TRUE
10.1016/j.jval.2018.03.015	study_information	NA	1	Patient-level data used	Yes
10.1016/j.jval.2018.03.015	study_information	NA	1	Clinical Trial	Yes
10.1016/j.jval.2018.03.015	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01827904
10.1016/j.jval.2018.03.015	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.jval.2018.03.015	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.jval.2018.03.015	study_information	NA	2	Patient-level data used	No
10.1016/j.jval.2018.03.015	study_information	NA	2	Clinical Trial	No
10.1016/j.jval.2018.03.015	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	putzke et al. (2005)
10.1016/j.jval.2018.03.015	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Medical Condition of Interest Name	non-squamous non-small cell lung cancer
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 1	pembrolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Treatment name 2	atezolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Anchored comparison?	No
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.lungcan.2021.03.020	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 1	pembrolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Treatment name 2	atezolizumab + bevacizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Anchored comparison?	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.lungcan.2021.03.020	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	451
10.1016/j.lungcan.2021.03.020	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	469
10.1016/j.lungcan.2021.03.020	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	428
10.1016/j.lungcan.2021.03.020	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.lungcan.2021.03.020	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.lungcan.2021.03.020	results	1	NA	Number of covariates adjusted for/matched on	6
10.1016/j.lungcan.2021.03.020	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.1016/j.lungcan.2021.03.020	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.lungcan.2021.03.020	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.lungcan.2021.03.020	results	1	NA	Primary outcome: unadjusted treatment effect	0.8
10.1016/j.lungcan.2021.03.020	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	Primary outcome: adjusted treatment effect	0.8
10.1016/j.lungcan.2021.03.020	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	geographical region	No
10.1016/j.lungcan.2021.03.020	results	1	NA	lb_ci	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ub_ci	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	pval	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	num_pval	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	ci_cutoff	1
10.1016/j.lungcan.2021.03.020	results	1	NA	significant	TRUE
10.1016/j.lungcan.2021.03.020	results	1	NA	lb_ci	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ub_ci	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	pval	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	num_pval	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	ci_cutoff	1
10.1016/j.lungcan.2021.03.020	results	1	NA	significant	TRUE
10.1016/j.lungcan.2021.03.020	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	356
10.1016/j.lungcan.2021.03.020	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	469
10.1016/j.lungcan.2021.03.020	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	389
10.1016/j.lungcan.2021.03.020	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1016/j.lungcan.2021.03.020	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.lungcan.2021.03.020	results	2	NA	Number of covariates adjusted for/matched on	6
10.1016/j.lungcan.2021.03.020	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.1016/j.lungcan.2021.03.020	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1016/j.lungcan.2021.03.020	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.lungcan.2021.03.020	results	2	NA	Primary outcome: unadjusted treatment effect	0.84
10.1016/j.lungcan.2021.03.020	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	Primary outcome: adjusted treatment effect	0.86
10.1016/j.lungcan.2021.03.020	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	geographical region	No
10.1016/j.lungcan.2021.03.020	results	2	NA	lb_ci	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ub_ci	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	pval	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	num_pval	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	ci_cutoff	1
10.1016/j.lungcan.2021.03.020	results	2	NA	significant	TRUE
10.1016/j.lungcan.2021.03.020	results	2	NA	lb_ci	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ub_ci	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	pval	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	num_pval	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	ci_cutoff	1
10.1016/j.lungcan.2021.03.020	results	2	NA	significant	FALSE
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Patient-level data used	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02039674
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	International
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Patient-level data used	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02578680
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Patient-level data used	No
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02367781
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.lungcan.2021.03.020	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Patient-level data used	No
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Clinical Trial	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02366143
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.lungcan.2021.03.020	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of first author affiliations	usa
10.1016/j.msard.2021.102972	general_information	NA	NA	Countries of last author affiliations	usa
10.1016/j.msard.2021.102972	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.msard.2021.102972	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1016/j.msard.2021.102972	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1016/j.msard.2021.102972	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1016/j.msard.2021.102972	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 1	ozanimod
10.1016/j.msard.2021.102972	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1016/j.msard.2021.102972	methodology	1	NA	Treatment name 2	teriflunomide
10.1016/j.msard.2021.102972	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5;6;7;8
10.1016/j.msard.2021.102972	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1016/j.msard.2021.102972	methodology	1	NA	Anchored comparison?	No
10.1016/j.msard.2021.102972	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.msard.2021.102972	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.msard.2021.102972	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate
10.1016/j.msard.2021.102972	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1016/j.msard.2021.102972	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.msard.2021.102972	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1016/j.msard.2021.102972	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1016/j.msard.2021.102972	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	2290
10.1016/j.msard.2021.102972	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	880
10.1016/j.msard.2021.102972	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	663.53
10.1016/j.msard.2021.102972	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1016/j.msard.2021.102972	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1016/j.msard.2021.102972	results	1	NA	Number of covariates adjusted for/matched on	9
10.1016/j.msard.2021.102972	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1016/j.msard.2021.102972	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1016/j.msard.2021.102972	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1016/j.msard.2021.102972	results	1	NA	Primary outcome: adjusted treatment effect	0.73
10.1016/j.msard.2021.102972	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.62;0.84]
10.1016/j.msard.2021.102972	results	1	NA	geographical region	No
10.1016/j.msard.2021.102972	results	1	NA	lb_ci	0.62
10.1016/j.msard.2021.102972	results	1	NA	ub_ci	0.84
10.1016/j.msard.2021.102972	results	1	NA	pval	NA
10.1016/j.msard.2021.102972	results	1	NA	num_pval	NA
10.1016/j.msard.2021.102972	results	1	NA	ci_cutoff	0
10.1016/j.msard.2021.102972	results	1	NA	significant	FALSE
10.1016/j.msard.2021.102972	study_information	NA	1	Patient-level data used	Yes
10.1016/j.msard.2021.102972	study_information	NA	1	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734
10.1016/j.msard.2021.102972	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	2	Patient-level data used	Yes
10.1016/j.msard.2021.102972	study_information	NA	2	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058
10.1016/j.msard.2021.102972	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	3	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	3	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792218
10.1016/j.msard.2021.102972	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	4	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	4	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02792231
10.1016/j.msard.2021.102972	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	5	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	5	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00751881
10.1016/j.msard.2021.102972	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	6	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	6	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425644
10.1016/j.msard.2021.102972	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	7	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	7	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00134563
10.1016/j.msard.2021.102972	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1016/j.msard.2021.102972	study_information	NA	8	Patient-level data used	No
10.1016/j.msard.2021.102972	study_information	NA	8	Clinical Trial	Yes
10.1016/j.msard.2021.102972	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00883337
10.1016/j.msard.2021.102972	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1016/j.msard.2021.102972	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1016/j.msard.2021.102972	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	general_information	NA	NA	Medical Condition of Interest Name	multiple sclerosis
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2016.1248380	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2016.1248380	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/03007995.2016.1248380	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/03007995.2016.1248380	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2016.1248380	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2016.1248380	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 1	dimethyl fumarate
10.1080/03007995.2016.1248380	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1080/03007995.2016.1248380	methodology	1	NA	Treatment name 2	fingolimod
10.1080/03007995.2016.1248380	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1080/03007995.2016.1248380	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2016.1248380	methodology	1	NA	Anchored comparison?	Yes
10.1080/03007995.2016.1248380	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/03007995.2016.1248380	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2016.1248380	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate
10.1080/03007995.2016.1248380	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2016.1248380	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/03007995.2016.1248380	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2016.1248380	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2016.1248380	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2016.1248380	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2016.1248380	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	783
10.1080/03007995.2016.1248380	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	773
10.1080/03007995.2016.1248380	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	769
10.1080/03007995.2016.1248380	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	587
10.1080/03007995.2016.1248380	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	771
10.1080/03007995.2016.1248380	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	599
10.1080/03007995.2016.1248380	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2016.1248380	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2016.1248380	results	1	NA	Number of covariates adjusted for/matched on	6
10.1080/03007995.2016.1248380	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2016.1248380	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1080/03007995.2016.1248380	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2016.1248380	results	1	NA	Primary outcome: unadjusted treatment effect	1.07
10.1080/03007995.2016.1248380	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.5501
10.1080/03007995.2016.1248380	results	1	NA	Primary outcome: adjusted treatment effect	1.11
10.1080/03007995.2016.1248380	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.3893
10.1080/03007995.2016.1248380	results	1	NA	lb_ci	NA
10.1080/03007995.2016.1248380	results	1	NA	ub_ci	NA
10.1080/03007995.2016.1248380	results	1	NA	pval	0.5501
10.1080/03007995.2016.1248380	results	1	NA	num_pval	0.5501
10.1080/03007995.2016.1248380	results	1	NA	ci_cutoff	1
10.1080/03007995.2016.1248380	results	1	NA	significant	FALSE
10.1080/03007995.2016.1248380	results	1	NA	lb_ci	NA
10.1080/03007995.2016.1248380	results	1	NA	ub_ci	NA
10.1080/03007995.2016.1248380	results	1	NA	pval	0.3893
10.1080/03007995.2016.1248380	results	1	NA	num_pval	0.3893
10.1080/03007995.2016.1248380	results	1	NA	ci_cutoff	1
10.1080/03007995.2016.1248380	results	1	NA	significant	FALSE
10.1080/03007995.2016.1248380	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2016.1248380	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.1080/03007995.2016.1248380	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	study_information	NA	2	Patient-level data used	Yes
10.1080/03007995.2016.1248380	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.1080/03007995.2016.1248380	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2016.1248380	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978
10.1080/03007995.2016.1248380	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2016.1248380	study_information	NA	4	Patient-level data used	No
10.1080/03007995.2016.1248380	study_information	NA	4	Clinical Trial	Yes
10.1080/03007995.2016.1248380	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134
10.1080/03007995.2016.1248380	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2016.1248380	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2016.1248380	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2018.1510225	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2018.1510225	general_information	NA	NA	Countries of last author affiliations	italy
10.1080/03007995.2018.1510225	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1510225	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2018.1510225	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2018.1510225	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2018.1510225	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 1	ponatinib
10.1080/03007995.2018.1510225	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1510225	methodology	1	NA	Treatment name 2	bosutinib
10.1080/03007995.2018.1510225	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2018.1510225	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2018.1510225	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2018.1510225	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1510225	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1510225	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	cytogenetic response rate
10.1080/03007995.2018.1510225	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2018.1510225	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/03007995.2018.1510225	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2018.1510225	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2018.1510225	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2018.1510225	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2018.1510225	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	119
10.1080/03007995.2018.1510225	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	97
10.1080/03007995.2018.1510225	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70
10.1080/03007995.2018.1510225	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2018.1510225	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2018.1510225	results	1	NA	Number of covariates adjusted for/matched on	6
10.1080/03007995.2018.1510225	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/03007995.2018.1510225	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2018.1510225	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2018.1510225	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01207440
10.1080/03007995.2018.1510225	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1510225	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2018.1510225	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1510225	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2018.1510225	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2018.1510225	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846
10.1080/03007995.2018.1510225	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1510225	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2018.1510225	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	general_information	NA	NA	Medical Condition of Interest Name	anaplastic lymphoma kinase-positive non-small cell lung cancer
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2018.1520696	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2018.1520696	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1520696	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2018.1520696	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2018.1520696	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2018.1520696	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	1	NA	Treatment name 2	ceritinib
10.1080/03007995.2018.1520696	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2018.1520696	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2018.1520696	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2018.1520696	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate
10.1080/03007995.2018.1520696	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2018.1520696	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	2	NA	Treatment name 2	ceritinib
10.1080/03007995.2018.1520696	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2018.1520696	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2018.1520696	methodology	2	NA	Anchored comparison?	No
10.1080/03007995.2018.1520696	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate
10.1080/03007995.2018.1520696	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2018.1520696	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	3	NA	Treatment name 2	alectinib
10.1080/03007995.2018.1520696	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1080/03007995.2018.1520696	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2018.1520696	methodology	3	NA	Anchored comparison?	No
10.1080/03007995.2018.1520696	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate
10.1080/03007995.2018.1520696	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2018.1520696	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 1	brigatinib
10.1080/03007995.2018.1520696	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1520696	methodology	4	NA	Treatment name 2	alectinib
10.1080/03007995.2018.1520696	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.1080/03007995.2018.1520696	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2018.1520696	methodology	4	NA	Anchored comparison?	No
10.1080/03007995.2018.1520696	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate
10.1080/03007995.2018.1520696	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2018.1520696	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2018.1520696	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2018.1520696	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	163
10.1080/03007995.2018.1520696	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	110
10.1080/03007995.2018.1520696	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75.8
10.1080/03007995.2018.1520696	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2018.1520696	results	1	NA	Number of covariates adjusted for/matched on	7
10.1080/03007995.2018.1520696	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2018.1520696	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	1	NA	Primary outcome: unadjusted treatment effect	0.96
10.1080/03007995.2018.1520696	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.872
10.1080/03007995.2018.1520696	results	1	NA	Primary outcome: adjusted treatment effect	0.88
10.1080/03007995.2018.1520696	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.659
10.1080/03007995.2018.1520696	results	1	NA	geographical region	No
10.1080/03007995.2018.1520696	results	1	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	1	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	1	NA	pval	0.872
10.1080/03007995.2018.1520696	results	1	NA	num_pval	0.872
10.1080/03007995.2018.1520696	results	1	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	1	NA	significant	FALSE
10.1080/03007995.2018.1520696	results	1	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	1	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	1	NA	pval	0.659
10.1080/03007995.2018.1520696	results	1	NA	num_pval	0.659
10.1080/03007995.2018.1520696	results	1	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	1	NA	significant	FALSE
10.1080/03007995.2018.1520696	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	140
10.1080/03007995.2018.1520696	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	110
10.1080/03007995.2018.1520696	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	50.8
10.1080/03007995.2018.1520696	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2018.1520696	results	2	NA	Number of covariates adjusted for/matched on	7
10.1080/03007995.2018.1520696	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1080/03007995.2018.1520696	results	2	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2018.1520696	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	2	NA	Primary outcome: unadjusted treatment effect	2.16
10.1080/03007995.2018.1520696	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.003
10.1080/03007995.2018.1520696	results	2	NA	Primary outcome: adjusted treatment effect	2.17
10.1080/03007995.2018.1520696	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.02
10.1080/03007995.2018.1520696	results	2	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	2	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	2	NA	pval	0.003
10.1080/03007995.2018.1520696	results	2	NA	num_pval	0.003
10.1080/03007995.2018.1520696	results	2	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	2	NA	significant	TRUE
10.1080/03007995.2018.1520696	results	2	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	2	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	2	NA	pval	0.02
10.1080/03007995.2018.1520696	results	2	NA	num_pval	0.02
10.1080/03007995.2018.1520696	results	2	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	2	NA	significant	TRUE
10.1080/03007995.2018.1520696	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	87
10.1080/03007995.2018.1520696	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	110
10.1080/03007995.2018.1520696	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	77.5
10.1080/03007995.2018.1520696	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2018.1520696	results	3	NA	Number of covariates adjusted for/matched on	7
10.1080/03007995.2018.1520696	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	3	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2018.1520696	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	3	NA	Primary outcome: unadjusted treatment effect	1.78
10.1080/03007995.2018.1520696	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.047
10.1080/03007995.2018.1520696	results	3	NA	Primary outcome: adjusted treatment effect	1.69
10.1080/03007995.2018.1520696	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.096
10.1080/03007995.2018.1520696	results	3	NA	geographical region	No
10.1080/03007995.2018.1520696	results	3	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	3	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	3	NA	pval	0.047
10.1080/03007995.2018.1520696	results	3	NA	num_pval	0.047
10.1080/03007995.2018.1520696	results	3	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	3	NA	significant	TRUE
10.1080/03007995.2018.1520696	results	3	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	3	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	3	NA	pval	0.096
10.1080/03007995.2018.1520696	results	3	NA	num_pval	0.096
10.1080/03007995.2018.1520696	results	3	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	3	NA	significant	FALSE
10.1080/03007995.2018.1520696	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	138
10.1080/03007995.2018.1520696	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	110
10.1080/03007995.2018.1520696	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70.7
10.1080/03007995.2018.1520696	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2018.1520696	results	4	NA	Number of covariates adjusted for/matched on	8
10.1080/03007995.2018.1520696	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	4	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2018.1520696	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	4	NA	Primary outcome: unadjusted treatment effect	1.47
10.1080/03007995.2018.1520696	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.133
10.1080/03007995.2018.1520696	results	4	NA	Primary outcome: adjusted treatment effect	1.44
10.1080/03007995.2018.1520696	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.212
10.1080/03007995.2018.1520696	results	4	NA	geographical region	No
10.1080/03007995.2018.1520696	results	4	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	4	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	4	NA	pval	0.133
10.1080/03007995.2018.1520696	results	4	NA	num_pval	0.133
10.1080/03007995.2018.1520696	results	4	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	4	NA	significant	FALSE
10.1080/03007995.2018.1520696	results	4	NA	lb_ci	NA
10.1080/03007995.2018.1520696	results	4	NA	ub_ci	NA
10.1080/03007995.2018.1520696	results	4	NA	pval	0.212
10.1080/03007995.2018.1520696	results	4	NA	num_pval	0.212
10.1080/03007995.2018.1520696	results	4	NA	ci_cutoff	1
10.1080/03007995.2018.1520696	results	4	NA	significant	FALSE
10.1080/03007995.2018.1520696	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2018.1520696	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02094573
10.1080/03007995.2018.1520696	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2018.1520696	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01283516
10.1080/03007995.2018.1520696	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01685060
10.1080/03007995.2018.1520696	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2018.1520696	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	4	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	4	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01871805
10.1080/03007995.2018.1520696	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2018.1520696	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1520696	study_information	NA	5	Patient-level data used	No
10.1080/03007995.2018.1520696	study_information	NA	5	Clinical Trial	Yes
10.1080/03007995.2018.1520696	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01801111
10.1080/03007995.2018.1520696	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1520696	study_information	NA	5	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2018.1520696	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2018.1541443	general_information	NA	NA	Medical Condition of Interest Name	advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer
10.1080/03007995.2018.1541443	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2018.1541443	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2018.1541443	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1541443	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2018.1541443	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2018.1541443	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2018.1541443	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 1	ceritinib
10.1080/03007995.2018.1541443	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2018.1541443	methodology	1	NA	Treatment name 2	crizotinib
10.1080/03007995.2018.1541443	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2018.1541443	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2018.1541443	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2018.1541443	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1541443	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1541443	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/03007995.2018.1541443	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2018.1541443	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/03007995.2018.1541443	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2018.1541443	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2018.1541443	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2018.1541443	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2018.1541443	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	172
10.1080/03007995.2018.1541443	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	189
10.1080/03007995.2018.1541443	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/03007995.2018.1541443	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2018.1541443	results	1	NA	Number of covariates adjusted for/matched on	8
10.1080/03007995.2018.1541443	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/03007995.2018.1541443	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2018.1541443	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1541443	results	1	NA	Primary outcome: unadjusted treatment effect	0.68
10.1080/03007995.2018.1541443	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.01
10.1080/03007995.2018.1541443	results	1	NA	Primary outcome: adjusted treatment effect	0.64
10.1080/03007995.2018.1541443	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.004
10.1080/03007995.2018.1541443	results	1	NA	lb_ci	NA
10.1080/03007995.2018.1541443	results	1	NA	ub_ci	NA
10.1080/03007995.2018.1541443	results	1	NA	pval	0.01
10.1080/03007995.2018.1541443	results	1	NA	num_pval	0.01
10.1080/03007995.2018.1541443	results	1	NA	ci_cutoff	1
10.1080/03007995.2018.1541443	results	1	NA	significant	TRUE
10.1080/03007995.2018.1541443	results	1	NA	lb_ci	NA
10.1080/03007995.2018.1541443	results	1	NA	ub_ci	NA
10.1080/03007995.2018.1541443	results	1	NA	pval	0.004
10.1080/03007995.2018.1541443	results	1	NA	num_pval	0.004
10.1080/03007995.2018.1541443	results	1	NA	ci_cutoff	1
10.1080/03007995.2018.1541443	results	1	NA	significant	TRUE
10.1080/03007995.2018.1541443	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2018.1541443	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2018.1541443	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099
10.1080/03007995.2018.1541443	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1541443	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2018.1541443	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2018.1541443	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2018.1541443	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2018.1541443	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01154140
10.1080/03007995.2018.1541443	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2018.1541443	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2018.1541443	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2019.1585779	general_information	NA	NA	Medical Condition of Interest Name	active relapsing-remitting multiple sclerosis
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of first author affiliations	uk
10.1080/03007995.2019.1585779	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2019.1585779	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2019.1585779	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2019.1585779	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2019.1585779	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2019.1585779	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 1	cladribine
10.1080/03007995.2019.1585779	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2019.1585779	methodology	1	NA	Treatment name 2	alemtuzumab
10.1080/03007995.2019.1585779	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2019.1585779	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2019.1585779	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2019.1585779	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1585779	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1585779	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	confirmed disability progression
10.1080/03007995.2019.1585779	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2019.1585779	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/03007995.2019.1585779	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1585779	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1585779	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2019.1585779	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2019.1585779	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	426
10.1080/03007995.2019.1585779	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	113
10.1080/03007995.2019.1585779	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	41
10.1080/03007995.2019.1585779	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2019.1585779	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2019.1585779	results	1	NA	Number of covariates adjusted for/matched on	6
10.1080/03007995.2019.1585779	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1585779	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2019.1585779	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1585779	results	1	NA	Primary outcome: unadjusted treatment effect	0.96
10.1080/03007995.2019.1585779	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.51;1.80]
10.1080/03007995.2019.1585779	results	1	NA	Primary outcome: adjusted treatment effect	1
10.1080/03007995.2019.1585779	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.44;2.27]
10.1080/03007995.2019.1585779	results	1	NA	lb_ci	0.51
10.1080/03007995.2019.1585779	results	1	NA	ub_ci	1.8
10.1080/03007995.2019.1585779	results	1	NA	pval	NA
10.1080/03007995.2019.1585779	results	1	NA	num_pval	NA
10.1080/03007995.2019.1585779	results	1	NA	ci_cutoff	1
10.1080/03007995.2019.1585779	results	1	NA	significant	TRUE
10.1080/03007995.2019.1585779	results	1	NA	lb_ci	0.44
10.1080/03007995.2019.1585779	results	1	NA	ub_ci	2.27
10.1080/03007995.2019.1585779	results	1	NA	pval	NA
10.1080/03007995.2019.1585779	results	1	NA	num_pval	NA
10.1080/03007995.2019.1585779	results	1	NA	ci_cutoff	1
10.1080/03007995.2019.1585779	results	1	NA	significant	TRUE
10.1080/03007995.2019.1585779	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2019.1585779	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2019.1585779	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00213135
10.1080/03007995.2019.1585779	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2019.1585779	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2019.1585779	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1585779	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2019.1585779	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2019.1585779	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00548405
10.1080/03007995.2019.1585779	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1585779	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2019.1585779	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2019.1605239	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia
10.1080/03007995.2019.1605239	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2019.1605239	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2019.1605239	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2019.1605239	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2019.1605239	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2019.1605239	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2019.1605239	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 1	bosutinib
10.1080/03007995.2019.1605239	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2019.1605239	methodology	1	NA	Treatment name 2	dasatinib
10.1080/03007995.2019.1605239	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2019.1605239	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2019.1605239	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2019.1605239	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1605239	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1605239	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1080/03007995.2019.1605239	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2019.1605239	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2019.1605239	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1605239	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1605239	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2019.1605239	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 1	bosutinib
10.1080/03007995.2019.1605239	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2019.1605239	methodology	2	NA	Treatment name 2	nilotinib
10.1080/03007995.2019.1605239	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2019.1605239	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2019.1605239	methodology	2	NA	Anchored comparison?	No
10.1080/03007995.2019.1605239	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1605239	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1605239	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1080/03007995.2019.1605239	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2019.1605239	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2019.1605239	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1605239	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1605239	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2019.1605239	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1080/03007995.2019.1605239	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	167
10.1080/03007995.2019.1605239	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	283
10.1080/03007995.2019.1605239	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2019.1605239	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2019.1605239	results	1	NA	Number of covariates adjusted for/matched on	4
10.1080/03007995.2019.1605239	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1605239	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2019.1605239	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1605239	results	1	NA	Primary outcome: adjusted treatment effect	0.82
10.1080/03007995.2019.1605239	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.37
10.1080/03007995.2019.1605239	results	1	NA	geographical region	No
10.1080/03007995.2019.1605239	results	1	NA	lb_ci	NA
10.1080/03007995.2019.1605239	results	1	NA	ub_ci	NA
10.1080/03007995.2019.1605239	results	1	NA	pval	0.37
10.1080/03007995.2019.1605239	results	1	NA	num_pval	0.37
10.1080/03007995.2019.1605239	results	1	NA	ci_cutoff	1
10.1080/03007995.2019.1605239	results	1	NA	significant	FALSE
10.1080/03007995.2019.1605239	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	321
10.1080/03007995.2019.1605239	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	283
10.1080/03007995.2019.1605239	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2019.1605239	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2019.1605239	results	2	NA	Number of covariates adjusted for/matched on	3
10.1080/03007995.2019.1605239	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1605239	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2019.1605239	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1605239	results	2	NA	Primary outcome: adjusted treatment effect	0.72
10.1080/03007995.2019.1605239	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.16
10.1080/03007995.2019.1605239	results	2	NA	geographical region	No
10.1080/03007995.2019.1605239	results	2	NA	lb_ci	NA
10.1080/03007995.2019.1605239	results	2	NA	ub_ci	NA
10.1080/03007995.2019.1605239	results	2	NA	pval	0.16
10.1080/03007995.2019.1605239	results	2	NA	num_pval	0.16
10.1080/03007995.2019.1605239	results	2	NA	ci_cutoff	1
10.1080/03007995.2019.1605239	results	2	NA	significant	FALSE
10.1080/03007995.2019.1605239	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2019.1605239	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2019.1605239	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00261846
10.1080/03007995.2019.1605239	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1605239	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2019.1605239	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2019.1605239	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2019.1605239	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2019.1605239	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00123474
10.1080/03007995.2019.1605239	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1605239	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2019.1605239	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2019.1605239	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2019.1605239	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2019.1605239	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109707
10.1080/03007995.2019.1605239	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2019.1605239	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2019.1605239	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2020.1747999	general_information	NA	NA	Medical Condition of Interest Name	secondary progressive multiple sclerosis
10.1080/03007995.2020.1747999	general_information	NA	NA	Countries of first author affiliations	canada
10.1080/03007995.2020.1747999	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1080/03007995.2020.1747999	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2020.1747999	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2020.1747999	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2020.1747999	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2020.1747999	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	1	NA	Treatment name 2	ifn-1b 250 g once every other day (q2d)
10.1080/03007995.2020.1747999	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.1080/03007995.2020.1747999	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	1	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to confirmed disability progression at six months (cdp-6)
10.1080/03007995.2020.1747999	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2020.1747999	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	2	NA	Treatment name 2	ifn-1a 22 g once weekly (qw)
10.1080/03007995.2020.1747999	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2020.1747999	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	2	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to confirmed disability progression at six months (cdp-6)
10.1080/03007995.2020.1747999	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2020.1747999	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	3	NA	Treatment name 2	natalizumab
10.1080/03007995.2020.1747999	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2020.1747999	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	3	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	the proportion of patients who experienced cdp-6 (confirmed disability progression at six months) by 96 weeks based on an increase in edss alone
10.1080/03007995.2020.1747999	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2020.1747999	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	4	NA	Treatment name 2	sc ifn-1a 22 g three times weekly
10.1080/03007995.2020.1747999	methodology	4	NA	Study 'number(s)' for treatment 2	6
10.1080/03007995.2020.1747999	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	4	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	4	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2020.1747999	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	5	NA	Treatment name 2	sc ifn-1a 44 g three times weekly
10.1080/03007995.2020.1747999	methodology	5	NA	Study 'number(s)' for treatment 2	6
10.1080/03007995.2020.1747999	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	5	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	5	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2020.1747999	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	6	NA	Treatment name 2	ifn-1b 8 miu once every other day
10.1080/03007995.2020.1747999	methodology	6	NA	Study 'number(s)' for treatment 2	7
10.1080/03007995.2020.1747999	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	6	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	6	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2020.1747999	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 1	siponimod
10.1080/03007995.2020.1747999	methodology	7	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2020.1747999	methodology	7	NA	Treatment name 2	im ifn-1a 60 g once weekly
10.1080/03007995.2020.1747999	methodology	7	NA	Study 'number(s)' for treatment 2	5
10.1080/03007995.2020.1747999	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2020.1747999	methodology	7	NA	Anchored comparison?	Yes
10.1080/03007995.2020.1747999	methodology	7	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	7	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2020.1747999	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2020.1747999	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2020.1747999	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2020.1747999	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2020.1747999	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	1	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2020.1747999	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	1	NA	Primary outcome: adjusted treatment effect	0.55
10.1080/03007995.2020.1747999	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.33;0.91]
10.1080/03007995.2020.1747999	results	1	NA	If anchored, total initial sample size IPD	543
10.1080/03007995.2020.1747999	results	1	NA	If anchored, total ESS IPD	410
10.1080/03007995.2020.1747999	results	1	NA	If anchored, total sample size non IPD	939
10.1080/03007995.2020.1747999	results	1	NA	lb_ci	0.33
10.1080/03007995.2020.1747999	results	1	NA	ub_ci	0.91
10.1080/03007995.2020.1747999	results	1	NA	pval	NA
10.1080/03007995.2020.1747999	results	1	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	1	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	1	NA	significant	FALSE
10.1080/03007995.2020.1747999	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	2	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2020.1747999	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	2	NA	Primary outcome: adjusted treatment effect	0.43
10.1080/03007995.2020.1747999	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.93]
10.1080/03007995.2020.1747999	results	2	NA	If anchored, total initial sample size IPD	578
10.1080/03007995.2020.1747999	results	2	NA	If anchored, total ESS IPD	157
10.1080/03007995.2020.1747999	results	2	NA	If anchored, total sample size non IPD	364
10.1080/03007995.2020.1747999	results	2	NA	lb_ci	0.2
10.1080/03007995.2020.1747999	results	2	NA	ub_ci	0.93
10.1080/03007995.2020.1747999	results	2	NA	pval	NA
10.1080/03007995.2020.1747999	results	2	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	2	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	2	NA	significant	FALSE
10.1080/03007995.2020.1747999	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	3	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	3	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2020.1747999	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	3	NA	Primary outcome: adjusted treatment effect	0.76
10.1080/03007995.2020.1747999	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.44;1.30]
10.1080/03007995.2020.1747999	results	3	NA	If anchored, total initial sample size IPD	608
10.1080/03007995.2020.1747999	results	3	NA	If anchored, total ESS IPD	516
10.1080/03007995.2020.1747999	results	3	NA	If anchored, total sample size non IPD	887
10.1080/03007995.2020.1747999	results	3	NA	geographical region	No
10.1080/03007995.2020.1747999	results	3	NA	lb_ci	0.44
10.1080/03007995.2020.1747999	results	3	NA	ub_ci	1.3
10.1080/03007995.2020.1747999	results	3	NA	pval	NA
10.1080/03007995.2020.1747999	results	3	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	3	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	3	NA	significant	TRUE
10.1080/03007995.2020.1747999	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	4	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	4	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2020.1747999	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	4	NA	Primary outcome: adjusted treatment effect	0.8
10.1080/03007995.2020.1747999	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;1.38]
10.1080/03007995.2020.1747999	results	4	NA	If anchored, total initial sample size IPD	455
10.1080/03007995.2020.1747999	results	4	NA	If anchored, total ESS IPD	237
10.1080/03007995.2020.1747999	results	4	NA	If anchored, total sample size non IPD	618
10.1080/03007995.2020.1747999	results	4	NA	lb_ci	0.46
10.1080/03007995.2020.1747999	results	4	NA	ub_ci	1.38
10.1080/03007995.2020.1747999	results	4	NA	pval	NA
10.1080/03007995.2020.1747999	results	4	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	4	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	4	NA	significant	TRUE
10.1080/03007995.2020.1747999	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	5	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	5	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2020.1747999	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	5	NA	Primary outcome: adjusted treatment effect	0.84
10.1080/03007995.2020.1747999	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.49;1.47]
10.1080/03007995.2020.1747999	results	5	NA	If anchored, total initial sample size IPD	455
10.1080/03007995.2020.1747999	results	5	NA	If anchored, total ESS IPD	237
10.1080/03007995.2020.1747999	results	5	NA	If anchored, total sample size non IPD	618
10.1080/03007995.2020.1747999	results	5	NA	lb_ci	0.49
10.1080/03007995.2020.1747999	results	5	NA	ub_ci	1.47
10.1080/03007995.2020.1747999	results	5	NA	pval	NA
10.1080/03007995.2020.1747999	results	5	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	5	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	5	NA	significant	TRUE
10.1080/03007995.2020.1747999	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	6	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	6	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2020.1747999	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	6	NA	Primary outcome: adjusted treatment effect	0.82
10.1080/03007995.2020.1747999	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.42;1.63]
10.1080/03007995.2020.1747999	results	6	NA	If anchored, total initial sample size IPD	455
10.1080/03007995.2020.1747999	results	6	NA	If anchored, total ESS IPD	140
10.1080/03007995.2020.1747999	results	6	NA	If anchored, total sample size non IPD	718
10.1080/03007995.2020.1747999	results	6	NA	lb_ci	0.42
10.1080/03007995.2020.1747999	results	6	NA	ub_ci	1.63
10.1080/03007995.2020.1747999	results	6	NA	pval	NA
10.1080/03007995.2020.1747999	results	6	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	6	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	6	NA	significant	TRUE
10.1080/03007995.2020.1747999	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2020.1747999	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2020.1747999	results	7	NA	Number of covariates adjusted for/matched on	10
10.1080/03007995.2020.1747999	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	7	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2020.1747999	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	7	NA	Primary outcome: adjusted treatment effect	0.42
10.1080/03007995.2020.1747999	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.88]
10.1080/03007995.2020.1747999	results	7	NA	If anchored, total initial sample size IPD	563
10.1080/03007995.2020.1747999	results	7	NA	If anchored, total ESS IPD	113
10.1080/03007995.2020.1747999	results	7	NA	If anchored, total sample size non IPD	436
10.1080/03007995.2020.1747999	results	7	NA	lb_ci	0.2
10.1080/03007995.2020.1747999	results	7	NA	ub_ci	0.88
10.1080/03007995.2020.1747999	results	7	NA	pval	NA
10.1080/03007995.2020.1747999	results	7	NA	num_pval	NA
10.1080/03007995.2020.1747999	results	7	NA	ci_cutoff	1
10.1080/03007995.2020.1747999	results	7	NA	significant	FALSE
10.1080/03007995.2020.1747999	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2020.1747999	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01665144
10.1080/03007995.2020.1747999	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2020.1747999	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01416181
10.1080/03007995.2020.1747999	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2020.1747999	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	nordic spms study
10.1080/03007995.2020.1747999	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2020.1747999	study_information	NA	4	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	4	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	panitch et al. (2004) (north american study)
10.1080/03007995.2020.1747999	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	5	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	5	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	cohen et al. (2002) (impact)
10.1080/03007995.2020.1747999	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	6	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	6	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	spectrims study group (2001) li et al. (2001)
10.1080/03007995.2020.1747999	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2020.1747999	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	7	Patient-level data used	No
10.1080/03007995.2020.1747999	study_information	NA	7	Clinical Trial	Yes
10.1080/03007995.2020.1747999	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	european study group (1998) kappos et al. (2001)
10.1080/03007995.2020.1747999	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2020.1747999	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1896489	general_information	NA	NA	Medical Condition of Interest Name	chronic phase chronic myeloid leukemia
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of first author affiliations	the netherlands
10.1080/03007995.2021.1896489	general_information	NA	NA	Countries of last author affiliations	the netherlands
10.1080/03007995.2021.1896489	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1896489	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1896489	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1896489	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1896489	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 1	bosutinib
10.1080/03007995.2021.1896489	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1896489	methodology	1	NA	Treatment name 2	nilotinib
10.1080/03007995.2021.1896489	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2021.1896489	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2021.1896489	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2021.1896489	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1896489	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1896489	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response at 24 months
10.1080/03007995.2021.1896489	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2021.1896489	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2021.1896489	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2021.1896489	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2021.1896489	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2021.1896489	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 1	bosutinib
10.1080/03007995.2021.1896489	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1896489	methodology	2	NA	Treatment name 2	dasatinib
10.1080/03007995.2021.1896489	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2021.1896489	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2021.1896489	methodology	2	NA	Anchored comparison?	No
10.1080/03007995.2021.1896489	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1896489	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1896489	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response by 24 months
10.1080/03007995.2021.1896489	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2021.1896489	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2021.1896489	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2021.1896489	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1080/03007995.2021.1896489	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	282
10.1080/03007995.2021.1896489	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	248
10.1080/03007995.2021.1896489	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	190
10.1080/03007995.2021.1896489	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2021.1896489	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2021.1896489	results	1	NA	Number of covariates adjusted for/matched on	3
10.1080/03007995.2021.1896489	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/03007995.2021.1896489	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2021.1896489	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1080/03007995.2021.1896489	results	1	NA	Primary outcome: adjusted treatment effect	1.01
10.1080/03007995.2021.1896489	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.70;1.45]
10.1080/03007995.2021.1896489	results	1	NA	lb_ci	0.7
10.1080/03007995.2021.1896489	results	1	NA	ub_ci	1.45
10.1080/03007995.2021.1896489	results	1	NA	pval	NA
10.1080/03007995.2021.1896489	results	1	NA	num_pval	NA
10.1080/03007995.2021.1896489	results	1	NA	ci_cutoff	1
10.1080/03007995.2021.1896489	results	1	NA	significant	TRUE
10.1080/03007995.2021.1896489	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	259
10.1080/03007995.2021.1896489	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	244
10.1080/03007995.2021.1896489	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	118
10.1080/03007995.2021.1896489	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2021.1896489	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2021.1896489	results	2	NA	Number of covariates adjusted for/matched on	5
10.1080/03007995.2021.1896489	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/03007995.2021.1896489	results	2	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2021.1896489	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1080/03007995.2021.1896489	results	2	NA	Primary outcome: adjusted treatment effect	0.81
10.1080/03007995.2021.1896489	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.54;1.22]
10.1080/03007995.2021.1896489	results	2	NA	lb_ci	0.54
10.1080/03007995.2021.1896489	results	2	NA	ub_ci	1.22
10.1080/03007995.2021.1896489	results	2	NA	pval	NA
10.1080/03007995.2021.1896489	results	2	NA	num_pval	NA
10.1080/03007995.2021.1896489	results	2	NA	ci_cutoff	1
10.1080/03007995.2021.1896489	results	2	NA	significant	TRUE
10.1080/03007995.2021.1896489	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1896489	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1896489	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02130557
10.1080/03007995.2021.1896489	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1896489	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1896489	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1896489	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2021.1896489	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1896489	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497
10.1080/03007995.2021.1896489	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1896489	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1896489	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1896489	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2021.1896489	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2021.1896489	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247
10.1080/03007995.2021.1896489	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1896489	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1896489	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1947216	general_information	NA	NA	Medical Condition of Interest Name	spinal muscular atrophy type 1
10.1080/03007995.2021.1947216	general_information	NA	NA	Countries of first author affiliations	switzerland
10.1080/03007995.2021.1947216	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2021.1947216	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1947216	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1947216	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1947216	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1947216	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 1	onasemnogene abeparvovec
10.1080/03007995.2021.1947216	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1080/03007995.2021.1947216	methodology	1	NA	Treatment name 2	nusinersen
10.1080/03007995.2021.1947216	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1080/03007995.2021.1947216	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2021.1947216	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2021.1947216	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/03007995.2021.1947216	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1947216	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	event-free survival
10.1080/03007995.2021.1947216	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/03007995.2021.1947216	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2021.1947216	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2021.1947216	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	81
10.1080/03007995.2021.1947216	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	34
10.1080/03007995.2021.1947216	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24.6
10.1080/03007995.2021.1947216	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/03007995.2021.1947216	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2021.1947216	results	1	NA	Number of covariates adjusted for/matched on	2
10.1080/03007995.2021.1947216	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1080/03007995.2021.1947216	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/03007995.2021.1947216	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1947216	results	1	NA	Primary outcome: adjusted treatment effect	0.19
10.1080/03007995.2021.1947216	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.07;0.54]
10.1080/03007995.2021.1947216	results	1	NA	lb_ci	0.07
10.1080/03007995.2021.1947216	results	1	NA	ub_ci	0.54
10.1080/03007995.2021.1947216	results	1	NA	pval	NA
10.1080/03007995.2021.1947216	results	1	NA	num_pval	NA
10.1080/03007995.2021.1947216	results	1	NA	ci_cutoff	1
10.1080/03007995.2021.1947216	results	1	NA	significant	FALSE
10.1080/03007995.2021.1947216	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1947216	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1947216	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02122952
10.1080/03007995.2021.1947216	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/03007995.2021.1947216	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1080/03007995.2021.1947216	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1947216	study_information	NA	2	Patient-level data used	Yes
10.1080/03007995.2021.1947216	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1947216	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03306277
10.1080/03007995.2021.1947216	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/03007995.2021.1947216	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1947216	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1947216	study_information	NA	3	Patient-level data used	No
10.1080/03007995.2021.1947216	study_information	NA	3	Clinical Trial	Yes
10.1080/03007995.2021.1947216	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02594124
10.1080/03007995.2021.1947216	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1947216	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1947216	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1953456	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory multiple myeloma
10.1080/03007995.2021.1953456	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2021.1953456	general_information	NA	NA	Countries of last author affiliations	canada
10.1080/03007995.2021.1953456	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1953456	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1953456	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1953456	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1953456	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 1	ciltacabtagene autoleucel
10.1080/03007995.2021.1953456	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1953456	methodology	1	NA	Treatment name 2	idecabtagene vicleucel
10.1080/03007995.2021.1953456	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2021.1953456	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2021.1953456	methodology	1	NA	Anchored comparison?	No
10.1080/03007995.2021.1953456	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1953456	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1953456	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1080/03007995.2021.1953456	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2021.1953456	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2021.1953456	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2021.1953456	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2021.1953456	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2021.1953456	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2021.1953456	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	124
10.1080/03007995.2021.1953456	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	97
10.1080/03007995.2021.1953456	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	52
10.1080/03007995.2021.1953456	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/03007995.2021.1953456	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2021.1953456	results	1	NA	Number of covariates adjusted for/matched on	4
10.1080/03007995.2021.1953456	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1080/03007995.2021.1953456	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1080/03007995.2021.1953456	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1953456	results	1	NA	Primary outcome: unadjusted treatment effect	16.52
10.1080/03007995.2021.1953456	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.0002
10.1080/03007995.2021.1953456	results	1	NA	Primary outcome: adjusted treatment effect	94.93
10.1080/03007995.2021.1953456	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.1080/03007995.2021.1953456	results	1	NA	lb_ci	NA
10.1080/03007995.2021.1953456	results	1	NA	ub_ci	NA
10.1080/03007995.2021.1953456	results	1	NA	pval	0.0002
10.1080/03007995.2021.1953456	results	1	NA	num_pval	2e-04
10.1080/03007995.2021.1953456	results	1	NA	ci_cutoff	1
10.1080/03007995.2021.1953456	results	1	NA	significant	TRUE
10.1080/03007995.2021.1953456	results	1	NA	lb_ci	NA
10.1080/03007995.2021.1953456	results	1	NA	ub_ci	NA
10.1080/03007995.2021.1953456	results	1	NA	pval	<0.0001
10.1080/03007995.2021.1953456	results	1	NA	num_pval	NA
10.1080/03007995.2021.1953456	results	1	NA	ci_cutoff	1
10.1080/03007995.2021.1953456	results	1	NA	significant	TRUE
10.1080/03007995.2021.1953456	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1953456	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1953456	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03548207
10.1080/03007995.2021.1953456	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1953456	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.1080/03007995.2021.1953456	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1953456	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2021.1953456	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1953456	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03361748
10.1080/03007995.2021.1953456	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1953456	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1080/03007995.2021.1953456	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/03007995.2021.1971182	general_information	NA	NA	Medical Condition of Interest Name	paroxysmal nocturnal hemoglobinuria
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/03007995.2021.1971182	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/03007995.2021.1971182	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1971182	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2021.1971182	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2021.1971182	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2021.1971182	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 1	pegcetacoplan
10.1080/03007995.2021.1971182	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2021.1971182	methodology	1	NA	Treatment name 2	ravulizumab
10.1080/03007995.2021.1971182	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2021.1971182	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/03007995.2021.1971182	methodology	1	NA	Anchored comparison?	Yes
10.1080/03007995.2021.1971182	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1971182	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1971182	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	proportion of patients with transfusion avoidance
10.1080/03007995.2021.1971182	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/03007995.2021.1971182	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2021.1971182	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/03007995.2021.1971182	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2021.1971182	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2021.1971182	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2021.1971182	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	97
10.1080/03007995.2021.1971182	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	98
10.1080/03007995.2021.1971182	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	36
10.1080/03007995.2021.1971182	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	32
10.1080/03007995.2021.1971182	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2021.1971182	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2021.1971182	results	1	NA	Number of covariates adjusted for/matched on	5
10.1080/03007995.2021.1971182	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/03007995.2021.1971182	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1971182	results	1	NA	Primary outcome: adjusted treatment effect	0.714
10.1080/03007995.2021.1971182	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.1080/03007995.2021.1971182	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	24
10.1080/03007995.2021.1971182	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	12
10.1080/03007995.2021.1971182	results	1	NA	lb_ci	NA
10.1080/03007995.2021.1971182	results	1	NA	ub_ci	NA
10.1080/03007995.2021.1971182	results	1	NA	pval	<0.0001
10.1080/03007995.2021.1971182	results	1	NA	num_pval	NA
10.1080/03007995.2021.1971182	results	1	NA	ci_cutoff	NA
10.1080/03007995.2021.1971182	results	1	NA	significant	TRUE
10.1080/03007995.2021.1971182	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2021.1971182	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2021.1971182	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03500549
10.1080/03007995.2021.1971182	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1971182	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1971182	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2021.1971182	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2021.1971182	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2021.1971182	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03056040
10.1080/03007995.2021.1971182	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2021.1971182	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2021.1971182	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2022.2030112	general_information	NA	NA	Medical Condition of Interest Name	uncontrolled hypertension
10.1080/03007995.2022.2030112	general_information	NA	NA	Countries of first author affiliations	germany
10.1080/03007995.2022.2030112	general_information	NA	NA	Countries of last author affiliations	germany
10.1080/03007995.2022.2030112	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry
10.1080/03007995.2022.2030112	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/03007995.2022.2030112	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/03007995.2022.2030112	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/03007995.2022.2030112	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 1	amlodipine 5 mg + bisoprolol 5 mg
10.1080/03007995.2022.2030112	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/03007995.2022.2030112	methodology	1	NA	Treatment name 2	amlodipine 10mg,
10.1080/03007995.2022.2030112	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/03007995.2022.2030112	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.1080/03007995.2022.2030112	methodology	1	NA	Anchored comparison?	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2022.2030112	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2022.2030112	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in systolic blood pressures from baseline to following 8 weeks of treatment
10.1080/03007995.2022.2030112	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1080/03007995.2022.2030112	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2022.2030112	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/03007995.2022.2030112	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/03007995.2022.2030112	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	261
10.1080/03007995.2022.2030112	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	255
10.1080/03007995.2022.2030112	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	178
10.1080/03007995.2022.2030112	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	178
10.1080/03007995.2022.2030112	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	179
10.1080/03007995.2022.2030112	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	179
10.1080/03007995.2022.2030112	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/03007995.2022.2030112	results	1	NA	Number of covariates adjusted for/matched on	7
10.1080/03007995.2022.2030112	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1080/03007995.2022.2030112	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1080/03007995.2022.2030112	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/03007995.2022.2030112	results	1	NA	Primary outcome: unadjusted treatment effect	-0.3
10.1080/03007995.2022.2030112	results	1	NA	Primary outcome: adjusted treatment effect	-1.6
10.1080/03007995.2022.2030112	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-5.3;2.2]
10.1080/03007995.2022.2030112	results	1	NA	geographical region	No
10.1080/03007995.2022.2030112	results	1	NA	lb_ci	-5.3
10.1080/03007995.2022.2030112	results	1	NA	ub_ci	2.2
10.1080/03007995.2022.2030112	results	1	NA	pval	NA
10.1080/03007995.2022.2030112	results	1	NA	num_pval	NA
10.1080/03007995.2022.2030112	results	1	NA	ci_cutoff	0
10.1080/03007995.2022.2030112	results	1	NA	significant	TRUE
10.1080/03007995.2022.2030112	study_information	NA	1	Patient-level data used	Yes
10.1080/03007995.2022.2030112	study_information	NA	1	Clinical Trial	Yes
10.1080/03007995.2022.2030112	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2019-000751-13
10.1080/03007995.2022.2030112	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	poland
10.1080/03007995.2022.2030112	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2022.2030112	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/03007995.2022.2030112	study_information	NA	2	Patient-level data used	No
10.1080/03007995.2022.2030112	study_information	NA	2	Clinical Trial	Yes
10.1080/03007995.2022.2030112	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00558428
10.1080/03007995.2022.2030112	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/03007995.2022.2030112	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/03007995.2022.2030112	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis
10.1080/09546634.2020.1747592	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/09546634.2020.1747592	general_information	NA	NA	Countries of last author affiliations	germany
10.1080/09546634.2020.1747592	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/09546634.2020.1747592	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/09546634.2020.1747592	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/09546634.2020.1747592	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/09546634.2020.1747592	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	1	NA	Treatment name 2	guselkumab
10.1080/09546634.2020.1747592	methodology	1	NA	Study 'number(s)' for treatment 2	5
10.1080/09546634.2020.1747592	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	1	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	2	NA	Treatment name 2	tildrakizumab 100mg
10.1080/09546634.2020.1747592	methodology	2	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	2	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	3	NA	Treatment name 2	tildrakizumab 200mg
10.1080/09546634.2020.1747592	methodology	3	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	3	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	4	NA	Study 'number(s)' for treatment 1	2;3
10.1080/09546634.2020.1747592	methodology	4	NA	Treatment name 2	tildrakizumab 100mg
10.1080/09546634.2020.1747592	methodology	4	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	4	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	5	NA	Study 'number(s)' for treatment 1	2;3
10.1080/09546634.2020.1747592	methodology	5	NA	Treatment name 2	tildrakizumab 200mg
10.1080/09546634.2020.1747592	methodology	5	NA	Study 'number(s)' for treatment 2	6;7
10.1080/09546634.2020.1747592	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	5	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	6	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/09546634.2020.1747592	methodology	6	NA	Treatment name 2	risankizumab
10.1080/09546634.2020.1747592	methodology	6	NA	Study 'number(s)' for treatment 2	8
10.1080/09546634.2020.1747592	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	6	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	6	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 1	ixekizumab
10.1080/09546634.2020.1747592	methodology	7	NA	Study 'number(s)' for treatment 1	4
10.1080/09546634.2020.1747592	methodology	7	NA	Treatment name 2	risankizumab
10.1080/09546634.2020.1747592	methodology	7	NA	Study 'number(s)' for treatment 2	8;9
10.1080/09546634.2020.1747592	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/09546634.2020.1747592	methodology	7	NA	Anchored comparison?	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	7	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/09546634.2020.1747592	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/09546634.2020.1747592	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	1	NA	Number of covariates adjusted for/matched on	8
10.1080/09546634.2020.1747592	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	1	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	1	NA	Primary outcome: unadjusted treatment effect	8.3
10.1080/09546634.2020.1747592	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[2.4;14.2] p<0.01
10.1080/09546634.2020.1747592	results	1	NA	Primary outcome: adjusted treatment effect	8
10.1080/09546634.2020.1747592	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.0;14.1] p<0.01
10.1080/09546634.2020.1747592	results	1	NA	If anchored, total initial sample size IPD	1952
10.1080/09546634.2020.1747592	results	1	NA	If anchored, total ESS IPD	1717
10.1080/09546634.2020.1747592	results	1	NA	If anchored, total sample size non IPD	503
10.1080/09546634.2020.1747592	results	1	NA	geographical region	No
10.1080/09546634.2020.1747592	results	1	NA	lb_ci	2.4
10.1080/09546634.2020.1747592	results	1	NA	ub_ci	14.2
10.1080/09546634.2020.1747592	results	1	NA	pval	<0.01
10.1080/09546634.2020.1747592	results	1	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	1	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	1	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	1	NA	lb_ci	2
10.1080/09546634.2020.1747592	results	1	NA	ub_ci	14.1
10.1080/09546634.2020.1747592	results	1	NA	pval	<0.01
10.1080/09546634.2020.1747592	results	1	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	1	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	1	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	2	NA	Number of covariates adjusted for/matched on	5
10.1080/09546634.2020.1747592	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	2	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	2	NA	Primary outcome: unadjusted treatment effect	27.7
10.1080/09546634.2020.1747592	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[22.5;32.8] p<0.001
10.1080/09546634.2020.1747592	results	2	NA	Primary outcome: adjusted treatment effect	27
10.1080/09546634.2020.1747592	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[21.6;32.3] p<0.001
10.1080/09546634.2020.1747592	results	2	NA	If anchored, total initial sample size IPD	1952
10.1080/09546634.2020.1747592	results	2	NA	If anchored, total ESS IPD	1565
10.1080/09546634.2020.1747592	results	2	NA	If anchored, total sample size non IPD	927
10.1080/09546634.2020.1747592	results	2	NA	lb_ci	22.5
10.1080/09546634.2020.1747592	results	2	NA	ub_ci	32.8
10.1080/09546634.2020.1747592	results	2	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	2	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	2	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	2	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	2	NA	lb_ci	21.6
10.1080/09546634.2020.1747592	results	2	NA	ub_ci	32.3
10.1080/09546634.2020.1747592	results	2	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	2	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	2	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	2	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	3	NA	Number of covariates adjusted for/matched on	5
10.1080/09546634.2020.1747592	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	3	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	3	NA	Primary outcome: unadjusted treatment effect	26.4
10.1080/09546634.2020.1747592	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[21.3;31.5] p<0.001
10.1080/09546634.2020.1747592	results	3	NA	Primary outcome: adjusted treatment effect	25.7
10.1080/09546634.2020.1747592	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[20.4;31.0] p<0.001
10.1080/09546634.2020.1747592	results	3	NA	If anchored, total initial sample size IPD	1952
10.1080/09546634.2020.1747592	results	3	NA	If anchored, total ESS IPD	1588
10.1080/09546634.2020.1747592	results	3	NA	If anchored, total sample size non IPD	927
10.1080/09546634.2020.1747592	results	3	NA	lb_ci	21.3
10.1080/09546634.2020.1747592	results	3	NA	ub_ci	31.5
10.1080/09546634.2020.1747592	results	3	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	3	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	3	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	3	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	3	NA	lb_ci	20.4
10.1080/09546634.2020.1747592	results	3	NA	ub_ci	31
10.1080/09546634.2020.1747592	results	3	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	3	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	3	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	3	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	4	NA	Number of covariates adjusted for/matched on	5
10.1080/09546634.2020.1747592	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	4	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	4	NA	Primary outcome: unadjusted treatment effect	28.1
10.1080/09546634.2020.1747592	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[19.2;37.0] p<0.001
10.1080/09546634.2020.1747592	results	4	NA	Primary outcome: adjusted treatment effect	25.7
10.1080/09546634.2020.1747592	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[16.5;34.9] p<0.001
10.1080/09546634.2020.1747592	results	4	NA	If anchored, total initial sample size IPD	1470
10.1080/09546634.2020.1747592	results	4	NA	If anchored, total ESS IPD	1108
10.1080/09546634.2020.1747592	results	4	NA	If anchored, total sample size non IPD	463
10.1080/09546634.2020.1747592	results	4	NA	lb_ci	19.2
10.1080/09546634.2020.1747592	results	4	NA	ub_ci	37
10.1080/09546634.2020.1747592	results	4	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	4	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	4	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	4	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	4	NA	lb_ci	16.5
10.1080/09546634.2020.1747592	results	4	NA	ub_ci	34.9
10.1080/09546634.2020.1747592	results	4	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	4	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	4	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	4	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	5	NA	Number of covariates adjusted for/matched on	5
10.1080/09546634.2020.1747592	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	5	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	5	NA	Primary outcome: unadjusted treatment effect	24.1
10.1080/09546634.2020.1747592	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[15.3;32.9] p<0.001
10.1080/09546634.2020.1747592	results	5	NA	Primary outcome: adjusted treatment effect	21.7
10.1080/09546634.2020.1747592	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[12.7;30.7] p<0.001
10.1080/09546634.2020.1747592	results	5	NA	If anchored, total initial sample size IPD	1470
10.1080/09546634.2020.1747592	results	5	NA	If anchored, total ESS IPD	1163
10.1080/09546634.2020.1747592	results	5	NA	If anchored, total sample size non IPD	470
10.1080/09546634.2020.1747592	results	5	NA	lb_ci	15.3
10.1080/09546634.2020.1747592	results	5	NA	ub_ci	32.9
10.1080/09546634.2020.1747592	results	5	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	5	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	5	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	5	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	5	NA	lb_ci	12.7
10.1080/09546634.2020.1747592	results	5	NA	ub_ci	30.7
10.1080/09546634.2020.1747592	results	5	NA	pval	<0.001
10.1080/09546634.2020.1747592	results	5	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	5	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	5	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	6	NA	Number of covariates adjusted for/matched on	8
10.1080/09546634.2020.1747592	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	6	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	6	NA	Primary outcome: unadjusted treatment effect	5.5
10.1080/09546634.2020.1747592	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.2;10.8] p<0.05
10.1080/09546634.2020.1747592	results	6	NA	Primary outcome: adjusted treatment effect	5.5
10.1080/09546634.2020.1747592	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.1;11.0]
10.1080/09546634.2020.1747592	results	6	NA	If anchored, total initial sample size IPD	1952
10.1080/09546634.2020.1747592	results	6	NA	If anchored, total ESS IPD	1398
10.1080/09546634.2020.1747592	results	6	NA	If anchored, total sample size non IPD	798
10.1080/09546634.2020.1747592	results	6	NA	geographical region	No
10.1080/09546634.2020.1747592	results	6	NA	lb_ci	0.2
10.1080/09546634.2020.1747592	results	6	NA	ub_ci	10.8
10.1080/09546634.2020.1747592	results	6	NA	pval	<0.05
10.1080/09546634.2020.1747592	results	6	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	6	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	6	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	6	NA	lb_ci	-0.1
10.1080/09546634.2020.1747592	results	6	NA	ub_ci	11
10.1080/09546634.2020.1747592	results	6	NA	pval	NA
10.1080/09546634.2020.1747592	results	6	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	6	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	6	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/09546634.2020.1747592	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/09546634.2020.1747592	results	7	NA	Number of covariates adjusted for/matched on	8
10.1080/09546634.2020.1747592	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	7	NA	Primary outcome: treatment effect contrast	Risk difference
10.1080/09546634.2020.1747592	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	7	NA	Primary outcome: unadjusted treatment effect	0.8
10.1080/09546634.2020.1747592	results	7	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-10.9;12.6]
10.1080/09546634.2020.1747592	results	7	NA	Primary outcome: adjusted treatment effect	7.8
10.1080/09546634.2020.1747592	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-6.7;22.3]
10.1080/09546634.2020.1747592	results	7	NA	If anchored, total initial sample size IPD	256
10.1080/09546634.2020.1747592	results	7	NA	If anchored, total ESS IPD	116
10.1080/09546634.2020.1747592	results	7	NA	If anchored, total sample size non IPD	797
10.1080/09546634.2020.1747592	results	7	NA	geographical region	No
10.1080/09546634.2020.1747592	results	7	NA	lb_ci	-10.9
10.1080/09546634.2020.1747592	results	7	NA	ub_ci	12.6
10.1080/09546634.2020.1747592	results	7	NA	pval	NA
10.1080/09546634.2020.1747592	results	7	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	7	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	7	NA	significant	TRUE
10.1080/09546634.2020.1747592	results	7	NA	lb_ci	-6.7
10.1080/09546634.2020.1747592	results	7	NA	ub_ci	22.3
10.1080/09546634.2020.1747592	results	7	NA	pval	NA
10.1080/09546634.2020.1747592	results	7	NA	num_pval	NA
10.1080/09546634.2020.1747592	results	7	NA	ci_cutoff	0
10.1080/09546634.2020.1747592	results	7	NA	significant	TRUE
10.1080/09546634.2020.1747592	study_information	NA	1	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	1	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01474512
10.1080/09546634.2020.1747592	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	2	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	2	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597245
10.1080/09546634.2020.1747592	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	3	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	3	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646177
10.1080/09546634.2020.1747592	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	4	Patient-level data used	Yes
10.1080/09546634.2020.1747592	study_information	NA	4	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561806
10.1080/09546634.2020.1747592	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	5	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	5	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02207244
10.1080/09546634.2020.1747592	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/09546634.2020.1747592	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	6	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	6	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722331
10.1080/09546634.2020.1747592	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	7	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	7	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01729754
10.1080/09546634.2020.1747592	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	8	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	8	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02684370
10.1080/09546634.2020.1747592	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1080/09546634.2020.1747592	study_information	NA	9	Patient-level data used	No
10.1080/09546634.2020.1747592	study_information	NA	9	Clinical Trial	Yes
10.1080/09546634.2020.1747592	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02684357
10.1080/09546634.2020.1747592	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3
10.1080/09546634.2020.1747592	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1648806	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory multiple myeloma
10.1080/10428194.2019.1648806	general_information	NA	NA	Countries of first author affiliations	germany
10.1080/10428194.2019.1648806	general_information	NA	NA	Countries of last author affiliations	greece
10.1080/10428194.2019.1648806	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/10428194.2019.1648806	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/10428194.2019.1648806	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2019.1648806	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2019.1648806	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/10428194.2019.1648806	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2019.1648806	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2019.1648806	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01568866
10.1080/10428194.2019.1648806	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1648806	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1648806	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1648806	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2019.1648806	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2019.1648806	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02136134
10.1080/10428194.2019.1648806	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1648806	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1648806	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1675881	general_information	NA	NA	Medical Condition of Interest Name	transplant ineligible multiple myeloma
10.1080/10428194.2019.1675881	general_information	NA	NA	Countries of first author affiliations	spain
10.1080/10428194.2019.1675881	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/10428194.2019.1675881	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2019.1675881	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2019.1675881	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2019.1675881	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2019.1675881	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 1	vmp (bortezomib/melphalan/prednisone)
10.1080/10428194.2019.1675881	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1675881	methodology	1	NA	Treatment name 2	modified vmp schedule
10.1080/10428194.2019.1675881	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1080/10428194.2019.1675881	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2019.1675881	methodology	1	NA	Anchored comparison?	No
10.1080/10428194.2019.1675881	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/10428194.2019.1675881	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1675881	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2019.1675881	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2019.1675881	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2019.1675881	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2019.1675881	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2019.1675881	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	547
10.1080/10428194.2019.1675881	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	344
10.1080/10428194.2019.1675881	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	114
10.1080/10428194.2019.1675881	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/10428194.2019.1675881	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2019.1675881	results	1	NA	Number of covariates adjusted for/matched on	8
10.1080/10428194.2019.1675881	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1675881	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2019.1675881	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1675881	results	1	NA	Primary outcome: unadjusted treatment effect	0.911
10.1080/10428194.2019.1675881	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.326
10.1080/10428194.2019.1675881	results	1	NA	Primary outcome: adjusted treatment effect	0.991
10.1080/10428194.2019.1675881	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.935
10.1080/10428194.2019.1675881	results	1	NA	lb_ci	NA
10.1080/10428194.2019.1675881	results	1	NA	ub_ci	NA
10.1080/10428194.2019.1675881	results	1	NA	pval	0.326
10.1080/10428194.2019.1675881	results	1	NA	num_pval	0.326
10.1080/10428194.2019.1675881	results	1	NA	ci_cutoff	1
10.1080/10428194.2019.1675881	results	1	NA	significant	FALSE
10.1080/10428194.2019.1675881	results	1	NA	lb_ci	NA
10.1080/10428194.2019.1675881	results	1	NA	ub_ci	NA
10.1080/10428194.2019.1675881	results	1	NA	pval	0.935
10.1080/10428194.2019.1675881	results	1	NA	num_pval	0.935
10.1080/10428194.2019.1675881	results	1	NA	ci_cutoff	1
10.1080/10428194.2019.1675881	results	1	NA	significant	FALSE
10.1080/10428194.2019.1675881	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2019.1675881	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2019.1675881	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00111319
10.1080/10428194.2019.1675881	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/10428194.2019.1675881	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1675881	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1675881	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2019.1675881	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2019.1675881	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479
10.1080/10428194.2019.1675881	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1675881	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1675881	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1675881	study_information	NA	3	Patient-level data used	No
10.1080/10428194.2019.1675881	study_information	NA	3	Clinical Trial	Yes
10.1080/10428194.2019.1675881	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01063179
10.1080/10428194.2019.1675881	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1080/10428194.2019.1675881	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1675881	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1682571	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of first author affiliations	greece
10.1080/10428194.2019.1682571	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/10428194.2019.1682571	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2019.1682571	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2019.1682571	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2019.1682571	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2019.1682571	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1682571	methodology	1	NA	Treatment name 2	lenalidomidedexamethasone continuous
10.1080/10428194.2019.1682571	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2019.1682571	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2019.1682571	methodology	1	NA	Anchored comparison?	No
10.1080/10428194.2019.1682571	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1080/10428194.2019.1682571	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2019.1682571	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2019.1682571	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1682571	methodology	2	NA	Treatment name 2	lenalidomidedexamethasone 18 months (rd18)
10.1080/10428194.2019.1682571	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2019.1682571	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2019.1682571	methodology	2	NA	Anchored comparison?	No
10.1080/10428194.2019.1682571	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1080/10428194.2019.1682571	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2019.1682571	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2019.1682571	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 1	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2019.1682571	methodology	3	NA	Treatment name 2	melphalanprednisonethalidomide
10.1080/10428194.2019.1682571	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2019.1682571	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2019.1682571	methodology	3	NA	Anchored comparison?	No
10.1080/10428194.2019.1682571	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1080/10428194.2019.1682571	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2019.1682571	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2019.1682571	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2019.1682571	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	535
10.1080/10428194.2019.1682571	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	350
10.1080/10428194.2019.1682571	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	248
10.1080/10428194.2019.1682571	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2019.1682571	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2019.1682571	results	1	NA	Number of covariates adjusted for/matched on	7
10.1080/10428194.2019.1682571	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2019.1682571	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	1	NA	Primary outcome: unadjusted treatment effect	0.88
10.1080/10428194.2019.1682571	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.51
10.1080/10428194.2019.1682571	results	1	NA	Primary outcome: adjusted treatment effect	0.68
10.1080/10428194.2019.1682571	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.086
10.1080/10428194.2019.1682571	results	1	NA	lb_ci	NA
10.1080/10428194.2019.1682571	results	1	NA	ub_ci	NA
10.1080/10428194.2019.1682571	results	1	NA	pval	0.51
10.1080/10428194.2019.1682571	results	1	NA	num_pval	0.51
10.1080/10428194.2019.1682571	results	1	NA	ci_cutoff	1
10.1080/10428194.2019.1682571	results	1	NA	significant	FALSE
10.1080/10428194.2019.1682571	results	1	NA	lb_ci	NA
10.1080/10428194.2019.1682571	results	1	NA	ub_ci	NA
10.1080/10428194.2019.1682571	results	1	NA	pval	0.086
10.1080/10428194.2019.1682571	results	1	NA	num_pval	0.086
10.1080/10428194.2019.1682571	results	1	NA	ci_cutoff	1
10.1080/10428194.2019.1682571	results	1	NA	significant	FALSE
10.1080/10428194.2019.1682571	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	541
10.1080/10428194.2019.1682571	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	350
10.1080/10428194.2019.1682571	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	246
10.1080/10428194.2019.1682571	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2019.1682571	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2019.1682571	results	2	NA	Number of covariates adjusted for/matched on	7
10.1080/10428194.2019.1682571	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2019.1682571	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	2	NA	Primary outcome: unadjusted treatment effect	0.78
10.1080/10428194.2019.1682571	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.16
10.1080/10428194.2019.1682571	results	2	NA	Primary outcome: adjusted treatment effect	0.6
10.1080/10428194.2019.1682571	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.02
10.1080/10428194.2019.1682571	results	2	NA	lb_ci	NA
10.1080/10428194.2019.1682571	results	2	NA	ub_ci	NA
10.1080/10428194.2019.1682571	results	2	NA	pval	0.16
10.1080/10428194.2019.1682571	results	2	NA	num_pval	0.16
10.1080/10428194.2019.1682571	results	2	NA	ci_cutoff	1
10.1080/10428194.2019.1682571	results	2	NA	significant	FALSE
10.1080/10428194.2019.1682571	results	2	NA	lb_ci	NA
10.1080/10428194.2019.1682571	results	2	NA	ub_ci	NA
10.1080/10428194.2019.1682571	results	2	NA	pval	0.02
10.1080/10428194.2019.1682571	results	2	NA	num_pval	0.02
10.1080/10428194.2019.1682571	results	2	NA	ci_cutoff	1
10.1080/10428194.2019.1682571	results	2	NA	significant	TRUE
10.1080/10428194.2019.1682571	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	547
10.1080/10428194.2019.1682571	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	350
10.1080/10428194.2019.1682571	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	248
10.1080/10428194.2019.1682571	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2019.1682571	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2019.1682571	results	3	NA	Number of covariates adjusted for/matched on	7
10.1080/10428194.2019.1682571	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	3	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2019.1682571	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	3	NA	Primary outcome: unadjusted treatment effect	0.68
10.1080/10428194.2019.1682571	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.024
10.1080/10428194.2019.1682571	results	3	NA	Primary outcome: adjusted treatment effect	0.53
10.1080/10428194.2019.1682571	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.003
10.1080/10428194.2019.1682571	results	3	NA	lb_ci	NA
10.1080/10428194.2019.1682571	results	3	NA	ub_ci	NA
10.1080/10428194.2019.1682571	results	3	NA	pval	0.024
10.1080/10428194.2019.1682571	results	3	NA	num_pval	0.024
10.1080/10428194.2019.1682571	results	3	NA	ci_cutoff	1
10.1080/10428194.2019.1682571	results	3	NA	significant	TRUE
10.1080/10428194.2019.1682571	results	3	NA	lb_ci	NA
10.1080/10428194.2019.1682571	results	3	NA	ub_ci	NA
10.1080/10428194.2019.1682571	results	3	NA	pval	0.003
10.1080/10428194.2019.1682571	results	3	NA	num_pval	0.003
10.1080/10428194.2019.1682571	results	3	NA	ci_cutoff	1
10.1080/10428194.2019.1682571	results	3	NA	significant	TRUE
10.1080/10428194.2019.1682571	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2019.1682571	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2019.1682571	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02195479
10.1080/10428194.2019.1682571	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1682571	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1682571	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2019.1682571	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2019.1682571	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2019.1682571	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00689936
10.1080/10428194.2019.1682571	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2019.1682571	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2019.1682571	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913143	general_information	NA	NA	Medical Condition of Interest Name	relapsed and refractory multiple myeloma
10.1080/10428194.2021.1913143	general_information	NA	NA	Countries of first author affiliations	spain
10.1080/10428194.2021.1913143	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1080/10428194.2021.1913143	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2021.1913143	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2021.1913143	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2021.1913143	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2021.1913143	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 1	idecabtagene vicleucel
10.1080/10428194.2021.1913143	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913143	methodology	1	NA	Treatment name 2	selinexor + dexamethasone
10.1080/10428194.2021.1913143	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.1913143	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913143	methodology	1	NA	Anchored comparison?	No
10.1080/10428194.2021.1913143	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913143	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913143	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1080/10428194.2021.1913143	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/10428194.2021.1913143	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.1913143	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/10428194.2021.1913143	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913143	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913143	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 1	idecabtagene + vicleucel
10.1080/10428194.2021.1913143	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913143	methodology	2	NA	Treatment name 2	belantamab mafodotin
10.1080/10428194.2021.1913143	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1080/10428194.2021.1913143	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913143	methodology	2	NA	Anchored comparison?	No
10.1080/10428194.2021.1913143	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913143	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913143	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1080/10428194.2021.1913143	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/10428194.2021.1913143	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.1913143	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/10428194.2021.1913143	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913143	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913143	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913143	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	122
10.1080/10428194.2021.1913143	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	128
10.1080/10428194.2021.1913143	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC	56
10.1080/10428194.2021.1913143	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2021.1913143	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913143	results	1	NA	Number of covariates adjusted for/matched on	6
10.1080/10428194.2021.1913143	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/10428194.2021.1913143	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1080/10428194.2021.1913143	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913143	results	1	NA	Primary outcome: unadjusted treatment effect	7.78
10.1080/10428194.2021.1913143	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[4.43;13.65]
10.1080/10428194.2021.1913143	results	1	NA	Primary outcome: adjusted treatment effect	7.74
10.1080/10428194.2021.1913143	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	[3.83;15.62]
10.1080/10428194.2021.1913143	results	1	NA	lb_ci	4.43
10.1080/10428194.2021.1913143	results	1	NA	ub_ci	13.65
10.1080/10428194.2021.1913143	results	1	NA	pval	NA
10.1080/10428194.2021.1913143	results	1	NA	num_pval	NA
10.1080/10428194.2021.1913143	results	1	NA	ci_cutoff	1
10.1080/10428194.2021.1913143	results	1	NA	significant	FALSE
10.1080/10428194.2021.1913143	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	97
10.1080/10428194.2021.1913143	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	128
10.1080/10428194.2021.1913143	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC	45
10.1080/10428194.2021.1913143	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2021.1913143	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913143	results	2	NA	Number of covariates adjusted for/matched on	6
10.1080/10428194.2021.1913143	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/10428194.2021.1913143	results	2	NA	Primary outcome: treatment effect contrast	OR
10.1080/10428194.2021.1913143	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913143	results	2	NA	Primary outcome: unadjusted treatment effect	6.17
10.1080/10428194.2021.1913143	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[3.45;11.05]
10.1080/10428194.2021.1913143	results	2	NA	Primary outcome: adjusted treatment effect	5.12
10.1080/10428194.2021.1913143	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX	[2.35;11.13]
10.1080/10428194.2021.1913143	results	2	NA	lb_ci	3.45
10.1080/10428194.2021.1913143	results	2	NA	ub_ci	11.05
10.1080/10428194.2021.1913143	results	2	NA	pval	NA
10.1080/10428194.2021.1913143	results	2	NA	num_pval	NA
10.1080/10428194.2021.1913143	results	2	NA	ci_cutoff	1
10.1080/10428194.2021.1913143	results	2	NA	significant	FALSE
10.1080/10428194.2021.1913143	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2021.1913143	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2021.1913143	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03361748
10.1080/10428194.2021.1913143	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913143	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.1913143	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.1913143	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2021.1913143	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2021.1913143	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336815
10.1080/10428194.2021.1913143	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913143	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.1913143	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.1913143	study_information	NA	3	Patient-level data used	No
10.1080/10428194.2021.1913143	study_information	NA	3	Clinical Trial	Yes
10.1080/10428194.2021.1913143	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03525678
10.1080/10428194.2021.1913143	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913143	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.1913143	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.1913144	general_information	NA	NA	Medical Condition of Interest Name	chronic lymphocytic leukemia
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/10428194.2021.1913144	general_information	NA	NA	Countries of last author affiliations	uk
10.1080/10428194.2021.1913144	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/10428194.2021.1913144	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/10428194.2021.1913144	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2021.1913144	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2021.1913144	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 1	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	1	NA	Treatment name 2	ibrutinib
10.1080/10428194.2021.1913144	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.1913144	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913144	methodology	1	NA	Anchored comparison?	No
10.1080/10428194.2021.1913144	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2021.1913144	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2021.1913144	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913144	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 1	acalabrutinib
10.1080/10428194.2021.1913144	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	2	NA	Treatment name 2	ibrutinib
10.1080/10428194.2021.1913144	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.1913144	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913144	methodology	2	NA	Anchored comparison?	No
10.1080/10428194.2021.1913144	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2021.1913144	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2021.1913144	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913144	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 1	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	3	NA	Treatment name 2	ibrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.1080/10428194.2021.1913144	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913144	methodology	3	NA	Anchored comparison?	No
10.1080/10428194.2021.1913144	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2021.1913144	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2021.1913144	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913144	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 1	acalabrutinib
10.1080/10428194.2021.1913144	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	4	NA	Treatment name 2	ibrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	4	NA	Study 'number(s)' for treatment 2	3
10.1080/10428194.2021.1913144	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913144	methodology	4	NA	Anchored comparison?	No
10.1080/10428194.2021.1913144	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2021.1913144	methodology	4	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2021.1913144	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913144	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 1	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	5	NA	Treatment name 2	venetoclax + obinutuzumab
10.1080/10428194.2021.1913144	methodology	5	NA	Study 'number(s)' for treatment 2	4
10.1080/10428194.2021.1913144	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913144	methodology	5	NA	Anchored comparison?	No
10.1080/10428194.2021.1913144	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2021.1913144	methodology	5	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2021.1913144	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913144	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 1	acalabrutinib
10.1080/10428194.2021.1913144	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.1913144	methodology	6	NA	Treatment name 2	venetoclax + obinutuzumab
10.1080/10428194.2021.1913144	methodology	6	NA	Study 'number(s)' for treatment 2	4
10.1080/10428194.2021.1913144	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.1913144	methodology	6	NA	Anchored comparison?	No
10.1080/10428194.2021.1913144	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2021.1913144	methodology	6	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2021.1913144	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.1913144	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.1913144	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	136
10.1080/10428194.2021.1913144	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	126
10.1080/10428194.2021.1913144	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	59
10.1080/10428194.2021.1913144	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913144	results	1	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.1913144	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2021.1913144	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	1	NA	Primary outcome: adjusted treatment effect	0.61
10.1080/10428194.2021.1913144	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.3
10.1080/10428194.2021.1913144	results	1	NA	geographical region	No
10.1080/10428194.2021.1913144	results	1	NA	lb_ci	NA
10.1080/10428194.2021.1913144	results	1	NA	ub_ci	NA
10.1080/10428194.2021.1913144	results	1	NA	pval	0.3
10.1080/10428194.2021.1913144	results	1	NA	num_pval	0.3
10.1080/10428194.2021.1913144	results	1	NA	ci_cutoff	1
10.1080/10428194.2021.1913144	results	1	NA	significant	FALSE
10.1080/10428194.2021.1913144	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	136
10.1080/10428194.2021.1913144	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	136
10.1080/10428194.2021.1913144	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	79
10.1080/10428194.2021.1913144	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913144	results	2	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.1913144	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2021.1913144	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	2	NA	Primary outcome: adjusted treatment effect	0.92
10.1080/10428194.2021.1913144	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.83
10.1080/10428194.2021.1913144	results	2	NA	geographical region	No
10.1080/10428194.2021.1913144	results	2	NA	lb_ci	NA
10.1080/10428194.2021.1913144	results	2	NA	ub_ci	NA
10.1080/10428194.2021.1913144	results	2	NA	pval	0.83
10.1080/10428194.2021.1913144	results	2	NA	num_pval	0.83
10.1080/10428194.2021.1913144	results	2	NA	ci_cutoff	1
10.1080/10428194.2021.1913144	results	2	NA	significant	FALSE
10.1080/10428194.2021.1913144	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	113
10.1080/10428194.2021.1913144	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	113
10.1080/10428194.2021.1913144	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	97
10.1080/10428194.2021.1913144	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913144	results	3	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.1913144	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	3	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2021.1913144	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	3	NA	Primary outcome: adjusted treatment effect	0.55
10.1080/10428194.2021.1913144	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.11
10.1080/10428194.2021.1913144	results	3	NA	geographical region	No
10.1080/10428194.2021.1913144	results	3	NA	lb_ci	NA
10.1080/10428194.2021.1913144	results	3	NA	ub_ci	NA
10.1080/10428194.2021.1913144	results	3	NA	pval	0.11
10.1080/10428194.2021.1913144	results	3	NA	num_pval	0.11
10.1080/10428194.2021.1913144	results	3	NA	ci_cutoff	1
10.1080/10428194.2021.1913144	results	3	NA	significant	FALSE
10.1080/10428194.2021.1913144	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	113
10.1080/10428194.2021.1913144	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	114
10.1080/10428194.2021.1913144	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	97
10.1080/10428194.2021.1913144	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913144	results	4	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.1913144	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	4	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2021.1913144	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	4	NA	Primary outcome: adjusted treatment effect	0.53
10.1080/10428194.2021.1913144	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.08
10.1080/10428194.2021.1913144	results	4	NA	geographical region	No
10.1080/10428194.2021.1913144	results	4	NA	lb_ci	NA
10.1080/10428194.2021.1913144	results	4	NA	ub_ci	NA
10.1080/10428194.2021.1913144	results	4	NA	pval	0.08
10.1080/10428194.2021.1913144	results	4	NA	num_pval	0.08
10.1080/10428194.2021.1913144	results	4	NA	ci_cutoff	1
10.1080/10428194.2021.1913144	results	4	NA	significant	FALSE
10.1080/10428194.2021.1913144	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	216
10.1080/10428194.2021.1913144	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	83
10.1080/10428194.2021.1913144	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43
10.1080/10428194.2021.1913144	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913144	results	5	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.1913144	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	5	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2021.1913144	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	5	NA	Primary outcome: adjusted treatment effect	0.78
10.1080/10428194.2021.1913144	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.57
10.1080/10428194.2021.1913144	results	5	NA	geographical region	No
10.1080/10428194.2021.1913144	results	5	NA	lb_ci	NA
10.1080/10428194.2021.1913144	results	5	NA	ub_ci	NA
10.1080/10428194.2021.1913144	results	5	NA	pval	0.57
10.1080/10428194.2021.1913144	results	5	NA	num_pval	0.57
10.1080/10428194.2021.1913144	results	5	NA	ci_cutoff	1
10.1080/10428194.2021.1913144	results	5	NA	significant	FALSE
10.1080/10428194.2021.1913144	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	216
10.1080/10428194.2021.1913144	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	96
10.1080/10428194.2021.1913144	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	51
10.1080/10428194.2021.1913144	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.1913144	results	6	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.1913144	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	6	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2021.1913144	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	6	NA	Primary outcome: adjusted treatment effect	1.24
10.1080/10428194.2021.1913144	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.59
10.1080/10428194.2021.1913144	results	6	NA	geographical region	No
10.1080/10428194.2021.1913144	results	6	NA	lb_ci	NA
10.1080/10428194.2021.1913144	results	6	NA	ub_ci	NA
10.1080/10428194.2021.1913144	results	6	NA	pval	0.59
10.1080/10428194.2021.1913144	results	6	NA	num_pval	0.59
10.1080/10428194.2021.1913144	results	6	NA	ci_cutoff	1
10.1080/10428194.2021.1913144	results	6	NA	significant	FALSE
10.1080/10428194.2021.1913144	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2021.1913144	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02475681
10.1080/10428194.2021.1913144	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913144	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2021.1913144	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01722487
10.1080/10428194.2021.1913144	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913144	study_information	NA	3	Patient-level data used	No
10.1080/10428194.2021.1913144	study_information	NA	3	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02264574
10.1080/10428194.2021.1913144	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.1913144	study_information	NA	4	Patient-level data used	No
10.1080/10428194.2021.1913144	study_information	NA	4	Clinical Trial	Yes
10.1080/10428194.2021.1913144	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02242942
10.1080/10428194.2021.1913144	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.1913144	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2021.1913144	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2021.2010069	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory large b-cell lymphomas
10.1080/10428194.2021.2010069	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/10428194.2021.2010069	general_information	NA	NA	Countries of last author affiliations	netherlands
10.1080/10428194.2021.2010069	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2021.2010069	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2021.2010069	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2021.2010069	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2021.2010069	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 1	tisagenlecleucel
10.1080/10428194.2021.2010069	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2021.2010069	methodology	1	NA	Treatment name 2	lisocabtagene
10.1080/10428194.2021.2010069	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2021.2010069	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2021.2010069	methodology	1	NA	Anchored comparison?	No
10.1080/10428194.2021.2010069	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.2010069	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.2010069	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall response rate
10.1080/10428194.2021.2010069	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/10428194.2021.2010069	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.2010069	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/10428194.2021.2010069	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.2010069	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2021.2010069	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2021.2010069	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	256
10.1080/10428194.2021.2010069	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	106
10.1080/10428194.2021.2010069	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	29
10.1080/10428194.2021.2010069	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2021.2010069	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2021.2010069	results	1	NA	Number of covariates adjusted for/matched on	12
10.1080/10428194.2021.2010069	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.2010069	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1080/10428194.2021.2010069	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2021.2010069	results	1	NA	Primary outcome: unadjusted treatment effect	-15.50
10.1080/10428194.2021.2010069	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.01
10.1080/10428194.2021.2010069	results	1	NA	Primary outcome: adjusted treatment effect	-9.70
10.1080/10428194.2021.2010069	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.07
10.1080/10428194.2021.2010069	results	1	NA	lb_ci	NA
10.1080/10428194.2021.2010069	results	1	NA	ub_ci	NA
10.1080/10428194.2021.2010069	results	1	NA	pval	<0.01
10.1080/10428194.2021.2010069	results	1	NA	num_pval	NA
10.1080/10428194.2021.2010069	results	1	NA	ci_cutoff	0
10.1080/10428194.2021.2010069	results	1	NA	significant	TRUE
10.1080/10428194.2021.2010069	results	1	NA	lb_ci	NA
10.1080/10428194.2021.2010069	results	1	NA	ub_ci	NA
10.1080/10428194.2021.2010069	results	1	NA	pval	0.07
10.1080/10428194.2021.2010069	results	1	NA	num_pval	0.07
10.1080/10428194.2021.2010069	results	1	NA	ci_cutoff	0
10.1080/10428194.2021.2010069	results	1	NA	significant	FALSE
10.1080/10428194.2021.2010069	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2021.2010069	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2021.2010069	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248
10.1080/10428194.2021.2010069	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2021.2010069	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/10428194.2021.2010069	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2021.2010069	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2021.2010069	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2021.2010069	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1080/10428194.2021.2010069	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/10428194.2021.2010069	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.1080/10428194.2021.2010069	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1080/10428194.2022.2047962	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma
10.1080/10428194.2022.2047962	general_information	NA	NA	Countries of first author affiliations	germany
10.1080/10428194.2022.2047962	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/10428194.2022.2047962	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/10428194.2022.2047962	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/10428194.2022.2047962	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/10428194.2022.2047962	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/10428194.2022.2047962	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 1	carfizomib + dexamethasone+daratumumab
10.1080/10428194.2022.2047962	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/10428194.2022.2047962	methodology	1	NA	Treatment name 2	daratumumab + velcade+dexamethasone
10.1080/10428194.2022.2047962	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/10428194.2022.2047962	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/10428194.2022.2047962	methodology	1	NA	Anchored comparison?	No
10.1080/10428194.2022.2047962	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2022.2047962	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/10428194.2022.2047962	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/10428194.2022.2047962	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2022.2047962	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2022.2047962	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/10428194.2022.2047962	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/10428194.2022.2047962	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	251
10.1080/10428194.2022.2047962	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	198
10.1080/10428194.2022.2047962	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	82
10.1080/10428194.2022.2047962	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/10428194.2022.2047962	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/10428194.2022.2047962	results	1	NA	Number of covariates adjusted for/matched on	10
10.1080/10428194.2022.2047962	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1080/10428194.2022.2047962	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/10428194.2022.2047962	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/10428194.2022.2047962	results	1	NA	Primary outcome: unadjusted treatment effect	0.54
10.1080/10428194.2022.2047962	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.41;0.70]
10.1080/10428194.2022.2047962	results	1	NA	Primary outcome: adjusted treatment effect	0.64
10.1080/10428194.2022.2047962	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.46;0.90]
10.1080/10428194.2022.2047962	results	1	NA	geographical region	No
10.1080/10428194.2022.2047962	results	1	NA	lb_ci	0.41
10.1080/10428194.2022.2047962	results	1	NA	ub_ci	0.7
10.1080/10428194.2022.2047962	results	1	NA	pval	NA
10.1080/10428194.2022.2047962	results	1	NA	num_pval	NA
10.1080/10428194.2022.2047962	results	1	NA	ci_cutoff	1
10.1080/10428194.2022.2047962	results	1	NA	significant	FALSE
10.1080/10428194.2022.2047962	results	1	NA	lb_ci	0.46
10.1080/10428194.2022.2047962	results	1	NA	ub_ci	0.9
10.1080/10428194.2022.2047962	results	1	NA	pval	NA
10.1080/10428194.2022.2047962	results	1	NA	num_pval	NA
10.1080/10428194.2022.2047962	results	1	NA	ci_cutoff	1
10.1080/10428194.2022.2047962	results	1	NA	significant	FALSE
10.1080/10428194.2022.2047962	study_information	NA	1	Patient-level data used	Yes
10.1080/10428194.2022.2047962	study_information	NA	1	Clinical Trial	Yes
10.1080/10428194.2022.2047962	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03158688
10.1080/10428194.2022.2047962	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2022.2047962	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2022.2047962	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/10428194.2022.2047962	study_information	NA	2	Patient-level data used	No
10.1080/10428194.2022.2047962	study_information	NA	2	Clinical Trial	Yes
10.1080/10428194.2022.2047962	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02136134
10.1080/10428194.2022.2047962	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/10428194.2022.2047962	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/10428194.2022.2047962	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2018.1443111	general_information	NA	NA	Medical Condition of Interest Name	(ALK)-positive metastatic non-small cell lung cancer
10.1080/13696998.2018.1443111	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/13696998.2018.1443111	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/13696998.2018.1443111	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/13696998.2018.1443111	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/13696998.2018.1443111	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/13696998.2018.1443111	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/13696998.2018.1443111	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 1	ceritinib
10.1080/13696998.2018.1443111	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/13696998.2018.1443111	methodology	1	NA	Treatment name 2	crizotinib
10.1080/13696998.2018.1443111	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/13696998.2018.1443111	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/13696998.2018.1443111	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/13696998.2018.1443111	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/13696998.2018.1443111	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/13696998.2018.1443111	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/13696998.2018.1443111	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/13696998.2018.1443111	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/13696998.2018.1443111	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/13696998.2018.1443111	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/13696998.2018.1443111	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/13696998.2018.1443111	methodology	1	NA	Anchored comparison?	No
10.1080/13696998.2018.1443111	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/13696998.2018.1443111	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.1080/13696998.2018.1443111	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/13696998.2018.1443111	results	1	NA	Primary outcome: adjusted treatment effect	0.64
10.1080/13696998.2018.1443111	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.47;0.87]
10.1080/13696998.2018.1443111	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/13696998.2018.1443111	results	1	NA	lb_ci	0.47
10.1080/13696998.2018.1443111	results	1	NA	ub_ci	0.87
10.1080/13696998.2018.1443111	results	1	NA	pval	NA
10.1080/13696998.2018.1443111	results	1	NA	num_pval	NA
10.1080/13696998.2018.1443111	results	1	NA	ci_cutoff	1
10.1080/13696998.2018.1443111	results	1	NA	significant	FALSE
10.1080/13696998.2018.1443111	study_information	NA	1	Patient-level data used	Yes
10.1080/13696998.2018.1443111	study_information	NA	1	Clinical Trial	Yes
10.1080/13696998.2018.1443111	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099
10.1080/13696998.2018.1443111	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/13696998.2018.1443111	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2018.1443111	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2018.1443111	study_information	NA	2	Patient-level data used	No
10.1080/13696998.2018.1443111	study_information	NA	2	Clinical Trial	Yes
10.1080/13696998.2018.1443111	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01154140
10.1080/13696998.2018.1443111	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/13696998.2018.1443111	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2018.1443111	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	general_information	NA	NA	Medical Condition of Interest Name	plaque psoriasis
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/13696998.2020.1722139	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/13696998.2020.1722139	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1080/13696998.2020.1722139	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1080/13696998.2020.1722139	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/13696998.2020.1722139	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/13696998.2020.1722139	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 1	calcipotriene 0.005/betamethasone dipropionate 0.064% foam
10.1080/13696998.2020.1722139	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/13696998.2020.1722139	methodology	1	NA	Treatment name 2	halobetasol 0.01/tazarotene 0.045%
10.1080/13696998.2020.1722139	methodology	1	NA	Study 'number(s)' for treatment 2	4;5
10.1080/13696998.2020.1722139	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/13696998.2020.1722139	methodology	1	NA	Anchored comparison?	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/13696998.2020.1722139	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	physicians global assessment treatment success
10.1080/13696998.2020.1722139	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1080/13696998.2020.1722139	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/13696998.2020.1722139	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1080/13696998.2020.1722139	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/13696998.2020.1722139	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/13696998.2020.1722139	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	276
10.1080/13696998.2020.1722139	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	142
10.1080/13696998.2020.1722139	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	649
10.1080/13696998.2020.1722139	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	199
10.1080/13696998.2020.1722139	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/13696998.2020.1722139	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/13696998.2020.1722139	results	1	NA	Number of covariates adjusted for/matched on	4
10.1080/13696998.2020.1722139	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/13696998.2020.1722139	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1080/13696998.2020.1722139	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/13696998.2020.1722139	results	1	NA	Primary outcome: adjusted treatment effect	20.7
10.1080/13696998.2020.1722139	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1080/13696998.2020.1722139	results	1	NA	If anchored, total initial sample size IPD	848
10.1080/13696998.2020.1722139	results	1	NA	If anchored, total ESS IPD	586
10.1080/13696998.2020.1722139	results	1	NA	If anchored, total sample size non IPD	418
10.1080/13696998.2020.1722139	results	1	NA	lb_ci	NA
10.1080/13696998.2020.1722139	results	1	NA	ub_ci	NA
10.1080/13696998.2020.1722139	results	1	NA	pval	<0.001
10.1080/13696998.2020.1722139	results	1	NA	num_pval	NA
10.1080/13696998.2020.1722139	results	1	NA	ci_cutoff	0
10.1080/13696998.2020.1722139	results	1	NA	significant	TRUE
10.1080/13696998.2020.1722139	study_information	NA	1	Patient-level data used	Yes
10.1080/13696998.2020.1722139	study_information	NA	1	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163
10.1080/13696998.2020.1722139	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	2	Patient-level data used	Yes
10.1080/13696998.2020.1722139	study_information	NA	2	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936
10.1080/13696998.2020.1722139	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1080/13696998.2020.1722139	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	3	Patient-level data used	Yes
10.1080/13696998.2020.1722139	study_information	NA	3	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886
10.1080/13696998.2020.1722139	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1080/13696998.2020.1722139	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	4	Patient-level data used	No
10.1080/13696998.2020.1722139	study_information	NA	4	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462070
10.1080/13696998.2020.1722139	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/13696998.2020.1722139	study_information	NA	5	Patient-level data used	No
10.1080/13696998.2020.1722139	study_information	NA	5	Clinical Trial	Yes
10.1080/13696998.2020.1722139	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02462122
10.1080/13696998.2020.1722139	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1080/13696998.2020.1722139	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1080/13696998.2020.1722139	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1080/14656566.2020.1811850	general_information	NA	NA	Medical Condition of Interest Name	amyloidosis with polyneuropathy
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of first author affiliations	usa
10.1080/14656566.2020.1811850	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/14656566.2020.1811850	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/14656566.2020.1811850	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/14656566.2020.1811850	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/14656566.2020.1811850	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/14656566.2020.1811850	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 1	patisiran
10.1080/14656566.2020.1811850	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/14656566.2020.1811850	methodology	1	NA	Treatment name 2	inotersen
10.1080/14656566.2020.1811850	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/14656566.2020.1811850	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/14656566.2020.1811850	methodology	1	NA	Anchored comparison?	Yes
10.1080/14656566.2020.1811850	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/14656566.2020.1811850	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/14656566.2020.1811850	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	15-month changes from baseline in mnis+7ionis (modified neuropathy impairment score +7)
10.1080/14656566.2020.1811850	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1080/14656566.2020.1811850	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1080/14656566.2020.1811850	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/14656566.2020.1811850	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/14656566.2020.1811850	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1080/14656566.2020.1811850	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/14656566.2020.1811850	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	112
10.1080/14656566.2020.1811850	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	60
10.1080/14656566.2020.1811850	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	148
10.1080/14656566.2020.1811850	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	90
10.1080/14656566.2020.1811850	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	77
10.1080/14656566.2020.1811850	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	47
10.1080/14656566.2020.1811850	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/14656566.2020.1811850	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/14656566.2020.1811850	results	1	NA	Number of covariates adjusted for/matched on	9
10.1080/14656566.2020.1811850	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/14656566.2020.1811850	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1080/14656566.2020.1811850	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/14656566.2020.1811850	results	1	NA	Primary outcome: unadjusted treatment effect	-16.2
10.1080/14656566.2020.1811850	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.001
10.1080/14656566.2020.1811850	results	1	NA	Primary outcome: adjusted treatment effect	-12.3
10.1080/14656566.2020.1811850	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.007
10.1080/14656566.2020.1811850	results	1	NA	geographical region	No
10.1080/14656566.2020.1811850	results	1	NA	lb_ci	NA
10.1080/14656566.2020.1811850	results	1	NA	ub_ci	NA
10.1080/14656566.2020.1811850	results	1	NA	pval	0.001
10.1080/14656566.2020.1811850	results	1	NA	num_pval	0.001
10.1080/14656566.2020.1811850	results	1	NA	ci_cutoff	0
10.1080/14656566.2020.1811850	results	1	NA	significant	TRUE
10.1080/14656566.2020.1811850	results	1	NA	lb_ci	NA
10.1080/14656566.2020.1811850	results	1	NA	ub_ci	NA
10.1080/14656566.2020.1811850	results	1	NA	pval	0.007
10.1080/14656566.2020.1811850	results	1	NA	num_pval	0.007
10.1080/14656566.2020.1811850	results	1	NA	ci_cutoff	0
10.1080/14656566.2020.1811850	results	1	NA	significant	TRUE
10.1080/14656566.2020.1811850	study_information	NA	1	Patient-level data used	Yes
10.1080/14656566.2020.1811850	study_information	NA	1	Clinical Trial	Yes
10.1080/14656566.2020.1811850	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01960348
10.1080/14656566.2020.1811850	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14656566.2020.1811850	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/14656566.2020.1811850	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/14656566.2020.1811850	study_information	NA	2	Patient-level data used	No
10.1080/14656566.2020.1811850	study_information	NA	2	Clinical Trial	Yes
10.1080/14656566.2020.1811850	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01737398
10.1080/14656566.2020.1811850	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14656566.2020.1811850	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.1080/14656566.2020.1811850	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	general_information	NA	NA	Medical Condition of Interest Name	pneumococcal disease
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of first author affiliations	switzerland
10.1080/14760584.2021.1994858	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/14760584.2021.1994858	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry
10.1080/14760584.2021.1994858	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/14760584.2021.1994858	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/14760584.2021.1994858	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/14760584.2021.1994858	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 1	15-valent pneumococcal conjugate vaccine
10.1080/14760584.2021.1994858	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.1080/14760584.2021.1994858	methodology	1	NA	Treatment name 2	20-valent pneumococcal conjugate vaccine
10.1080/14760584.2021.1994858	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.1080/14760584.2021.1994858	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1080/14760584.2021.1994858	methodology	1	NA	Anchored comparison?	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/14760584.2021.1994858	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	30 days post-vaccination serotype-specific opa (opsonophagocytic activity)
10.1080/14760584.2021.1994858	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1080/14760584.2021.1994858	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/14760584.2021.1994858	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.1080/14760584.2021.1994858	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1507
10.1080/14760584.2021.1994858	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	1490
10.1080/14760584.2021.1994858	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	2196
10.1080/14760584.2021.1994858	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	843
10.1080/14760584.2021.1994858	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1080/14760584.2021.1994858	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/14760584.2021.1994858	results	1	NA	Number of covariates adjusted for/matched on	2
10.1080/14760584.2021.1994858	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex
10.1080/14760584.2021.1994858	results	1	NA	Primary outcome: treatment effect contrast	Means Ratio
10.1080/14760584.2021.1994858	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1080/14760584.2021.1994858	results	1	NA	Primary outcome: unadjusted treatment effect	0.89
10.1080/14760584.2021.1994858	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1080/14760584.2021.1994858	results	1	NA	Primary outcome: adjusted treatment effect	0.91
10.1080/14760584.2021.1994858	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1080/14760584.2021.1994858	results	1	NA	If anchored, total initial sample size IPD	3033
10.1080/14760584.2021.1994858	results	1	NA	If anchored, total ESS IPD	1710
10.1080/14760584.2021.1994858	results	1	NA	If anchored, total sample size non IPD	2997
10.1080/14760584.2021.1994858	results	1	NA	lb_ci	NA
10.1080/14760584.2021.1994858	results	1	NA	ub_ci	NA
10.1080/14760584.2021.1994858	results	1	NA	pval	<0.001
10.1080/14760584.2021.1994858	results	1	NA	num_pval	NA
10.1080/14760584.2021.1994858	results	1	NA	ci_cutoff	1
10.1080/14760584.2021.1994858	results	1	NA	significant	TRUE
10.1080/14760584.2021.1994858	results	1	NA	lb_ci	NA
10.1080/14760584.2021.1994858	results	1	NA	ub_ci	NA
10.1080/14760584.2021.1994858	results	1	NA	pval	<0.001
10.1080/14760584.2021.1994858	results	1	NA	num_pval	NA
10.1080/14760584.2021.1994858	results	1	NA	ci_cutoff	1
10.1080/14760584.2021.1994858	results	1	NA	significant	TRUE
10.1080/14760584.2021.1994858	study_information	NA	1	Patient-level data used	Yes
10.1080/14760584.2021.1994858	study_information	NA	1	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950622
10.1080/14760584.2021.1994858	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	study_information	NA	2	Patient-level data used	Yes
10.1080/14760584.2021.1994858	study_information	NA	2	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03480763
10.1080/14760584.2021.1994858	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	study_information	NA	3	Patient-level data used	Yes
10.1080/14760584.2021.1994858	study_information	NA	3	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03950856
10.1080/14760584.2021.1994858	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1080/14760584.2021.1994858	study_information	NA	4	Patient-level data used	No
10.1080/14760584.2021.1994858	study_information	NA	4	Clinical Trial	Yes
10.1080/14760584.2021.1994858	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03760146
10.1080/14760584.2021.1994858	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1080/14760584.2021.1994858	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1080/14760584.2021.1994858	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1080/17474086.2018.1475226	general_information	NA	NA	Medical Condition of Interest Name	relapsed and refractory classical hodgkins lymphoma
10.1080/17474086.2018.1475226	general_information	NA	NA	Countries of first author affiliations	canada
10.1080/17474086.2018.1475226	general_information	NA	NA	Countries of last author affiliations	usa
10.1080/17474086.2018.1475226	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1080/17474086.2018.1475226	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1080/17474086.2018.1475226	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1080/17474086.2018.1475226	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1080/17474086.2018.1475226	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 1	pembrolizumab
10.1080/17474086.2018.1475226	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1080/17474086.2018.1475226	methodology	1	NA	Treatment name 2	st + ard of care
10.1080/17474086.2018.1475226	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1080/17474086.2018.1475226	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.1080/17474086.2018.1475226	methodology	1	NA	Anchored comparison?	No
10.1080/17474086.2018.1475226	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1080/17474086.2018.1475226	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1080/17474086.2018.1475226	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1080/17474086.2018.1475226	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/17474086.2018.1475226	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/17474086.2018.1475226	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1080/17474086.2018.1475226	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	83
10.1080/17474086.2018.1475226	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	175
10.1080/17474086.2018.1475226	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1080/17474086.2018.1475226	results	1	NA	Number of covariates adjusted for/matched on	7
10.1080/17474086.2018.1475226	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/17474086.2018.1475226	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1080/17474086.2018.1475226	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1080/17474086.2018.1475226	results	1	NA	Primary outcome: unadjusted treatment effect	5
10.1080/17474086.2018.1475226	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[3.56;7.01]
10.1080/17474086.2018.1475226	results	1	NA	Primary outcome: adjusted treatment effect	6.35
10.1080/17474086.2018.1475226	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[4.04;9.98]
10.1080/17474086.2018.1475226	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	175
10.1080/17474086.2018.1475226	results	1	NA	lb_ci	3.56
10.1080/17474086.2018.1475226	results	1	NA	ub_ci	7.01
10.1080/17474086.2018.1475226	results	1	NA	pval	NA
10.1080/17474086.2018.1475226	results	1	NA	num_pval	NA
10.1080/17474086.2018.1475226	results	1	NA	ci_cutoff	1
10.1080/17474086.2018.1475226	results	1	NA	significant	FALSE
10.1080/17474086.2018.1475226	results	1	NA	lb_ci	4.04
10.1080/17474086.2018.1475226	results	1	NA	ub_ci	9.98
10.1080/17474086.2018.1475226	results	1	NA	pval	NA
10.1080/17474086.2018.1475226	results	1	NA	num_pval	NA
10.1080/17474086.2018.1475226	results	1	NA	ci_cutoff	1
10.1080/17474086.2018.1475226	results	1	NA	significant	FALSE
10.1080/17474086.2018.1475226	study_information	NA	1	Patient-level data used	Yes
10.1080/17474086.2018.1475226	study_information	NA	1	Clinical Trial	Yes
10.1080/17474086.2018.1475226	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02453594
10.1080/17474086.2018.1475226	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1080/17474086.2018.1475226	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1080/17474086.2018.1475226	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1080/17474086.2018.1475226	study_information	NA	2	Patient-level data used	No
10.1080/17474086.2018.1475226	study_information	NA	2	Clinical Trial	No
10.1080/17474086.2018.1475226	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	cheah et al., 2016
10.1080/17474086.2018.1475226	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1093/europace/euy160	general_information	NA	NA	Medical Condition of Interest Name	non-valvular atrial fibrillation
10.1093/europace/euy160	general_information	NA	NA	Countries of first author affiliations	uk
10.1093/europace/euy160	general_information	NA	NA	Countries of last author affiliations	canada
10.1093/europace/euy160	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1093/europace/euy160	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1093/europace/euy160	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1093/europace/euy160	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1093/europace/euy160	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1093/europace/euy160	methodology	1	NA	Treatment name 1	rivaroxaban
10.1093/europace/euy160	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1093/europace/euy160	methodology	1	NA	Treatment name 2	rivaroxaban
10.1093/europace/euy160	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1093/europace/euy160	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1093/europace/euy160	methodology	1	NA	Anchored comparison?	No
10.1093/europace/euy160	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1093/europace/euy160	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1093/europace/euy160	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	treatment-emergent adjudicated major bleeding
10.1093/europace/euy160	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1093/europace/euy160	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1093/europace/euy160	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1093/europace/euy160	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1093/europace/euy160	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1093/europace/euy160	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1093/europace/euy160	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	7061
10.1093/europace/euy160	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	4020
10.1093/europace/euy160	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	2492
10.1093/europace/euy160	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1093/europace/euy160	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1093/europace/euy160	results	1	NA	Number of covariates adjusted for/matched on	2
10.1093/europace/euy160	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1093/europace/euy160	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1093/europace/euy160	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1093/europace/euy160	results	1	NA	Primary outcome: adjusted treatment effect	0.86
10.1093/europace/euy160	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.67;1.12]
10.1093/europace/euy160	results	1	NA	lb_ci	0.67
10.1093/europace/euy160	results	1	NA	ub_ci	1.12
10.1093/europace/euy160	results	1	NA	pval	NA
10.1093/europace/euy160	results	1	NA	num_pval	NA
10.1093/europace/euy160	results	1	NA	ci_cutoff	1
10.1093/europace/euy160	results	1	NA	significant	TRUE
10.1093/europace/euy160	study_information	NA	1	Patient-level data used	Yes
10.1093/europace/euy160	study_information	NA	1	Clinical Trial	No
10.1093/europace/euy160	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01606995
10.1093/europace/euy160	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1093/europace/euy160	study_information	NA	2	Patient-level data used	No
10.1093/europace/euy160	study_information	NA	2	Clinical Trial	Yes
10.1093/europace/euy160	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00403767
10.1093/europace/euy160	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1093/europace/euy160	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1093/europace/euy160	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1093/jnci/djab071	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer
10.1093/jnci/djab071	general_information	NA	NA	Countries of first author affiliations	usa
10.1093/jnci/djab071	general_information	NA	NA	Countries of last author affiliations	usa
10.1093/jnci/djab071	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.1093/jnci/djab071	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1093/jnci/djab071	general_information	NA	NA	Mentioned sources of funding	Public grants, Pharmaceutical Industry
10.1093/jnci/djab071	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1093/jnci/djab071	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1093/jnci/djab071	methodology	1	NA	Treatment name 1	abiraterone acetate
10.1093/jnci/djab071	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1093/jnci/djab071	methodology	1	NA	Treatment name 2	placebo
10.1093/jnci/djab071	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1093/jnci/djab071	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1093/jnci/djab071	methodology	1	NA	Anchored comparison?	No
10.1093/jnci/djab071	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1093/jnci/djab071	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1093/jnci/djab071	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	metastasis-free survival
10.1093/jnci/djab071	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1093/jnci/djab071	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1093/jnci/djab071	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1093/jnci/djab071	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1093/jnci/djab071	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1093/jnci/djab071	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1093/jnci/djab071	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1207
10.1093/jnci/djab071	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	131
10.1093/jnci/djab071	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	81
10.1093/jnci/djab071	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1093/jnci/djab071	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1093/jnci/djab071	results	1	NA	Number of covariates adjusted for/matched on	4
10.1093/jnci/djab071	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1093/jnci/djab071	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1093/jnci/djab071	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1093/jnci/djab071	results	1	NA	Primary outcome: adjusted treatment effect	0.22
10.1093/jnci/djab071	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.12;0.41]
10.1093/jnci/djab071	results	1	NA	lb_ci	0.12
10.1093/jnci/djab071	results	1	NA	ub_ci	0.41
10.1093/jnci/djab071	results	1	NA	pval	NA
10.1093/jnci/djab071	results	1	NA	num_pval	NA
10.1093/jnci/djab071	results	1	NA	ci_cutoff	1
10.1093/jnci/djab071	results	1	NA	significant	FALSE
10.1093/jnci/djab071	study_information	NA	1	Patient-level data used	Yes
10.1093/jnci/djab071	study_information	NA	1	Clinical Trial	Yes
10.1093/jnci/djab071	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01314118
10.1093/jnci/djab071	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1093/jnci/djab071	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1093/jnci/djab071	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1093/jnci/djab071	study_information	NA	2	Patient-level data used	No
10.1093/jnci/djab071	study_information	NA	2	Clinical Trial	Yes
10.1093/jnci/djab071	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1093/jnci/djab071	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1093/jnci/djab071	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1093/jnci/djab071	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1097/brs.0000000000002647	general_information	NA	NA	Medical Condition of Interest Name	lumbar disc degeneration
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of first author affiliations	usa
10.1097/brs.0000000000002647	general_information	NA	NA	Countries of last author affiliations	canada
10.1097/brs.0000000000002647	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company
10.1097/brs.0000000000002647	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1097/brs.0000000000002647	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1097/brs.0000000000002647	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1097/brs.0000000000002647	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 1	total disc replacement
10.1097/brs.0000000000002647	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1097/brs.0000000000002647	methodology	1	NA	Treatment name 2	fusion
10.1097/brs.0000000000002647	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1097/brs.0000000000002647	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1097/brs.0000000000002647	methodology	1	NA	Anchored comparison?	No
10.1097/brs.0000000000002647	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1097/brs.0000000000002647	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1097/brs.0000000000002647	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	5-year change in radiographic adjacent-level degeneration
10.1097/brs.0000000000002647	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1097/brs.0000000000002647	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1097/brs.0000000000002647	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1097/brs.0000000000002647	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1097/brs.0000000000002647	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1097/brs.0000000000002647	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1097/brs.0000000000002647	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	43
10.1097/brs.0000000000002647	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	175
10.1097/brs.0000000000002647	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	139
10.1097/brs.0000000000002647	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1097/brs.0000000000002647	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1097/brs.0000000000002647	results	1	NA	Number of covariates adjusted for/matched on	7
10.1097/brs.0000000000002647	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1097/brs.0000000000002647	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1097/brs.0000000000002647	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1097/brs.0000000000002647	results	1	NA	Primary outcome: unadjusted treatment effect	0.28
10.1097/brs.0000000000002647	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.12;0.63]
10.1097/brs.0000000000002647	results	1	NA	Primary outcome: adjusted treatment effect	0.32
10.1097/brs.0000000000002647	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.13;0.76]
10.1097/brs.0000000000002647	results	1	NA	geographical region	No
10.1097/brs.0000000000002647	results	1	NA	lb_ci	0.12
10.1097/brs.0000000000002647	results	1	NA	ub_ci	0.63
10.1097/brs.0000000000002647	results	1	NA	pval	NA
10.1097/brs.0000000000002647	results	1	NA	num_pval	NA
10.1097/brs.0000000000002647	results	1	NA	ci_cutoff	1
10.1097/brs.0000000000002647	results	1	NA	significant	FALSE
10.1097/brs.0000000000002647	results	1	NA	lb_ci	0.13
10.1097/brs.0000000000002647	results	1	NA	ub_ci	0.76
10.1097/brs.0000000000002647	results	1	NA	pval	NA
10.1097/brs.0000000000002647	results	1	NA	num_pval	NA
10.1097/brs.0000000000002647	results	1	NA	ci_cutoff	1
10.1097/brs.0000000000002647	results	1	NA	significant	FALSE
10.1097/brs.0000000000002647	study_information	NA	1	Patient-level data used	Yes
10.1097/brs.0000000000002647	study_information	NA	1	Clinical Trial	Yes
10.1097/brs.0000000000002647	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00589797
10.1097/brs.0000000000002647	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1097/brs.0000000000002647	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1097/brs.0000000000002647	study_information	NA	2	Patient-level data used	No
10.1097/brs.0000000000002647	study_information	NA	2	Clinical Trial	Yes
10.1097/brs.0000000000002647	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00295009
10.1097/brs.0000000000002647	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1097/brs.0000000000002647	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1097/ju.0000000000001767	general_information	NA	NA	Medical Condition of Interest Name	nonmetastatic castration-resistant prostate cancer
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of first author affiliations	usa
10.1097/ju.0000000000001767	general_information	NA	NA	Countries of last author affiliations	usa
10.1097/ju.0000000000001767	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1097/ju.0000000000001767	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1097/ju.0000000000001767	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1097/ju.0000000000001767	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1097/ju.0000000000001767	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 1	darolutamide
10.1097/ju.0000000000001767	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1097/ju.0000000000001767	methodology	1	NA	Treatment name 2	apalutamide
10.1097/ju.0000000000001767	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1097/ju.0000000000001767	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1097/ju.0000000000001767	methodology	1	NA	Anchored comparison?	Yes
10.1097/ju.0000000000001767	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1097/ju.0000000000001767	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1097/ju.0000000000001767	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	Risk of fall
10.1097/ju.0000000000001767	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1097/ju.0000000000001767	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1097/ju.0000000000001767	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1097/ju.0000000000001767	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1097/ju.0000000000001767	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1097/ju.0000000000001767	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 1	darolutamide
10.1097/ju.0000000000001767	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1097/ju.0000000000001767	methodology	2	NA	Treatment name 2	enzalutamide
10.1097/ju.0000000000001767	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1097/ju.0000000000001767	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1097/ju.0000000000001767	methodology	2	NA	Anchored comparison?	Yes
10.1097/ju.0000000000001767	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1097/ju.0000000000001767	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1097/ju.0000000000001767	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	Risk of fall
10.1097/ju.0000000000001767	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1097/ju.0000000000001767	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1097/ju.0000000000001767	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1097/ju.0000000000001767	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1097/ju.0000000000001767	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1097/ju.0000000000001767	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1097/ju.0000000000001767	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	806
10.1097/ju.0000000000001767	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	401
10.1097/ju.0000000000001767	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	943
10.1097/ju.0000000000001767	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	604
10.1097/ju.0000000000001767	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	553
10.1097/ju.0000000000001767	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	391
10.1097/ju.0000000000001767	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1097/ju.0000000000001767	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1097/ju.0000000000001767	results	1	NA	Number of covariates adjusted for/matched on	7
10.1097/ju.0000000000001767	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1097/ju.0000000000001767	results	1	NA	Primary outcome: treatment effect contrast	Risk difference
10.1097/ju.0000000000001767	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1097/ju.0000000000001767	results	1	NA	Primary outcome: adjusted treatment effect	-6.3
10.1097/ju.0000000000001767	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.043
10.1097/ju.0000000000001767	results	1	NA	lb_ci	NA
10.1097/ju.0000000000001767	results	1	NA	ub_ci	NA
10.1097/ju.0000000000001767	results	1	NA	pval	0.043
10.1097/ju.0000000000001767	results	1	NA	num_pval	0.043
10.1097/ju.0000000000001767	results	1	NA	ci_cutoff	0
10.1097/ju.0000000000001767	results	1	NA	significant	TRUE
10.1097/ju.0000000000001767	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	933
10.1097/ju.0000000000001767	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	468
10.1097/ju.0000000000001767	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	943
10.1097/ju.0000000000001767	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	580
10.1097/ju.0000000000001767	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	553
10.1097/ju.0000000000001767	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	395
10.1097/ju.0000000000001767	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1097/ju.0000000000001767	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1097/ju.0000000000001767	results	2	NA	Number of covariates adjusted for/matched on	8
10.1097/ju.0000000000001767	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1097/ju.0000000000001767	results	2	NA	Primary outcome: treatment effect contrast	Risk difference
10.1097/ju.0000000000001767	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1097/ju.0000000000001767	results	2	NA	Primary outcome: adjusted treatment effect	-6.3
10.1097/ju.0000000000001767	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.004
10.1097/ju.0000000000001767	results	2	NA	geographical region	Yes
10.1097/ju.0000000000001767	results	2	NA	lb_ci	NA
10.1097/ju.0000000000001767	results	2	NA	ub_ci	NA
10.1097/ju.0000000000001767	results	2	NA	pval	0.004
10.1097/ju.0000000000001767	results	2	NA	num_pval	0.004
10.1097/ju.0000000000001767	results	2	NA	ci_cutoff	0
10.1097/ju.0000000000001767	results	2	NA	significant	TRUE
10.1097/ju.0000000000001767	study_information	NA	1	Patient-level data used	Yes
10.1097/ju.0000000000001767	study_information	NA	1	Clinical Trial	Yes
10.1097/ju.0000000000001767	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02200614
10.1097/ju.0000000000001767	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1097/ju.0000000000001767	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1097/ju.0000000000001767	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1097/ju.0000000000001767	study_information	NA	2	Patient-level data used	No
10.1097/ju.0000000000001767	study_information	NA	2	Clinical Trial	Yes
10.1097/ju.0000000000001767	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01946204
10.1097/ju.0000000000001767	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1097/ju.0000000000001767	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1097/ju.0000000000001767	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1097/ju.0000000000001767	study_information	NA	3	Patient-level data used	No
10.1097/ju.0000000000001767	study_information	NA	3	Clinical Trial	Yes
10.1097/ju.0000000000001767	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02003924
10.1097/ju.0000000000001767	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1097/ju.0000000000001767	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1097/ju.0000000000001767	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis
10.1111/bjd.16140	general_information	NA	NA	Countries of first author affiliations	uk
10.1111/bjd.16140	general_information	NA	NA	Countries of last author affiliations	germany
10.1111/bjd.16140	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1111/bjd.16140	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/bjd.16140	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/bjd.16140	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/bjd.16140	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/bjd.16140	methodology	3	NA	Treatment name 1	ixekizumab
10.1111/bjd.16140	methodology	3	NA	Study 'number(s)' for treatment 1	2;3
10.1111/bjd.16140	methodology	3	NA	Treatment name 2	secukinumab
10.1111/bjd.16140	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.1111/bjd.16140	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/bjd.16140	methodology	3	NA	Anchored comparison?	Yes
10.1111/bjd.16140	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/bjd.16140	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/bjd.16140	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	psoriasis area severity index 75 response rate at week 12
10.1111/bjd.16140	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1111/bjd.16140	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/bjd.16140	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/bjd.16140	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1111/bjd.16140	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/bjd.16140	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/bjd.16140	methodology	5	NA	Treatment name 1	ixekizumab
10.1111/bjd.16140	methodology	5	NA	Study 'number(s)' for treatment 1	4
10.1111/bjd.16140	methodology	5	NA	Treatment name 2	secukinumab
10.1111/bjd.16140	methodology	5	NA	Study 'number(s)' for treatment 2	9
10.1111/bjd.16140	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/bjd.16140	methodology	5	NA	Anchored comparison?	Yes
10.1111/bjd.16140	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/bjd.16140	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/bjd.16140	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	psoriasis area severity index 75 response rate at week 12
10.1111/bjd.16140	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)
10.1111/bjd.16140	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/bjd.16140	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/bjd.16140	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1111/bjd.16140	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/bjd.16140	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/bjd.16140	results	1	NA	If anchored, total sample size non IPD	653
10.1111/bjd.16140	results	1	NA	geographical region	No
10.1111/bjd.16140	results	1	NA	If anchored, total initial sample size IPD	1956
10.1111/bjd.16140	results	1	NA	If anchored, total ESS IPD	1666
10.1111/bjd.16140	results	2	NA	geographical region	No
10.1111/bjd.16140	results	2	NA	If anchored, total initial sample size IPD	1956
10.1111/bjd.16140	results	2	NA	If anchored, total ESS IPD	1666
10.1111/bjd.16140	results	2	NA	If anchored, total sample size non IPD	653
10.1111/bjd.16140	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	1465
10.1111/bjd.16140	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	989
10.1111/bjd.16140	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/bjd.16140	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/bjd.16140	results	3	NA	Number of covariates adjusted for/matched on	7
10.1111/bjd.16140	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/bjd.16140	results	3	NA	Primary outcome: treatment effect contrast	Risk difference
10.1111/bjd.16140	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/bjd.16140	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.1
10.1111/bjd.16140	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.7
10.1111/bjd.16140	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	653
10.1111/bjd.16140	results	3	NA	If anchored, total sample size non IPD	653
10.1111/bjd.16140	results	3	NA	geographical region	No
10.1111/bjd.16140	results	3	NA	If anchored, total initial sample size IPD	1465
10.1111/bjd.16140	results	3	NA	If anchored, total ESS IPD	989
10.1111/bjd.16140	results	3	NA	lb_ci	NA
10.1111/bjd.16140	results	3	NA	ub_ci	NA
10.1111/bjd.16140	results	3	NA	pval	0.1
10.1111/bjd.16140	results	3	NA	num_pval	0.1
10.1111/bjd.16140	results	3	NA	ci_cutoff	0
10.1111/bjd.16140	results	3	NA	significant	FALSE
10.1111/bjd.16140	results	3	NA	lb_ci	NA
10.1111/bjd.16140	results	3	NA	ub_ci	NA
10.1111/bjd.16140	results	3	NA	pval	0.7
10.1111/bjd.16140	results	3	NA	num_pval	0.7
10.1111/bjd.16140	results	3	NA	ci_cutoff	0
10.1111/bjd.16140	results	3	NA	significant	FALSE
10.1111/bjd.16140	results	4	NA	geographical region	No
10.1111/bjd.16140	results	4	NA	If anchored, total initial sample size IPD	1465
10.1111/bjd.16140	results	4	NA	If anchored, total ESS IPD	989
10.1111/bjd.16140	results	4	NA	If anchored, total sample size non IPD	653
10.1111/bjd.16140	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	259
10.1111/bjd.16140	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	122
10.1111/bjd.16140	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/bjd.16140	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/bjd.16140	results	5	NA	Number of covariates adjusted for/matched on	8
10.1111/bjd.16140	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/bjd.16140	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/bjd.16140	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.21
10.1111/bjd.16140	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.26
10.1111/bjd.16140	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	676
10.1111/bjd.16140	results	5	NA	If anchored, total sample size non IPD	676
10.1111/bjd.16140	results	5	NA	geographical region	No
10.1111/bjd.16140	results	5	NA	If anchored, total initial sample size IPD	259
10.1111/bjd.16140	results	5	NA	If anchored, total ESS IPD	122
10.1111/bjd.16140	results	5	NA	lb_ci	NA
10.1111/bjd.16140	results	5	NA	ub_ci	NA
10.1111/bjd.16140	results	5	NA	pval	0.21
10.1111/bjd.16140	results	5	NA	num_pval	0.21
10.1111/bjd.16140	results	5	NA	ci_cutoff	NA
10.1111/bjd.16140	results	5	NA	significant	FALSE
10.1111/bjd.16140	results	5	NA	lb_ci	NA
10.1111/bjd.16140	results	5	NA	ub_ci	NA
10.1111/bjd.16140	results	5	NA	pval	0.26
10.1111/bjd.16140	results	5	NA	num_pval	0.26
10.1111/bjd.16140	results	5	NA	ci_cutoff	NA
10.1111/bjd.16140	results	5	NA	significant	FALSE
10.1111/bjd.16140	results	6	NA	geographical region	No
10.1111/bjd.16140	results	6	NA	If anchored, total initial sample size IPD	259
10.1111/bjd.16140	results	6	NA	If anchored, total ESS IPD	122
10.1111/bjd.16140	results	6	NA	If anchored, total sample size non IPD	676
10.1111/bjd.16140	study_information	NA	1	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	1	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01474512
10.1111/bjd.16140	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	2	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	2	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597245
10.1111/bjd.16140	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	3	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	3	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01646177
10.1111/bjd.16140	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	4	Patient-level data used	Yes
10.1111/bjd.16140	study_information	NA	4	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561806
10.1111/bjd.16140	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	5	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	5	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01358578
10.1111/bjd.16140	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	6	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	6	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01365455
10.1111/bjd.16140	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	7	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	7	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01555125
10.1111/bjd.16140	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	8	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	8	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01636687
10.1111/bjd.16140	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.1111/bjd.16140	study_information	NA	9	Patient-level data used	No
10.1111/bjd.16140	study_information	NA	9	Clinical Trial	Yes
10.1111/bjd.16140	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02074982
10.1111/bjd.16140	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/bjd.16140	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3
10.1111/bjd.16140	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.1111/cea.13561	general_information	NA	NA	Medical Condition of Interest Name	asthma
10.1111/cea.13561	general_information	NA	NA	Countries of first author affiliations	france
10.1111/cea.13561	general_information	NA	NA	Countries of last author affiliations	usa
10.1111/cea.13561	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/cea.13561	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/cea.13561	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/cea.13561	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/cea.13561	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/cea.13561	methodology	1	NA	Treatment name 1	benralizumab
10.1111/cea.13561	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/cea.13561	methodology	1	NA	Treatment name 2	mepolizumab
10.1111/cea.13561	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1111/cea.13561	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/cea.13561	methodology	1	NA	Anchored comparison?	Yes
10.1111/cea.13561	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/cea.13561	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/cea.13561	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	ocs (oral corticosteroids) dosage reduction from baseline to week 24
10.1111/cea.13561	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/cea.13561	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/cea.13561	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1111/cea.13561	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1111/cea.13561	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/cea.13561	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/cea.13561	methodology	2	NA	Treatment name 1	benralizumab
10.1111/cea.13561	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1111/cea.13561	methodology	2	NA	Treatment name 2	dupilumab
10.1111/cea.13561	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1111/cea.13561	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/cea.13561	methodology	2	NA	Anchored comparison?	Yes
10.1111/cea.13561	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/cea.13561	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/cea.13561	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	ocs (oral corticosteroids) dosage reduction from baseline to week 24
10.1111/cea.13561	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/cea.13561	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/cea.13561	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1111/cea.13561	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1111/cea.13561	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/cea.13561	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/cea.13561	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/cea.13561	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/cea.13561	results	1	NA	Number of covariates adjusted for/matched on	5
10.1111/cea.13561	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1111/cea.13561	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/cea.13561	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/cea.13561	results	1	NA	Primary outcome: unadjusted treatment effect	20.1
10.1111/cea.13561	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.1584
10.1111/cea.13561	results	1	NA	Primary outcome: adjusted treatment effect	6.08
10.1111/cea.13561	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.67
10.1111/cea.13561	results	1	NA	geographical region	No
10.1111/cea.13561	results	1	NA	If anchored, total initial sample size IPD	148
10.1111/cea.13561	results	1	NA	If anchored, total ESS IPD	72
10.1111/cea.13561	results	1	NA	If anchored, total sample size non IPD	135
10.1111/cea.13561	results	1	NA	lb_ci	NA
10.1111/cea.13561	results	1	NA	ub_ci	NA
10.1111/cea.13561	results	1	NA	pval	0.1584
10.1111/cea.13561	results	1	NA	num_pval	0.1584
10.1111/cea.13561	results	1	NA	ci_cutoff	0
10.1111/cea.13561	results	1	NA	significant	FALSE
10.1111/cea.13561	results	1	NA	lb_ci	NA
10.1111/cea.13561	results	1	NA	ub_ci	NA
10.1111/cea.13561	results	1	NA	pval	0.67
10.1111/cea.13561	results	1	NA	num_pval	0.67
10.1111/cea.13561	results	1	NA	ci_cutoff	0
10.1111/cea.13561	results	1	NA	significant	FALSE
10.1111/cea.13561	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/cea.13561	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/cea.13561	results	2	NA	Number of covariates adjusted for/matched on	5
10.1111/cea.13561	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1111/cea.13561	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/cea.13561	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/cea.13561	results	2	NA	Primary outcome: unadjusted treatment effect	8.1
10.1111/cea.13561	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.46
10.1111/cea.13561	results	2	NA	Primary outcome: adjusted treatment effect	-0.71
10.1111/cea.13561	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.94
10.1111/cea.13561	results	2	NA	geographical region	No
10.1111/cea.13561	results	2	NA	If anchored, total initial sample size IPD	148
10.1111/cea.13561	results	2	NA	If anchored, total ESS IPD	36
10.1111/cea.13561	results	2	NA	If anchored, total sample size non IPD	210
10.1111/cea.13561	results	2	NA	lb_ci	NA
10.1111/cea.13561	results	2	NA	ub_ci	NA
10.1111/cea.13561	results	2	NA	pval	0.46
10.1111/cea.13561	results	2	NA	num_pval	0.46
10.1111/cea.13561	results	2	NA	ci_cutoff	0
10.1111/cea.13561	results	2	NA	significant	FALSE
10.1111/cea.13561	results	2	NA	lb_ci	NA
10.1111/cea.13561	results	2	NA	ub_ci	NA
10.1111/cea.13561	results	2	NA	pval	0.94
10.1111/cea.13561	results	2	NA	num_pval	0.94
10.1111/cea.13561	results	2	NA	ci_cutoff	0
10.1111/cea.13561	results	2	NA	significant	FALSE
10.1111/cea.13561	study_information	NA	1	Patient-level data used	Yes
10.1111/cea.13561	study_information	NA	1	Clinical Trial	Yes
10.1111/cea.13561	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02075255
10.1111/cea.13561	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/cea.13561	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/cea.13561	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/cea.13561	study_information	NA	2	Patient-level data used	No
10.1111/cea.13561	study_information	NA	2	Clinical Trial	Yes
10.1111/cea.13561	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691508
10.1111/cea.13561	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/cea.13561	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/cea.13561	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/cea.13561	study_information	NA	3	Patient-level data used	No
10.1111/cea.13561	study_information	NA	3	Clinical Trial	Yes
10.1111/cea.13561	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02528214
10.1111/cea.13561	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/cea.13561	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1111/cea.13561	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/dom.14497	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes
10.1111/dom.14497	general_information	NA	NA	Countries of first author affiliations	usa
10.1111/dom.14497	general_information	NA	NA	Countries of last author affiliations	denmark
10.1111/dom.14497	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/dom.14497	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/dom.14497	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/dom.14497	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/dom.14497	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1111/dom.14497	methodology	1	NA	Treatment name 1	semaglutide 1.0mg
10.1111/dom.14497	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/dom.14497	methodology	1	NA	Treatment name 2	dulaglutide 3.0mg
10.1111/dom.14497	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1111/dom.14497	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/dom.14497	methodology	1	NA	Anchored comparison?	Yes
10.1111/dom.14497	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/dom.14497	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/dom.14497	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in hba1c
10.1111/dom.14497	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/dom.14497	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/dom.14497	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1111/dom.14497	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1111/dom.14497	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1111/dom.14497	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/dom.14497	methodology	2	NA	Treatment name 1	semaglutide 1.0mg
10.1111/dom.14497	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1111/dom.14497	methodology	2	NA	Treatment name 2	dulaglutide 4.5mg
10.1111/dom.14497	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1111/dom.14497	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/dom.14497	methodology	2	NA	Anchored comparison?	Yes
10.1111/dom.14497	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/dom.14497	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/dom.14497	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in hba1c
10.1111/dom.14497	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/dom.14497	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/dom.14497	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1111/dom.14497	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1111/dom.14497	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1111/dom.14497	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/dom.14497	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	616
10.1111/dom.14497	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612
10.1111/dom.14497	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	300
10.1111/dom.14497	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	299
10.1111/dom.14497	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/dom.14497	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/dom.14497	results	1	NA	Number of covariates adjusted for/matched on	3
10.1111/dom.14497	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1111/dom.14497	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/dom.14497	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/dom.14497	results	1	NA	Primary outcome: unadjusted treatment effect	-0.24
10.1111/dom.14497	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.016
10.1111/dom.14497	results	1	NA	Primary outcome: adjusted treatment effect	-0.25
10.1111/dom.14497	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.037
10.1111/dom.14497	results	1	NA	geographical region	No
10.1111/dom.14497	results	1	NA	lb_ci	NA
10.1111/dom.14497	results	1	NA	ub_ci	NA
10.1111/dom.14497	results	1	NA	pval	0.016
10.1111/dom.14497	results	1	NA	num_pval	0.016
10.1111/dom.14497	results	1	NA	ci_cutoff	0
10.1111/dom.14497	results	1	NA	significant	TRUE
10.1111/dom.14497	results	1	NA	lb_ci	NA
10.1111/dom.14497	results	1	NA	ub_ci	NA
10.1111/dom.14497	results	1	NA	pval	0.037
10.1111/dom.14497	results	1	NA	num_pval	0.037
10.1111/dom.14497	results	1	NA	ci_cutoff	0
10.1111/dom.14497	results	1	NA	significant	TRUE
10.1111/dom.14497	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	614
10.1111/dom.14497	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612
10.1111/dom.14497	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	300
10.1111/dom.14497	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	299
10.1111/dom.14497	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/dom.14497	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/dom.14497	results	2	NA	Number of covariates adjusted for/matched on	3
10.1111/dom.14497	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1111/dom.14497	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/dom.14497	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/dom.14497	results	2	NA	Primary outcome: unadjusted treatment effect	-0.07
10.1111/dom.14497	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.484
10.1111/dom.14497	results	2	NA	Primary outcome: adjusted treatment effect	-0.08
10.1111/dom.14497	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.523
10.1111/dom.14497	results	2	NA	geographical region	No
10.1111/dom.14497	results	2	NA	lb_ci	NA
10.1111/dom.14497	results	2	NA	ub_ci	NA
10.1111/dom.14497	results	2	NA	pval	0.484
10.1111/dom.14497	results	2	NA	num_pval	0.484
10.1111/dom.14497	results	2	NA	ci_cutoff	0
10.1111/dom.14497	results	2	NA	significant	FALSE
10.1111/dom.14497	results	2	NA	lb_ci	NA
10.1111/dom.14497	results	2	NA	ub_ci	NA
10.1111/dom.14497	results	2	NA	pval	0.523
10.1111/dom.14497	results	2	NA	num_pval	0.523
10.1111/dom.14497	results	2	NA	ci_cutoff	0
10.1111/dom.14497	results	2	NA	significant	FALSE
10.1111/dom.14497	study_information	NA	1	Patient-level data used	Yes
10.1111/dom.14497	study_information	NA	1	Clinical Trial	Yes
10.1111/dom.14497	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02648204
10.1111/dom.14497	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/dom.14497	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/dom.14497	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/dom.14497	study_information	NA	2	Patient-level data used	No
10.1111/dom.14497	study_information	NA	2	Clinical Trial	Yes
10.1111/dom.14497	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102
10.1111/dom.14497	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/dom.14497	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/dom.14497	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/dom.14497	study_information	NA	3	Patient-level data used	xx
10.1111/dom.14497	study_information	NA	3	Clinical Trial	xx
10.1111/dom.14497	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	xx
10.1111/dom.14497	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	xx
10.1111/dom.14497	study_information	NA	3	Phase of the clinical trial (clinical trial only)	xx
10.1111/dom.14497	study_information	NA	3	Number of treatment arms (clinical trial only)	xx
10.1111/head.14128	general_information	NA	NA	Medical Condition of Interest Name	migraine
10.1111/head.14128	general_information	NA	NA	Countries of first author affiliations	canada
10.1111/head.14128	general_information	NA	NA	Countries of last author affiliations	usa
10.1111/head.14128	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/head.14128	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/head.14128	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/head.14128	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/head.14128	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1111/head.14128	methodology	1	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	1	NA	Treatment name 2	placebo
10.1111/head.14128	methodology	1	NA	Study 'number(s)' for treatment 2	2;3
10.1111/head.14128	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/head.14128	methodology	1	NA	Anchored comparison?	No
10.1111/head.14128	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/head.14128	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/head.14128	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1111/head.14128	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/head.14128	methodology	2	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	2	NA	Treatment name 2	galcanezumab
10.1111/head.14128	methodology	2	NA	Study 'number(s)' for treatment 2	2;3
10.1111/head.14128	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/head.14128	methodology	2	NA	Anchored comparison?	No
10.1111/head.14128	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/head.14128	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/head.14128	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1111/head.14128	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/head.14128	methodology	3	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	3	NA	Treatment name 2	placebo
10.1111/head.14128	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1111/head.14128	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/head.14128	methodology	3	NA	Anchored comparison?	No
10.1111/head.14128	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/head.14128	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/head.14128	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1111/head.14128	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/head.14128	methodology	4	NA	Treatment name 1	rimegepant
10.1111/head.14128	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1111/head.14128	methodology	4	NA	Treatment name 2	erenumab
10.1111/head.14128	methodology	4	NA	Study 'number(s)' for treatment 2	4
10.1111/head.14128	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/head.14128	methodology	4	NA	Anchored comparison?	No
10.1111/head.14128	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/head.14128	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	4	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1111/head.14128	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.1111/head.14128	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/head.14128	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1773
10.1111/head.14128	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	257
10.1111/head.14128	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	169
10.1111/head.14128	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/head.14128	results	1	NA	Number of covariates adjusted for/matched on	6
10.1111/head.14128	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/head.14128	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/head.14128	results	1	NA	Primary outcome: unadjusted treatment effect	-5.54
10.1111/head.14128	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.026
10.1111/head.14128	results	1	NA	Primary outcome: adjusted treatment effect	-7.37
10.1111/head.14128	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.009
10.1111/head.14128	results	1	NA	lb_ci	NA
10.1111/head.14128	results	1	NA	ub_ci	NA
10.1111/head.14128	results	1	NA	pval	0.026
10.1111/head.14128	results	1	NA	num_pval	0.026
10.1111/head.14128	results	1	NA	ci_cutoff	0
10.1111/head.14128	results	1	NA	significant	TRUE
10.1111/head.14128	results	1	NA	lb_ci	NA
10.1111/head.14128	results	1	NA	ub_ci	NA
10.1111/head.14128	results	1	NA	pval	0.009
10.1111/head.14128	results	1	NA	num_pval	0.009
10.1111/head.14128	results	1	NA	ci_cutoff	0
10.1111/head.14128	results	1	NA	significant	TRUE
10.1111/head.14128	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	257
10.1111/head.14128	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	169
10.1111/head.14128	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/head.14128	results	2	NA	Number of covariates adjusted for/matched on	6
10.1111/head.14128	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/head.14128	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/head.14128	results	2	NA	Primary outcome: unadjusted treatment effect	1.75
10.1111/head.14128	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.528
10.1111/head.14128	results	2	NA	Primary outcome: adjusted treatment effect	-0.09
10.1111/head.14128	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.979
10.1111/head.14128	results	2	NA	lb_ci	NA
10.1111/head.14128	results	2	NA	ub_ci	NA
10.1111/head.14128	results	2	NA	pval	0.528
10.1111/head.14128	results	2	NA	num_pval	0.528
10.1111/head.14128	results	2	NA	ci_cutoff	0
10.1111/head.14128	results	2	NA	significant	FALSE
10.1111/head.14128	results	2	NA	lb_ci	NA
10.1111/head.14128	results	2	NA	ub_ci	NA
10.1111/head.14128	results	2	NA	pval	0.979
10.1111/head.14128	results	2	NA	num_pval	0.979
10.1111/head.14128	results	2	NA	ci_cutoff	0
10.1111/head.14128	results	2	NA	significant	FALSE
10.1111/head.14128	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	257
10.1111/head.14128	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	214
10.1111/head.14128	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/head.14128	results	3	NA	Number of covariates adjusted for/matched on	4
10.1111/head.14128	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/head.14128	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/head.14128	results	3	NA	Primary outcome: unadjusted treatment effect	-3.94
10.1111/head.14128	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.121
10.1111/head.14128	results	3	NA	Primary outcome: adjusted treatment effect	-5.67
10.1111/head.14128	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.025
10.1111/head.14128	results	3	NA	lb_ci	NA
10.1111/head.14128	results	3	NA	ub_ci	NA
10.1111/head.14128	results	3	NA	pval	0.121
10.1111/head.14128	results	3	NA	num_pval	0.121
10.1111/head.14128	results	3	NA	ci_cutoff	0
10.1111/head.14128	results	3	NA	significant	FALSE
10.1111/head.14128	results	3	NA	lb_ci	NA
10.1111/head.14128	results	3	NA	ub_ci	NA
10.1111/head.14128	results	3	NA	pval	0.025
10.1111/head.14128	results	3	NA	num_pval	0.025
10.1111/head.14128	results	3	NA	ci_cutoff	0
10.1111/head.14128	results	3	NA	significant	TRUE
10.1111/head.14128	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	257
10.1111/head.14128	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	214
10.1111/head.14128	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/head.14128	results	4	NA	Number of covariates adjusted for/matched on	4
10.1111/head.14128	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	4	NA	Primary outcome: treatment effect contrast	Means difference
10.1111/head.14128	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/head.14128	results	4	NA	Primary outcome: unadjusted treatment effect	3.48
10.1111/head.14128	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.172
10.1111/head.14128	results	4	NA	Primary outcome: adjusted treatment effect	1.75
10.1111/head.14128	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.501
10.1111/head.14128	results	4	NA	lb_ci	NA
10.1111/head.14128	results	4	NA	ub_ci	NA
10.1111/head.14128	results	4	NA	pval	0.172
10.1111/head.14128	results	4	NA	num_pval	0.172
10.1111/head.14128	results	4	NA	ci_cutoff	0
10.1111/head.14128	results	4	NA	significant	FALSE
10.1111/head.14128	results	4	NA	lb_ci	NA
10.1111/head.14128	results	4	NA	ub_ci	NA
10.1111/head.14128	results	4	NA	pval	0.501
10.1111/head.14128	results	4	NA	num_pval	0.501
10.1111/head.14128	results	4	NA	ci_cutoff	0
10.1111/head.14128	results	4	NA	significant	FALSE
10.1111/head.14128	study_information	NA	1	Patient-level data used	Yes
10.1111/head.14128	study_information	NA	1	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03266588
10.1111/head.14128	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/head.14128	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.1111/head.14128	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1111/head.14128	study_information	NA	2	Patient-level data used	No
10.1111/head.14128	study_information	NA	2	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614183
10.1111/head.14128	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/head.14128	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/head.14128	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/head.14128	study_information	NA	3	Patient-level data used	No
10.1111/head.14128	study_information	NA	3	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02614196
10.1111/head.14128	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/head.14128	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1111/head.14128	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/head.14128	study_information	NA	4	Patient-level data used	No
10.1111/head.14128	study_information	NA	4	Clinical Trial	Yes
10.1111/head.14128	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02456740
10.1111/head.14128	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/head.14128	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1111/head.14128	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Medical Condition of Interest Name	non-squamous non-small cell lung cancer
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Countries of first author affiliations	taiwan
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Countries of last author affiliations	switzerland
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/j.1743-7563.2011.01400.x	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 1	bevacizumab + cisplatin
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Treatment name 2	pemetrexed + cisplatin
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Type of population-adjusted indirect comparisons performed	Other kind of ""Matching-Adjusted Indirect Comparison""
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Anchored comparison?	No
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier)
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/j.1743-7563.2011.01400.x	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	67
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	72
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	46
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Number of covariates adjusted for/matched on	2
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Primary outcome: treatment effect contrast	Median difference
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/j.1743-7563.2011.01400.x	results	1	NA	Primary outcome: adjusted treatment effect	1
10.1111/j.1743-7563.2011.01400.x	results	1	NA	If anchored, total initial sample size IPD	72
10.1111/j.1743-7563.2011.01400.x	results	1	NA	If anchored, total ESS IPD	46
10.1111/j.1743-7563.2011.01400.x	results	1	NA	If anchored, total sample size non IPD	67
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Patient-level data used	Yes
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Clinical Trial	Yes
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451906
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Phase of the clinical trial (clinical trial only)	4
10.1111/j.1743-7563.2011.01400.x	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Patient-level data used	No
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Clinical Trial	Yes
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	yang et al. (2010)
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/j.1743-7563.2011.01400.x	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	general_information	NA	NA	Medical Condition of Interest Name	plaque psoriasis
10.1111/jdv.15369	general_information	NA	NA	Countries of first author affiliations	uk
10.1111/jdv.15369	general_information	NA	NA	Countries of last author affiliations	usa
10.1111/jdv.15369	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/jdv.15369	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1111/jdv.15369	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1111/jdv.15369	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1111/jdv.15369	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1111/jdv.15369	methodology	1	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	1	NA	Treatment name 2	apremilast
10.1111/jdv.15369	methodology	1	NA	Study 'number(s)' for treatment 2	5
10.1111/jdv.15369	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/jdv.15369	methodology	1	NA	Anchored comparison?	No
10.1111/jdv.15369	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	physician global assessment (pga) 0/1 responders rate
10.1111/jdv.15369	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1111/jdv.15369	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/jdv.15369	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/jdv.15369	methodology	2	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	2	NA	Treatment name 2	methotrexate
10.1111/jdv.15369	methodology	2	NA	Study 'number(s)' for treatment 2	6
10.1111/jdv.15369	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/jdv.15369	methodology	2	NA	Anchored comparison?	No
10.1111/jdv.15369	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1111/jdv.15369	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1111/jdv.15369	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/jdv.15369	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/jdv.15369	methodology	3	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	3	NA	Treatment name 2	acitretin
10.1111/jdv.15369	methodology	3	NA	Study 'number(s)' for treatment 2	7
10.1111/jdv.15369	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/jdv.15369	methodology	3	NA	Anchored comparison?	No
10.1111/jdv.15369	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1111/jdv.15369	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	3	NA	Primary outcome: variable type	pasi 75 locf
10.1111/jdv.15369	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/jdv.15369	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/jdv.15369	methodology	4	NA	Treatment name 1	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	4	NA	Study 'number(s)' for treatment 1	1;2;3;4
10.1111/jdv.15369	methodology	4	NA	Treatment name 2	fumaric acid esters
10.1111/jdv.15369	methodology	4	NA	Study 'number(s)' for treatment 2	8
10.1111/jdv.15369	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1111/jdv.15369	methodology	4	NA	Anchored comparison?	No
10.1111/jdv.15369	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1111/jdv.15369	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1111/jdv.15369	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1111/jdv.15369	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1111/jdv.15369	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	148
10.1111/jdv.15369	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	748
10.1111/jdv.15369	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	640
10.1111/jdv.15369	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/jdv.15369	results	1	NA	Number of covariates adjusted for/matched on	3
10.1111/jdv.15369	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/jdv.15369	results	1	NA	Primary outcome: treatment effect contrast	Proportions difference
10.1111/jdv.15369	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	1	NA	Primary outcome: adjusted treatment effect	22.3
10.1111/jdv.15369	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1111/jdv.15369	results	1	NA	geographical region	No
10.1111/jdv.15369	results	1	NA	lb_ci	NA
10.1111/jdv.15369	results	1	NA	ub_ci	NA
10.1111/jdv.15369	results	1	NA	pval	<0.001
10.1111/jdv.15369	results	1	NA	num_pval	NA
10.1111/jdv.15369	results	1	NA	ci_cutoff	0
10.1111/jdv.15369	results	1	NA	significant	TRUE
10.1111/jdv.15369	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	218
10.1111/jdv.15369	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	749
10.1111/jdv.15369	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	633
10.1111/jdv.15369	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/jdv.15369	results	2	NA	Number of covariates adjusted for/matched on	2
10.1111/jdv.15369	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1111/jdv.15369	results	2	NA	Primary outcome: treatment effect contrast	Proportions difference
10.1111/jdv.15369	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	2	NA	Primary outcome: adjusted treatment effect	17.3
10.1111/jdv.15369	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1111/jdv.15369	results	2	NA	lb_ci	NA
10.1111/jdv.15369	results	2	NA	ub_ci	NA
10.1111/jdv.15369	results	2	NA	pval	<0.001
10.1111/jdv.15369	results	2	NA	num_pval	NA
10.1111/jdv.15369	results	2	NA	ci_cutoff	0
10.1111/jdv.15369	results	2	NA	significant	TRUE
10.1111/jdv.15369	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	41
10.1111/jdv.15369	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	748
10.1111/jdv.15369	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	102
10.1111/jdv.15369	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/jdv.15369	results	3	NA	Number of covariates adjusted for/matched on	4
10.1111/jdv.15369	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1111/jdv.15369	results	3	NA	Primary outcome: treatment effect contrast	Proportions difference
10.1111/jdv.15369	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	3	NA	Primary outcome: adjusted treatment effect	19.2
10.1111/jdv.15369	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.009
10.1111/jdv.15369	results	3	NA	geographical region	No
10.1111/jdv.15369	results	3	NA	lb_ci	NA
10.1111/jdv.15369	results	3	NA	ub_ci	NA
10.1111/jdv.15369	results	3	NA	pval	0.009
10.1111/jdv.15369	results	3	NA	num_pval	0.009
10.1111/jdv.15369	results	3	NA	ci_cutoff	0
10.1111/jdv.15369	results	3	NA	significant	TRUE
10.1111/jdv.15369	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	115
10.1111/jdv.15369	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	749
10.1111/jdv.15369	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	224
10.1111/jdv.15369	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1111/jdv.15369	results	4	NA	Number of covariates adjusted for/matched on	2
10.1111/jdv.15369	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1111/jdv.15369	results	4	NA	Primary outcome: treatment effect contrast	Proportions difference
10.1111/jdv.15369	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	4	NA	Primary outcome: adjusted treatment effect	-4.4
10.1111/jdv.15369	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.451
10.1111/jdv.15369	results	4	NA	lb_ci	NA
10.1111/jdv.15369	results	4	NA	ub_ci	NA
10.1111/jdv.15369	results	4	NA	pval	0.451
10.1111/jdv.15369	results	4	NA	num_pval	0.451
10.1111/jdv.15369	results	4	NA	ci_cutoff	0
10.1111/jdv.15369	results	4	NA	significant	FALSE
10.1111/jdv.15369	study_information	NA	1	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	1	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02132936
10.1111/jdv.15369	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.1111/jdv.15369	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1111/jdv.15369	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	2	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	2	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01866163
10.1111/jdv.15369	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1111/jdv.15369	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	3	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	3	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536886
10.1111/jdv.15369	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.1111/jdv.15369	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	4	Patient-level data used	Yes
10.1111/jdv.15369	study_information	NA	4	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01536938
10.1111/jdv.15369	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1111/jdv.15369	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	5	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	5	Clinical Trial	Yes
10.1111/jdv.15369	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02425826
10.1111/jdv.15369	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1111/jdv.15369	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4
10.1111/jdv.15369	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1111/jdv.15369	study_information	NA	6	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	6	Clinical Trial	No
10.1111/jdv.15369	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	zurita et al., (2017)
10.1111/jdv.15369	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	spain
10.1111/jdv.15369	study_information	NA	7	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	7	Clinical Trial	No
10.1111/jdv.15369	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	chiricozzi et al. (2016)
10.1111/jdv.15369	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1111/jdv.15369	study_information	NA	8	Patient-level data used	No
10.1111/jdv.15369	study_information	NA	8	Clinical Trial	No
10.1111/jdv.15369	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	inzinger et al. (2013)
10.1111/jdv.15369	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	austria
10.1136/rmdopen-2019-001131	general_information	NA	NA	Medical Condition of Interest Name	rheumatoid arthritis
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of first author affiliations	france
10.1136/rmdopen-2019-001131	general_information	NA	NA	Countries of last author affiliations	usa
10.1136/rmdopen-2019-001131	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1136/rmdopen-2019-001131	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1136/rmdopen-2019-001131	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1136/rmdopen-2019-001131	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 1	baricitinib
10.1136/rmdopen-2019-001131	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1136/rmdopen-2019-001131	methodology	1	NA	Treatment name 2	adalimumab
10.1136/rmdopen-2019-001131	methodology	1	NA	Study 'number(s)' for treatment 2	5
10.1136/rmdopen-2019-001131	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1136/rmdopen-2019-001131	methodology	1	NA	Anchored comparison?	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1136/rmdopen-2019-001131	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1136/rmdopen-2019-001131	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 1	baricitinib
10.1136/rmdopen-2019-001131	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1136/rmdopen-2019-001131	methodology	2	NA	Treatment name 2	tocilizumab
10.1136/rmdopen-2019-001131	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1136/rmdopen-2019-001131	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1136/rmdopen-2019-001131	methodology	2	NA	Anchored comparison?	Yes
10.1136/rmdopen-2019-001131	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1136/rmdopen-2019-001131	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1136/rmdopen-2019-001131	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1136/rmdopen-2019-001131	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 1	baricitinib
10.1136/rmdopen-2019-001131	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1136/rmdopen-2019-001131	methodology	3	NA	Treatment name 2	tofacitinib
10.1136/rmdopen-2019-001131	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1136/rmdopen-2019-001131	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1136/rmdopen-2019-001131	methodology	3	NA	Anchored comparison?	Yes
10.1136/rmdopen-2019-001131	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1136/rmdopen-2019-001131	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1136/rmdopen-2019-001131	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1136/rmdopen-2019-001131	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1136/rmdopen-2019-001131	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	274
10.1136/rmdopen-2019-001131	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	257
10.1136/rmdopen-2019-001131	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	159
10.1136/rmdopen-2019-001131	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	151.5
10.1136/rmdopen-2019-001131	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	210
10.1136/rmdopen-2019-001131	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	181.4
10.1136/rmdopen-2019-001131	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1136/rmdopen-2019-001131	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1136/rmdopen-2019-001131	results	1	NA	Number of covariates adjusted for/matched on	5
10.1136/rmdopen-2019-001131	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1136/rmdopen-2019-001131	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	1	NA	Primary outcome: unadjusted treatment effect	-12.1
10.1136/rmdopen-2019-001131	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	Primary outcome: adjusted treatment effect	-12.3
10.1136/rmdopen-2019-001131	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	geographical region	No
10.1136/rmdopen-2019-001131	results	1	NA	lb_ci	NA
10.1136/rmdopen-2019-001131	results	1	NA	ub_ci	NA
10.1136/rmdopen-2019-001131	results	1	NA	pval	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	num_pval	NA
10.1136/rmdopen-2019-001131	results	1	NA	ci_cutoff	0
10.1136/rmdopen-2019-001131	results	1	NA	significant	TRUE
10.1136/rmdopen-2019-001131	results	1	NA	lb_ci	NA
10.1136/rmdopen-2019-001131	results	1	NA	ub_ci	NA
10.1136/rmdopen-2019-001131	results	1	NA	pval	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	num_pval	NA
10.1136/rmdopen-2019-001131	results	1	NA	ci_cutoff	0
10.1136/rmdopen-2019-001131	results	1	NA	significant	TRUE
10.1136/rmdopen-2019-001131	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	159
10.1136/rmdopen-2019-001131	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	210
10.1136/rmdopen-2019-001131	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1136/rmdopen-2019-001131	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1136/rmdopen-2019-001131	results	2	NA	Number of covariates adjusted for/matched on	5
10.1136/rmdopen-2019-001131	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1136/rmdopen-2019-001131	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	2	NA	Primary outcome: unadjusted treatment effect	-8.7
10.1136/rmdopen-2019-001131	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	Primary outcome: adjusted treatment effect	-7.3
10.1136/rmdopen-2019-001131	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	292
10.1136/rmdopen-2019-001131	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	287
10.1136/rmdopen-2019-001131	results	2	NA	geographical region	No
10.1136/rmdopen-2019-001131	results	2	NA	If anchored, total initial sample size IPD	369
10.1136/rmdopen-2019-001131	results	2	NA	If anchored, total ESS IPD	331
10.1136/rmdopen-2019-001131	results	2	NA	lb_ci	NA
10.1136/rmdopen-2019-001131	results	2	NA	ub_ci	NA
10.1136/rmdopen-2019-001131	results	2	NA	pval	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	num_pval	NA
10.1136/rmdopen-2019-001131	results	2	NA	ci_cutoff	0
10.1136/rmdopen-2019-001131	results	2	NA	significant	TRUE
10.1136/rmdopen-2019-001131	results	2	NA	lb_ci	NA
10.1136/rmdopen-2019-001131	results	2	NA	ub_ci	NA
10.1136/rmdopen-2019-001131	results	2	NA	pval	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	num_pval	NA
10.1136/rmdopen-2019-001131	results	2	NA	ci_cutoff	0
10.1136/rmdopen-2019-001131	results	2	NA	significant	TRUE
10.1136/rmdopen-2019-001131	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	373
10.1136/rmdopen-2019-001131	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	186
10.1136/rmdopen-2019-001131	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	159
10.1136/rmdopen-2019-001131	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	146.5
10.1136/rmdopen-2019-001131	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	210
10.1136/rmdopen-2019-001131	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	177.8
10.1136/rmdopen-2019-001131	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1136/rmdopen-2019-001131	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1136/rmdopen-2019-001131	results	3	NA	Number of covariates adjusted for/matched on	5
10.1136/rmdopen-2019-001131	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.1136/rmdopen-2019-001131	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	3	NA	Primary outcome: unadjusted treatment effect	-7.1
10.1136/rmdopen-2019-001131	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<=0.05
10.1136/rmdopen-2019-001131	results	3	NA	Primary outcome: adjusted treatment effect	-5.4
10.1136/rmdopen-2019-001131	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	>0.05
10.1136/rmdopen-2019-001131	results	3	NA	geographical region	No
10.1136/rmdopen-2019-001131	results	3	NA	lb_ci	NA
10.1136/rmdopen-2019-001131	results	3	NA	ub_ci	NA
10.1136/rmdopen-2019-001131	results	3	NA	pval	<=0.05
10.1136/rmdopen-2019-001131	results	3	NA	num_pval	NA
10.1136/rmdopen-2019-001131	results	3	NA	ci_cutoff	0
10.1136/rmdopen-2019-001131	results	3	NA	significant	TRUE
10.1136/rmdopen-2019-001131	results	3	NA	lb_ci	NA
10.1136/rmdopen-2019-001131	results	3	NA	ub_ci	NA
10.1136/rmdopen-2019-001131	results	3	NA	pval	>0.05
10.1136/rmdopen-2019-001131	results	3	NA	num_pval	NA
10.1136/rmdopen-2019-001131	results	3	NA	ci_cutoff	0
10.1136/rmdopen-2019-001131	results	3	NA	significant	NA
10.1136/rmdopen-2019-001131	study_information	NA	1	Patient-level data used	Yes
10.1136/rmdopen-2019-001131	study_information	NA	1	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01711359
10.1136/rmdopen-2019-001131	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	2	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	2	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00109408
10.1136/rmdopen-2019-001131	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	3	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	3	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01007435
10.1136/rmdopen-2019-001131	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	4	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	4	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01039688
10.1136/rmdopen-2019-001131	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	5	Patient-level data used	No
10.1136/rmdopen-2019-001131	study_information	NA	5	Clinical Trial	Yes
10.1136/rmdopen-2019-001131	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195663
10.1136/rmdopen-2019-001131	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1136/rmdopen-2019-001131	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.1136/rmdopen-2019-001131	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1155/2017/6121760	general_information	NA	NA	Medical Condition of Interest Name	basal cell carcinoma
10.1155/2017/6121760	general_information	NA	NA	Countries of first author affiliations	usa
10.1155/2017/6121760	general_information	NA	NA	Countries of last author affiliations	usa
10.1155/2017/6121760	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1155/2017/6121760	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1155/2017/6121760	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1155/2017/6121760	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1155/2017/6121760	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1155/2017/6121760	methodology	1	NA	Treatment name 1	sonidegib
10.1155/2017/6121760	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1155/2017/6121760	methodology	1	NA	Treatment name 2	vismodegib
10.1155/2017/6121760	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1155/2017/6121760	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1155/2017/6121760	methodology	1	NA	Anchored comparison?	No
10.1155/2017/6121760	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1155/2017/6121760	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1155/2017/6121760	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate
10.1155/2017/6121760	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1155/2017/6121760	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1155/2017/6121760	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1155/2017/6121760	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1155/2017/6121760	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1155/2017/6121760	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1155/2017/6121760	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	63
10.1155/2017/6121760	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	66
10.1155/2017/6121760	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1155/2017/6121760	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1155/2017/6121760	results	1	NA	Number of covariates adjusted for/matched on	2
10.1155/2017/6121760	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Past treatments for the disease of interest
10.1155/2017/6121760	study_information	NA	1	Patient-level data used	Yes
10.1155/2017/6121760	study_information	NA	1	Clinical Trial	Yes
10.1155/2017/6121760	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01327053
10.1155/2017/6121760	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1155/2017/6121760	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1155/2017/6121760	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1155/2017/6121760	study_information	NA	2	Patient-level data used	No
10.1155/2017/6121760	study_information	NA	2	Clinical Trial	Yes
10.1155/2017/6121760	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00833417
10.1155/2017/6121760	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1155/2017/6121760	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1155/2017/6121760	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1177/1756286420975916	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis
10.1177/1756286420975916	general_information	NA	NA	Countries of first author affiliations	usa
10.1177/1756286420975916	general_information	NA	NA	Countries of last author affiliations	usa
10.1177/1756286420975916	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1177/1756286420975916	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.1177/1756286420975916	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1177/1756286420975916	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1177/1756286420975916	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1177/1756286420975916	methodology	1	NA	Treatment name 1	peginterferon beta-1a
10.1177/1756286420975916	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1177/1756286420975916	methodology	1	NA	Treatment name 2	glatiramer acetate
10.1177/1756286420975916	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1177/1756286420975916	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1177/1756286420975916	methodology	1	NA	Anchored comparison?	No
10.1177/1756286420975916	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1177/1756286420975916	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1177/1756286420975916	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate (arr) at 1 year
10.1177/1756286420975916	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1177/1756286420975916	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1177/1756286420975916	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1177/1756286420975916	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1177/1756286420975916	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1177/1756286420975916	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1177/1756286420975916	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	834
10.1177/1756286420975916	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	407
10.1177/1756286420975916	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	276
10.1177/1756286420975916	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1177/1756286420975916	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1177/1756286420975916	results	1	NA	Number of covariates adjusted for/matched on	5
10.1177/1756286420975916	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1177/1756286420975916	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1177/1756286420975916	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1177/1756286420975916	results	1	NA	Primary outcome: adjusted treatment effect	-0.04
10.1177/1756286420975916	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.375
10.1177/1756286420975916	results	1	NA	geographical region	Yes
10.1177/1756286420975916	results	1	NA	lb_ci	NA
10.1177/1756286420975916	results	1	NA	ub_ci	NA
10.1177/1756286420975916	results	1	NA	pval	0.375
10.1177/1756286420975916	results	1	NA	num_pval	0.375
10.1177/1756286420975916	results	1	NA	ci_cutoff	0
10.1177/1756286420975916	results	1	NA	significant	FALSE
10.1177/1756286420975916	study_information	NA	1	Patient-level data used	Yes
10.1177/1756286420975916	study_information	NA	1	Clinical Trial	Yes
10.1177/1756286420975916	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00906399
10.1177/1756286420975916	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/1756286420975916	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1177/1756286420975916	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1177/1756286420975916	study_information	NA	2	Patient-level data used	No
10.1177/1756286420975916	study_information	NA	2	Clinical Trial	Yes
10.1177/1756286420975916	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01067521
10.1177/1756286420975916	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/1756286420975916	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1177/1756286420975916	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1177/17588359211049639	general_information	NA	NA	Medical Condition of Interest Name	advanced ovarian cancer
10.1177/17588359211049639	general_information	NA	NA	Countries of first author affiliations	uk
10.1177/17588359211049639	general_information	NA	NA	Countries of last author affiliations	uk
10.1177/17588359211049639	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1177/17588359211049639	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1177/17588359211049639	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1177/17588359211049639	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1177/17588359211049639	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1177/17588359211049639	methodology	1	NA	Treatment name 1	olaparib + bevacizumab
10.1177/17588359211049639	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	1	NA	Treatment name 2	niraparib
10.1177/17588359211049639	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1177/17588359211049639	methodology	1	NA	Anchored comparison?	No
10.1177/17588359211049639	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1177/17588359211049639	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1177/17588359211049639	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1177/17588359211049639	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1177/17588359211049639	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1177/17588359211049639	methodology	2	NA	Treatment name 1	bevacizumab + placebo
10.1177/17588359211049639	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	2	NA	Treatment name 2	niraparib
10.1177/17588359211049639	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1177/17588359211049639	methodology	2	NA	Anchored comparison?	No
10.1177/17588359211049639	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1177/17588359211049639	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1177/17588359211049639	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1177/17588359211049639	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1177/17588359211049639	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1177/17588359211049639	methodology	3	NA	Treatment name 1	olaparib + bevacizumab
10.1177/17588359211049639	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	3	NA	Treatment name 2	placebo
10.1177/17588359211049639	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1177/17588359211049639	methodology	3	NA	Anchored comparison?	No
10.1177/17588359211049639	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1177/17588359211049639	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1177/17588359211049639	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.1177/17588359211049639	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1177/17588359211049639	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1177/17588359211049639	methodology	4	NA	Treatment name 1	placebo + bevacizumab
10.1177/17588359211049639	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1177/17588359211049639	methodology	4	NA	Treatment name 2	placebo
10.1177/17588359211049639	methodology	4	NA	Study 'number(s)' for treatment 2	2
10.1177/17588359211049639	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1177/17588359211049639	methodology	4	NA	Anchored comparison?	No
10.1177/17588359211049639	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1177/17588359211049639	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1177/17588359211049639	methodology	4	NA	Primary outcome: variable type	Time-to-event
10.1177/17588359211049639	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1177/17588359211049639	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1177/17588359211049639	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1177/17588359211049639	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	487
10.1177/17588359211049639	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	399
10.1177/17588359211049639	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	358
10.1177/17588359211049639	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1177/17588359211049639	results	1	NA	Number of covariates adjusted for/matched on	8
10.1177/17588359211049639	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1177/17588359211049639	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	1	NA	Primary outcome: adjusted treatment effect	0.57
10.1177/17588359211049639	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.47;0.69]
10.1177/17588359211049639	results	1	NA	lb_ci	0.47
10.1177/17588359211049639	results	1	NA	ub_ci	0.69
10.1177/17588359211049639	results	1	NA	pval	NA
10.1177/17588359211049639	results	1	NA	num_pval	NA
10.1177/17588359211049639	results	1	NA	ci_cutoff	1
10.1177/17588359211049639	results	1	NA	significant	FALSE
10.1177/17588359211049639	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	487
10.1177/17588359211049639	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	196
10.1177/17588359211049639	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	174
10.1177/17588359211049639	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1177/17588359211049639	results	2	NA	Number of covariates adjusted for/matched on	8
10.1177/17588359211049639	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1177/17588359211049639	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.1177/17588359211049639	results	2	NA	Primary outcome: adjusted treatment effect	1.07
10.1177/17588359211049639	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.87;1.32]
10.1177/17588359211049639	results	2	NA	lb_ci	0.87
10.1177/17588359211049639	results	2	NA	ub_ci	1.32
10.1177/17588359211049639	results	2	NA	pval	NA
10.1177/17588359211049639	results	2	NA	num_pval	NA
10.1177/17588359211049639	results	2	NA	ci_cutoff	1
10.1177/17588359211049639	results	2	NA	significant	TRUE
10.1177/17588359211049639	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	246
10.1177/17588359211049639	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	399
10.1177/17588359211049639	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	358
10.1177/17588359211049639	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1177/17588359211049639	results	3	NA	Number of covariates adjusted for/matched on	8
10.1177/17588359211049639	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	3	NA	Primary outcome: treatment effect contrast	HR
10.1177/17588359211049639	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	3	NA	Primary outcome: adjusted treatment effect	0.33
10.1177/17588359211049639	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.26;0.42]
10.1177/17588359211049639	results	3	NA	lb_ci	0.26
10.1177/17588359211049639	results	3	NA	ub_ci	0.42
10.1177/17588359211049639	results	3	NA	pval	NA
10.1177/17588359211049639	results	3	NA	num_pval	NA
10.1177/17588359211049639	results	3	NA	ci_cutoff	1
10.1177/17588359211049639	results	3	NA	significant	FALSE
10.1177/17588359211049639	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	246
10.1177/17588359211049639	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	196
10.1177/17588359211049639	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	174
10.1177/17588359211049639	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1177/17588359211049639	results	4	NA	Number of covariates adjusted for/matched on	8
10.1177/17588359211049639	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	4	NA	Primary outcome: treatment effect contrast	HR
10.1177/17588359211049639	results	4	NA	Primary outcome: adjusted treatment effect	0.55
10.1177/17588359211049639	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.43;0.70]
10.1177/17588359211049639	results	4	NA	lb_ci	0.43
10.1177/17588359211049639	results	4	NA	ub_ci	0.7
10.1177/17588359211049639	results	4	NA	pval	NA
10.1177/17588359211049639	results	4	NA	num_pval	NA
10.1177/17588359211049639	results	4	NA	ci_cutoff	1
10.1177/17588359211049639	results	4	NA	significant	FALSE
10.1177/17588359211049639	study_information	NA	1	Patient-level data used	Yes
10.1177/17588359211049639	study_information	NA	1	Clinical Trial	Yes
10.1177/17588359211049639	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477644
10.1177/17588359211049639	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/17588359211049639	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1177/17588359211049639	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1177/17588359211049639	study_information	NA	2	Patient-level data used	No
10.1177/17588359211049639	study_information	NA	2	Clinical Trial	Yes
10.1177/17588359211049639	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02655016
10.1177/17588359211049639	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1177/17588359211049639	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1177/17588359211049639	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	general_information	NA	NA	Medical Condition of Interest Name	severe uncontrolled asthma
10.1183/13993003.01393-2018	general_information	NA	NA	Countries of first author affiliations	france
10.1183/13993003.01393-2018	general_information	NA	NA	Countries of last author affiliations	usa
10.1183/13993003.01393-2018	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1183/13993003.01393-2018	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1183/13993003.01393-2018	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1183/13993003.01393-2018	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1183/13993003.01393-2018	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 1	benralizumab
10.1183/13993003.01393-2018	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1183/13993003.01393-2018	methodology	1	NA	Treatment name 2	mepolizumab
10.1183/13993003.01393-2018	methodology	1	NA	Study 'number(s)' for treatment 2	3;4
10.1183/13993003.01393-2018	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1183/13993003.01393-2018	methodology	1	NA	Anchored comparison?	Yes
10.1183/13993003.01393-2018	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1183/13993003.01393-2018	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1183/13993003.01393-2018	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annual rate of clinically significant exacerbations
10.1183/13993003.01393-2018	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1183/13993003.01393-2018	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1183/13993003.01393-2018	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1183/13993003.01393-2018	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1183/13993003.01393-2018	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1183/13993003.01393-2018	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1183/13993003.01393-2018	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	538
10.1183/13993003.01393-2018	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	346
10.1183/13993003.01393-2018	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1183/13993003.01393-2018	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1183/13993003.01393-2018	results	1	NA	Number of covariates adjusted for/matched on	7
10.1183/13993003.01393-2018	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1183/13993003.01393-2018	results	1	NA	Primary outcome: treatment effect contrast	RR
10.1183/13993003.01393-2018	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1183/13993003.01393-2018	results	1	NA	Primary outcome: unadjusted treatment effect	1.06
10.1183/13993003.01393-2018	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.5553
10.1183/13993003.01393-2018	results	1	NA	Primary outcome: adjusted treatment effect	0.94
10.1183/13993003.01393-2018	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.5207
10.1183/13993003.01393-2018	results	1	NA	If anchored, total initial sample size IPD	959
10.1183/13993003.01393-2018	results	1	NA	If anchored, total ESS IPD	639
10.1183/13993003.01393-2018	results	1	NA	geographical region	No
10.1183/13993003.01393-2018	results	1	NA	If anchored, total sample size non IPD	884
10.1183/13993003.01393-2018	results	1	NA	lb_ci	NA
10.1183/13993003.01393-2018	results	1	NA	ub_ci	NA
10.1183/13993003.01393-2018	results	1	NA	pval	0.5553
10.1183/13993003.01393-2018	results	1	NA	num_pval	0.5553
10.1183/13993003.01393-2018	results	1	NA	ci_cutoff	1
10.1183/13993003.01393-2018	results	1	NA	significant	FALSE
10.1183/13993003.01393-2018	results	1	NA	lb_ci	NA
10.1183/13993003.01393-2018	results	1	NA	ub_ci	NA
10.1183/13993003.01393-2018	results	1	NA	pval	0.5207
10.1183/13993003.01393-2018	results	1	NA	num_pval	0.5207
10.1183/13993003.01393-2018	results	1	NA	ci_cutoff	1
10.1183/13993003.01393-2018	results	1	NA	significant	FALSE
10.1183/13993003.01393-2018	study_information	NA	1	Patient-level data used	Yes
10.1183/13993003.01393-2018	study_information	NA	1	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01928771
10.1183/13993003.01393-2018	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1183/13993003.01393-2018	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	study_information	NA	2	Patient-level data used	Yes
10.1183/13993003.01393-2018	study_information	NA	2	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01914757
10.1183/13993003.01393-2018	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1183/13993003.01393-2018	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	study_information	NA	3	Patient-level data used	No
10.1183/13993003.01393-2018	study_information	NA	3	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01691521
10.1183/13993003.01393-2018	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1183/13993003.01393-2018	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1183/13993003.01393-2018	study_information	NA	4	Patient-level data used	No
10.1183/13993003.01393-2018	study_information	NA	4	Clinical Trial	Yes
10.1183/13993003.01393-2018	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01000506
10.1183/13993003.01393-2018	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1183/13993003.01393-2018	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.1183/13993003.01393-2018	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2011.576238	general_information	NA	NA	Medical Condition of Interest Name	chronic myeloid leukemia
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of first author affiliations	usa
10.1185/03007995.2011.576238	general_information	NA	NA	Countries of last author affiliations	usa
10.1185/03007995.2011.576238	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2011.576238	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1185/03007995.2011.576238	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1185/03007995.2011.576238	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1185/03007995.2011.576238	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 1	nilotinib
10.1185/03007995.2011.576238	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2011.576238	methodology	1	NA	Treatment name 2	dasatinib
10.1185/03007995.2011.576238	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1185/03007995.2011.576238	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2011.576238	methodology	1	NA	Anchored comparison?	No
10.1185/03007995.2011.576238	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2011.576238	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1185/03007995.2011.576238	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response by 12 months
10.1185/03007995.2011.576238	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2011.576238	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1185/03007995.2011.576238	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1185/03007995.2011.576238	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1185/03007995.2011.576238	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2011.576238	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2011.576238	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	259
10.1185/03007995.2011.576238	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	273
10.1185/03007995.2011.576238	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2011.576238	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2011.576238	results	1	NA	Number of covariates adjusted for/matched on	6
10.1185/03007995.2011.576238	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1185/03007995.2011.576238	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1185/03007995.2011.576238	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2011.576238	results	1	NA	Primary outcome: unadjusted treatment effect	9.4
10.1185/03007995.2011.576238	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.03
10.1185/03007995.2011.576238	results	1	NA	Primary outcome: adjusted treatment effect	10.8
10.1185/03007995.2011.576238	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.014
10.1185/03007995.2011.576238	results	1	NA	lb_ci	NA
10.1185/03007995.2011.576238	results	1	NA	ub_ci	NA
10.1185/03007995.2011.576238	results	1	NA	pval	0.03
10.1185/03007995.2011.576238	results	1	NA	num_pval	0.03
10.1185/03007995.2011.576238	results	1	NA	ci_cutoff	0
10.1185/03007995.2011.576238	results	1	NA	significant	TRUE
10.1185/03007995.2011.576238	results	1	NA	lb_ci	NA
10.1185/03007995.2011.576238	results	1	NA	ub_ci	NA
10.1185/03007995.2011.576238	results	1	NA	pval	0.014
10.1185/03007995.2011.576238	results	1	NA	num_pval	0.014
10.1185/03007995.2011.576238	results	1	NA	ci_cutoff	0
10.1185/03007995.2011.576238	results	1	NA	significant	TRUE
10.1185/03007995.2011.576238	study_information	NA	1	Patient-level data used	Yes
10.1185/03007995.2011.576238	study_information	NA	1	Clinical Trial	Yes
10.1185/03007995.2011.576238	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497
10.1185/03007995.2011.576238	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2011.576238	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2011.576238	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2011.576238	study_information	NA	2	Patient-level data used	No
10.1185/03007995.2011.576238	study_information	NA	2	Clinical Trial	Yes
10.1185/03007995.2011.576238	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247
10.1185/03007995.2011.576238	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2011.576238	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2011.576238	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2014.977992	general_information	NA	NA	Medical Condition of Interest Name	chronic myeloid leukemia in chronic phase
10.1185/03007995.2014.977992	general_information	NA	NA	Countries of first author affiliations	usa
10.1185/03007995.2014.977992	general_information	NA	NA	Countries of last author affiliations	usa
10.1185/03007995.2014.977992	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2014.977992	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1185/03007995.2014.977992	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1185/03007995.2014.977992	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1185/03007995.2014.977992	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 1	nilotinib
10.1185/03007995.2014.977992	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2014.977992	methodology	1	NA	Treatment name 2	dasatinib
10.1185/03007995.2014.977992	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1185/03007995.2014.977992	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2014.977992	methodology	1	NA	Anchored comparison?	Yes
10.1185/03007995.2014.977992	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2014.977992	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1185/03007995.2014.977992	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	major molecular response by 12 months
10.1185/03007995.2014.977992	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2014.977992	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1185/03007995.2014.977992	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1185/03007995.2014.977992	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1185/03007995.2014.977992	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2014.977992	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2014.977992	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	259
10.1185/03007995.2014.977992	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	260
10.1185/03007995.2014.977992	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	278
10.1185/03007995.2014.977992	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	282
10.1185/03007995.2014.977992	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2014.977992	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2014.977992	results	1	NA	Number of covariates adjusted for/matched on	5
10.1185/03007995.2014.977992	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1185/03007995.2014.977992	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.1185/03007995.2014.977992	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2014.977992	results	1	NA	Primary outcome: adjusted treatment effect	11.70
10.1185/03007995.2014.977992	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.045
10.1185/03007995.2014.977992	results	1	NA	lb_ci	NA
10.1185/03007995.2014.977992	results	1	NA	ub_ci	NA
10.1185/03007995.2014.977992	results	1	NA	pval	0.045
10.1185/03007995.2014.977992	results	1	NA	num_pval	0.045
10.1185/03007995.2014.977992	results	1	NA	ci_cutoff	0
10.1185/03007995.2014.977992	results	1	NA	significant	TRUE
10.1185/03007995.2014.977992	study_information	NA	1	Patient-level data used	Yes
10.1185/03007995.2014.977992	study_information	NA	1	Clinical Trial	Yes
10.1185/03007995.2014.977992	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00471497
10.1185/03007995.2014.977992	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2014.977992	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2014.977992	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2014.977992	study_information	NA	2	Patient-level data used	No
10.1185/03007995.2014.977992	study_information	NA	2	Clinical Trial	Yes
10.1185/03007995.2014.977992	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00481247
10.1185/03007995.2014.977992	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2014.977992	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2014.977992	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2015.1106934	general_information	NA	NA	Medical Condition of Interest Name	genotype 4 hepatitis c virus (hcv) infection
10.1185/03007995.2015.1106934	general_information	NA	NA	Countries of first author affiliations	belgium
10.1185/03007995.2015.1106934	general_information	NA	NA	Countries of last author affiliations	uk
10.1185/03007995.2015.1106934	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2015.1106934	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1185/03007995.2015.1106934	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1185/03007995.2015.1106934	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1185/03007995.2015.1106934	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	1	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1185/03007995.2015.1106934	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2015.1106934	methodology	1	NA	Anchored comparison?	No
10.1185/03007995.2015.1106934	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained viral response
10.1185/03007995.2015.1106934	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1185/03007995.2015.1106934	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2015.1106934	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	2	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1185/03007995.2015.1106934	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2015.1106934	methodology	2	NA	Anchored comparison?	No
10.1185/03007995.2015.1106934	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1185/03007995.2015.1106934	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained viral response
10.1185/03007995.2015.1106934	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1185/03007995.2015.1106934	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1185/03007995.2015.1106934	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2015.1106934	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	3	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.1185/03007995.2015.1106934	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2015.1106934	methodology	3	NA	Anchored comparison?	No
10.1185/03007995.2015.1106934	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1185/03007995.2015.1106934	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained viral response
10.1185/03007995.2015.1106934	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1185/03007995.2015.1106934	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1185/03007995.2015.1106934	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2015.1106934	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	4	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.1185/03007995.2015.1106934	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2015.1106934	methodology	4	NA	Anchored comparison?	No
10.1185/03007995.2015.1106934	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1185/03007995.2015.1106934	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained viral response
10.1185/03007995.2015.1106934	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1185/03007995.2015.1106934	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1185/03007995.2015.1106934	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2015.1106934	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 1	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.1185/03007995.2015.1106934	methodology	5	NA	Treatment name 2	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	5	NA	Study 'number(s)' for treatment 2	6
10.1185/03007995.2015.1106934	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1185/03007995.2015.1106934	methodology	5	NA	Anchored comparison?	No
10.1185/03007995.2015.1106934	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1185/03007995.2015.1106934	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained viral response
10.1185/03007995.2015.1106934	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1185/03007995.2015.1106934	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1185/03007995.2015.1106934	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1185/03007995.2015.1106934	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1185/03007995.2015.1106934	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	30
10.1185/03007995.2015.1106934	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	35
10.1185/03007995.2015.1106934	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	29
10.1185/03007995.2015.1106934	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2015.1106934	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2015.1106934	results	1	NA	Number of covariates adjusted for/matched on	5
10.1185/03007995.2015.1106934	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1185/03007995.2015.1106934	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1185/03007995.2015.1106934	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	1	NA	Primary outcome: adjusted treatment effect	3.28
10.1185/03007995.2015.1106934	results	1	NA	geographical region	No
10.1185/03007995.2015.1106934	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	18
10.1185/03007995.2015.1106934	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	35
10.1185/03007995.2015.1106934	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	15
10.1185/03007995.2015.1106934	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2015.1106934	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2015.1106934	results	2	NA	Number of covariates adjusted for/matched on	5
10.1185/03007995.2015.1106934	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1185/03007995.2015.1106934	results	2	NA	Primary outcome: treatment effect contrast	OR
10.1185/03007995.2015.1106934	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	2	NA	Primary outcome: adjusted treatment effect	4.26
10.1185/03007995.2015.1106934	results	2	NA	geographical region	No
10.1185/03007995.2015.1106934	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	95
10.1185/03007995.2015.1106934	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	14
10.1185/03007995.2015.1106934	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2015.1106934	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2015.1106934	results	3	NA	Number of covariates adjusted for/matched on	2
10.1185/03007995.2015.1106934	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	3	NA	Primary outcome: treatment effect contrast	OR
10.1185/03007995.2015.1106934	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	3	NA	Primary outcome: adjusted treatment effect	10.02
10.1185/03007995.2015.1106934	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	40
10.1185/03007995.2015.1106934	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	35
10.1185/03007995.2015.1106934	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	26
10.1185/03007995.2015.1106934	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2015.1106934	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2015.1106934	results	4	NA	Number of covariates adjusted for/matched on	2
10.1185/03007995.2015.1106934	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	4	NA	Primary outcome: treatment effect contrast	OR
10.1185/03007995.2015.1106934	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	4	NA	Primary outcome: adjusted treatment effect	6.69
10.1185/03007995.2015.1106934	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	109
10.1185/03007995.2015.1106934	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	19
10.1185/03007995.2015.1106934	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	17
10.1185/03007995.2015.1106934	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1185/03007995.2015.1106934	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1185/03007995.2015.1106934	results	5	NA	Number of covariates adjusted for/matched on	2
10.1185/03007995.2015.1106934	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	5	NA	Primary outcome: treatment effect contrast	OR
10.1185/03007995.2015.1106934	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	5	NA	Primary outcome: adjusted treatment effect	5.43
10.1185/03007995.2015.1106934	study_information	NA	1	Patient-level data used	Yes
10.1185/03007995.2015.1106934	study_information	NA	1	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01567735
10.1185/03007995.2015.1106934	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1185/03007995.2015.1106934	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1185/03007995.2015.1106934	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1185/03007995.2015.1106934	study_information	NA	2	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	2	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	varghese et al. (2009)
10.1185/03007995.2015.1106934	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	kuwait
10.1185/03007995.2015.1106934	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1185/03007995.2015.1106934	study_information	NA	3	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	3	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	rumi et al. (2010)
10.1185/03007995.2015.1106934	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.1185/03007995.2015.1106934	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2015.1106934	study_information	NA	4	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	4	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	el makhzangy et al. (2009)
10.1185/03007995.2015.1106934	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	egypt
10.1185/03007995.2015.1106934	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.1185/03007995.2015.1106934	study_information	NA	5	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	5	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00421434
10.1185/03007995.2015.1106934	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	egypt
10.1185/03007995.2015.1106934	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2, 3
10.1185/03007995.2015.1106934	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.1185/03007995.2015.1106934	study_information	NA	6	Patient-level data used	No
10.1185/03007995.2015.1106934	study_information	NA	6	Clinical Trial	Yes
10.1185/03007995.2015.1106934	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00502099
10.1185/03007995.2015.1106934	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	egypt
10.1185/03007995.2015.1106934	study_information	NA	6	Phase of the clinical trial (clinical trial only)	4
10.1185/03007995.2015.1106934	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.1186/2162-3619-2-32	general_information	NA	NA	Medical Condition of Interest Name	advanced pancreatic neuroendocrine tumor
10.1186/2162-3619-2-32	general_information	NA	NA	Countries of first author affiliations	usa
10.1186/2162-3619-2-32	general_information	NA	NA	Countries of last author affiliations	canada
10.1186/2162-3619-2-32	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/2162-3619-2-32	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/2162-3619-2-32	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/2162-3619-2-32	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/2162-3619-2-32	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 1	everolimus
10.1186/2162-3619-2-32	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/2162-3619-2-32	methodology	1	NA	Treatment name 2	sunitinib
10.1186/2162-3619-2-32	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/2162-3619-2-32	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/2162-3619-2-32	methodology	1	NA	Anchored comparison?	No
10.1186/2162-3619-2-32	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1186/2162-3619-2-32	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1186/2162-3619-2-32	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/2162-3619-2-32	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 1	everolimus
10.1186/2162-3619-2-32	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1186/2162-3619-2-32	methodology	2	NA	Treatment name 2	placebo
10.1186/2162-3619-2-32	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1186/2162-3619-2-32	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/2162-3619-2-32	methodology	2	NA	Anchored comparison?	No
10.1186/2162-3619-2-32	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1186/2162-3619-2-32	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1186/2162-3619-2-32	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/2162-3619-2-32	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 1	everolimus
10.1186/2162-3619-2-32	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.1186/2162-3619-2-32	methodology	3	NA	Treatment name 2	sunitinib
10.1186/2162-3619-2-32	methodology	3	NA	Study 'number(s)' for treatment 2	2
10.1186/2162-3619-2-32	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/2162-3619-2-32	methodology	3	NA	Anchored comparison?	Yes
10.1186/2162-3619-2-32	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1186/2162-3619-2-32	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.1186/2162-3619-2-32	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/2162-3619-2-32	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/2162-3619-2-32	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	86
10.1186/2162-3619-2-32	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1186/2162-3619-2-32	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/2162-3619-2-32	results	1	NA	Number of covariates adjusted for/matched on	8
10.1186/2162-3619-2-32	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1186/2162-3619-2-32	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	1	NA	Primary outcome: unadjusted treatment effect	0.69
10.1186/2162-3619-2-32	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.087
10.1186/2162-3619-2-32	results	1	NA	Primary outcome: adjusted treatment effect	0.81
10.1186/2162-3619-2-32	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.383
10.1186/2162-3619-2-32	results	1	NA	lb_ci	NA
10.1186/2162-3619-2-32	results	1	NA	ub_ci	NA
10.1186/2162-3619-2-32	results	1	NA	pval	0.087
10.1186/2162-3619-2-32	results	1	NA	num_pval	0.087
10.1186/2162-3619-2-32	results	1	NA	ci_cutoff	1
10.1186/2162-3619-2-32	results	1	NA	significant	FALSE
10.1186/2162-3619-2-32	results	1	NA	lb_ci	NA
10.1186/2162-3619-2-32	results	1	NA	ub_ci	NA
10.1186/2162-3619-2-32	results	1	NA	pval	0.383
10.1186/2162-3619-2-32	results	1	NA	num_pval	0.383
10.1186/2162-3619-2-32	results	1	NA	ci_cutoff	1
10.1186/2162-3619-2-32	results	1	NA	significant	FALSE
10.1186/2162-3619-2-32	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	85
10.1186/2162-3619-2-32	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1186/2162-3619-2-32	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/2162-3619-2-32	results	2	NA	Number of covariates adjusted for/matched on	8
10.1186/2162-3619-2-32	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1186/2162-3619-2-32	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	2	NA	Primary outcome: unadjusted treatment effect	0.53
10.1186/2162-3619-2-32	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.002
10.1186/2162-3619-2-32	results	2	NA	Primary outcome: adjusted treatment effect	0.61
10.1186/2162-3619-2-32	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.042
10.1186/2162-3619-2-32	results	2	NA	lb_ci	NA
10.1186/2162-3619-2-32	results	2	NA	ub_ci	NA
10.1186/2162-3619-2-32	results	2	NA	pval	0.002
10.1186/2162-3619-2-32	results	2	NA	num_pval	0.002
10.1186/2162-3619-2-32	results	2	NA	ci_cutoff	1
10.1186/2162-3619-2-32	results	2	NA	significant	TRUE
10.1186/2162-3619-2-32	results	2	NA	lb_ci	NA
10.1186/2162-3619-2-32	results	2	NA	ub_ci	NA
10.1186/2162-3619-2-32	results	2	NA	pval	0.042
10.1186/2162-3619-2-32	results	2	NA	num_pval	0.042
10.1186/2162-3619-2-32	results	2	NA	ci_cutoff	1
10.1186/2162-3619-2-32	results	2	NA	significant	TRUE
10.1186/2162-3619-2-32	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	86
10.1186/2162-3619-2-32	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	85
10.1186/2162-3619-2-32	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1186/2162-3619-2-32	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/2162-3619-2-32	results	3	NA	Number of covariates adjusted for/matched on	8
10.1186/2162-3619-2-32	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	3	NA	Primary outcome: treatment effect contrast	HR
10.1186/2162-3619-2-32	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	3	NA	Primary outcome: unadjusted treatment effect	0.9
10.1186/2162-3619-2-32	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.695
10.1186/2162-3619-2-32	results	3	NA	Primary outcome: adjusted treatment effect	0.84
10.1186/2162-3619-2-32	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.578
10.1186/2162-3619-2-32	results	3	NA	If anchored, total initial sample size IPD	394
10.1186/2162-3619-2-32	results	3	NA	lb_ci	NA
10.1186/2162-3619-2-32	results	3	NA	ub_ci	NA
10.1186/2162-3619-2-32	results	3	NA	pval	0.695
10.1186/2162-3619-2-32	results	3	NA	num_pval	0.695
10.1186/2162-3619-2-32	results	3	NA	ci_cutoff	1
10.1186/2162-3619-2-32	results	3	NA	significant	FALSE
10.1186/2162-3619-2-32	results	3	NA	lb_ci	NA
10.1186/2162-3619-2-32	results	3	NA	ub_ci	NA
10.1186/2162-3619-2-32	results	3	NA	pval	0.578
10.1186/2162-3619-2-32	results	3	NA	num_pval	0.578
10.1186/2162-3619-2-32	results	3	NA	ci_cutoff	1
10.1186/2162-3619-2-32	results	3	NA	significant	FALSE
10.1186/2162-3619-2-32	study_information	NA	1	Patient-level data used	Yes
10.1186/2162-3619-2-32	study_information	NA	1	Clinical Trial	Yes
10.1186/2162-3619-2-32	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068
10.1186/2162-3619-2-32	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/2162-3619-2-32	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1186/2162-3619-2-32	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1186/2162-3619-2-32	study_information	NA	2	Patient-level data used	No
10.1186/2162-3619-2-32	study_information	NA	2	Clinical Trial	Yes
10.1186/2162-3619-2-32	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597
10.1186/2162-3619-2-32	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/2162-3619-2-32	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1186/2162-3619-2-32	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1186/s12885-018-5157-0	general_information	NA	NA	Medical Condition of Interest Name	metastatic renal cell carcinoma
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of first author affiliations	canada
10.1186/s12885-018-5157-0	general_information	NA	NA	Countries of last author affiliations	uk
10.1186/s12885-018-5157-0	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s12885-018-5157-0	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s12885-018-5157-0	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s12885-018-5157-0	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s12885-018-5157-0	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 1	axitinib
10.1186/s12885-018-5157-0	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s12885-018-5157-0	methodology	1	NA	Treatment name 2	cabozantinib
10.1186/s12885-018-5157-0	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s12885-018-5157-0	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/s12885-018-5157-0	methodology	1	NA	Anchored comparison?	No
10.1186/s12885-018-5157-0	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/s12885-018-5157-0	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1186/s12885-018-5157-0	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1186/s12885-018-5157-0	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1186/s12885-018-5157-0	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1186/s12885-018-5157-0	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1186/s12885-018-5157-0	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s12885-018-5157-0	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/s12885-018-5157-0	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 1	axitinib
10.1186/s12885-018-5157-0	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1186/s12885-018-5157-0	methodology	2	NA	Treatment name 2	everolimus
10.1186/s12885-018-5157-0	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.1186/s12885-018-5157-0	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/s12885-018-5157-0	methodology	2	NA	Anchored comparison?	No
10.1186/s12885-018-5157-0	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/s12885-018-5157-0	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1186/s12885-018-5157-0	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.1186/s12885-018-5157-0	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1186/s12885-018-5157-0	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.1186/s12885-018-5157-0	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1186/s12885-018-5157-0	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s12885-018-5157-0	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/s12885-018-5157-0	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/s12885-018-5157-0	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	135
10.1186/s12885-018-5157-0	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	104
10.1186/s12885-018-5157-0	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1186/s12885-018-5157-0	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/s12885-018-5157-0	results	1	NA	Number of covariates adjusted for/matched on	9
10.1186/s12885-018-5157-0	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1186/s12885-018-5157-0	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1186/s12885-018-5157-0	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/s12885-018-5157-0	results	1	NA	Primary outcome: adjusted treatment effect	1.15
10.1186/s12885-018-5157-0	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.423
10.1186/s12885-018-5157-0	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	194
10.1186/s12885-018-5157-0	results	1	NA	geographical region	Yes
10.1186/s12885-018-5157-0	results	1	NA	lb_ci	NA
10.1186/s12885-018-5157-0	results	1	NA	ub_ci	NA
10.1186/s12885-018-5157-0	results	1	NA	pval	0.423
10.1186/s12885-018-5157-0	results	1	NA	num_pval	0.423
10.1186/s12885-018-5157-0	results	1	NA	ci_cutoff	1
10.1186/s12885-018-5157-0	results	1	NA	significant	FALSE
10.1186/s12885-018-5157-0	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	132
10.1186/s12885-018-5157-0	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	61
10.1186/s12885-018-5157-0	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1186/s12885-018-5157-0	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/s12885-018-5157-0	results	2	NA	Number of covariates adjusted for/matched on	9
10.1186/s12885-018-5157-0	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1186/s12885-018-5157-0	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1186/s12885-018-5157-0	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/s12885-018-5157-0	results	2	NA	Primary outcome: adjusted treatment effect	0.53
10.1186/s12885-018-5157-0	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.002
10.1186/s12885-018-5157-0	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	194
10.1186/s12885-018-5157-0	results	2	NA	geographical region	Yes
10.1186/s12885-018-5157-0	results	2	NA	lb_ci	NA
10.1186/s12885-018-5157-0	results	2	NA	ub_ci	NA
10.1186/s12885-018-5157-0	results	2	NA	pval	0.002
10.1186/s12885-018-5157-0	results	2	NA	num_pval	0.002
10.1186/s12885-018-5157-0	results	2	NA	ci_cutoff	1
10.1186/s12885-018-5157-0	results	2	NA	significant	TRUE
10.1186/s12885-018-5157-0	study_information	NA	1	Patient-level data used	Yes
10.1186/s12885-018-5157-0	study_information	NA	1	Clinical Trial	Yes
10.1186/s12885-018-5157-0	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00678392
10.1186/s12885-018-5157-0	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s12885-018-5157-0	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1186/s12885-018-5157-0	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1186/s12885-018-5157-0	study_information	NA	2	Patient-level data used	No
10.1186/s12885-018-5157-0	study_information	NA	2	Clinical Trial	Yes
10.1186/s12885-018-5157-0	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01865747
10.1186/s12885-018-5157-0	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s12885-018-5157-0	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1186/s12885-018-5157-0	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1186/s13045-021-01144-9	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory large b cell lymphoma
10.1186/s13045-021-01144-9	general_information	NA	NA	Countries of first author affiliations	usa
10.1186/s13045-021-01144-9	general_information	NA	NA	Countries of last author affiliations	france
10.1186/s13045-021-01144-9	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s13045-021-01144-9	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s13045-021-01144-9	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s13045-021-01144-9	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s13045-021-01144-9	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel
10.1186/s13045-021-01144-9	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s13045-021-01144-9	methodology	1	NA	Treatment name 2	axicabtagene ciloleucel
10.1186/s13045-021-01144-9	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s13045-021-01144-9	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/s13045-021-01144-9	methodology	1	NA	Anchored comparison?	No
10.1186/s13045-021-01144-9	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/s13045-021-01144-9	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s13045-021-01144-9	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate (orr)
10.1186/s13045-021-01144-9	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1186/s13045-021-01144-9	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1186/s13045-021-01144-9	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/s13045-021-01144-9	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/s13045-021-01144-9	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	101
10.1186/s13045-021-01144-9	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	110
10.1186/s13045-021-01144-9	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	42.1
10.1186/s13045-021-01144-9	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1186/s13045-021-01144-9	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/s13045-021-01144-9	results	1	NA	Number of covariates adjusted for/matched on	10
10.1186/s13045-021-01144-9	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1186/s13045-021-01144-9	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1186/s13045-021-01144-9	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/s13045-021-01144-9	results	1	NA	Primary outcome: unadjusted treatment effect	0.92
10.1186/s13045-021-01144-9	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.753
10.1186/s13045-021-01144-9	results	1	NA	Primary outcome: adjusted treatment effect	1.4
10.1186/s13045-021-01144-9	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.476
10.1186/s13045-021-01144-9	results	1	NA	geographical region	No
10.1186/s13045-021-01144-9	results	1	NA	lb_ci	NA
10.1186/s13045-021-01144-9	results	1	NA	ub_ci	NA
10.1186/s13045-021-01144-9	results	1	NA	pval	0.753
10.1186/s13045-021-01144-9	results	1	NA	num_pval	0.753
10.1186/s13045-021-01144-9	results	1	NA	ci_cutoff	1
10.1186/s13045-021-01144-9	results	1	NA	significant	FALSE
10.1186/s13045-021-01144-9	results	1	NA	lb_ci	NA
10.1186/s13045-021-01144-9	results	1	NA	ub_ci	NA
10.1186/s13045-021-01144-9	results	1	NA	pval	0.476
10.1186/s13045-021-01144-9	results	1	NA	num_pval	0.476
10.1186/s13045-021-01144-9	results	1	NA	ci_cutoff	1
10.1186/s13045-021-01144-9	results	1	NA	significant	FALSE
10.1186/s13045-021-01144-9	study_information	NA	1	Patient-level data used	Yes
10.1186/s13045-021-01144-9	study_information	NA	1	Clinical Trial	Yes
10.1186/s13045-021-01144-9	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1186/s13045-021-01144-9	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1186/s13045-021-01144-9	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1186/s13045-021-01144-9	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1186/s13045-021-01144-9	study_information	NA	2	Patient-level data used	No
10.1186/s13045-021-01144-9	study_information	NA	2	Clinical Trial	Yes
10.1186/s13045-021-01144-9	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02348216
10.1186/s13045-021-01144-9	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s13045-021-01144-9	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2
10.1186/s13045-021-01144-9	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1186/s40164-022-00268-z	general_information	NA	NA	Medical Condition of Interest Name	relapsed or refractory aggressive large b-cell lymphomas
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of first author affiliations	france
10.1186/s40164-022-00268-z	general_information	NA	NA	Countries of last author affiliations	canada
10.1186/s40164-022-00268-z	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Private Data Analysis Company, Pharmaceutical Industry
10.1186/s40164-022-00268-z	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s40164-022-00268-z	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s40164-022-00268-z	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s40164-022-00268-z	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 1	lisocabtagene maraleucel
10.1186/s40164-022-00268-z	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s40164-022-00268-z	methodology	1	NA	Treatment name 2	tisagenlecleucel
10.1186/s40164-022-00268-z	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s40164-022-00268-z	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/s40164-022-00268-z	methodology	1	NA	Anchored comparison?	No
10.1186/s40164-022-00268-z	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/s40164-022-00268-z	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s40164-022-00268-z	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate
10.1186/s40164-022-00268-z	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1186/s40164-022-00268-z	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1186/s40164-022-00268-z	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1186/s40164-022-00268-z	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1186/s40164-022-00268-z	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/s40164-022-00268-z	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/s40164-022-00268-z	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	111
10.1186/s40164-022-00268-z	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	256
10.1186/s40164-022-00268-z	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	164
10.1186/s40164-022-00268-z	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1186/s40164-022-00268-z	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/s40164-022-00268-z	results	1	NA	Number of covariates adjusted for/matched on	6
10.1186/s40164-022-00268-z	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1186/s40164-022-00268-z	results	1	NA	Primary outcome: treatment effect contrast	OR
10.1186/s40164-022-00268-z	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/s40164-022-00268-z	results	1	NA	Primary outcome: unadjusted treatment effect	2.49
10.1186/s40164-022-00268-z	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[1.52;4.07]
10.1186/s40164-022-00268-z	results	1	NA	Primary outcome: adjusted treatment effect	2.78
10.1186/s40164-022-00268-z	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.63;4.74]
10.1186/s40164-022-00268-z	results	1	NA	lb_ci	1.52
10.1186/s40164-022-00268-z	results	1	NA	ub_ci	4.07
10.1186/s40164-022-00268-z	results	1	NA	pval	NA
10.1186/s40164-022-00268-z	results	1	NA	num_pval	NA
10.1186/s40164-022-00268-z	results	1	NA	ci_cutoff	1
10.1186/s40164-022-00268-z	results	1	NA	significant	FALSE
10.1186/s40164-022-00268-z	results	1	NA	lb_ci	1.63
10.1186/s40164-022-00268-z	results	1	NA	ub_ci	4.74
10.1186/s40164-022-00268-z	results	1	NA	pval	NA
10.1186/s40164-022-00268-z	results	1	NA	num_pval	NA
10.1186/s40164-022-00268-z	results	1	NA	ci_cutoff	1
10.1186/s40164-022-00268-z	results	1	NA	significant	FALSE
10.1186/s40164-022-00268-z	study_information	NA	1	Patient-level data used	Yes
10.1186/s40164-022-00268-z	study_information	NA	1	Clinical Trial	Yes
10.1186/s40164-022-00268-z	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02631044
10.1186/s40164-022-00268-z	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.1186/s40164-022-00268-z	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1186/s40164-022-00268-z	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.1186/s40164-022-00268-z	study_information	NA	2	Patient-level data used	No
10.1186/s40164-022-00268-z	study_information	NA	2	Clinical Trial	Yes
10.1186/s40164-022-00268-z	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02445248
10.1186/s40164-022-00268-z	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1186/s40164-022-00268-z	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.1186/s40164-022-00268-z	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s40734-017-0051-5	general_information	NA	NA	Medical Condition of Interest Name	huntington disease
10.1186/s40734-017-0051-5	general_information	NA	NA	Countries of first author affiliations	usa
10.1186/s40734-017-0051-5	general_information	NA	NA	Countries of last author affiliations	usa
10.1186/s40734-017-0051-5	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s40734-017-0051-5	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1186/s40734-017-0051-5	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1186/s40734-017-0051-5	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1186/s40734-017-0051-5	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 1	deutetrabenazine
10.1186/s40734-017-0051-5	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1186/s40734-017-0051-5	methodology	1	NA	Treatment name 2	tetrabenazine
10.1186/s40734-017-0051-5	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.1186/s40734-017-0051-5	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1186/s40734-017-0051-5	methodology	1	NA	Anchored comparison?	Yes
10.1186/s40734-017-0051-5	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.1186/s40734-017-0051-5	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s40734-017-0051-5	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall adverse events
10.1186/s40734-017-0051-5	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.1186/s40734-017-0051-5	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1186/s40734-017-0051-5	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/s40734-017-0051-5	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s40734-017-0051-5	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1186/s40734-017-0051-5	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1186/s40734-017-0051-5	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	54
10.1186/s40734-017-0051-5	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	30
10.1186/s40734-017-0051-5	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	45
10.1186/s40734-017-0051-5	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	45
10.1186/s40734-017-0051-5	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1186/s40734-017-0051-5	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1186/s40734-017-0051-5	results	1	NA	Number of covariates adjusted for/matched on	3
10.1186/s40734-017-0051-5	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1186/s40734-017-0051-5	results	1	NA	Primary outcome: treatment effect contrast	Risk difference
10.1186/s40734-017-0051-5	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1186/s40734-017-0051-5	results	1	NA	Primary outcome: unadjusted treatment effect	-20.70
10.1186/s40734-017-0051-5	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.135
10.1186/s40734-017-0051-5	results	1	NA	Primary outcome: adjusted treatment effect	-35.30
10.1186/s40734-017-0051-5	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.063
10.1186/s40734-017-0051-5	results	1	NA	lb_ci	NA
10.1186/s40734-017-0051-5	results	1	NA	ub_ci	NA
10.1186/s40734-017-0051-5	results	1	NA	pval	0.135
10.1186/s40734-017-0051-5	results	1	NA	num_pval	0.135
10.1186/s40734-017-0051-5	results	1	NA	ci_cutoff	0
10.1186/s40734-017-0051-5	results	1	NA	significant	FALSE
10.1186/s40734-017-0051-5	results	1	NA	lb_ci	NA
10.1186/s40734-017-0051-5	results	1	NA	ub_ci	NA
10.1186/s40734-017-0051-5	results	1	NA	pval	0.063
10.1186/s40734-017-0051-5	results	1	NA	num_pval	0.063
10.1186/s40734-017-0051-5	results	1	NA	ci_cutoff	0
10.1186/s40734-017-0051-5	results	1	NA	significant	FALSE
10.1186/s40734-017-0051-5	study_information	NA	1	Patient-level data used	Yes
10.1186/s40734-017-0051-5	study_information	NA	1	Clinical Trial	Yes
10.1186/s40734-017-0051-5	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01795859
10.1186/s40734-017-0051-5	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1186/s40734-017-0051-5	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1186/s40734-017-0051-5	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1186/s40734-017-0051-5	study_information	NA	2	Patient-level data used	No
10.1186/s40734-017-0051-5	study_information	NA	2	Clinical Trial	Yes
10.1186/s40734-017-0051-5	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00219804
10.1186/s40734-017-0051-5	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.1186/s40734-017-0051-5	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1186/s40734-017-0051-5	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.1210/clinem/dgab905	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes
10.1210/clinem/dgab905	general_information	NA	NA	Countries of first author affiliations	usa
10.1210/clinem/dgab905	general_information	NA	NA	Countries of last author affiliations	usa
10.1210/clinem/dgab905	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1210/clinem/dgab905	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1210/clinem/dgab905	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1210/clinem/dgab905	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1210/clinem/dgab905	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 1	semaglutide 2.0 mg
10.1210/clinem/dgab905	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.1210/clinem/dgab905	methodology	1	NA	Treatment name 2	dulaglutide 3.0 mg
10.1210/clinem/dgab905	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1210/clinem/dgab905	methodology	1	NA	Type of population-adjusted indirect comparisons performed	Multilevel network meta-regression
10.1210/clinem/dgab905	methodology	1	NA	Anchored comparison?	Yes
10.1210/clinem/dgab905	methodology	1	NA	Form of the indirect comparison	Larger network (ie involving more than 2 studies)
10.1210/clinem/dgab905	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1210/clinem/dgab905	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in hba1c
10.1210/clinem/dgab905	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1210/clinem/dgab905	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1210/clinem/dgab905	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1210/clinem/dgab905	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1210/clinem/dgab905	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 1	semaglutide 2.0 mg
10.1210/clinem/dgab905	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.1210/clinem/dgab905	methodology	2	NA	Treatment name 2	dulaglutide 4.5 mg
10.1210/clinem/dgab905	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.1210/clinem/dgab905	methodology	2	NA	Type of population-adjusted indirect comparisons performed	Multilevel network meta-regression
10.1210/clinem/dgab905	methodology	2	NA	Anchored comparison?	Yes
10.1210/clinem/dgab905	methodology	2	NA	Form of the indirect comparison	Larger network (ie involving more than 2 studies)
10.1210/clinem/dgab905	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1210/clinem/dgab905	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	change from baseline in hba1c
10.1210/clinem/dgab905	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.1210/clinem/dgab905	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1210/clinem/dgab905	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.1210/clinem/dgab905	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.1210/clinem/dgab905	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1210/clinem/dgab905	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	616
10.1210/clinem/dgab905	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612
10.1210/clinem/dgab905	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	480
10.1210/clinem/dgab905	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	480
10.1210/clinem/dgab905	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	481
10.1210/clinem/dgab905	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	481
10.1210/clinem/dgab905	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1210/clinem/dgab905	results	1	NA	Number of covariates adjusted for/matched on	3
10.1210/clinem/dgab905	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1210/clinem/dgab905	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.1210/clinem/dgab905	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1210/clinem/dgab905	results	1	NA	Primary outcome: unadjusted treatment effect	-0.47
10.1210/clinem/dgab905	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.69;-0.23]
10.1210/clinem/dgab905	results	1	NA	Primary outcome: adjusted treatment effect	-0.44
10.1210/clinem/dgab905	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.68;-0.19]
10.1210/clinem/dgab905	results	1	NA	geographical region	No
10.1210/clinem/dgab905	results	1	NA	lb_ci	-0.69
10.1210/clinem/dgab905	results	1	NA	ub_ci	-0.23
10.1210/clinem/dgab905	results	1	NA	pval	NA
10.1210/clinem/dgab905	results	1	NA	num_pval	NA
10.1210/clinem/dgab905	results	1	NA	ci_cutoff	0
10.1210/clinem/dgab905	results	1	NA	significant	FALSE
10.1210/clinem/dgab905	results	1	NA	lb_ci	-0.68
10.1210/clinem/dgab905	results	1	NA	ub_ci	-0.19
10.1210/clinem/dgab905	results	1	NA	pval	NA
10.1210/clinem/dgab905	results	1	NA	num_pval	NA
10.1210/clinem/dgab905	results	1	NA	ci_cutoff	0
10.1210/clinem/dgab905	results	1	NA	significant	FALSE
10.1210/clinem/dgab905	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	614
10.1210/clinem/dgab905	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	612
10.1210/clinem/dgab905	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	480
10.1210/clinem/dgab905	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	480
10.1210/clinem/dgab905	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	481
10.1210/clinem/dgab905	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	481
10.1210/clinem/dgab905	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1210/clinem/dgab905	results	2	NA	Number of covariates adjusted for/matched on	3
10.1210/clinem/dgab905	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1210/clinem/dgab905	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.1210/clinem/dgab905	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1210/clinem/dgab905	results	2	NA	Primary outcome: unadjusted treatment effect	-0.31
10.1210/clinem/dgab905	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.53;-0.08]
10.1210/clinem/dgab905	results	2	NA	Primary outcome: adjusted treatment effect	-0.28
10.1210/clinem/dgab905	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.52;-0.03]
10.1210/clinem/dgab905	results	2	NA	geographical region	No
10.1210/clinem/dgab905	results	2	NA	lb_ci	-0.53
10.1210/clinem/dgab905	results	2	NA	ub_ci	-0.08
10.1210/clinem/dgab905	results	2	NA	pval	NA
10.1210/clinem/dgab905	results	2	NA	num_pval	NA
10.1210/clinem/dgab905	results	2	NA	ci_cutoff	0
10.1210/clinem/dgab905	results	2	NA	significant	FALSE
10.1210/clinem/dgab905	results	2	NA	lb_ci	-0.52
10.1210/clinem/dgab905	results	2	NA	ub_ci	-0.03
10.1210/clinem/dgab905	results	2	NA	pval	NA
10.1210/clinem/dgab905	results	2	NA	num_pval	NA
10.1210/clinem/dgab905	results	2	NA	ci_cutoff	0
10.1210/clinem/dgab905	results	2	NA	significant	FALSE
10.1210/clinem/dgab905	study_information	NA	1	Patient-level data used	Yes
10.1210/clinem/dgab905	study_information	NA	1	Clinical Trial	Yes
10.1210/clinem/dgab905	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03989232
10.1210/clinem/dgab905	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1210/clinem/dgab905	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.1210/clinem/dgab905	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.1210/clinem/dgab905	study_information	NA	3	Patient-level data used	No
10.1210/clinem/dgab905	study_information	NA	3	Clinical Trial	Yes
10.1210/clinem/dgab905	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03495102
10.1210/clinem/dgab905	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1210/clinem/dgab905	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1210/clinem/dgab905	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1634/theoncologist.2017-0103	general_information	NA	NA	Medical Condition of Interest Name	relapsed/refractory multiple myeloma
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of first author affiliations	belgium
10.1634/theoncologist.2017-0103	general_information	NA	NA	Countries of last author affiliations	spain
10.1634/theoncologist.2017-0103	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.1634/theoncologist.2017-0103	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.1634/theoncologist.2017-0103	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.1634/theoncologist.2017-0103	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 1	daratumumab
10.1634/theoncologist.2017-0103	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.1634/theoncologist.2017-0103	methodology	1	NA	Treatment name 2	pomalidomide + low-dose dexamethasone
10.1634/theoncologist.2017-0103	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.1634/theoncologist.2017-0103	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1634/theoncologist.2017-0103	methodology	1	NA	Anchored comparison?	No
10.1634/theoncologist.2017-0103	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1634/theoncologist.2017-0103	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1634/theoncologist.2017-0103	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1634/theoncologist.2017-0103	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.1634/theoncologist.2017-0103	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1634/theoncologist.2017-0103	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1634/theoncologist.2017-0103	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1634/theoncologist.2017-0103	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1634/theoncologist.2017-0103	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 1	daratumumab
10.1634/theoncologist.2017-0103	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.1634/theoncologist.2017-0103	methodology	2	NA	Treatment name 2	pomalidomide + low-dose dexamethasone
10.1634/theoncologist.2017-0103	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.1634/theoncologist.2017-0103	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.1634/theoncologist.2017-0103	methodology	2	NA	Anchored comparison?	No
10.1634/theoncologist.2017-0103	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1634/theoncologist.2017-0103	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.1634/theoncologist.2017-0103	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.1634/theoncologist.2017-0103	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.1634/theoncologist.2017-0103	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1634/theoncologist.2017-0103	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.1634/theoncologist.2017-0103	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1634/theoncologist.2017-0103	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.1634/theoncologist.2017-0103	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.1634/theoncologist.2017-0103	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	302
10.1634/theoncologist.2017-0103	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	136
10.1634/theoncologist.2017-0103	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	55
10.1634/theoncologist.2017-0103	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1634/theoncologist.2017-0103	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1634/theoncologist.2017-0103	results	1	NA	Number of covariates adjusted for/matched on	10
10.1634/theoncologist.2017-0103	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1634/theoncologist.2017-0103	results	1	NA	Primary outcome: treatment effect contrast	HR
10.1634/theoncologist.2017-0103	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1634/theoncologist.2017-0103	results	1	NA	Primary outcome: unadjusted treatment effect	0.61
10.1634/theoncologist.2017-0103	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.0005
10.1634/theoncologist.2017-0103	results	1	NA	Primary outcome: adjusted treatment effect	0.56
10.1634/theoncologist.2017-0103	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	lb_ci	NA
10.1634/theoncologist.2017-0103	results	1	NA	ub_ci	NA
10.1634/theoncologist.2017-0103	results	1	NA	pval	0.0005
10.1634/theoncologist.2017-0103	results	1	NA	num_pval	5e-04
10.1634/theoncologist.2017-0103	results	1	NA	ci_cutoff	1
10.1634/theoncologist.2017-0103	results	1	NA	significant	TRUE
10.1634/theoncologist.2017-0103	results	1	NA	lb_ci	NA
10.1634/theoncologist.2017-0103	results	1	NA	ub_ci	NA
10.1634/theoncologist.2017-0103	results	1	NA	pval	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	num_pval	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	ci_cutoff	1
10.1634/theoncologist.2017-0103	results	1	NA	significant	TRUE
10.1634/theoncologist.2017-0103	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	682
10.1634/theoncologist.2017-0103	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	148
10.1634/theoncologist.2017-0103	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	95
10.1634/theoncologist.2017-0103	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.1634/theoncologist.2017-0103	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.1634/theoncologist.2017-0103	results	2	NA	Number of covariates adjusted for/matched on	7
10.1634/theoncologist.2017-0103	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1634/theoncologist.2017-0103	results	2	NA	Primary outcome: treatment effect contrast	HR
10.1634/theoncologist.2017-0103	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.1634/theoncologist.2017-0103	results	2	NA	Primary outcome: unadjusted treatment effect	0.55
10.1634/theoncologist.2017-0103	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	Primary outcome: adjusted treatment effect	0.51
10.1634/theoncologist.2017-0103	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	lb_ci	NA
10.1634/theoncologist.2017-0103	results	2	NA	ub_ci	NA
10.1634/theoncologist.2017-0103	results	2	NA	pval	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	num_pval	NA
10.1634/theoncologist.2017-0103	results	2	NA	ci_cutoff	1
10.1634/theoncologist.2017-0103	results	2	NA	significant	TRUE
10.1634/theoncologist.2017-0103	results	2	NA	lb_ci	NA
10.1634/theoncologist.2017-0103	results	2	NA	ub_ci	NA
10.1634/theoncologist.2017-0103	results	2	NA	pval	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	num_pval	NA
10.1634/theoncologist.2017-0103	results	2	NA	ci_cutoff	1
10.1634/theoncologist.2017-0103	results	2	NA	significant	TRUE
10.1634/theoncologist.2017-0103	study_information	NA	1	Patient-level data used	Yes
10.1634/theoncologist.2017-0103	study_information	NA	1	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00574288
10.1634/theoncologist.2017-0103	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.1634/theoncologist.2017-0103	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.1634/theoncologist.2017-0103	study_information	NA	2	Patient-level data used	Yes
10.1634/theoncologist.2017-0103	study_information	NA	2	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01985126
10.1634/theoncologist.2017-0103	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.1634/theoncologist.2017-0103	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.1634/theoncologist.2017-0103	study_information	NA	3	Patient-level data used	No
10.1634/theoncologist.2017-0103	study_information	NA	3	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01311687
10.1634/theoncologist.2017-0103	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.1634/theoncologist.2017-0103	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.1634/theoncologist.2017-0103	study_information	NA	4	Patient-level data used	No
10.1634/theoncologist.2017-0103	study_information	NA	4	Clinical Trial	Yes
10.1634/theoncologist.2017-0103	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01712789
10.1634/theoncologist.2017-0103	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.1634/theoncologist.2017-0103	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.1634/theoncologist.2017-0103	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2147/ceor.s203482	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia
10.2147/ceor.s203482	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/ceor.s203482	general_information	NA	NA	Countries of last author affiliations	uk
10.2147/ceor.s203482	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/ceor.s203482	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/ceor.s203482	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/ceor.s203482	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/ceor.s203482	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/ceor.s203482	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine
10.2147/ceor.s203482	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/ceor.s203482	methodology	1	NA	Treatment name 2	azacitidine
10.2147/ceor.s203482	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/ceor.s203482	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.2147/ceor.s203482	methodology	1	NA	Anchored comparison?	Yes
10.2147/ceor.s203482	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/ceor.s203482	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2147/ceor.s203482	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2147/ceor.s203482	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2147/ceor.s203482	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2147/ceor.s203482	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2147/ceor.s203482	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2147/ceor.s203482	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/ceor.s203482	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/ceor.s203482	methodology	2	NA	Treatment name 1	glasdegib + low-dose cytarabine
10.2147/ceor.s203482	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/ceor.s203482	methodology	2	NA	Treatment name 2	decitabine
10.2147/ceor.s203482	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2147/ceor.s203482	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.2147/ceor.s203482	methodology	2	NA	Anchored comparison?	Yes
10.2147/ceor.s203482	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/ceor.s203482	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2147/ceor.s203482	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2147/ceor.s203482	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2147/ceor.s203482	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2147/ceor.s203482	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2147/ceor.s203482	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2147/ceor.s203482	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/ceor.s203482	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/ceor.s203482	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	241
10.2147/ceor.s203482	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	158
10.2147/ceor.s203482	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	78
10.2147/ceor.s203482	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78
10.2147/ceor.s203482	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	38
10.2147/ceor.s203482	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	38
10.2147/ceor.s203482	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/ceor.s203482	results	1	NA	Number of covariates adjusted for/matched on	3
10.2147/ceor.s203482	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2147/ceor.s203482	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2147/ceor.s203482	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/ceor.s203482	results	1	NA	Primary outcome: unadjusted treatment effect	0.514
10.2147/ceor.s203482	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.310;0.852]
10.2147/ceor.s203482	results	1	NA	Primary outcome: adjusted treatment effect	0.424
10.2147/ceor.s203482	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.228;0.789]
10.2147/ceor.s203482	results	1	NA	lb_ci	0.31
10.2147/ceor.s203482	results	1	NA	ub_ci	0.852
10.2147/ceor.s203482	results	1	NA	pval	NA
10.2147/ceor.s203482	results	1	NA	num_pval	NA
10.2147/ceor.s203482	results	1	NA	ci_cutoff	1
10.2147/ceor.s203482	results	1	NA	significant	FALSE
10.2147/ceor.s203482	results	1	NA	lb_ci	0.228
10.2147/ceor.s203482	results	1	NA	ub_ci	0.789
10.2147/ceor.s203482	results	1	NA	pval	NA
10.2147/ceor.s203482	results	1	NA	num_pval	NA
10.2147/ceor.s203482	results	1	NA	ci_cutoff	1
10.2147/ceor.s203482	results	1	NA	significant	FALSE
10.2147/ceor.s203482	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	242
10.2147/ceor.s203482	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	215
10.2147/ceor.s203482	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	78
10.2147/ceor.s203482	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78
10.2147/ceor.s203482	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	38
10.2147/ceor.s203482	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	38
10.2147/ceor.s203482	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/ceor.s203482	results	2	NA	Number of covariates adjusted for/matched on	5
10.2147/ceor.s203482	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2147/ceor.s203482	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2147/ceor.s203482	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/ceor.s203482	results	2	NA	Primary outcome: unadjusted treatment effect	0.565
10.2147/ceor.s203482	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.351;0.909]
10.2147/ceor.s203482	results	2	NA	Primary outcome: adjusted treatment effect	0.505
10.2147/ceor.s203482	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.269;0.949]
10.2147/ceor.s203482	results	2	NA	lb_ci	0.351
10.2147/ceor.s203482	results	2	NA	ub_ci	0.909
10.2147/ceor.s203482	results	2	NA	pval	NA
10.2147/ceor.s203482	results	2	NA	num_pval	NA
10.2147/ceor.s203482	results	2	NA	ci_cutoff	1
10.2147/ceor.s203482	results	2	NA	significant	FALSE
10.2147/ceor.s203482	results	2	NA	lb_ci	0.269
10.2147/ceor.s203482	results	2	NA	ub_ci	0.949
10.2147/ceor.s203482	results	2	NA	pval	NA
10.2147/ceor.s203482	results	2	NA	num_pval	NA
10.2147/ceor.s203482	results	2	NA	ci_cutoff	1
10.2147/ceor.s203482	results	2	NA	significant	FALSE
10.2147/ceor.s203482	study_information	NA	1	Patient-level data used	Yes
10.2147/ceor.s203482	study_information	NA	1	Clinical Trial	Yes
10.2147/ceor.s203482	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038
10.2147/ceor.s203482	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ceor.s203482	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2147/ceor.s203482	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/ceor.s203482	study_information	NA	2	Patient-level data used	No
10.2147/ceor.s203482	study_information	NA	2	Clinical Trial	Yes
10.2147/ceor.s203482	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01074047
10.2147/ceor.s203482	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ceor.s203482	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/ceor.s203482	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/ceor.s203482	study_information	NA	3	Patient-level data used	No
10.2147/ceor.s203482	study_information	NA	3	Clinical Trial	Yes
10.2147/ceor.s203482	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00260832
10.2147/ceor.s203482	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ceor.s203482	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2147/ceor.s203482	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s163478	general_information	NA	NA	Medical Condition of Interest Name	hr+, her2- advanced breast cancer
10.2147/cmar.s163478	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/cmar.s163478	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/cmar.s163478	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2147/cmar.s163478	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/cmar.s163478	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/cmar.s163478	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/cmar.s163478	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/cmar.s163478	methodology	1	NA	Treatment name 1	ribociclib
10.2147/cmar.s163478	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/cmar.s163478	methodology	1	NA	Treatment name 2	palbociclib
10.2147/cmar.s163478	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/cmar.s163478	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/cmar.s163478	methodology	1	NA	Anchored comparison?	Yes
10.2147/cmar.s163478	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s163478	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2147/cmar.s163478	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.2147/cmar.s163478	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2147/cmar.s163478	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/cmar.s163478	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2147/cmar.s163478	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s163478	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/cmar.s163478	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/cmar.s163478	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	444
10.2147/cmar.s163478	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	222
10.2147/cmar.s163478	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/cmar.s163478	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/cmar.s163478	results	1	NA	Number of covariates adjusted for/matched on	9
10.2147/cmar.s163478	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2147/cmar.s163478	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2147/cmar.s163478	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/cmar.s163478	results	1	NA	Primary outcome: unadjusted treatment effect	0.959
10.2147/cmar.s163478	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.681;1.350]
10.2147/cmar.s163478	results	1	NA	Primary outcome: adjusted treatment effect	0.904
10.2147/cmar.s163478	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.644;1.268]
10.2147/cmar.s163478	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	227
10.2147/cmar.s163478	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	220
10.2147/cmar.s163478	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	244
10.2147/cmar.s163478	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	237
10.2147/cmar.s163478	results	1	NA	geographical region	Yes
10.2147/cmar.s163478	results	1	NA	lb_ci	0.681
10.2147/cmar.s163478	results	1	NA	ub_ci	1.35
10.2147/cmar.s163478	results	1	NA	pval	NA
10.2147/cmar.s163478	results	1	NA	num_pval	NA
10.2147/cmar.s163478	results	1	NA	ci_cutoff	1
10.2147/cmar.s163478	results	1	NA	significant	TRUE
10.2147/cmar.s163478	results	1	NA	lb_ci	0.644
10.2147/cmar.s163478	results	1	NA	ub_ci	1.268
10.2147/cmar.s163478	results	1	NA	pval	NA
10.2147/cmar.s163478	results	1	NA	num_pval	NA
10.2147/cmar.s163478	results	1	NA	ci_cutoff	1
10.2147/cmar.s163478	results	1	NA	significant	TRUE
10.2147/cmar.s163478	study_information	NA	1	Patient-level data used	Yes
10.2147/cmar.s163478	study_information	NA	1	Clinical Trial	Yes
10.2147/cmar.s163478	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01958021
10.2147/cmar.s163478	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s163478	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/cmar.s163478	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s163478	study_information	NA	2	Patient-level data used	No
10.2147/cmar.s163478	study_information	NA	2	Clinical Trial	Yes
10.2147/cmar.s163478	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01740427
10.2147/cmar.s163478	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s163478	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/cmar.s163478	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s325043	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2? advanced breast cancer
10.2147/cmar.s325043	general_information	NA	NA	Countries of first author affiliations	germany
10.2147/cmar.s325043	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/cmar.s325043	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/cmar.s325043	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/cmar.s325043	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/cmar.s325043	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/cmar.s325043	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/cmar.s325043	methodology	1	NA	Treatment name 1	ribociclib + fulvestrant
10.2147/cmar.s325043	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/cmar.s325043	methodology	1	NA	Treatment name 2	palbociclib + letrozole
10.2147/cmar.s325043	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/cmar.s325043	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/cmar.s325043	methodology	1	NA	Anchored comparison?	No
10.2147/cmar.s325043	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s325043	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/cmar.s325043	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.2147/cmar.s325043	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2147/cmar.s325043	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/cmar.s325043	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/cmar.s325043	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s325043	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/cmar.s325043	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/cmar.s325043	methodology	2	NA	Treatment name 1	placebo + fulvestrant
10.2147/cmar.s325043	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/cmar.s325043	methodology	2	NA	Treatment name 2	letrozole
10.2147/cmar.s325043	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2147/cmar.s325043	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/cmar.s325043	methodology	2	NA	Anchored comparison?	No
10.2147/cmar.s325043	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s325043	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/cmar.s325043	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.2147/cmar.s325043	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2147/cmar.s325043	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/cmar.s325043	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/cmar.s325043	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s325043	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/cmar.s325043	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/cmar.s325043	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	84
10.2147/cmar.s325043	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	329
10.2147/cmar.s325043	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	221
10.2147/cmar.s325043	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2147/cmar.s325043	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/cmar.s325043	results	1	NA	Number of covariates adjusted for/matched on	7
10.2147/cmar.s325043	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2147/cmar.s325043	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2147/cmar.s325043	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/cmar.s325043	results	1	NA	Primary outcome: unadjusted treatment effect	0.83
10.2147/cmar.s325043	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.2838
10.2147/cmar.s325043	results	1	NA	Primary outcome: adjusted treatment effect	0.77
10.2147/cmar.s325043	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.1553
10.2147/cmar.s325043	results	1	NA	lb_ci	NA
10.2147/cmar.s325043	results	1	NA	ub_ci	NA
10.2147/cmar.s325043	results	1	NA	pval	0.2838
10.2147/cmar.s325043	results	1	NA	num_pval	0.2838
10.2147/cmar.s325043	results	1	NA	ci_cutoff	1
10.2147/cmar.s325043	results	1	NA	significant	FALSE
10.2147/cmar.s325043	results	1	NA	lb_ci	NA
10.2147/cmar.s325043	results	1	NA	ub_ci	NA
10.2147/cmar.s325043	results	1	NA	pval	0.1553
10.2147/cmar.s325043	results	1	NA	num_pval	0.1553
10.2147/cmar.s325043	results	1	NA	ci_cutoff	1
10.2147/cmar.s325043	results	1	NA	significant	FALSE
10.2147/cmar.s325043	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	81
10.2147/cmar.s325043	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	178
10.2147/cmar.s325043	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	117
10.2147/cmar.s325043	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2147/cmar.s325043	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/cmar.s325043	results	2	NA	Number of covariates adjusted for/matched on	7
10.2147/cmar.s325043	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2147/cmar.s325043	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2147/cmar.s325043	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/cmar.s325043	results	2	NA	Primary outcome: unadjusted treatment effect	0.66
10.2147/cmar.s325043	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.0094
10.2147/cmar.s325043	results	2	NA	Primary outcome: adjusted treatment effect	0.58
10.2147/cmar.s325043	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.0019
10.2147/cmar.s325043	results	2	NA	lb_ci	NA
10.2147/cmar.s325043	results	2	NA	ub_ci	NA
10.2147/cmar.s325043	results	2	NA	pval	0.0094
10.2147/cmar.s325043	results	2	NA	num_pval	0.0094
10.2147/cmar.s325043	results	2	NA	ci_cutoff	1
10.2147/cmar.s325043	results	2	NA	significant	TRUE
10.2147/cmar.s325043	results	2	NA	lb_ci	NA
10.2147/cmar.s325043	results	2	NA	ub_ci	NA
10.2147/cmar.s325043	results	2	NA	pval	0.0019
10.2147/cmar.s325043	results	2	NA	num_pval	0.0019
10.2147/cmar.s325043	results	2	NA	ci_cutoff	1
10.2147/cmar.s325043	results	2	NA	significant	TRUE
10.2147/cmar.s325043	study_information	NA	1	Patient-level data used	Yes
10.2147/cmar.s325043	study_information	NA	1	Clinical Trial	Yes
10.2147/cmar.s325043	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02422615
10.2147/cmar.s325043	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s325043	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/cmar.s325043	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/cmar.s325043	study_information	NA	2	Patient-level data used	No
10.2147/cmar.s325043	study_information	NA	2	Clinical Trial	Yes
10.2147/cmar.s325043	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00721409
10.2147/cmar.s325043	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/cmar.s325043	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2147/cmar.s325043	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s104074	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a
10.2147/jbm.s104074	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/jbm.s104074	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/jbm.s104074	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s104074	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s104074	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s104074	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s104074	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/jbm.s104074	methodology	1	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2147/jbm.s104074	methodology	1	NA	Treatment name 2	rahf-pfm
10.2147/jbm.s104074	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.2147/jbm.s104074	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s104074	methodology	1	NA	Anchored comparison?	No
10.2147/jbm.s104074	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	square root transformed abr : annualized bleed rates at 1 year (all bleed)
10.2147/jbm.s104074	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s104074	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s104074	methodology	2	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2147/jbm.s104074	methodology	2	NA	Treatment name 2	rahf-pfm
10.2147/jbm.s104074	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2147/jbm.s104074	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s104074	methodology	2	NA	Anchored comparison?	No
10.2147/jbm.s104074	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleed rates for all bleeds (1-year)
10.2147/jbm.s104074	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s104074	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s104074	methodology	3	NA	Treatment name 1	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.2147/jbm.s104074	methodology	3	NA	Treatment name 2	turoctocog alfa
10.2147/jbm.s104074	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.2147/jbm.s104074	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s104074	methodology	3	NA	Anchored comparison?	No
10.2147/jbm.s104074	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleed rates for all bleeds (1-year)
10.2147/jbm.s104074	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s104074	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s104074	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	66
10.2147/jbm.s104074	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	121
10.2147/jbm.s104074	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s104074	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s104074	results	1	NA	Number of covariates adjusted for/matched on	2
10.2147/jbm.s104074	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity
10.2147/jbm.s104074	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s104074	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	1	NA	Primary outcome: unadjusted treatment effect	0.1
10.2147/jbm.s104074	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.3;0.4]
10.2147/jbm.s104074	results	1	NA	Primary outcome: adjusted treatment effect	0.1
10.2147/jbm.s104074	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.3;0.4]
10.2147/jbm.s104074	results	1	NA	lb_ci	-0.3
10.2147/jbm.s104074	results	1	NA	ub_ci	0.4
10.2147/jbm.s104074	results	1	NA	pval	NA
10.2147/jbm.s104074	results	1	NA	num_pval	NA
10.2147/jbm.s104074	results	1	NA	ci_cutoff	0
10.2147/jbm.s104074	results	1	NA	significant	TRUE
10.2147/jbm.s104074	results	1	NA	lb_ci	-0.3
10.2147/jbm.s104074	results	1	NA	ub_ci	0.4
10.2147/jbm.s104074	results	1	NA	pval	NA
10.2147/jbm.s104074	results	1	NA	num_pval	NA
10.2147/jbm.s104074	results	1	NA	ci_cutoff	0
10.2147/jbm.s104074	results	1	NA	significant	TRUE
10.2147/jbm.s104074	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	107
10.2147/jbm.s104074	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	121
10.2147/jbm.s104074	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s104074	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s104074	results	2	NA	Number of covariates adjusted for/matched on	2
10.2147/jbm.s104074	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity
10.2147/jbm.s104074	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s104074	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	2	NA	Primary outcome: unadjusted treatment effect	-1.9
10.2147/jbm.s104074	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.5;-0.4] p<0.05
10.2147/jbm.s104074	results	2	NA	Primary outcome: adjusted treatment effect	-1.5
10.2147/jbm.s104074	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.7;-0.7] p=0.18
10.2147/jbm.s104074	results	2	NA	lb_ci	-3.5
10.2147/jbm.s104074	results	2	NA	ub_ci	-0.4
10.2147/jbm.s104074	results	2	NA	pval	<0.05
10.2147/jbm.s104074	results	2	NA	num_pval	NA
10.2147/jbm.s104074	results	2	NA	ci_cutoff	0
10.2147/jbm.s104074	results	2	NA	significant	TRUE
10.2147/jbm.s104074	results	2	NA	lb_ci	-3.7
10.2147/jbm.s104074	results	2	NA	ub_ci	-0.7
10.2147/jbm.s104074	results	2	NA	pval	=0.18
10.2147/jbm.s104074	results	2	NA	num_pval	NA
10.2147/jbm.s104074	results	2	NA	ci_cutoff	0
10.2147/jbm.s104074	results	2	NA	significant	FALSE
10.2147/jbm.s104074	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	150
10.2147/jbm.s104074	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	121
10.2147/jbm.s104074	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s104074	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s104074	results	3	NA	Number of covariates adjusted for/matched on	3
10.2147/jbm.s104074	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Race/ethnicity, Other(s)
10.2147/jbm.s104074	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s104074	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	3	NA	Primary outcome: unadjusted treatment effect	-2.1
10.2147/jbm.s104074	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.3;-1.0] p<0.01
10.2147/jbm.s104074	results	3	NA	Primary outcome: adjusted treatment effect	-2.2
10.2147/jbm.s104074	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-3.4;-1.0] p<0.05
10.2147/jbm.s104074	results	3	NA	geographical region	No
10.2147/jbm.s104074	results	3	NA	lb_ci	-3.3
10.2147/jbm.s104074	results	3	NA	ub_ci	-1
10.2147/jbm.s104074	results	3	NA	pval	<0.01
10.2147/jbm.s104074	results	3	NA	num_pval	NA
10.2147/jbm.s104074	results	3	NA	ci_cutoff	0
10.2147/jbm.s104074	results	3	NA	significant	TRUE
10.2147/jbm.s104074	results	3	NA	lb_ci	-3.4
10.2147/jbm.s104074	results	3	NA	ub_ci	-1
10.2147/jbm.s104074	results	3	NA	pval	<0.05
10.2147/jbm.s104074	results	3	NA	num_pval	NA
10.2147/jbm.s104074	results	3	NA	ci_cutoff	0
10.2147/jbm.s104074	results	3	NA	significant	TRUE
10.2147/jbm.s104074	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s104074	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01029340
10.2147/jbm.s104074	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s104074	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s104074	study_information	NA	2	Patient-level data used	Yes
10.2147/jbm.s104074	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01233258
10.2147/jbm.s104074	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s104074	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s104074	study_information	NA	3	Patient-level data used	No
10.2147/jbm.s104074	study_information	NA	3	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)
10.2147/jbm.s104074	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	4	Patient-level data used	No
10.2147/jbm.s104074	study_information	NA	4	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386
10.2147/jbm.s104074	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4
10.2147/jbm.s104074	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s104074	study_information	NA	5	Patient-level data used	No
10.2147/jbm.s104074	study_information	NA	5	Clinical Trial	Yes
10.2147/jbm.s104074	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00840086
10.2147/jbm.s104074	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s104074	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s104074	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s206806	general_information	NA	NA	Medical Condition of Interest Name	severe hemophilia a
10.2147/jbm.s206806	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/jbm.s206806	general_information	NA	NA	Countries of last author affiliations	germany
10.2147/jbm.s206806	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s206806	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s206806	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s206806	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s206806	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/jbm.s206806	methodology	1	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	1	NA	Treatment name 2	rfviiifc
10.2147/jbm.s206806	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s206806	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s206806	methodology	1	NA	Anchored comparison?	No
10.2147/jbm.s206806	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate
10.2147/jbm.s206806	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s206806	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s206806	methodology	2	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	2	NA	Treatment name 2	bax 855
10.2147/jbm.s206806	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2147/jbm.s206806	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s206806	methodology	2	NA	Anchored comparison?	No
10.2147/jbm.s206806	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate
10.2147/jbm.s206806	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s206806	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s206806	methodology	3	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.2147/jbm.s206806	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s206806	methodology	3	NA	Anchored comparison?	No
10.2147/jbm.s206806	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate
10.2147/jbm.s206806	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s206806	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s206806	methodology	4	NA	Treatment name 1	bay 94-9027
10.2147/jbm.s206806	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s206806	methodology	4	NA	Treatment name 2	rahf-pfm 2012
10.2147/jbm.s206806	methodology	4	NA	Study 'number(s)' for treatment 2	5
10.2147/jbm.s206806	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s206806	methodology	4	NA	Anchored comparison?	No
10.2147/jbm.s206806	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate
10.2147/jbm.s206806	methodology	4	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s206806	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s206806	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	140
10.2147/jbm.s206806	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	103
10.2147/jbm.s206806	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	44.6
10.2147/jbm.s206806	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s206806	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s206806	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s206806	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	1	NA	Primary outcome: unadjusted treatment effect	0.17
10.2147/jbm.s206806	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-1.35;1.70]
10.2147/jbm.s206806	results	1	NA	Primary outcome: adjusted treatment effect	-0.12
10.2147/jbm.s206806	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-1.62;1.37]
10.2147/jbm.s206806	results	1	NA	Number of covariates adjusted for/matched on	7
10.2147/jbm.s206806	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s206806	results	1	NA	geographical region	Yes
10.2147/jbm.s206806	results	1	NA	lb_ci	-1.35
10.2147/jbm.s206806	results	1	NA	ub_ci	1.7
10.2147/jbm.s206806	results	1	NA	pval	NA
10.2147/jbm.s206806	results	1	NA	num_pval	NA
10.2147/jbm.s206806	results	1	NA	ci_cutoff	0
10.2147/jbm.s206806	results	1	NA	significant	TRUE
10.2147/jbm.s206806	results	1	NA	lb_ci	-1.62
10.2147/jbm.s206806	results	1	NA	ub_ci	1.37
10.2147/jbm.s206806	results	1	NA	pval	NA
10.2147/jbm.s206806	results	1	NA	num_pval	NA
10.2147/jbm.s206806	results	1	NA	ci_cutoff	0
10.2147/jbm.s206806	results	1	NA	significant	TRUE
10.2147/jbm.s206806	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	101
10.2147/jbm.s206806	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	104
10.2147/jbm.s206806	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78.3
10.2147/jbm.s206806	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s206806	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s206806	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s206806	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	2	NA	Primary outcome: unadjusted treatment effect	0.35
10.2147/jbm.s206806	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-1.00;1.70]
10.2147/jbm.s206806	results	2	NA	Primary outcome: adjusted treatment effect	0.25
10.2147/jbm.s206806	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-1.19;1.70]
10.2147/jbm.s206806	results	2	NA	Number of covariates adjusted for/matched on	5
10.2147/jbm.s206806	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s206806	results	2	NA	geographical region	Yes
10.2147/jbm.s206806	results	2	NA	lb_ci	-1
10.2147/jbm.s206806	results	2	NA	ub_ci	1.7
10.2147/jbm.s206806	results	2	NA	pval	NA
10.2147/jbm.s206806	results	2	NA	num_pval	NA
10.2147/jbm.s206806	results	2	NA	ci_cutoff	0
10.2147/jbm.s206806	results	2	NA	significant	TRUE
10.2147/jbm.s206806	results	2	NA	lb_ci	-1.19
10.2147/jbm.s206806	results	2	NA	ub_ci	1.7
10.2147/jbm.s206806	results	2	NA	pval	NA
10.2147/jbm.s206806	results	2	NA	num_pval	NA
10.2147/jbm.s206806	results	2	NA	ci_cutoff	0
10.2147/jbm.s206806	results	2	NA	significant	TRUE
10.2147/jbm.s206806	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	66
10.2147/jbm.s206806	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	104
10.2147/jbm.s206806	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	25.32
10.2147/jbm.s206806	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s206806	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s206806	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s206806	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	3	NA	Primary outcome: unadjusted treatment effect	-2.25
10.2147/jbm.s206806	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-3.64;-0.85]
10.2147/jbm.s206806	results	3	NA	Primary outcome: adjusted treatment effect	-2.02
10.2147/jbm.s206806	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-4.35;0.30]
10.2147/jbm.s206806	results	3	NA	Number of covariates adjusted for/matched on	3
10.2147/jbm.s206806	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2147/jbm.s206806	results	3	NA	lb_ci	-3.64
10.2147/jbm.s206806	results	3	NA	ub_ci	-0.85
10.2147/jbm.s206806	results	3	NA	pval	NA
10.2147/jbm.s206806	results	3	NA	num_pval	NA
10.2147/jbm.s206806	results	3	NA	ci_cutoff	0
10.2147/jbm.s206806	results	3	NA	significant	FALSE
10.2147/jbm.s206806	results	3	NA	lb_ci	-4.35
10.2147/jbm.s206806	results	3	NA	ub_ci	0.3
10.2147/jbm.s206806	results	3	NA	pval	NA
10.2147/jbm.s206806	results	3	NA	num_pval	NA
10.2147/jbm.s206806	results	3	NA	ci_cutoff	0
10.2147/jbm.s206806	results	3	NA	significant	TRUE
10.2147/jbm.s206806	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	107
10.2147/jbm.s206806	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	104
10.2147/jbm.s206806	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	55.33
10.2147/jbm.s206806	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s206806	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s206806	results	4	NA	Primary outcome: treatment effect contrast	Means difference
10.2147/jbm.s206806	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	4	NA	Primary outcome: unadjusted treatment effect	0.03
10.2147/jbm.s206806	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[-0.32;0.37]
10.2147/jbm.s206806	results	4	NA	Primary outcome: adjusted treatment effect	0.07
10.2147/jbm.s206806	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-0.32;0.46]
10.2147/jbm.s206806	results	4	NA	Number of covariates adjusted for/matched on	3
10.2147/jbm.s206806	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2147/jbm.s206806	results	4	NA	lb_ci	-0.32
10.2147/jbm.s206806	results	4	NA	ub_ci	0.37
10.2147/jbm.s206806	results	4	NA	pval	NA
10.2147/jbm.s206806	results	4	NA	num_pval	NA
10.2147/jbm.s206806	results	4	NA	ci_cutoff	0
10.2147/jbm.s206806	results	4	NA	significant	TRUE
10.2147/jbm.s206806	results	4	NA	lb_ci	-0.32
10.2147/jbm.s206806	results	4	NA	ub_ci	0.46
10.2147/jbm.s206806	results	4	NA	pval	NA
10.2147/jbm.s206806	results	4	NA	num_pval	NA
10.2147/jbm.s206806	results	4	NA	ci_cutoff	0
10.2147/jbm.s206806	results	4	NA	significant	TRUE
10.2147/jbm.s206806	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s206806	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293
10.2147/jbm.s206806	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s206806	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.2147/jbm.s206806	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s206806	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	3	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	3	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01736475
10.2147/jbm.s206806	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s206806	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	4	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	4	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	tarantino et al. (2004)
10.2147/jbm.s206806	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s206806	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	5	Patient-level data used	No
10.2147/jbm.s206806	study_information	NA	5	Clinical Trial	Yes
10.2147/jbm.s206806	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00243386
10.2147/jbm.s206806	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s206806	study_information	NA	5	Phase of the clinical trial (clinical trial only)	4
10.2147/jbm.s206806	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s288283	general_information	NA	NA	Medical Condition of Interest Name	hemophilia a without inhibitors
10.2147/jbm.s288283	general_information	NA	NA	Countries of first author affiliations	germany
10.2147/jbm.s288283	general_information	NA	NA	Countries of last author affiliations	usa
10.2147/jbm.s288283	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s288283	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s288283	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s288283	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s288283	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/jbm.s288283	methodology	1	NA	Treatment name 1	rfviiifc
10.2147/jbm.s288283	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s288283	methodology	1	NA	Treatment name 2	emicizumab every week
10.2147/jbm.s288283	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s288283	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s288283	methodology	1	NA	Anchored comparison?	No
10.2147/jbm.s288283	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2147/jbm.s288283	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2147/jbm.s288283	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s288283	methodology	2	NA	Treatment name 1	rfviiifc
10.2147/jbm.s288283	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s288283	methodology	2	NA	Treatment name 2	emicizumab every 2 weeks
10.2147/jbm.s288283	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s288283	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s288283	methodology	2	NA	Anchored comparison?	No
10.2147/jbm.s288283	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.2147/jbm.s288283	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2147/jbm.s288283	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s288283	methodology	3	NA	Treatment name 1	rfviiifc
10.2147/jbm.s288283	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s288283	methodology	3	NA	Treatment name 2	emicizumab every 4 weeks
10.2147/jbm.s288283	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.2147/jbm.s288283	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s288283	methodology	3	NA	Anchored comparison?	No
10.2147/jbm.s288283	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.2147/jbm.s288283	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2147/jbm.s288283	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s288283	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	99
10.2147/jbm.s288283	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.2147/jbm.s288283	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	94
10.2147/jbm.s288283	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s288283	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s288283	results	1	NA	Number of covariates adjusted for/matched on	5
10.2147/jbm.s288283	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	1	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio
10.2147/jbm.s288283	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	1	NA	Primary outcome: adjusted treatment effect	0.93
10.2147/jbm.s288283	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.63;1.39]
10.2147/jbm.s288283	results	1	NA	lb_ci	0.63
10.2147/jbm.s288283	results	1	NA	ub_ci	1.39
10.2147/jbm.s288283	results	1	NA	pval	NA
10.2147/jbm.s288283	results	1	NA	num_pval	NA
10.2147/jbm.s288283	results	1	NA	ci_cutoff	1
10.2147/jbm.s288283	results	1	NA	significant	TRUE
10.2147/jbm.s288283	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	35
10.2147/jbm.s288283	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.2147/jbm.s288283	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	19
10.2147/jbm.s288283	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s288283	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s288283	results	2	NA	Number of covariates adjusted for/matched on	5
10.2147/jbm.s288283	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	2	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio
10.2147/jbm.s288283	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	2	NA	Primary outcome: adjusted treatment effect	0.57
10.2147/jbm.s288283	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.28;1.17]
10.2147/jbm.s288283	results	2	NA	lb_ci	0.28
10.2147/jbm.s288283	results	2	NA	ub_ci	1.17
10.2147/jbm.s288283	results	2	NA	pval	NA
10.2147/jbm.s288283	results	2	NA	num_pval	NA
10.2147/jbm.s288283	results	2	NA	ci_cutoff	1
10.2147/jbm.s288283	results	2	NA	significant	TRUE
10.2147/jbm.s288283	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	41
10.2147/jbm.s288283	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	117
10.2147/jbm.s288283	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36
10.2147/jbm.s288283	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s288283	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s288283	results	3	NA	Number of covariates adjusted for/matched on	5
10.2147/jbm.s288283	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	3	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio
10.2147/jbm.s288283	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	3	NA	Primary outcome: adjusted treatment effect	0.61
10.2147/jbm.s288283	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.37;1.02]
10.2147/jbm.s288283	results	3	NA	lb_ci	0.37
10.2147/jbm.s288283	results	3	NA	ub_ci	1.02
10.2147/jbm.s288283	results	3	NA	pval	NA
10.2147/jbm.s288283	results	3	NA	num_pval	NA
10.2147/jbm.s288283	results	3	NA	ci_cutoff	1
10.2147/jbm.s288283	results	3	NA	significant	TRUE
10.2147/jbm.s288283	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s288283	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s288283	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01181128
10.2147/jbm.s288283	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s288283	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s288283	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s288283	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s288283	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s288283	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02847637
10.2147/jbm.s288283	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s288283	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s288283	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s288283	study_information	NA	3	Patient-level data used	No
10.2147/jbm.s288283	study_information	NA	3	Clinical Trial	Yes
10.2147/jbm.s288283	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03020160
10.2147/jbm.s288283	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s288283	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s288283	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s312885	general_information	NA	NA	Medical Condition of Interest Name	hemophilia b
10.2147/jbm.s312885	general_information	NA	NA	Countries of first author affiliations	sweden
10.2147/jbm.s312885	general_information	NA	NA	Countries of last author affiliations	germany
10.2147/jbm.s312885	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s312885	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s312885	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s312885	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s312885	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/jbm.s312885	methodology	1	NA	Treatment name 1	prior prophylaxis rfixfc
10.2147/jbm.s312885	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s312885	methodology	1	NA	Treatment name 2	prior prophylaxis rix-fp
10.2147/jbm.s312885	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s312885	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s312885	methodology	1	NA	Anchored comparison?	No
10.2147/jbm.s312885	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s312885	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2147/jbm.s312885	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr)
10.2147/jbm.s312885	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s312885	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s312885	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s312885	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s312885	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s312885	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s312885	methodology	2	NA	Treatment name 1	prior episodic treatment rfixfc
10.2147/jbm.s312885	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s312885	methodology	2	NA	Treatment name 2	prior episodic treatment rix-fp
10.2147/jbm.s312885	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s312885	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s312885	methodology	2	NA	Anchored comparison?	No
10.2147/jbm.s312885	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s312885	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2147/jbm.s312885	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized bleeding rate (abr)
10.2147/jbm.s312885	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s312885	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s312885	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s312885	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s312885	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s312885	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	40
10.2147/jbm.s312885	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	45
10.2147/jbm.s312885	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	26
10.2147/jbm.s312885	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s312885	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s312885	results	1	NA	Number of covariates adjusted for/matched on	4
10.2147/jbm.s312885	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.2147/jbm.s312885	results	1	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio
10.2147/jbm.s312885	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s312885	results	1	NA	Primary outcome: adjusted treatment effect	1.18
10.2147/jbm.s312885	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.67;2.10]
10.2147/jbm.s312885	results	1	NA	geographical region	No
10.2147/jbm.s312885	results	1	NA	lb_ci	0.67
10.2147/jbm.s312885	results	1	NA	ub_ci	2.1
10.2147/jbm.s312885	results	1	NA	pval	NA
10.2147/jbm.s312885	results	1	NA	num_pval	NA
10.2147/jbm.s312885	results	1	NA	ci_cutoff	1
10.2147/jbm.s312885	results	1	NA	significant	TRUE
10.2147/jbm.s312885	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	19
10.2147/jbm.s312885	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	42
10.2147/jbm.s312885	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	10
10.2147/jbm.s312885	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s312885	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s312885	results	2	NA	Number of covariates adjusted for/matched on	4
10.2147/jbm.s312885	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.2147/jbm.s312885	results	2	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio
10.2147/jbm.s312885	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s312885	results	2	NA	Primary outcome: adjusted treatment effect	1.01
10.2147/jbm.s312885	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.40;2.57]
10.2147/jbm.s312885	results	2	NA	geographical region	No
10.2147/jbm.s312885	results	2	NA	lb_ci	0.4
10.2147/jbm.s312885	results	2	NA	ub_ci	2.57
10.2147/jbm.s312885	results	2	NA	pval	NA
10.2147/jbm.s312885	results	2	NA	num_pval	NA
10.2147/jbm.s312885	results	2	NA	ci_cutoff	1
10.2147/jbm.s312885	results	2	NA	significant	TRUE
10.2147/jbm.s312885	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s312885	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s312885	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01027364
10.2147/jbm.s312885	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s312885	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s312885	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s312885	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s312885	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s312885	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01496274
10.2147/jbm.s312885	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s312885	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s312885	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2147/jbm.s321288	general_information	NA	NA	Medical Condition of Interest Name	hemophilia a
10.2147/jbm.s321288	general_information	NA	NA	Countries of first author affiliations	usa
10.2147/jbm.s321288	general_information	NA	NA	Countries of last author affiliations	italy
10.2147/jbm.s321288	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s321288	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2147/jbm.s321288	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/jbm.s321288	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/jbm.s321288	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2147/jbm.s321288	methodology	1	NA	Treatment name 1	damoctocog alfa pegol (bay 94-9027)
10.2147/jbm.s321288	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2147/jbm.s321288	methodology	1	NA	Treatment name 2	turoctocog alfa pegol (n8-gp)
10.2147/jbm.s321288	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2147/jbm.s321288	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/jbm.s321288	methodology	1	NA	Anchored comparison?	No
10.2147/jbm.s321288	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s321288	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s321288	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	mean annualized bleeding rate
10.2147/jbm.s321288	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2147/jbm.s321288	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/jbm.s321288	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s321288	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s321288	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/jbm.s321288	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/jbm.s321288	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	175
10.2147/jbm.s321288	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	102
10.2147/jbm.s321288	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	61.94
10.2147/jbm.s321288	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2147/jbm.s321288	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/jbm.s321288	results	1	NA	Number of covariates adjusted for/matched on	6
10.2147/jbm.s321288	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s321288	results	1	NA	Primary outcome: treatment effect contrast	Incidence Rate Ratio
10.2147/jbm.s321288	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/jbm.s321288	results	1	NA	Primary outcome: unadjusted treatment effect	1.1
10.2147/jbm.s321288	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.4492
10.2147/jbm.s321288	results	1	NA	Primary outcome: adjusted treatment effect	1.11
10.2147/jbm.s321288	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.449
10.2147/jbm.s321288	results	1	NA	geographical region	No
10.2147/jbm.s321288	results	1	NA	lb_ci	NA
10.2147/jbm.s321288	results	1	NA	ub_ci	NA
10.2147/jbm.s321288	results	1	NA	pval	0.4492
10.2147/jbm.s321288	results	1	NA	num_pval	0.4492
10.2147/jbm.s321288	results	1	NA	ci_cutoff	1
10.2147/jbm.s321288	results	1	NA	significant	FALSE
10.2147/jbm.s321288	results	1	NA	lb_ci	NA
10.2147/jbm.s321288	results	1	NA	ub_ci	NA
10.2147/jbm.s321288	results	1	NA	pval	0.449
10.2147/jbm.s321288	results	1	NA	num_pval	0.449
10.2147/jbm.s321288	results	1	NA	ci_cutoff	1
10.2147/jbm.s321288	results	1	NA	significant	FALSE
10.2147/jbm.s321288	study_information	NA	1	Patient-level data used	Yes
10.2147/jbm.s321288	study_information	NA	1	Clinical Trial	Yes
10.2147/jbm.s321288	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01580293
10.2147/jbm.s321288	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s321288	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.2147/jbm.s321288	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/jbm.s321288	study_information	NA	2	Patient-level data used	No
10.2147/jbm.s321288	study_information	NA	2	Clinical Trial	Yes
10.2147/jbm.s321288	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01480180
10.2147/jbm.s321288	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/jbm.s321288	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/jbm.s321288	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2147/ptt.s326121	general_information	NA	NA	Medical Condition of Interest Name	moderate-to-severe plaque psoriasis
10.2147/ptt.s326121	general_information	NA	NA	Countries of first author affiliations	uk
10.2147/ptt.s326121	general_information	NA	NA	Countries of last author affiliations	germany
10.2147/ptt.s326121	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.2147/ptt.s326121	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.2147/ptt.s326121	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2147/ptt.s326121	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2147/ptt.s326121	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2147/ptt.s326121	methodology	1	NA	Treatment name 1	brodalumab
10.2147/ptt.s326121	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2147/ptt.s326121	methodology	1	NA	Treatment name 2	guselkumab
10.2147/ptt.s326121	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2147/ptt.s326121	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2147/ptt.s326121	methodology	1	NA	Anchored comparison?	No
10.2147/ptt.s326121	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/ptt.s326121	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/ptt.s326121	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	proportions of patients who achieved pasi 90 (psoriasis area severity index) at weeks 12
10.2147/ptt.s326121	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2147/ptt.s326121	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2147/ptt.s326121	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/ptt.s326121	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/ptt.s326121	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2147/ptt.s326121	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2147/ptt.s326121	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	135
10.2147/ptt.s326121	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	121
10.2147/ptt.s326121	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	90
10.2147/ptt.s326121	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2147/ptt.s326121	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2147/ptt.s326121	results	1	NA	Number of covariates adjusted for/matched on	11
10.2147/ptt.s326121	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2147/ptt.s326121	results	1	NA	Primary outcome: treatment effect contrast	Risk difference
10.2147/ptt.s326121	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2147/ptt.s326121	results	1	NA	Primary outcome: adjusted treatment effect	14.6
10.2147/ptt.s326121	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.002
10.2147/ptt.s326121	results	1	NA	geographical region	No
10.2147/ptt.s326121	results	1	NA	lb_ci	NA
10.2147/ptt.s326121	results	1	NA	ub_ci	NA
10.2147/ptt.s326121	results	1	NA	pval	0.002
10.2147/ptt.s326121	results	1	NA	num_pval	0.002
10.2147/ptt.s326121	results	1	NA	ci_cutoff	0
10.2147/ptt.s326121	results	1	NA	significant	TRUE
10.2147/ptt.s326121	study_information	NA	1	Patient-level data used	Yes
10.2147/ptt.s326121	study_information	NA	1	Clinical Trial	Yes
10.2147/ptt.s326121	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708603
10.2147/ptt.s326121	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ptt.s326121	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2147/ptt.s326121	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2147/ptt.s326121	study_information	NA	2	Patient-level data used	Yes
10.2147/ptt.s326121	study_information	NA	2	Clinical Trial	Yes
10.2147/ptt.s326121	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01708629
10.2147/ptt.s326121	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ptt.s326121	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2147/ptt.s326121	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2147/ptt.s326121	study_information	NA	3	Patient-level data used	No
10.2147/ptt.s326121	study_information	NA	3	Clinical Trial	Yes
10.2147/ptt.s326121	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02203032
10.2147/ptt.s326121	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2147/ptt.s326121	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2147/ptt.s326121	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	general_information	NA	NA	Medical Condition of Interest Name	type 2 diabetes mellitus
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of first author affiliations	usa
10.2165/11592490-000000000-00000	general_information	NA	NA	Countries of last author affiliations	switzerland
10.2165/11592490-000000000-00000	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2165/11592490-000000000-00000	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2165/11592490-000000000-00000	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2165/11592490-000000000-00000	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2165/11592490-000000000-00000	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 1	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2165/11592490-000000000-00000	methodology	1	NA	Treatment name 2	sitagliptin 50 mg once daily
10.2165/11592490-000000000-00000	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2165/11592490-000000000-00000	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2165/11592490-000000000-00000	methodology	1	NA	Anchored comparison?	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2165/11592490-000000000-00000	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2165/11592490-000000000-00000	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 1	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	2	NA	Study 'number(s)' for treatment 1	2
10.2165/11592490-000000000-00000	methodology	2	NA	Treatment name 2	sitagliptin 50 mg once daily
10.2165/11592490-000000000-00000	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.2165/11592490-000000000-00000	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2165/11592490-000000000-00000	methodology	2	NA	Anchored comparison?	Yes
10.2165/11592490-000000000-00000	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2165/11592490-000000000-00000	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2165/11592490-000000000-00000	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2165/11592490-000000000-00000	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 1	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	3	NA	Study 'number(s)' for treatment 1	2
10.2165/11592490-000000000-00000	methodology	3	NA	Treatment name 2	sitagliptin 100 mg once daily
10.2165/11592490-000000000-00000	methodology	3	NA	Study 'number(s)' for treatment 2	4;5
10.2165/11592490-000000000-00000	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2165/11592490-000000000-00000	methodology	3	NA	Anchored comparison?	Yes
10.2165/11592490-000000000-00000	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2165/11592490-000000000-00000	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2165/11592490-000000000-00000	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	3	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2165/11592490-000000000-00000	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2165/11592490-000000000-00000	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	163
10.2165/11592490-000000000-00000	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	156
10.2165/11592490-000000000-00000	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2165/11592490-000000000-00000	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2165/11592490-000000000-00000	results	1	NA	Number of covariates adjusted for/matched on	7
10.2165/11592490-000000000-00000	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.2165/11592490-000000000-00000	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	1	NA	Primary outcome: unadjusted treatment effect	-0.17
10.2165/11592490-000000000-00000	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.024
10.2165/11592490-000000000-00000	results	1	NA	Primary outcome: adjusted treatment effect	-0.2
10.2165/11592490-000000000-00000	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.009
10.2165/11592490-000000000-00000	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	188
10.2165/11592490-000000000-00000	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	192
10.2165/11592490-000000000-00000	results	1	NA	geographical region	No
10.2165/11592490-000000000-00000	results	1	NA	lb_ci	NA
10.2165/11592490-000000000-00000	results	1	NA	ub_ci	NA
10.2165/11592490-000000000-00000	results	1	NA	pval	0.024
10.2165/11592490-000000000-00000	results	1	NA	num_pval	0.024
10.2165/11592490-000000000-00000	results	1	NA	ci_cutoff	0
10.2165/11592490-000000000-00000	results	1	NA	significant	TRUE
10.2165/11592490-000000000-00000	results	1	NA	lb_ci	NA
10.2165/11592490-000000000-00000	results	1	NA	ub_ci	NA
10.2165/11592490-000000000-00000	results	1	NA	pval	0.009
10.2165/11592490-000000000-00000	results	1	NA	num_pval	0.009
10.2165/11592490-000000000-00000	results	1	NA	ci_cutoff	0
10.2165/11592490-000000000-00000	results	1	NA	significant	TRUE
10.2165/11592490-000000000-00000	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	72
10.2165/11592490-000000000-00000	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	73
10.2165/11592490-000000000-00000	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	76
10.2165/11592490-000000000-00000	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	72
10.2165/11592490-000000000-00000	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2165/11592490-000000000-00000	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2165/11592490-000000000-00000	results	2	NA	Number of covariates adjusted for/matched on	6
10.2165/11592490-000000000-00000	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	2	NA	Primary outcome: treatment effect contrast	Means difference
10.2165/11592490-000000000-00000	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	2	NA	Primary outcome: unadjusted treatment effect	-0.2
10.2165/11592490-000000000-00000	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.133
10.2165/11592490-000000000-00000	results	2	NA	Primary outcome: adjusted treatment effect	-0.56
10.2165/11592490-000000000-00000	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.2165/11592490-000000000-00000	results	2	NA	geographical region	No
10.2165/11592490-000000000-00000	results	2	NA	lb_ci	NA
10.2165/11592490-000000000-00000	results	2	NA	ub_ci	NA
10.2165/11592490-000000000-00000	results	2	NA	pval	0.133
10.2165/11592490-000000000-00000	results	2	NA	num_pval	0.133
10.2165/11592490-000000000-00000	results	2	NA	ci_cutoff	0
10.2165/11592490-000000000-00000	results	2	NA	significant	FALSE
10.2165/11592490-000000000-00000	results	2	NA	lb_ci	NA
10.2165/11592490-000000000-00000	results	2	NA	ub_ci	NA
10.2165/11592490-000000000-00000	results	2	NA	pval	<0.001
10.2165/11592490-000000000-00000	results	2	NA	num_pval	NA
10.2165/11592490-000000000-00000	results	2	NA	ci_cutoff	0
10.2165/11592490-000000000-00000	results	2	NA	significant	TRUE
10.2165/11592490-000000000-00000	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	145
10.2165/11592490-000000000-00000	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	149
10.2165/11592490-000000000-00000	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	76
10.2165/11592490-000000000-00000	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	72
10.2165/11592490-000000000-00000	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2165/11592490-000000000-00000	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2165/11592490-000000000-00000	results	3	NA	Number of covariates adjusted for/matched on	6
10.2165/11592490-000000000-00000	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	3	NA	Primary outcome: treatment effect contrast	Means difference
10.2165/11592490-000000000-00000	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	3	NA	Primary outcome: unadjusted treatment effect	-0.19
10.2165/11592490-000000000-00000	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.113
10.2165/11592490-000000000-00000	results	3	NA	Primary outcome: adjusted treatment effect	-0.35
10.2165/11592490-000000000-00000	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.013
10.2165/11592490-000000000-00000	results	3	NA	geographical region	No
10.2165/11592490-000000000-00000	results	3	NA	lb_ci	NA
10.2165/11592490-000000000-00000	results	3	NA	ub_ci	NA
10.2165/11592490-000000000-00000	results	3	NA	pval	0.113
10.2165/11592490-000000000-00000	results	3	NA	num_pval	0.113
10.2165/11592490-000000000-00000	results	3	NA	ci_cutoff	0
10.2165/11592490-000000000-00000	results	3	NA	significant	FALSE
10.2165/11592490-000000000-00000	results	3	NA	lb_ci	NA
10.2165/11592490-000000000-00000	results	3	NA	ub_ci	NA
10.2165/11592490-000000000-00000	results	3	NA	pval	0.013
10.2165/11592490-000000000-00000	results	3	NA	num_pval	0.013
10.2165/11592490-000000000-00000	results	3	NA	ci_cutoff	0
10.2165/11592490-000000000-00000	results	3	NA	significant	TRUE
10.2165/11592490-000000000-00000	study_information	NA	1	Patient-level data used	Yes
10.2165/11592490-000000000-00000	study_information	NA	1	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00368134
10.2165/11592490-000000000-00000	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2165/11592490-000000000-00000	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	2	Patient-level data used	Yes
10.2165/11592490-000000000-00000	study_information	NA	2	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00351832
10.2165/11592490-000000000-00000	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2165/11592490-000000000-00000	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	3	Patient-level data used	No
10.2165/11592490-000000000-00000	study_information	NA	3	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00411554
10.2165/11592490-000000000-00000	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2165/11592490-000000000-00000	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	4	Patient-level data used	No
10.2165/11592490-000000000-00000	study_information	NA	4	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00127192
10.2165/11592490-000000000-00000	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2165/11592490-000000000-00000	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	5	Patient-level data used	No
10.2165/11592490-000000000-00000	study_information	NA	5	Clinical Trial	Yes
10.2165/11592490-000000000-00000	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2165/11592490-000000000-00000	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.2165/11592490-000000000-00000	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2165/11592490-000000000-00000	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00371007
10.2217/cer-2016-0085	general_information	NA	NA	Medical Condition of Interest Name	relapsingremitting multiple sclerosis
10.2217/cer-2016-0085	general_information	NA	NA	Countries of first author affiliations	switzerland
10.2217/cer-2016-0085	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2016-0085	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry
10.2217/cer-2016-0085	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2016-0085	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2016-0085	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2016-0085	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 1	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2016-0085	methodology	1	NA	Treatment name 2	glatiramer acetate
10.2217/cer-2016-0085	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2016-0085	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2016-0085	methodology	1	NA	Anchored comparison?	Yes
10.2217/cer-2016-0085	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate at 2 years
10.2217/cer-2016-0085	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2217/cer-2016-0085	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2016-0085	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 1	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2016-0085	methodology	2	NA	Treatment name 2	glatiramer acetate
10.2217/cer-2016-0085	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.2217/cer-2016-0085	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2016-0085	methodology	2	NA	Anchored comparison?	Yes
10.2217/cer-2016-0085	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	annualized relapse rate at 2 years
10.2217/cer-2016-0085	methodology	2	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2217/cer-2016-0085	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2016-0085	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 1	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	3	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2016-0085	methodology	3	NA	Treatment name 2	glatiramer acetate
10.2217/cer-2016-0085	methodology	3	NA	Study 'number(s)' for treatment 2	5
10.2217/cer-2016-0085	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2016-0085	methodology	3	NA	Anchored comparison?	No
10.2217/cer-2016-0085	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	12-week confirmed disability progression
10.2217/cer-2016-0085	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer-2016-0085	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2016-0085	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2016-0085	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2016-0085	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2016-0085	results	1	NA	Number of covariates adjusted for/matched on	7
10.2217/cer-2016-0085	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2016-0085	results	1	NA	Primary outcome: treatment effect contrast	Rate ratio
10.2217/cer-2016-0085	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	1	NA	If anchored, total initial sample size IPD	2651
10.2217/cer-2016-0085	results	1	NA	If anchored, total ESS IPD	1032
10.2217/cer-2016-0085	results	1	NA	If anchored, total sample size non IPD	251
10.2217/cer-2016-0085	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2016-0085	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2016-0085	results	2	NA	Number of covariates adjusted for/matched on	5
10.2217/cer-2016-0085	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.2217/cer-2016-0085	results	2	NA	Primary outcome: treatment effect contrast	Rate ratio
10.2217/cer-2016-0085	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	2	NA	If anchored, total initial sample size IPD	2651
10.2217/cer-2016-0085	results	2	NA	If anchored, total ESS IPD	1206
10.2217/cer-2016-0085	results	2	NA	If anchored, total sample size non IPD	239
10.2217/cer-2016-0085	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2016-0085	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2016-0085	results	3	NA	Number of covariates adjusted for/matched on	7
10.2217/cer-2016-0085	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2016-0085	results	3	NA	Primary outcome: treatment effect contrast	RR
10.2217/cer-2016-0085	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	3	NA	Primary outcome: unadjusted treatment effect	0.73
10.2217/cer-2016-0085	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.015
10.2217/cer-2016-0085	results	3	NA	Primary outcome: adjusted treatment effect	0.51
10.2217/cer-2016-0085	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.2217/cer-2016-0085	results	3	NA	If anchored, total initial sample size IPD	2651
10.2217/cer-2016-0085	results	3	NA	If anchored, total ESS IPD	364
10.2217/cer-2016-0085	results	3	NA	If anchored, total sample size non IPD	448
10.2217/cer-2016-0085	results	3	NA	lb_ci	NA
10.2217/cer-2016-0085	results	3	NA	ub_ci	NA
10.2217/cer-2016-0085	results	3	NA	pval	0.015
10.2217/cer-2016-0085	results	3	NA	num_pval	0.015
10.2217/cer-2016-0085	results	3	NA	ci_cutoff	1
10.2217/cer-2016-0085	results	3	NA	significant	TRUE
10.2217/cer-2016-0085	results	3	NA	lb_ci	NA
10.2217/cer-2016-0085	results	3	NA	ub_ci	NA
10.2217/cer-2016-0085	results	3	NA	pval	<0.001
10.2217/cer-2016-0085	results	3	NA	num_pval	NA
10.2217/cer-2016-0085	results	3	NA	ci_cutoff	1
10.2217/cer-2016-0085	results	3	NA	significant	TRUE
10.2217/cer-2016-0085	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2016-0085	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00420212
10.2217/cer-2016-0085	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2016-0085	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00451451
10.2217/cer-2016-0085	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	3	Patient-level data used	No
10.2217/cer-2016-0085	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00004814
10.2217/cer-2016-0085	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2016-0085	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	4	Patient-level data used	No
10.2217/cer-2016-0085	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	4	Data source name (only if observational study or clinical trial without NCT)	eur/can study
10.2217/cer-2016-0085	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2016-0085	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	5	Patient-level data used	No
10.2217/cer-2016-0085	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2016-0085	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00099502
10.2217/cer-2016-0085	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2016-0085	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2016-0085	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0020	general_information	NA	NA	Medical Condition of Interest Name	advanced pancreatic neuroendocrine tumors
10.2217/cer-2018-0020	general_information	NA	NA	Countries of first author affiliations	canada
10.2217/cer-2018-0020	general_information	NA	NA	Countries of last author affiliations	uk
10.2217/cer-2018-0020	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2018-0020	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2018-0020	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2018-0020	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2018-0020	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 1	sunitinib
10.2217/cer-2018-0020	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2018-0020	methodology	1	NA	Treatment name 2	everolimus
10.2217/cer-2018-0020	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2018-0020	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2018-0020	methodology	1	NA	Anchored comparison?	Yes
10.2217/cer-2018-0020	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2018-0020	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer-2018-0020	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.2217/cer-2018-0020	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2018-0020	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2018-0020	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2018-0020	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2018-0020	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2018-0020	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 1	sunitinib
10.2217/cer-2018-0020	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2018-0020	methodology	2	NA	Treatment name 2	everolimus
10.2217/cer-2018-0020	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2018-0020	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2018-0020	methodology	2	NA	Anchored comparison?	No
10.2217/cer-2018-0020	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2018-0020	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer-2018-0020	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2018-0020	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2018-0020	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2018-0020	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2018-0020	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2018-0020	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2018-0020	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2018-0020	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	207
10.2217/cer-2018-0020	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	203
10.2217/cer-2018-0020	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	86
10.2217/cer-2018-0020	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43
10.2217/cer-2018-0020	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	85
10.2217/cer-2018-0020	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	31
10.2217/cer-2018-0020	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2018-0020	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2018-0020	results	1	NA	Number of covariates adjusted for/matched on	11
10.2217/cer-2018-0020	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2018-0020	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2018-0020	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2018-0020	results	1	NA	Primary outcome: unadjusted treatment effect	1.2
10.2217/cer-2018-0020	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.72;2.01]
10.2217/cer-2018-0020	results	1	NA	Primary outcome: adjusted treatment effect	0.85
10.2217/cer-2018-0020	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.39;1.89]
10.2217/cer-2018-0020	results	1	NA	geographical region	No
10.2217/cer-2018-0020	results	1	NA	lb_ci	0.72
10.2217/cer-2018-0020	results	1	NA	ub_ci	2.01
10.2217/cer-2018-0020	results	1	NA	pval	NA
10.2217/cer-2018-0020	results	1	NA	num_pval	NA
10.2217/cer-2018-0020	results	1	NA	ci_cutoff	1
10.2217/cer-2018-0020	results	1	NA	significant	TRUE
10.2217/cer-2018-0020	results	1	NA	lb_ci	0.39
10.2217/cer-2018-0020	results	1	NA	ub_ci	1.89
10.2217/cer-2018-0020	results	1	NA	pval	NA
10.2217/cer-2018-0020	results	1	NA	num_pval	NA
10.2217/cer-2018-0020	results	1	NA	ci_cutoff	1
10.2217/cer-2018-0020	results	1	NA	significant	TRUE
10.2217/cer-2018-0020	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	207
10.2217/cer-2018-0020	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	86
10.2217/cer-2018-0020	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2018-0020	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2018-0020	results	2	NA	Number of covariates adjusted for/matched on	11
10.2217/cer-2018-0020	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2018-0020	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2018-0020	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2018-0020	results	2	NA	Primary outcome: unadjusted treatment effect	1.03
10.2217/cer-2018-0020	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.75;1.42]
10.2217/cer-2018-0020	results	2	NA	Primary outcome: adjusted treatment effect	0.82
10.2217/cer-2018-0020	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.53;1.27]
10.2217/cer-2018-0020	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43
10.2217/cer-2018-0020	results	2	NA	geographical region	No
10.2217/cer-2018-0020	results	2	NA	lb_ci	0.75
10.2217/cer-2018-0020	results	2	NA	ub_ci	1.42
10.2217/cer-2018-0020	results	2	NA	pval	NA
10.2217/cer-2018-0020	results	2	NA	num_pval	NA
10.2217/cer-2018-0020	results	2	NA	ci_cutoff	1
10.2217/cer-2018-0020	results	2	NA	significant	TRUE
10.2217/cer-2018-0020	results	2	NA	lb_ci	0.53
10.2217/cer-2018-0020	results	2	NA	ub_ci	1.27
10.2217/cer-2018-0020	results	2	NA	pval	NA
10.2217/cer-2018-0020	results	2	NA	num_pval	NA
10.2217/cer-2018-0020	results	2	NA	ci_cutoff	1
10.2217/cer-2018-0020	results	2	NA	significant	TRUE
10.2217/cer-2018-0020	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2018-0020	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2018-0020	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00428597
10.2217/cer-2018-0020	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0020	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0020	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0020	study_information	NA	2	Patient-level data used	No
10.2217/cer-2018-0020	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2018-0020	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00510068
10.2217/cer-2018-0020	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0020	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0020	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis
10.2217/cer-2018-0141	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2018-0141	general_information	NA	NA	Countries of last author affiliations	uk
10.2217/cer-2018-0141	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2018-0141	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2018-0141	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2018-0141	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2018-0141	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 1	secukinumab 150mg
10.2217/cer-2018-0141	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2018-0141	methodology	1	NA	Treatment name 2	infliximab
10.2217/cer-2018-0141	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2018-0141	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2018-0141	methodology	1	NA	Anchored comparison?	No
10.2217/cer-2018-0141	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2018-0141	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2018-0141	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	american college of rheumatology (acr) responses rate at week 24
10.2217/cer-2018-0141	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer-2018-0141	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2018-0141	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2018-0141	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2018-0141	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2018-0141	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 1	secukinumab 300mg
10.2217/cer-2018-0141	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2018-0141	methodology	2	NA	Treatment name 2	infliximab
10.2217/cer-2018-0141	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2018-0141	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2018-0141	methodology	2	NA	Anchored comparison?	No
10.2217/cer-2018-0141	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2018-0141	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2018-0141	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	american college of rheumatology (acr) responses at week 54
10.2217/cer-2018-0141	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer-2018-0141	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2018-0141	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2018-0141	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2018-0141	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2018-0141	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.2217/cer-2018-0141	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	100
10.2217/cer-2018-0141	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	84
10.2217/cer-2018-0141	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2018-0141	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2018-0141	results	1	NA	Number of covariates adjusted for/matched on	11
10.2217/cer-2018-0141	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2018-0141	results	1	NA	Primary outcome: treatment effect contrast	OR
10.2217/cer-2018-0141	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2018-0141	results	1	NA	Primary outcome: adjusted treatment effect	2.31
10.2217/cer-2018-0141	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.008
10.2217/cer-2018-0141	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	238
10.2217/cer-2018-0141	results	1	NA	geographical region	No
10.2217/cer-2018-0141	results	1	NA	lb_ci	NA
10.2217/cer-2018-0141	results	1	NA	ub_ci	NA
10.2217/cer-2018-0141	results	1	NA	pval	0.008
10.2217/cer-2018-0141	results	1	NA	num_pval	0.008
10.2217/cer-2018-0141	results	1	NA	ci_cutoff	1
10.2217/cer-2018-0141	results	1	NA	significant	TRUE
10.2217/cer-2018-0141	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	100
10.2217/cer-2018-0141	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	70
10.2217/cer-2018-0141	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2018-0141	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2018-0141	results	2	NA	Number of covariates adjusted for/matched on	11
10.2217/cer-2018-0141	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2018-0141	results	2	NA	Primary outcome: treatment effect contrast	OR
10.2217/cer-2018-0141	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2018-0141	results	2	NA	Primary outcome: adjusted treatment effect	2.72
10.2217/cer-2018-0141	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.006
10.2217/cer-2018-0141	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	239
10.2217/cer-2018-0141	results	2	NA	geographical region	No
10.2217/cer-2018-0141	results	2	NA	lb_ci	NA
10.2217/cer-2018-0141	results	2	NA	ub_ci	NA
10.2217/cer-2018-0141	results	2	NA	pval	0.006
10.2217/cer-2018-0141	results	2	NA	num_pval	0.006
10.2217/cer-2018-0141	results	2	NA	ci_cutoff	1
10.2217/cer-2018-0141	results	2	NA	significant	TRUE
10.2217/cer-2018-0141	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2018-0141	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2018-0141	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.2217/cer-2018-0141	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0141	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0141	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2018-0141	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2018-0141	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01989468
10.2217/cer-2018-0141	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2018-0141	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0141	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	study_information	NA	3	Patient-level data used	No
10.2217/cer-2018-0141	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2018-0141	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00051623
10.2217/cer-2018-0141	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2018-0141	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2018-0141	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer-2019-0145	general_information	NA	NA	Medical Condition of Interest Name	advanced gastric or gastroesophageal junction cancer
10.2217/cer-2019-0145	general_information	NA	NA	Countries of first author affiliations	UK
10.2217/cer-2019-0145	general_information	NA	NA	Countries of last author affiliations	USA
10.2217/cer-2019-0145	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2019-0145	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2019-0145	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2019-0145	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2019-0145	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 1	nivolumab
10.2217/cer-2019-0145	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2019-0145	methodology	1	NA	Treatment name 2	routine clinical practice
10.2217/cer-2019-0145	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2019-0145	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/cer-2019-0145	methodology	1	NA	Anchored comparison?	No
10.2217/cer-2019-0145	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2019-0145	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer-2019-0145	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2019-0145	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2019-0145	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2019-0145	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2019-0145	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2019-0145	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2217/cer-2019-0145	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2019-0145	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	34
10.2217/cer-2019-0145	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	42
10.2217/cer-2019-0145	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2019-0145	results	1	NA	Number of covariates adjusted for/matched on	6
10.2217/cer-2019-0145	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2019-0145	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2019-0145	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2019-0145	results	1	NA	Primary outcome: adjusted treatment effect	0.5
10.2217/cer-2019-0145	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.36;0.68]
10.2217/cer-2019-0145	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	42
10.2217/cer-2019-0145	results	1	NA	Primary outcome: unadjusted treatment effect	0.46
10.2217/cer-2019-0145	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.36;0.59]
10.2217/cer-2019-0145	results	1	NA	lb_ci	0.36
10.2217/cer-2019-0145	results	1	NA	ub_ci	0.68
10.2217/cer-2019-0145	results	1	NA	pval	NA
10.2217/cer-2019-0145	results	1	NA	num_pval	NA
10.2217/cer-2019-0145	results	1	NA	ci_cutoff	1
10.2217/cer-2019-0145	results	1	NA	significant	FALSE
10.2217/cer-2019-0145	results	1	NA	lb_ci	0.36
10.2217/cer-2019-0145	results	1	NA	ub_ci	0.59
10.2217/cer-2019-0145	results	1	NA	pval	NA
10.2217/cer-2019-0145	results	1	NA	num_pval	NA
10.2217/cer-2019-0145	results	1	NA	ci_cutoff	1
10.2217/cer-2019-0145	results	1	NA	significant	FALSE
10.2217/cer-2019-0145	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2019-0145	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2019-0145	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01928394
10.2217/cer-2019-0145	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0145	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2019-0145	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0145	study_information	NA	2	Patient-level data used	No
10.2217/cer-2019-0145	study_information	NA	2	Clinical Trial	No
10.2217/cer-2019-0145	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	flatiron healths electronic health record database
10.2217/cer-2019-0145	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2019-0169	general_information	NA	NA	Medical Condition of Interest Name	relapsing multiple sclerosis
10.2217/cer-2019-0169	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2019-0169	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2019-0169	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2019-0169	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2019-0169	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2019-0169	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2019-0169	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 1	ozanimod
10.2217/cer-2019-0169	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2019-0169	methodology	1	NA	Treatment name 2	fingolimod
10.2217/cer-2019-0169	methodology	1	NA	Study 'number(s)' for treatment 2	3;4;5
10.2217/cer-2019-0169	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2019-0169	methodology	1	NA	Anchored comparison?	No
10.2217/cer-2019-0169	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	percentage of patients whose lowest hourly recorded heart rate was <45 bpm in the first 6 h after their first dose ( first-dose cardiac monitoring outcomes)
10.2217/cer-2019-0169	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2217/cer-2019-0169	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 1	ozanimod
10.2217/cer-2019-0169	methodology	2	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer-2019-0169	methodology	2	NA	Treatment name 2	fingolimod
10.2217/cer-2019-0169	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2019-0169	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2019-0169	methodology	2	NA	Anchored comparison?	Yes
10.2217/cer-2019-0169	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	risk of any adverse events at year 1 (1-year outcomes)
10.2217/cer-2019-0169	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2217/cer-2019-0169	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 1	ozanimod
10.2217/cer-2019-0169	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2019-0169	methodology	3	NA	Treatment name 2	fingolimod
10.2217/cer-2019-0169	methodology	3	NA	Study 'number(s)' for treatment 2	4;5
10.2217/cer-2019-0169	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2019-0169	methodology	3	NA	Anchored comparison?	No
10.2217/cer-2019-0169	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	risk of any adverse effect at 2 years
10.2217/cer-2019-0169	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2217/cer-2019-0169	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2019-0169	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1212
10.2217/cer-2019-0169	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1773
10.2217/cer-2019-0169	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	597
10.2217/cer-2019-0169	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2019-0169	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2019-0169	results	1	NA	Number of covariates adjusted for/matched on	11
10.2217/cer-2019-0169	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.2217/cer-2019-0169	results	1	NA	Primary outcome: treatment effect contrast	Risk difference
10.2217/cer-2019-0169	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	1	NA	Primary outcome: adjusted treatment effect	-1.4
10.2217/cer-2019-0169	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.2217/cer-2019-0169	results	1	NA	geographical region	No
10.2217/cer-2019-0169	results	1	NA	lb_ci	NA
10.2217/cer-2019-0169	results	1	NA	ub_ci	NA
10.2217/cer-2019-0169	results	1	NA	pval	<0.001
10.2217/cer-2019-0169	results	1	NA	num_pval	NA
10.2217/cer-2019-0169	results	1	NA	ci_cutoff	0
10.2217/cer-2019-0169	results	1	NA	significant	TRUE
10.2217/cer-2019-0169	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	429
10.2217/cer-2019-0169	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	431
10.2217/cer-2019-0169	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	882
10.2217/cer-2019-0169	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	276
10.2217/cer-2019-0169	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	885
10.2217/cer-2019-0169	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	317
10.2217/cer-2019-0169	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2019-0169	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2019-0169	results	2	NA	Number of covariates adjusted for/matched on	9
10.2217/cer-2019-0169	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer-2019-0169	results	2	NA	Primary outcome: treatment effect contrast	Risk difference
10.2217/cer-2019-0169	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	2	NA	Primary outcome: adjusted treatment effect	-9.9
10.2217/cer-2019-0169	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.05
10.2217/cer-2019-0169	results	2	NA	geographical region	No
10.2217/cer-2019-0169	results	2	NA	lb_ci	NA
10.2217/cer-2019-0169	results	2	NA	ub_ci	NA
10.2217/cer-2019-0169	results	2	NA	pval	<0.05
10.2217/cer-2019-0169	results	2	NA	num_pval	NA
10.2217/cer-2019-0169	results	2	NA	ci_cutoff	0
10.2217/cer-2019-0169	results	2	NA	significant	TRUE
10.2217/cer-2019-0169	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	783
10.2217/cer-2019-0169	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	434
10.2217/cer-2019-0169	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	158
10.2217/cer-2019-0169	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2019-0169	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2019-0169	results	3	NA	Number of covariates adjusted for/matched on	8
10.2217/cer-2019-0169	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.2217/cer-2019-0169	results	3	NA	Primary outcome: treatment effect contrast	Risk difference
10.2217/cer-2019-0169	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	3	NA	Primary outcome: adjusted treatment effect	-22.7
10.2217/cer-2019-0169	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.2217/cer-2019-0169	results	3	NA	lb_ci	NA
10.2217/cer-2019-0169	results	3	NA	ub_ci	NA
10.2217/cer-2019-0169	results	3	NA	pval	<0.001
10.2217/cer-2019-0169	results	3	NA	num_pval	NA
10.2217/cer-2019-0169	results	3	NA	ci_cutoff	0
10.2217/cer-2019-0169	results	3	NA	significant	TRUE
10.2217/cer-2019-0169	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2019-0169	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02047734
10.2217/cer-2019-0169	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2019-0169	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02294058
10.2217/cer-2019-0169	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	3	Patient-level data used	No
10.2217/cer-2019-0169	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00340834
10.2217/cer-2019-0169	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	4	Patient-level data used	No
10.2217/cer-2019-0169	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00289978
10.2217/cer-2019-0169	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2019-0169	study_information	NA	5	Patient-level data used	No
10.2217/cer-2019-0169	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2019-0169	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00355134
10.2217/cer-2019-0169	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2019-0169	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2019-0169	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0063	general_information	NA	NA	Medical Condition of Interest Name	non-small cell lung cancer
10.2217/cer-2020-0063	general_information	NA	NA	Countries of first author affiliations	switzerland
10.2217/cer-2020-0063	general_information	NA	NA	Countries of last author affiliations	switzerland
10.2217/cer-2020-0063	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0063	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0063	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0063	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0063	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 1	entrectinib
10.2217/cer-2020-0063	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer-2020-0063	methodology	1	NA	Treatment name 2	crizotinib
10.2217/cer-2020-0063	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.2217/cer-2020-0063	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0063	methodology	1	NA	Anchored comparison?	No
10.2217/cer-2020-0063	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0063	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0063	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2020-0063	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2020-0063	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0063	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 1	entrectinib
10.2217/cer-2020-0063	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer-2020-0063	methodology	2	NA	Treatment name 2	pemetrexed + platinum followed by pemetrexed maintenance
10.2217/cer-2020-0063	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.2217/cer-2020-0063	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0063	methodology	2	NA	Anchored comparison?	No
10.2217/cer-2020-0063	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0063	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0063	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2020-0063	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2020-0063	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0063	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 1	entrectinib
10.2217/cer-2020-0063	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer-2020-0063	methodology	3	NA	Treatment name 2	pemetrexed/docetaxel
10.2217/cer-2020-0063	methodology	3	NA	Study 'number(s)' for treatment 2	6
10.2217/cer-2020-0063	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0063	methodology	3	NA	Anchored comparison?	No
10.2217/cer-2020-0063	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0063	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0063	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2020-0063	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2020-0063	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0063	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0063	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	53
10.2217/cer-2020-0063	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	53
10.2217/cer-2020-0063	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	34.18
10.2217/cer-2020-0063	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0063	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0063	results	1	NA	Number of covariates adjusted for/matched on	6
10.2217/cer-2020-0063	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0063	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	1	NA	Primary outcome: adjusted treatment effect	0.471
10.2217/cer-2020-0063	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.112;1.034]
10.2217/cer-2020-0063	results	1	NA	lb_ci	0.112
10.2217/cer-2020-0063	results	1	NA	ub_ci	1.034
10.2217/cer-2020-0063	results	1	NA	pval	NA
10.2217/cer-2020-0063	results	1	NA	num_pval	NA
10.2217/cer-2020-0063	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0063	results	1	NA	significant	TRUE
10.2217/cer-2020-0063	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	187
10.2217/cer-2020-0063	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	53
10.2217/cer-2020-0063	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	47.5
10.2217/cer-2020-0063	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0063	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0063	results	2	NA	Number of covariates adjusted for/matched on	5
10.2217/cer-2020-0063	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0063	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	2	NA	Primary outcome: adjusted treatment effect	0.478
10.2217/cer-2020-0063	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.167;0.918]
10.2217/cer-2020-0063	results	2	NA	lb_ci	0.167
10.2217/cer-2020-0063	results	2	NA	ub_ci	0.918
10.2217/cer-2020-0063	results	2	NA	pval	NA
10.2217/cer-2020-0063	results	2	NA	num_pval	NA
10.2217/cer-2020-0063	results	2	NA	ci_cutoff	1
10.2217/cer-2020-0063	results	2	NA	significant	FALSE
10.2217/cer-2020-0063	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	174
10.2217/cer-2020-0063	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	53
10.2217/cer-2020-0063	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36.09
10.2217/cer-2020-0063	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0063	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0063	results	3	NA	Number of covariates adjusted for/matched on	5
10.2217/cer-2020-0063	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	3	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0063	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	3	NA	Primary outcome: adjusted treatment effect	0.434
10.2217/cer-2020-0063	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.157;0.755]
10.2217/cer-2020-0063	results	3	NA	lb_ci	0.157
10.2217/cer-2020-0063	results	3	NA	ub_ci	0.755
10.2217/cer-2020-0063	results	3	NA	pval	NA
10.2217/cer-2020-0063	results	3	NA	num_pval	NA
10.2217/cer-2020-0063	results	3	NA	ci_cutoff	1
10.2217/cer-2020-0063	results	3	NA	significant	FALSE
10.2217/cer-2020-0063	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0063	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	1	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88
10.2217/cer-2020-0063	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/cer-2020-0063	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2020-0063	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810
10.2217/cer-2020-0063	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	3	Patient-level data used	Yes
10.2217/cer-2020-0063	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267
10.2217/cer-2020-0063	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0063	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	4	Patient-level data used	No
10.2217/cer-2020-0063	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.2217/cer-2020-0063	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0063	study_information	NA	5	Patient-level data used	No
10.2217/cer-2020-0063	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01828099
10.2217/cer-2020-0063	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0063	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0063	study_information	NA	6	Patient-level data used	No
10.2217/cer-2020-0063	study_information	NA	6	Clinical Trial	Yes
10.2217/cer-2020-0063	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00932893
10.2217/cer-2020-0063	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0063	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0063	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0069	general_information	NA	NA	Medical Condition of Interest Name	pediatric relapsed/refractory acute lymphoblastic leukemia
10.2217/cer-2020-0069	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2020-0069	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2020-0069	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0069	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0069	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0069	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0069	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	1	NA	Treatment name 2	blinatumomab
10.2217/cer-2020-0069	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0069	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0069	methodology	1	NA	Anchored comparison?	No
10.2217/cer-2020-0069	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0069	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0069	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0069	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	2	NA	Treatment name 2	clofarabine
10.2217/cer-2020-0069	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2020-0069	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0069	methodology	2	NA	Anchored comparison?	No
10.2217/cer-2020-0069	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0069	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0069	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0069	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	3	NA	Treatment name 2	clofarabine + etoposide plus cyclophosphamide
10.2217/cer-2020-0069	methodology	3	NA	Study 'number(s)' for treatment 2	4;5;6
10.2217/cer-2020-0069	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0069	methodology	3	NA	Anchored comparison?	No
10.2217/cer-2020-0069	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0069	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0069	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0069	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0069	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	4	NA	Treatment name 2	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)
10.2217/cer-2020-0069	methodology	4	NA	Study 'number(s)' for treatment 2	7
10.2217/cer-2020-0069	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0069	methodology	4	NA	Anchored comparison?	No
10.2217/cer-2020-0069	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0069	methodology	4	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0069	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0069	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 1	tisagenlecleucel
10.2217/cer-2020-0069	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0069	methodology	5	NA	Treatment name 2	palliative therapy/salvage therapy  second stem-cell transplantation (salvage-2)
10.2217/cer-2020-0069	methodology	5	NA	Study 'number(s)' for treatment 2	8
10.2217/cer-2020-0069	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0069	methodology	5	NA	Anchored comparison?	No
10.2217/cer-2020-0069	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0069	methodology	5	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0069	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0069	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0069	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	70
10.2217/cer-2020-0069	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	79
10.2217/cer-2020-0069	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	28.7
10.2217/cer-2020-0069	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0069	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0069	results	1	NA	Number of covariates adjusted for/matched on	9
10.2217/cer-2020-0069	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0069	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0069	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	1	NA	Primary outcome: unadjusted treatment effect	0.28
10.2217/cer-2020-0069	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001
10.2217/cer-2020-0069	results	1	NA	Primary outcome: adjusted treatment effect	0.32
10.2217/cer-2020-0069	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.0015
10.2217/cer-2020-0069	results	1	NA	geographical region	Yes
10.2217/cer-2020-0069	results	1	NA	lb_ci	NA
10.2217/cer-2020-0069	results	1	NA	ub_ci	NA
10.2217/cer-2020-0069	results	1	NA	pval	<0.0001
10.2217/cer-2020-0069	results	1	NA	num_pval	NA
10.2217/cer-2020-0069	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	1	NA	significant	TRUE
10.2217/cer-2020-0069	results	1	NA	lb_ci	NA
10.2217/cer-2020-0069	results	1	NA	ub_ci	NA
10.2217/cer-2020-0069	results	1	NA	pval	0.0015
10.2217/cer-2020-0069	results	1	NA	num_pval	0.0015
10.2217/cer-2020-0069	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	1	NA	significant	TRUE
10.2217/cer-2020-0069	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	61
10.2217/cer-2020-0069	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	79
10.2217/cer-2020-0069	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	43
10.2217/cer-2020-0069	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0069	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0069	results	2	NA	Number of covariates adjusted for/matched on	5
10.2217/cer-2020-0069	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0069	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	2	NA	Primary outcome: unadjusted treatment effect	0.17
10.2217/cer-2020-0069	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001
10.2217/cer-2020-0069	results	2	NA	Primary outcome: adjusted treatment effect	0.24
10.2217/cer-2020-0069	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.2217/cer-2020-0069	results	2	NA	lb_ci	NA
10.2217/cer-2020-0069	results	2	NA	ub_ci	NA
10.2217/cer-2020-0069	results	2	NA	pval	<0.0001
10.2217/cer-2020-0069	results	2	NA	num_pval	NA
10.2217/cer-2020-0069	results	2	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	2	NA	significant	TRUE
10.2217/cer-2020-0069	results	2	NA	lb_ci	NA
10.2217/cer-2020-0069	results	2	NA	ub_ci	NA
10.2217/cer-2020-0069	results	2	NA	pval	<0.0001
10.2217/cer-2020-0069	results	2	NA	num_pval	NA
10.2217/cer-2020-0069	results	2	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	2	NA	significant	TRUE
10.2217/cer-2020-0069	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	74
10.2217/cer-2020-0069	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	79
10.2217/cer-2020-0069	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53.5
10.2217/cer-2020-0069	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0069	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0069	results	3	NA	Number of covariates adjusted for/matched on	2
10.2217/cer-2020-0069	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	3	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0069	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	3	NA	Primary outcome: unadjusted treatment effect	0.22
10.2217/cer-2020-0069	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001
10.2217/cer-2020-0069	results	3	NA	Primary outcome: adjusted treatment effect	0.26
10.2217/cer-2020-0069	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.2217/cer-2020-0069	results	3	NA	lb_ci	NA
10.2217/cer-2020-0069	results	3	NA	ub_ci	NA
10.2217/cer-2020-0069	results	3	NA	pval	<0.0001
10.2217/cer-2020-0069	results	3	NA	num_pval	NA
10.2217/cer-2020-0069	results	3	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	3	NA	significant	TRUE
10.2217/cer-2020-0069	results	3	NA	lb_ci	NA
10.2217/cer-2020-0069	results	3	NA	ub_ci	NA
10.2217/cer-2020-0069	results	3	NA	pval	<0.0001
10.2217/cer-2020-0069	results	3	NA	num_pval	NA
10.2217/cer-2020-0069	results	3	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	3	NA	significant	TRUE
10.2217/cer-2020-0069	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	51
10.2217/cer-2020-0069	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	79
10.2217/cer-2020-0069	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75
10.2217/cer-2020-0069	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0069	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0069	results	4	NA	Number of covariates adjusted for/matched on	3
10.2217/cer-2020-0069	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	4	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0069	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	4	NA	Primary outcome: unadjusted treatment effect	0.14
10.2217/cer-2020-0069	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001
10.2217/cer-2020-0069	results	4	NA	Primary outcome: adjusted treatment effect	0.15
10.2217/cer-2020-0069	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.2217/cer-2020-0069	results	4	NA	lb_ci	NA
10.2217/cer-2020-0069	results	4	NA	ub_ci	NA
10.2217/cer-2020-0069	results	4	NA	pval	<0.0001
10.2217/cer-2020-0069	results	4	NA	num_pval	NA
10.2217/cer-2020-0069	results	4	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	4	NA	significant	TRUE
10.2217/cer-2020-0069	results	4	NA	lb_ci	NA
10.2217/cer-2020-0069	results	4	NA	ub_ci	NA
10.2217/cer-2020-0069	results	4	NA	pval	<0.0001
10.2217/cer-2020-0069	results	4	NA	num_pval	NA
10.2217/cer-2020-0069	results	4	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	4	NA	significant	TRUE
10.2217/cer-2020-0069	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	242
10.2217/cer-2020-0069	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	79
10.2217/cer-2020-0069	results	5	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	36.2
10.2217/cer-2020-0069	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0069	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0069	results	5	NA	Number of covariates adjusted for/matched on	3
10.2217/cer-2020-0069	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2020-0069	results	5	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0069	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	5	NA	Primary outcome: unadjusted treatment effect	0.28
10.2217/cer-2020-0069	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	<0.0001
10.2217/cer-2020-0069	results	5	NA	Primary outcome: adjusted treatment effect	0.27
10.2217/cer-2020-0069	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.0001
10.2217/cer-2020-0069	results	5	NA	lb_ci	NA
10.2217/cer-2020-0069	results	5	NA	ub_ci	NA
10.2217/cer-2020-0069	results	5	NA	pval	<0.0001
10.2217/cer-2020-0069	results	5	NA	num_pval	NA
10.2217/cer-2020-0069	results	5	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	5	NA	significant	TRUE
10.2217/cer-2020-0069	results	5	NA	lb_ci	NA
10.2217/cer-2020-0069	results	5	NA	ub_ci	NA
10.2217/cer-2020-0069	results	5	NA	pval	<0.0001
10.2217/cer-2020-0069	results	5	NA	num_pval	NA
10.2217/cer-2020-0069	results	5	NA	ci_cutoff	1
10.2217/cer-2020-0069	results	5	NA	significant	TRUE
10.2217/cer-2020-0069	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0069	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02435849
10.2217/cer-2020-0069	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0069	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0069	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01471782
10.2217/cer-2020-0069	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0069	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2020-0069	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	3	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	jeha et al. (2006)
10.2217/cer-2020-0069	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0069	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2020-0069	study_information	NA	4	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00315705
10.2217/cer-2020-0069	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2020-0069	study_information	NA	4	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2020-0069	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	5	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2020-0069	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	locatelli et al. (2017)
10.2217/cer-2020-0069	study_information	NA	5	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0069	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/cer-2020-0069	study_information	NA	6	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	6	Clinical Trial	No
10.2217/cer-2020-0069	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	miano et al. (2012)
10.2217/cer-2020-0069	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/cer-2020-0069	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.2217/cer-2020-0069	study_information	NA	7	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	7	Clinical Trial	No
10.2217/cer-2020-0069	study_information	NA	7	Data source name (only if observational study or clinical trial without NCT)	von stackelbeg et al. (2010)
10.2217/cer-2020-0069	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	germany
10.2217/cer-2020-0069	study_information	NA	8	Patient-level data used	No
10.2217/cer-2020-0069	study_information	NA	8	Clinical Trial	No
10.2217/cer-2020-0069	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	all-sct-bfm 2003 & all-sct-bfm
10.2217/cer-2020-0069	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0236	general_information	NA	NA	Medical Condition of Interest Name	advanced hepatocellular carcinoma
10.2217/cer-2020-0236	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2020-0236	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2020-0236	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0236	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0236	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0236	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0236	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 1	nivolumab + ipilimumab
10.2217/cer-2020-0236	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0236	methodology	1	NA	Treatment name 2	placebo
10.2217/cer-2020-0236	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0236	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0236	methodology	1	NA	Anchored comparison?	No
10.2217/cer-2020-0236	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0236	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0236	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0236	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0236	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.2217/cer-2020-0236	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2020-0236	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0236	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0236	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0236	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	237
10.2217/cer-2020-0236	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	50
10.2217/cer-2020-0236	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0236	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0236	results	1	NA	Number of covariates adjusted for/matched on	6
10.2217/cer-2020-0236	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2020-0236	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0236	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0236	results	1	NA	Primary outcome: adjusted treatment effect	0.35
10.2217/cer-2020-0236	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.21;0.58]
10.2217/cer-2020-0236	results	1	NA	lb_ci	0.21
10.2217/cer-2020-0236	results	1	NA	ub_ci	0.58
10.2217/cer-2020-0236	results	1	NA	pval	NA
10.2217/cer-2020-0236	results	1	NA	num_pval	NA
10.2217/cer-2020-0236	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0236	results	1	NA	significant	FALSE
10.2217/cer-2020-0236	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0236	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0236	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01658878
10.2217/cer-2020-0236	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0236	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.2217/cer-2020-0236	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0236	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0236	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0236	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01908426
10.2217/cer-2020-0236	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0236	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0236	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0272	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2- advanced breast cancer
10.2217/cer-2020-0272	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2020-0272	general_information	NA	NA	Countries of last author affiliations	canada
10.2217/cer-2020-0272	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0272	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0272	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0272	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0272	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 1	palbociclib + fulvestrant
10.2217/cer-2020-0272	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0272	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant
10.2217/cer-2020-0272	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0272	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0272	methodology	1	NA	Anchored comparison?	Yes
10.2217/cer-2020-0272	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0272	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer-2020-0272	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0272	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0272	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0272	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.2217/cer-2020-0272	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2020-0272	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0272	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 1	palbociclib + fulvestrant
10.2217/cer-2020-0272	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0272	methodology	2	NA	Treatment name 2	ribociclib + fulvestrant
10.2217/cer-2020-0272	methodology	2	NA	Study 'number(s)' for treatment 2	3
10.2217/cer-2020-0272	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2020-0272	methodology	2	NA	Anchored comparison?	Yes
10.2217/cer-2020-0272	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0272	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer-2020-0272	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0272	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0272	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0272	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.2217/cer-2020-0272	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2020-0272	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2020-0272	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2020-0272	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	183
10.2217/cer-2020-0272	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	97
10.2217/cer-2020-0272	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0272	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0272	results	1	NA	Number of covariates adjusted for/matched on	12
10.2217/cer-2020-0272	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0272	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0272	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0272	results	1	NA	Primary outcome: unadjusted treatment effect	1.02
10.2217/cer-2020-0272	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.69;1.52]
10.2217/cer-2020-0272	results	1	NA	Primary outcome: adjusted treatment effect	0.87
10.2217/cer-2020-0272	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.54;1.40]
10.2217/cer-2020-0272	results	1	NA	geographical region	Yes
10.2217/cer-2020-0272	results	1	NA	If anchored, total initial sample size IPD	280
10.2217/cer-2020-0272	results	1	NA	If anchored, total ESS IPD	135
10.2217/cer-2020-0272	results	1	NA	If anchored, total sample size non IPD	669
10.2217/cer-2020-0272	results	1	NA	lb_ci	0.69
10.2217/cer-2020-0272	results	1	NA	ub_ci	1.52
10.2217/cer-2020-0272	results	1	NA	pval	NA
10.2217/cer-2020-0272	results	1	NA	num_pval	NA
10.2217/cer-2020-0272	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0272	results	1	NA	significant	TRUE
10.2217/cer-2020-0272	results	1	NA	lb_ci	0.54
10.2217/cer-2020-0272	results	1	NA	ub_ci	1.4
10.2217/cer-2020-0272	results	1	NA	pval	NA
10.2217/cer-2020-0272	results	1	NA	num_pval	NA
10.2217/cer-2020-0272	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0272	results	1	NA	significant	TRUE
10.2217/cer-2020-0272	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	142
10.2217/cer-2020-0272	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	75
10.2217/cer-2020-0272	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer-2020-0272	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0272	results	2	NA	Number of covariates adjusted for/matched on	8
10.2217/cer-2020-0272	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0272	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0272	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0272	results	2	NA	Primary outcome: unadjusted treatment effect	1.09
10.2217/cer-2020-0272	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.70;1.69]
10.2217/cer-2020-0272	results	2	NA	Primary outcome: adjusted treatment effect	0.89
10.2217/cer-2020-0272	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.48;1.63]
10.2217/cer-2020-0272	results	2	NA	geographical region	Yes
10.2217/cer-2020-0272	results	2	NA	If anchored, total initial sample size IPD	217
10.2217/cer-2020-0272	results	2	NA	If anchored, total ESS IPD	64
10.2217/cer-2020-0272	results	2	NA	If anchored, total sample size non IPD	726
10.2217/cer-2020-0272	results	2	NA	lb_ci	0.7
10.2217/cer-2020-0272	results	2	NA	ub_ci	1.69
10.2217/cer-2020-0272	results	2	NA	pval	NA
10.2217/cer-2020-0272	results	2	NA	num_pval	NA
10.2217/cer-2020-0272	results	2	NA	ci_cutoff	1
10.2217/cer-2020-0272	results	2	NA	significant	TRUE
10.2217/cer-2020-0272	results	2	NA	lb_ci	0.48
10.2217/cer-2020-0272	results	2	NA	ub_ci	1.63
10.2217/cer-2020-0272	results	2	NA	pval	NA
10.2217/cer-2020-0272	results	2	NA	num_pval	NA
10.2217/cer-2020-0272	results	2	NA	ci_cutoff	1
10.2217/cer-2020-0272	results	2	NA	significant	TRUE
10.2217/cer-2020-0272	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0272	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0272	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01942135
10.2217/cer-2020-0272	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0272	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0272	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0272	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0272	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0272	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02107703
10.2217/cer-2020-0272	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0272	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0272	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0272	study_information	NA	3	Patient-level data used	No
10.2217/cer-2020-0272	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2020-0272	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02422615
10.2217/cer-2020-0272	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0272	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0272	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0280	general_information	NA	NA	Medical Condition of Interest Name	acute myeloid leukemia
10.2217/cer-2020-0280	general_information	NA	NA	Countries of first author affiliations	canada
10.2217/cer-2020-0280	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2020-0280	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0280	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2020-0280	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2020-0280	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2020-0280	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 1	glasdegib + low-dose cytarabine
10.2217/cer-2020-0280	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2020-0280	methodology	1	NA	Treatment name 2	venetoclax + low-dose cytarabine
10.2217/cer-2020-0280	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2020-0280	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/cer-2020-0280	methodology	1	NA	Anchored comparison?	Yes
10.2217/cer-2020-0280	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0280	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0280	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/cer-2020-0280	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/cer-2020-0280	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0280	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/cer-2020-0280	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2020-0280	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	Yes
10.2217/cer-2020-0280	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	Yes
10.2217/cer-2020-0280	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	143
10.2217/cer-2020-0280	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	68
10.2217/cer-2020-0280	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	78
10.2217/cer-2020-0280	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	78
10.2217/cer-2020-0280	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	38
10.2217/cer-2020-0280	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	38
10.2217/cer-2020-0280	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2020-0280	results	1	NA	Number of covariates adjusted for/matched on	6
10.2217/cer-2020-0280	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/cer-2020-0280	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/cer-2020-0280	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2020-0280	results	1	NA	Primary outcome: unadjusted treatment effect	0.66
10.2217/cer-2020-0280	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.38;1.15]
10.2217/cer-2020-0280	results	1	NA	Primary outcome: adjusted treatment effect	0.56
10.2217/cer-2020-0280	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.24;1.32]
10.2217/cer-2020-0280	results	1	NA	lb_ci	0.38
10.2217/cer-2020-0280	results	1	NA	ub_ci	1.15
10.2217/cer-2020-0280	results	1	NA	pval	NA
10.2217/cer-2020-0280	results	1	NA	num_pval	NA
10.2217/cer-2020-0280	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0280	results	1	NA	significant	TRUE
10.2217/cer-2020-0280	results	1	NA	lb_ci	0.24
10.2217/cer-2020-0280	results	1	NA	ub_ci	1.32
10.2217/cer-2020-0280	results	1	NA	pval	NA
10.2217/cer-2020-0280	results	1	NA	num_pval	NA
10.2217/cer-2020-0280	results	1	NA	ci_cutoff	1
10.2217/cer-2020-0280	results	1	NA	significant	TRUE
10.2217/cer-2020-0280	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2020-0280	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2020-0280	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01546038
10.2217/cer-2020-0280	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0280	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2217/cer-2020-0280	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2020-0280	study_information	NA	2	Patient-level data used	No
10.2217/cer-2020-0280	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2020-0280	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03069352
10.2217/cer-2020-0280	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2020-0280	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2020-0280	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0178	general_information	NA	NA	Medical Condition of Interest Name	parkinson's disease
10.2217/cer-2021-0178	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2021-0178	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer-2021-0178	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0178	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2021-0178	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2021-0178	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2021-0178	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2021-0178	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2021-0178	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2021-0178	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02469090
10.2217/cer-2021-0178	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0178	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0178	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0178	study_information	NA	2	Patient-level data used	No
10.2217/cer-2021-0178	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2021-0178	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0178	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0178	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0178	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02240030
10.2217/cer-2021-0216	general_information	NA	NA	Medical Condition of Interest Name	spinal muscular atrophy
10.2217/cer-2021-0216	general_information	NA	NA	Countries of first author affiliations	switzerland
10.2217/cer-2021-0216	general_information	NA	NA	Countries of last author affiliations	uk
10.2217/cer-2021-0216	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0216	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2021-0216	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2021-0216	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2021-0216	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer-2021-0216	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2021-0216	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02913482
10.2217/cer-2021-0216	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2, 3
10.2217/cer-2021-0216	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer-2021-0216	study_information	NA	2	Patient-level data used	Yes
10.2217/cer-2021-0216	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02908685
10.2217/cer-2021-0216	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.2217/cer-2021-0216	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0216	study_information	NA	3	Patient-level data used	No
10.2217/cer-2021-0216	study_information	NA	3	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02193074
10.2217/cer-2021-0216	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0216	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0216	study_information	NA	4	Patient-level data used	No
10.2217/cer-2021-0216	study_information	NA	4	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02292537
10.2217/cer-2021-0216	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0216	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0216	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0216	study_information	NA	5	Patient-level data used	No
10.2217/cer-2021-0216	study_information	NA	5	Clinical Trial	Yes
10.2217/cer-2021-0216	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03306277
10.2217/cer-2021-0216	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer-2021-0216	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0216	study_information	NA	5	Number of treatment arms (clinical trial only)	1
10.2217/cer-2021-0221	general_information	NA	NA	Medical Condition of Interest Name	hr+/her2- advanced breast cancer
10.2217/cer-2021-0221	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer-2021-0221	general_information	NA	NA	Countries of last author affiliations	canada
10.2217/cer-2021-0221	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0221	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer-2021-0221	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer-2021-0221	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer-2021-0221	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 1	palbociclib + fulvestrant
10.2217/cer-2021-0221	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/cer-2021-0221	methodology	1	NA	Treatment name 2	abemaciclib + fulvestrant
10.2217/cer-2021-0221	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/cer-2021-0221	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer-2021-0221	methodology	1	NA	Anchored comparison?	Yes
10.2217/cer-2021-0221	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0221	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0221	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	global quality of life (european organisation for research and treatment of cancerquality of life questionnaire core 30 items) change from baseline
10.2217/cer-2021-0221	methodology	1	NA	Primary outcome: variable type	Continuous (count, mean, ...)
10.2217/cer-2021-0221	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0221	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.2217/cer-2021-0221	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/cer-2021-0221	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer-2021-0221	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer-2021-0221	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	180
10.2217/cer-2021-0221	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	90
10.2217/cer-2021-0221	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0221	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer-2021-0221	results	1	NA	Number of covariates adjusted for/matched on	11
10.2217/cer-2021-0221	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2021-0221	results	1	NA	Primary outcome: treatment effect contrast	Means difference
10.2217/cer-2021-0221	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer-2021-0221	results	1	NA	Primary outcome: unadjusted treatment effect	4.6
10.2217/cer-2021-0221	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.016
10.2217/cer-2021-0221	results	1	NA	Primary outcome: adjusted treatment effect	6.95
10.2217/cer-2021-0221	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.004
10.2217/cer-2021-0221	results	1	NA	geographical region	Yes
10.2217/cer-2021-0221	results	1	NA	If anchored, total initial sample size IPD	270
10.2217/cer-2021-0221	results	1	NA	If anchored, total sample size non IPD	669
10.2217/cer-2021-0221	results	1	NA	lb_ci	NA
10.2217/cer-2021-0221	results	1	NA	ub_ci	NA
10.2217/cer-2021-0221	results	1	NA	pval	0.016
10.2217/cer-2021-0221	results	1	NA	num_pval	0.016
10.2217/cer-2021-0221	results	1	NA	ci_cutoff	0
10.2217/cer-2021-0221	results	1	NA	significant	TRUE
10.2217/cer-2021-0221	results	1	NA	lb_ci	NA
10.2217/cer-2021-0221	results	1	NA	ub_ci	NA
10.2217/cer-2021-0221	results	1	NA	pval	0.004
10.2217/cer-2021-0221	results	1	NA	num_pval	0.004
10.2217/cer-2021-0221	results	1	NA	ci_cutoff	0
10.2217/cer-2021-0221	results	1	NA	significant	TRUE
10.2217/cer-2021-0221	study_information	NA	1	Patient-level data used	Yes
10.2217/cer-2021-0221	study_information	NA	1	Clinical Trial	Yes
10.2217/cer-2021-0221	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01942135
10.2217/cer-2021-0221	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0221	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0221	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer-2021-0221	study_information	NA	2	Patient-level data used	No
10.2217/cer-2021-0221	study_information	NA	2	Clinical Trial	Yes
10.2217/cer-2021-0221	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02107703
10.2217/cer-2021-0221	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer-2021-0221	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer-2021-0221	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	general_information	NA	NA	Medical Condition of Interest Name	chronic genotype 1b hepatitis c
10.2217/cer.15.33	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer.15.33	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer.15.33	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.33	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer.15.33	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer.15.33	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer.15.33	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer.15.33	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	1	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	1	NA	Treatment name 2	telaprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	1	NA	Study 'number(s)' for treatment 2	4;5;6
10.2217/cer.15.33	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	1	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	2	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	2	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	2	NA	Treatment name 2	boceprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	2	NA	Study 'number(s)' for treatment 2	8
10.2217/cer.15.33	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	2	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	3	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	3	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	3	NA	Treatment name 2	simeprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	3	NA	Study 'number(s)' for treatment 2	10;11
10.2217/cer.15.33	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	3	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	4	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	4	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	4	NA	Treatment name 2	sofosbuvir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	4	NA	Study 'number(s)' for treatment 2	13
10.2217/cer.15.33	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	4	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	5	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	5	NA	Study 'number(s)' for treatment 1	2;3
10.2217/cer.15.33	methodology	5	NA	Treatment name 2	peginterferon- + ribavirin
10.2217/cer.15.33	methodology	5	NA	Study 'number(s)' for treatment 2	4;8;10;11
10.2217/cer.15.33	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	5	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	5	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	5	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	6	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	6	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	6	NA	Treatment name 2	telaprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	6	NA	Study 'number(s)' for treatment 2	7
10.2217/cer.15.33	methodology	6	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	6	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	6	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	6	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	7	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	7	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	7	NA	Treatment name 2	boceprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	7	NA	Study 'number(s)' for treatment 2	9
10.2217/cer.15.33	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	7	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	7	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	7	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	8	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	8	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	8	NA	Treatment name 2	simeprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	8	NA	Study 'number(s)' for treatment 2	12
10.2217/cer.15.33	methodology	8	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	8	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	8	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	8	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	8	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	8	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	8	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	8	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	8	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	8	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	8	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	methodology	9	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	9	NA	Study 'number(s)' for treatment 1	1;2;3
10.2217/cer.15.33	methodology	9	NA	Treatment name 2	peginterferon- + ribavirin
10.2217/cer.15.33	methodology	9	NA	Study 'number(s)' for treatment 2	9;12
10.2217/cer.15.33	methodology	9	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.33	methodology	9	NA	Anchored comparison?	No
10.2217/cer.15.33	methodology	9	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	9	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.33	methodology	9	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response
10.2217/cer.15.33	methodology	9	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.33	methodology	9	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	9	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	9	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	9	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.33	methodology	9	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.33	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	1643
10.2217/cer.15.33	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	1	NA	Primary outcome: adjusted treatment effect	8.7
10.2217/cer.15.33	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.2;17.3]
10.2217/cer.15.33	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	324
10.2217/cer.15.33	results	1	NA	lb_ci	0.2
10.2217/cer.15.33	results	1	NA	ub_ci	17.3
10.2217/cer.15.33	results	1	NA	pval	NA
10.2217/cer.15.33	results	1	NA	num_pval	NA
10.2217/cer.15.33	results	1	NA	ci_cutoff	0
10.2217/cer.15.33	results	1	NA	significant	FALSE
10.2217/cer.15.33	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	368
10.2217/cer.15.33	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	2	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	2	NA	Primary outcome: adjusted treatment effect	16.5
10.2217/cer.15.33	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[2.5;30.5]
10.2217/cer.15.33	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	324
10.2217/cer.15.33	results	2	NA	lb_ci	2.5
10.2217/cer.15.33	results	2	NA	ub_ci	30.5
10.2217/cer.15.33	results	2	NA	pval	NA
10.2217/cer.15.33	results	2	NA	num_pval	NA
10.2217/cer.15.33	results	2	NA	ci_cutoff	0
10.2217/cer.15.33	results	2	NA	significant	FALSE
10.2217/cer.15.33	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	521
10.2217/cer.15.33	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	3	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	3	NA	Primary outcome: adjusted treatment effect	0.4
10.2217/cer.15.33	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-8.9;9.7]
10.2217/cer.15.33	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	324
10.2217/cer.15.33	results	3	NA	lb_ci	-8.9
10.2217/cer.15.33	results	3	NA	ub_ci	9.7
10.2217/cer.15.33	results	3	NA	pval	NA
10.2217/cer.15.33	results	3	NA	num_pval	NA
10.2217/cer.15.33	results	3	NA	ci_cutoff	0
10.2217/cer.15.33	results	3	NA	significant	TRUE
10.2217/cer.15.33	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	327
10.2217/cer.15.33	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	4	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	4	NA	Primary outcome: adjusted treatment effect	3
10.2217/cer.15.33	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[-21.2;27.1]
10.2217/cer.15.33	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	324
10.2217/cer.15.33	results	4	NA	lb_ci	-21.2
10.2217/cer.15.33	results	4	NA	ub_ci	27.1
10.2217/cer.15.33	results	4	NA	pval	NA
10.2217/cer.15.33	results	4	NA	num_pval	NA
10.2217/cer.15.33	results	4	NA	ci_cutoff	0
10.2217/cer.15.33	results	4	NA	significant	TRUE
10.2217/cer.15.33	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	988
10.2217/cer.15.33	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	5	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	5	NA	Primary outcome: adjusted treatment effect	39.6
10.2217/cer.15.33	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[30.3;48.9]
10.2217/cer.15.33	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	324
10.2217/cer.15.33	results	5	NA	lb_ci	30.3
10.2217/cer.15.33	results	5	NA	ub_ci	48.9
10.2217/cer.15.33	results	5	NA	pval	NA
10.2217/cer.15.33	results	5	NA	num_pval	NA
10.2217/cer.15.33	results	5	NA	ci_cutoff	0
10.2217/cer.15.33	results	5	NA	significant	FALSE
10.2217/cer.15.33	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	266
10.2217/cer.15.33	results	6	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	6	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	6	NA	Primary outcome: adjusted treatment effect	17
10.2217/cer.15.33	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[5.3;28.7]
10.2217/cer.15.33	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	314
10.2217/cer.15.33	results	6	NA	lb_ci	5.3
10.2217/cer.15.33	results	6	NA	ub_ci	28.7
10.2217/cer.15.33	results	6	NA	pval	NA
10.2217/cer.15.33	results	6	NA	num_pval	NA
10.2217/cer.15.33	results	6	NA	ci_cutoff	0
10.2217/cer.15.33	results	6	NA	significant	FALSE
10.2217/cer.15.33	results	7	NA	Sample size of the population of interest in the non IPD treatment arm	162
10.2217/cer.15.33	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	7	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	7	NA	Primary outcome: adjusted treatment effect	22.8
10.2217/cer.15.33	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[6.9;38.7]
10.2217/cer.15.33	results	7	NA	Initial sample size of the population of interest in the IPD treatment arm	314
10.2217/cer.15.33	results	7	NA	lb_ci	6.9
10.2217/cer.15.33	results	7	NA	ub_ci	38.7
10.2217/cer.15.33	results	7	NA	pval	NA
10.2217/cer.15.33	results	7	NA	num_pval	NA
10.2217/cer.15.33	results	7	NA	ci_cutoff	0
10.2217/cer.15.33	results	7	NA	significant	FALSE
10.2217/cer.15.33	results	8	NA	Sample size of the population of interest in the non IPD treatment arm	260
10.2217/cer.15.33	results	8	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	8	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	8	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	8	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	8	NA	Primary outcome: adjusted treatment effect	10.3
10.2217/cer.15.33	results	8	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[1.1;19.5]
10.2217/cer.15.33	results	8	NA	Initial sample size of the population of interest in the IPD treatment arm	314
10.2217/cer.15.33	results	8	NA	lb_ci	1.1
10.2217/cer.15.33	results	8	NA	ub_ci	19.5
10.2217/cer.15.33	results	8	NA	pval	NA
10.2217/cer.15.33	results	8	NA	num_pval	NA
10.2217/cer.15.33	results	8	NA	ci_cutoff	0
10.2217/cer.15.33	results	8	NA	significant	FALSE
10.2217/cer.15.33	results	9	NA	Sample size of the population of interest in the non IPD treatment arm	213
10.2217/cer.15.33	results	9	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.33	results	9	NA	Reporting of the list of the covariates adjusted for/matched on	No
10.2217/cer.15.33	results	9	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.33	results	9	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	9	NA	Primary outcome: adjusted treatment effect	57.7
10.2217/cer.15.33	results	9	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[44.0;71.4]
10.2217/cer.15.33	results	9	NA	Initial sample size of the population of interest in the IPD treatment arm	314
10.2217/cer.15.33	results	9	NA	lb_ci	44
10.2217/cer.15.33	results	9	NA	ub_ci	71.4
10.2217/cer.15.33	results	9	NA	pval	NA
10.2217/cer.15.33	results	9	NA	num_pval	NA
10.2217/cer.15.33	results	9	NA	ci_cutoff	0
10.2217/cer.15.33	results	9	NA	significant	FALSE
10.2217/cer.15.33	study_information	NA	1	Patient-level data used	Yes
10.2217/cer.15.33	study_information	NA	1	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01497834
10.2217/cer.15.33	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.33	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.33	study_information	NA	10	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	10	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01289782
10.2217/cer.15.33	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	10	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	10	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	11	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	11	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	11	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01290679
10.2217/cer.15.33	study_information	NA	11	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	11	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	11	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	12	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	12	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	12	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01281839
10.2217/cer.15.33	study_information	NA	12	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	12	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	12	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	13	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	13	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	13	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01641640
10.2217/cer.15.33	study_information	NA	13	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/cer.15.33	study_information	NA	13	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	13	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.33	study_information	NA	2	Patient-level data used	Yes
10.2217/cer.15.33	study_information	NA	2	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01581203
10.2217/cer.15.33	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	3	Patient-level data used	Yes
10.2217/cer.15.33	study_information	NA	3	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01718145
10.2217/cer.15.33	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.33	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	4	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	4	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00627926
10.2217/cer.15.33	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	5	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	5	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01241760
10.2217/cer.15.33	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	6	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	6	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00758043
10.2217/cer.15.33	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	6	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	6	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	7	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	7	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00703118
10.2217/cer.15.33	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.33	study_information	NA	7	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	7	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	8	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	8	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	8	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00705432
10.2217/cer.15.33	study_information	NA	8	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	8	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer.15.33	study_information	NA	9	Patient-level data used	No
10.2217/cer.15.33	study_information	NA	9	Clinical Trial	Yes
10.2217/cer.15.33	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00708500
10.2217/cer.15.33	study_information	NA	9	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.33	study_information	NA	9	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.33	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer.15.49	general_information	NA	NA	Medical Condition of Interest Name	hepatitis c genotype 3
10.2217/cer.15.49	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer.15.49	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer.15.49	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.49	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer.15.49	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer.15.49	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer.15.49	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer.15.49	results	1	NA	geographical region	No
10.2217/cer.15.49	results	2	NA	geographical region	No
10.2217/cer.15.49	study_information	NA	1	Patient-level data used	Yes
10.2217/cer.15.49	study_information	NA	1	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02032901
10.2217/cer.15.49	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.49	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.49	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.49	study_information	NA	2	Patient-level data used	No
10.2217/cer.15.49	study_information	NA	2	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01682720
10.2217/cer.15.49	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.49	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.49	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.49	study_information	NA	3	Patient-level data used	No
10.2217/cer.15.49	study_information	NA	3	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	ferenci et al. (2008)
10.2217/cer.15.49	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.2217/cer.15.49	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.49	study_information	NA	4	Patient-level data used	No
10.2217/cer.15.49	study_information	NA	4	Clinical Trial	Yes
10.2217/cer.15.49	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00077636
10.2217/cer.15.49	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/cer.15.49	study_information	NA	4	Phase of the clinical trial (clinical trial only)	4
10.2217/cer.15.49	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.69	general_information	NA	NA	Medical Condition of Interest Name	hepatitis c virus genotype 1b
10.2217/cer.15.69	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/cer.15.69	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/cer.15.69	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.69	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/cer.15.69	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/cer.15.69	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/cer.15.69	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/cer.15.69	methodology	1	NA	Treatment name 1	daclatasvir + asunaprevir
10.2217/cer.15.69	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/cer.15.69	methodology	1	NA	Treatment name 2	sofosbuvir + ledipasvir
10.2217/cer.15.69	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/cer.15.69	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/cer.15.69	methodology	1	NA	Anchored comparison?	No
10.2217/cer.15.69	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/cer.15.69	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/cer.15.69	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	sustained virologic response at week 12 post-treatment
10.2217/cer.15.69	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/cer.15.69	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.2217/cer.15.69	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.69	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.69	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/cer.15.69	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/cer.15.69	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	171
10.2217/cer.15.69	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	252
10.2217/cer.15.69	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/cer.15.69	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/cer.15.69	results	1	NA	Number of covariates adjusted for/matched on	11
10.2217/cer.15.69	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer.15.69	results	1	NA	Primary outcome: treatment effect contrast	Rate difference
10.2217/cer.15.69	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/cer.15.69	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.004
10.2217/cer.15.69	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.398
10.2217/cer.15.69	results	1	NA	geographical region	No
10.2217/cer.15.69	results	1	NA	lb_ci	NA
10.2217/cer.15.69	results	1	NA	ub_ci	NA
10.2217/cer.15.69	results	1	NA	pval	0.004
10.2217/cer.15.69	results	1	NA	num_pval	0.004
10.2217/cer.15.69	results	1	NA	ci_cutoff	0
10.2217/cer.15.69	results	1	NA	significant	TRUE
10.2217/cer.15.69	results	1	NA	lb_ci	NA
10.2217/cer.15.69	results	1	NA	ub_ci	NA
10.2217/cer.15.69	results	1	NA	pval	0.398
10.2217/cer.15.69	results	1	NA	num_pval	0.398
10.2217/cer.15.69	results	1	NA	ci_cutoff	0
10.2217/cer.15.69	results	1	NA	significant	FALSE
10.2217/cer.15.69	study_information	NA	1	Patient-level data used	Yes
10.2217/cer.15.69	study_information	NA	1	Clinical Trial	Yes
10.2217/cer.15.69	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01497834
10.2217/cer.15.69	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.69	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.69	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/cer.15.69	study_information	NA	2	Patient-level data used	Yes
10.2217/cer.15.69	study_information	NA	2	Clinical Trial	Yes
10.2217/cer.15.69	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01718145
10.2217/cer.15.69	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.69	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.69	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/cer.15.69	study_information	NA	3	Patient-level data used	No
10.2217/cer.15.69	study_information	NA	3	Clinical Trial	Yes
10.2217/cer.15.69	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01975675
10.2217/cer.15.69	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	japan
10.2217/cer.15.69	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/cer.15.69	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/fon-2020-0823	general_information	NA	NA	Medical Condition of Interest Name	advanced cutaneous squamous cell carcinoma
10.2217/fon-2020-0823	general_information	NA	NA	Countries of first author affiliations	canada
10.2217/fon-2020-0823	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/fon-2020-0823	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2020-0823	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/fon-2020-0823	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/fon-2020-0823	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/fon-2020-0823	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	1	NA	Treatment name 2	erlotinib
10.2217/fon-2020-0823	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.2217/fon-2020-0823	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	1	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	10	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	10	NA	Treatment name 2	gefitinib
10.2217/fon-2020-0823	methodology	10	NA	Study 'number(s)' for treatment 2	6
10.2217/fon-2020-0823	methodology	10	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	10	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	10	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	10	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	10	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	10	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	10	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	10	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	10	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	10	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	10	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	11	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	11	NA	Treatment name 2	dacomitinib
10.2217/fon-2020-0823	methodology	11	NA	Study 'number(s)' for treatment 2	7
10.2217/fon-2020-0823	methodology	11	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	11	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	11	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	11	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	11	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	11	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	11	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	11	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	11	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	11	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	11	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	12	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	12	NA	Treatment name 2	dacomitinib
10.2217/fon-2020-0823	methodology	12	NA	Study 'number(s)' for treatment 2	7
10.2217/fon-2020-0823	methodology	12	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	12	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	12	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	12	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	12	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	12	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	12	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	12	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	12	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	12	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	12	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	13	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	13	NA	Treatment name 2	panitumumab
10.2217/fon-2020-0823	methodology	13	NA	Study 'number(s)' for treatment 2	8
10.2217/fon-2020-0823	methodology	13	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	13	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	13	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	13	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	13	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	13	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	13	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	13	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	13	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	13	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	13	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	14	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	14	NA	Treatment name 2	panitumumab
10.2217/fon-2020-0823	methodology	14	NA	Study 'number(s)' for treatment 2	8
10.2217/fon-2020-0823	methodology	14	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	14	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	14	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	14	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	14	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	14	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	14	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	14	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	14	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	14	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	14	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	15	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	15	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	15	NA	Study 'number(s)' for treatment 2	9
10.2217/fon-2020-0823	methodology	15	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	15	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	15	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	15	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	15	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	15	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	15	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	15	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	15	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	15	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	15	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	16	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	16	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	16	NA	Study 'number(s)' for treatment 2	9
10.2217/fon-2020-0823	methodology	16	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	16	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	16	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	16	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	16	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	16	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	16	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	16	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	16	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	16	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	16	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	17	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	17	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	17	NA	Study 'number(s)' for treatment 2	10
10.2217/fon-2020-0823	methodology	17	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	17	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	17	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	17	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	17	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	17	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	17	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	17	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	17	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	17	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	17	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	18	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	18	NA	Treatment name 2	pembrolizumab
10.2217/fon-2020-0823	methodology	18	NA	Study 'number(s)' for treatment 2	10
10.2217/fon-2020-0823	methodology	18	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	18	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	18	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	18	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	18	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	18	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	18	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	18	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	18	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	18	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	18	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	19	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	19	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	19	NA	Study 'number(s)' for treatment 2	11
10.2217/fon-2020-0823	methodology	19	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	19	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	19	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	19	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	19	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	19	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	19	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	19	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	19	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	19	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	19	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	2	NA	Treatment name 2	erlotinib
10.2217/fon-2020-0823	methodology	2	NA	Study 'number(s)' for treatment 2	2
10.2217/fon-2020-0823	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	2	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	20	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	20	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	20	NA	Study 'number(s)' for treatment 2	11
10.2217/fon-2020-0823	methodology	20	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	20	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	20	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	20	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	20	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	20	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	20	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	20	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	20	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	20	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	20	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	3	NA	Treatment name 2	platinum-based chemotherapy
10.2217/fon-2020-0823	methodology	3	NA	Study 'number(s)' for treatment 2	3
10.2217/fon-2020-0823	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	3	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	4	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	4	NA	Treatment name 2	platinum-based chemotherapy
10.2217/fon-2020-0823	methodology	4	NA	Study 'number(s)' for treatment 2	3
10.2217/fon-2020-0823	methodology	4	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	4	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	4	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	4	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	5	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	5	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	5	NA	Study 'number(s)' for treatment 2	4
10.2217/fon-2020-0823	methodology	5	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	5	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	5	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	5	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	5	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	5	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	5	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	5	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	5	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	5	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	5	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	6	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	6	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	6	NA	Study 'number(s)' for treatment 2	4
10.2217/fon-2020-0823	methodology	6	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	6	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	6	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	6	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	6	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	6	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	6	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	6	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	6	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	6	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	6	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	7	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	7	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	7	NA	Study 'number(s)' for treatment 2	5
10.2217/fon-2020-0823	methodology	7	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	7	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	7	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	7	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	7	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	7	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	7	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	7	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	7	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	7	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	7	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	8	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	8	NA	Treatment name 2	cetuximab
10.2217/fon-2020-0823	methodology	8	NA	Study 'number(s)' for treatment 2	5
10.2217/fon-2020-0823	methodology	8	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2020-0823	methodology	8	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	8	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	8	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	8	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	8	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	8	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	8	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	8	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	8	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	8	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 1	cemiplimab
10.2217/fon-2020-0823	methodology	9	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2020-0823	methodology	9	NA	Treatment name 2	gefitinib
10.2217/fon-2020-0823	methodology	9	NA	Study 'number(s)' for treatment 2	6
10.2217/fon-2020-0823	methodology	9	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/fon-2020-0823	methodology	9	NA	Anchored comparison?	No
10.2217/fon-2020-0823	methodology	9	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	9	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	9	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2020-0823	methodology	9	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2020-0823	methodology	9	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	9	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2020-0823	methodology	9	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	9	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2020-0823	methodology	9	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2020-0823	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	39
10.2217/fon-2020-0823	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	1	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	1	NA	Primary outcome: unadjusted treatment effect	0.28
10.2217/fon-2020-0823	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]
10.2217/fon-2020-0823	results	1	NA	Primary outcome: adjusted treatment effect	0.41
10.2217/fon-2020-0823	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.24;0.70]
10.2217/fon-2020-0823	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	1	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	1	NA	ub_ci	0.5
10.2217/fon-2020-0823	results	1	NA	pval	NA
10.2217/fon-2020-0823	results	1	NA	num_pval	NA
10.2217/fon-2020-0823	results	1	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	1	NA	significant	FALSE
10.2217/fon-2020-0823	results	1	NA	lb_ci	0.24
10.2217/fon-2020-0823	results	1	NA	ub_ci	0.7
10.2217/fon-2020-0823	results	1	NA	pval	NA
10.2217/fon-2020-0823	results	1	NA	num_pval	NA
10.2217/fon-2020-0823	results	1	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	1	NA	significant	FALSE
10.2217/fon-2020-0823	results	10	NA	Sample size of the population of interest in the non IPD treatment arm	40
10.2217/fon-2020-0823	results	10	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	10	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	10	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	10	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	10	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	10	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	10	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	10	NA	Primary outcome: unadjusted treatment effect	0.27
10.2217/fon-2020-0823	results	10	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.44]
10.2217/fon-2020-0823	results	10	NA	Primary outcome: adjusted treatment effect	0.29
10.2217/fon-2020-0823	results	10	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.18;0.45]
10.2217/fon-2020-0823	results	10	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	10	NA	ub_ci	0.44
10.2217/fon-2020-0823	results	10	NA	pval	NA
10.2217/fon-2020-0823	results	10	NA	num_pval	NA
10.2217/fon-2020-0823	results	10	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	10	NA	significant	FALSE
10.2217/fon-2020-0823	results	10	NA	lb_ci	0.18
10.2217/fon-2020-0823	results	10	NA	ub_ci	0.45
10.2217/fon-2020-0823	results	10	NA	pval	NA
10.2217/fon-2020-0823	results	10	NA	num_pval	NA
10.2217/fon-2020-0823	results	10	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	10	NA	significant	FALSE
10.2217/fon-2020-0823	results	11	NA	Sample size of the population of interest in the non IPD treatment arm	42
10.2217/fon-2020-0823	results	11	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	11	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	11	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	11	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	11	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	11	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	11	NA	Primary outcome: unadjusted treatment effect	0.2
10.2217/fon-2020-0823	results	11	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.33]
10.2217/fon-2020-0823	results	11	NA	Primary outcome: adjusted treatment effect	0.17
10.2217/fon-2020-0823	results	11	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.10;0.28]
10.2217/fon-2020-0823	results	11	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	11	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	11	NA	ub_ci	0.33
10.2217/fon-2020-0823	results	11	NA	pval	NA
10.2217/fon-2020-0823	results	11	NA	num_pval	NA
10.2217/fon-2020-0823	results	11	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	11	NA	significant	FALSE
10.2217/fon-2020-0823	results	11	NA	lb_ci	0.1
10.2217/fon-2020-0823	results	11	NA	ub_ci	0.28
10.2217/fon-2020-0823	results	11	NA	pval	NA
10.2217/fon-2020-0823	results	11	NA	num_pval	NA
10.2217/fon-2020-0823	results	11	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	11	NA	significant	FALSE
10.2217/fon-2020-0823	results	12	NA	Sample size of the population of interest in the non IPD treatment arm	42
10.2217/fon-2020-0823	results	12	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	12	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	12	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	12	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	12	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	12	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	12	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	12	NA	Primary outcome: unadjusted treatment effect	0.2
10.2217/fon-2020-0823	results	12	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.33]
10.2217/fon-2020-0823	results	12	NA	Primary outcome: adjusted treatment effect	0.07
10.2217/fon-2020-0823	results	12	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.04;0.13]
10.2217/fon-2020-0823	results	12	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	12	NA	ub_ci	0.33
10.2217/fon-2020-0823	results	12	NA	pval	NA
10.2217/fon-2020-0823	results	12	NA	num_pval	NA
10.2217/fon-2020-0823	results	12	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	12	NA	significant	FALSE
10.2217/fon-2020-0823	results	12	NA	lb_ci	0.04
10.2217/fon-2020-0823	results	12	NA	ub_ci	0.13
10.2217/fon-2020-0823	results	12	NA	pval	NA
10.2217/fon-2020-0823	results	12	NA	num_pval	NA
10.2217/fon-2020-0823	results	12	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	12	NA	significant	FALSE
10.2217/fon-2020-0823	results	13	NA	Sample size of the population of interest in the non IPD treatment arm	16
10.2217/fon-2020-0823	results	13	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	13	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	13	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	13	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	13	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	13	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	13	NA	Primary outcome: unadjusted treatment effect	0.27
10.2217/fon-2020-0823	results	13	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.54]
10.2217/fon-2020-0823	results	13	NA	Primary outcome: adjusted treatment effect	0.52
10.2217/fon-2020-0823	results	13	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.26;1.01]
10.2217/fon-2020-0823	results	13	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	13	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	13	NA	ub_ci	0.54
10.2217/fon-2020-0823	results	13	NA	pval	NA
10.2217/fon-2020-0823	results	13	NA	num_pval	NA
10.2217/fon-2020-0823	results	13	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	13	NA	significant	FALSE
10.2217/fon-2020-0823	results	13	NA	lb_ci	0.26
10.2217/fon-2020-0823	results	13	NA	ub_ci	1.01
10.2217/fon-2020-0823	results	13	NA	pval	NA
10.2217/fon-2020-0823	results	13	NA	num_pval	NA
10.2217/fon-2020-0823	results	13	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	13	NA	significant	TRUE
10.2217/fon-2020-0823	results	14	NA	Sample size of the population of interest in the non IPD treatment arm	16
10.2217/fon-2020-0823	results	14	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	14	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	14	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	14	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	14	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	14	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	14	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	14	NA	Primary outcome: unadjusted treatment effect	0.27
10.2217/fon-2020-0823	results	14	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.54]
10.2217/fon-2020-0823	results	14	NA	Primary outcome: adjusted treatment effect	0.36
10.2217/fon-2020-0823	results	14	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.18;0.70]
10.2217/fon-2020-0823	results	14	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	14	NA	ub_ci	0.54
10.2217/fon-2020-0823	results	14	NA	pval	NA
10.2217/fon-2020-0823	results	14	NA	num_pval	NA
10.2217/fon-2020-0823	results	14	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	14	NA	significant	FALSE
10.2217/fon-2020-0823	results	14	NA	lb_ci	0.18
10.2217/fon-2020-0823	results	14	NA	ub_ci	0.7
10.2217/fon-2020-0823	results	14	NA	pval	NA
10.2217/fon-2020-0823	results	14	NA	num_pval	NA
10.2217/fon-2020-0823	results	14	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	14	NA	significant	FALSE
10.2217/fon-2020-0823	results	15	NA	Sample size of the population of interest in the non IPD treatment arm	39
10.2217/fon-2020-0823	results	15	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	15	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	15	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	15	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	15	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	15	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	15	NA	Primary outcome: unadjusted treatment effect	0.41
10.2217/fon-2020-0823	results	15	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.20;0.87]
10.2217/fon-2020-0823	results	15	NA	Primary outcome: adjusted treatment effect	0.39
10.2217/fon-2020-0823	results	15	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.17;0.86]
10.2217/fon-2020-0823	results	15	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	15	NA	lb_ci	0.2
10.2217/fon-2020-0823	results	15	NA	ub_ci	0.87
10.2217/fon-2020-0823	results	15	NA	pval	NA
10.2217/fon-2020-0823	results	15	NA	num_pval	NA
10.2217/fon-2020-0823	results	15	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	15	NA	significant	FALSE
10.2217/fon-2020-0823	results	15	NA	lb_ci	0.17
10.2217/fon-2020-0823	results	15	NA	ub_ci	0.86
10.2217/fon-2020-0823	results	15	NA	pval	NA
10.2217/fon-2020-0823	results	15	NA	num_pval	NA
10.2217/fon-2020-0823	results	15	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	15	NA	significant	FALSE
10.2217/fon-2020-0823	results	16	NA	Sample size of the population of interest in the non IPD treatment arm	39
10.2217/fon-2020-0823	results	16	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	16	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	16	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	16	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	16	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	16	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	16	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	16	NA	Primary outcome: unadjusted treatment effect	0.41
10.2217/fon-2020-0823	results	16	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.20;0.87]
10.2217/fon-2020-0823	results	16	NA	Primary outcome: adjusted treatment effect	0.21
10.2217/fon-2020-0823	results	16	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.09;0.48]
10.2217/fon-2020-0823	results	16	NA	lb_ci	0.2
10.2217/fon-2020-0823	results	16	NA	ub_ci	0.87
10.2217/fon-2020-0823	results	16	NA	pval	NA
10.2217/fon-2020-0823	results	16	NA	num_pval	NA
10.2217/fon-2020-0823	results	16	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	16	NA	significant	FALSE
10.2217/fon-2020-0823	results	16	NA	lb_ci	0.09
10.2217/fon-2020-0823	results	16	NA	ub_ci	0.48
10.2217/fon-2020-0823	results	16	NA	pval	NA
10.2217/fon-2020-0823	results	16	NA	num_pval	NA
10.2217/fon-2020-0823	results	16	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	16	NA	significant	FALSE
10.2217/fon-2020-0823	results	17	NA	Sample size of the population of interest in the non IPD treatment arm	105
10.2217/fon-2020-0823	results	17	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	17	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	17	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	17	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	17	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	17	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	17	NA	Primary outcome: unadjusted treatment effect	0.4
10.2217/fon-2020-0823	results	17	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.25;0.63]
10.2217/fon-2020-0823	results	17	NA	Primary outcome: adjusted treatment effect	0.52
10.2217/fon-2020-0823	results	17	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.34;0.80]
10.2217/fon-2020-0823	results	17	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	17	NA	lb_ci	0.25
10.2217/fon-2020-0823	results	17	NA	ub_ci	0.63
10.2217/fon-2020-0823	results	17	NA	pval	NA
10.2217/fon-2020-0823	results	17	NA	num_pval	NA
10.2217/fon-2020-0823	results	17	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	17	NA	significant	FALSE
10.2217/fon-2020-0823	results	17	NA	lb_ci	0.34
10.2217/fon-2020-0823	results	17	NA	ub_ci	0.8
10.2217/fon-2020-0823	results	17	NA	pval	NA
10.2217/fon-2020-0823	results	17	NA	num_pval	NA
10.2217/fon-2020-0823	results	17	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	17	NA	significant	FALSE
10.2217/fon-2020-0823	results	18	NA	Sample size of the population of interest in the non IPD treatment arm	105
10.2217/fon-2020-0823	results	18	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	18	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	18	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	18	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	18	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	18	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	18	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	18	NA	Primary outcome: unadjusted treatment effect	0.4
10.2217/fon-2020-0823	results	18	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.25;0.63]
10.2217/fon-2020-0823	results	18	NA	Primary outcome: adjusted treatment effect	0.26
10.2217/fon-2020-0823	results	18	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.16;0.42]
10.2217/fon-2020-0823	results	18	NA	lb_ci	0.25
10.2217/fon-2020-0823	results	18	NA	ub_ci	0.63
10.2217/fon-2020-0823	results	18	NA	pval	NA
10.2217/fon-2020-0823	results	18	NA	num_pval	NA
10.2217/fon-2020-0823	results	18	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	18	NA	significant	FALSE
10.2217/fon-2020-0823	results	18	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	18	NA	ub_ci	0.42
10.2217/fon-2020-0823	results	18	NA	pval	NA
10.2217/fon-2020-0823	results	18	NA	num_pval	NA
10.2217/fon-2020-0823	results	18	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	18	NA	significant	FALSE
10.2217/fon-2020-0823	results	19	NA	Sample size of the population of interest in the non IPD treatment arm	58
10.2217/fon-2020-0823	results	19	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	19	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	19	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	19	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	19	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	19	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	19	NA	Primary outcome: unadjusted treatment effect	0.34
10.2217/fon-2020-0823	results	19	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.21;0.55]
10.2217/fon-2020-0823	results	19	NA	Primary outcome: adjusted treatment effect	0.29
10.2217/fon-2020-0823	results	19	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.16;0.54]
10.2217/fon-2020-0823	results	19	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	19	NA	lb_ci	0.21
10.2217/fon-2020-0823	results	19	NA	ub_ci	0.55
10.2217/fon-2020-0823	results	19	NA	pval	NA
10.2217/fon-2020-0823	results	19	NA	num_pval	NA
10.2217/fon-2020-0823	results	19	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	19	NA	significant	FALSE
10.2217/fon-2020-0823	results	19	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	19	NA	ub_ci	0.54
10.2217/fon-2020-0823	results	19	NA	pval	NA
10.2217/fon-2020-0823	results	19	NA	num_pval	NA
10.2217/fon-2020-0823	results	19	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	19	NA	significant	FALSE
10.2217/fon-2020-0823	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	39
10.2217/fon-2020-0823	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	2	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	2	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	2	NA	Primary outcome: unadjusted treatment effect	0.28
10.2217/fon-2020-0823	results	2	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]
10.2217/fon-2020-0823	results	2	NA	Primary outcome: adjusted treatment effect	0.23
10.2217/fon-2020-0823	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.14;0.39]
10.2217/fon-2020-0823	results	2	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	2	NA	ub_ci	0.5
10.2217/fon-2020-0823	results	2	NA	pval	NA
10.2217/fon-2020-0823	results	2	NA	num_pval	NA
10.2217/fon-2020-0823	results	2	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	2	NA	significant	FALSE
10.2217/fon-2020-0823	results	2	NA	lb_ci	0.14
10.2217/fon-2020-0823	results	2	NA	ub_ci	0.39
10.2217/fon-2020-0823	results	2	NA	pval	NA
10.2217/fon-2020-0823	results	2	NA	num_pval	NA
10.2217/fon-2020-0823	results	2	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	2	NA	significant	FALSE
10.2217/fon-2020-0823	results	20	NA	Sample size of the population of interest in the non IPD treatment arm	58
10.2217/fon-2020-0823	results	20	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	20	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	20	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	20	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	20	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	20	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	20	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	20	NA	Primary outcome: unadjusted treatment effect	0.34
10.2217/fon-2020-0823	results	20	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.21;0.55]
10.2217/fon-2020-0823	results	20	NA	Primary outcome: adjusted treatment effect	0.19
10.2217/fon-2020-0823	results	20	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.11;0.31]
10.2217/fon-2020-0823	results	20	NA	lb_ci	0.21
10.2217/fon-2020-0823	results	20	NA	ub_ci	0.55
10.2217/fon-2020-0823	results	20	NA	pval	NA
10.2217/fon-2020-0823	results	20	NA	num_pval	NA
10.2217/fon-2020-0823	results	20	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	20	NA	significant	FALSE
10.2217/fon-2020-0823	results	20	NA	lb_ci	0.11
10.2217/fon-2020-0823	results	20	NA	ub_ci	0.31
10.2217/fon-2020-0823	results	20	NA	pval	NA
10.2217/fon-2020-0823	results	20	NA	num_pval	NA
10.2217/fon-2020-0823	results	20	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	20	NA	significant	FALSE
10.2217/fon-2020-0823	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	18
10.2217/fon-2020-0823	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	3	NA	Number of covariates adjusted for/matched on	4
10.2217/fon-2020-0823	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/fon-2020-0823	results	3	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	3	NA	Primary outcome: unadjusted treatment effect	0.3
10.2217/fon-2020-0823	results	3	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.58]
10.2217/fon-2020-0823	results	3	NA	Primary outcome: adjusted treatment effect	0.19
10.2217/fon-2020-0823	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.10;0.39]
10.2217/fon-2020-0823	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	3	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	3	NA	ub_ci	0.58
10.2217/fon-2020-0823	results	3	NA	pval	NA
10.2217/fon-2020-0823	results	3	NA	num_pval	NA
10.2217/fon-2020-0823	results	3	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	3	NA	significant	FALSE
10.2217/fon-2020-0823	results	3	NA	lb_ci	0.1
10.2217/fon-2020-0823	results	3	NA	ub_ci	0.39
10.2217/fon-2020-0823	results	3	NA	pval	NA
10.2217/fon-2020-0823	results	3	NA	num_pval	NA
10.2217/fon-2020-0823	results	3	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	3	NA	significant	FALSE
10.2217/fon-2020-0823	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	18
10.2217/fon-2020-0823	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	4	NA	Number of covariates adjusted for/matched on	4
10.2217/fon-2020-0823	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/fon-2020-0823	results	4	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	4	NA	Primary outcome: unadjusted treatment effect	0.3
10.2217/fon-2020-0823	results	4	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.58]
10.2217/fon-2020-0823	results	4	NA	Primary outcome: adjusted treatment effect	0.17
10.2217/fon-2020-0823	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.09;0.33]
10.2217/fon-2020-0823	results	4	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	4	NA	ub_ci	0.58
10.2217/fon-2020-0823	results	4	NA	pval	NA
10.2217/fon-2020-0823	results	4	NA	num_pval	NA
10.2217/fon-2020-0823	results	4	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	4	NA	significant	FALSE
10.2217/fon-2020-0823	results	4	NA	lb_ci	0.09
10.2217/fon-2020-0823	results	4	NA	ub_ci	0.33
10.2217/fon-2020-0823	results	4	NA	pval	NA
10.2217/fon-2020-0823	results	4	NA	num_pval	NA
10.2217/fon-2020-0823	results	4	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	4	NA	significant	FALSE
10.2217/fon-2020-0823	results	5	NA	Sample size of the population of interest in the non IPD treatment arm	36
10.2217/fon-2020-0823	results	5	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	5	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	5	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	5	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	5	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	5	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	5	NA	Primary outcome: unadjusted treatment effect	0.25
10.2217/fon-2020-0823	results	5	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.46]
10.2217/fon-2020-0823	results	5	NA	Primary outcome: adjusted treatment effect	0.25
10.2217/fon-2020-0823	results	5	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.13;0.49]
10.2217/fon-2020-0823	results	5	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	5	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	5	NA	ub_ci	0.46
10.2217/fon-2020-0823	results	5	NA	pval	NA
10.2217/fon-2020-0823	results	5	NA	num_pval	NA
10.2217/fon-2020-0823	results	5	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	5	NA	significant	FALSE
10.2217/fon-2020-0823	results	5	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	5	NA	ub_ci	0.49
10.2217/fon-2020-0823	results	5	NA	pval	NA
10.2217/fon-2020-0823	results	5	NA	num_pval	NA
10.2217/fon-2020-0823	results	5	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	5	NA	significant	FALSE
10.2217/fon-2020-0823	results	6	NA	Sample size of the population of interest in the non IPD treatment arm	36
10.2217/fon-2020-0823	results	6	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	6	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	6	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	6	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	6	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	6	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	6	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	6	NA	Primary outcome: unadjusted treatment effect	0.25
10.2217/fon-2020-0823	results	6	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.13;0.46]
10.2217/fon-2020-0823	results	6	NA	Primary outcome: adjusted treatment effect	0.11
10.2217/fon-2020-0823	results	6	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.05;0.22]
10.2217/fon-2020-0823	results	6	NA	lb_ci	0.13
10.2217/fon-2020-0823	results	6	NA	ub_ci	0.46
10.2217/fon-2020-0823	results	6	NA	pval	NA
10.2217/fon-2020-0823	results	6	NA	num_pval	NA
10.2217/fon-2020-0823	results	6	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	6	NA	significant	FALSE
10.2217/fon-2020-0823	results	6	NA	lb_ci	0.05
10.2217/fon-2020-0823	results	6	NA	ub_ci	0.22
10.2217/fon-2020-0823	results	6	NA	pval	NA
10.2217/fon-2020-0823	results	6	NA	num_pval	NA
10.2217/fon-2020-0823	results	6	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	6	NA	significant	FALSE
10.2217/fon-2020-0823	results	7	NA	Sample size of the population of interest in the non IPD treatment arm	31
10.2217/fon-2020-0823	results	7	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	7	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	7	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	7	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	7	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	7	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	7	NA	Primary outcome: unadjusted treatment effect	0.28
10.2217/fon-2020-0823	results	7	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]
10.2217/fon-2020-0823	results	7	NA	Primary outcome: adjusted treatment effect	0.37
10.2217/fon-2020-0823	results	7	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.20;0.69]
10.2217/fon-2020-0823	results	7	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	7	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	7	NA	ub_ci	0.5
10.2217/fon-2020-0823	results	7	NA	pval	NA
10.2217/fon-2020-0823	results	7	NA	num_pval	NA
10.2217/fon-2020-0823	results	7	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	7	NA	significant	FALSE
10.2217/fon-2020-0823	results	7	NA	lb_ci	0.2
10.2217/fon-2020-0823	results	7	NA	ub_ci	0.69
10.2217/fon-2020-0823	results	7	NA	pval	NA
10.2217/fon-2020-0823	results	7	NA	num_pval	NA
10.2217/fon-2020-0823	results	7	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	7	NA	significant	FALSE
10.2217/fon-2020-0823	results	8	NA	Sample size of the population of interest in the non IPD treatment arm	31
10.2217/fon-2020-0823	results	8	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	8	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	193
10.2217/fon-2020-0823	results	8	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	8	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	8	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	8	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	8	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	8	NA	Primary outcome: unadjusted treatment effect	0.28
10.2217/fon-2020-0823	results	8	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.50]
10.2217/fon-2020-0823	results	8	NA	Primary outcome: adjusted treatment effect	0.25
10.2217/fon-2020-0823	results	8	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.14;0.44]
10.2217/fon-2020-0823	results	8	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	8	NA	ub_ci	0.5
10.2217/fon-2020-0823	results	8	NA	pval	NA
10.2217/fon-2020-0823	results	8	NA	num_pval	NA
10.2217/fon-2020-0823	results	8	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	8	NA	significant	FALSE
10.2217/fon-2020-0823	results	8	NA	lb_ci	0.14
10.2217/fon-2020-0823	results	8	NA	ub_ci	0.44
10.2217/fon-2020-0823	results	8	NA	pval	NA
10.2217/fon-2020-0823	results	8	NA	num_pval	NA
10.2217/fon-2020-0823	results	8	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	8	NA	significant	FALSE
10.2217/fon-2020-0823	results	9	NA	Sample size of the population of interest in the non IPD treatment arm	40
10.2217/fon-2020-0823	results	9	NA	Reporting of a weights' distribution evaluation (MAIC)	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	9	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2020-0823	results	9	NA	Number of covariates adjusted for/matched on	8
10.2217/fon-2020-0823	results	9	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	9	NA	Primary outcome: treatment effect contrast	HR
10.2217/fon-2020-0823	results	9	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	9	NA	Primary outcome: unadjusted treatment effect	0.27
10.2217/fon-2020-0823	results	9	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.16;0.44]
10.2217/fon-2020-0823	results	9	NA	Primary outcome: adjusted treatment effect	0.47
10.2217/fon-2020-0823	results	9	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.29;0.75]
10.2217/fon-2020-0823	results	9	NA	Initial sample size of the population of interest in the IPD treatment arm	193
10.2217/fon-2020-0823	results	9	NA	lb_ci	0.16
10.2217/fon-2020-0823	results	9	NA	ub_ci	0.44
10.2217/fon-2020-0823	results	9	NA	pval	NA
10.2217/fon-2020-0823	results	9	NA	num_pval	NA
10.2217/fon-2020-0823	results	9	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	9	NA	significant	FALSE
10.2217/fon-2020-0823	results	9	NA	lb_ci	0.29
10.2217/fon-2020-0823	results	9	NA	ub_ci	0.75
10.2217/fon-2020-0823	results	9	NA	pval	NA
10.2217/fon-2020-0823	results	9	NA	num_pval	NA
10.2217/fon-2020-0823	results	9	NA	ci_cutoff	1
10.2217/fon-2020-0823	results	9	NA	significant	FALSE
10.2217/fon-2020-0823	study_information	NA	1	Patient-level data used	Yes
10.2217/fon-2020-0823	study_information	NA	1	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02760498
10.2217/fon-2020-0823	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2020-0823	study_information	NA	1	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	10	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	10	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	10	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03284424
10.2217/fon-2020-0823	study_information	NA	10	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2020-0823	study_information	NA	10	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	10	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	11	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	11	Clinical Trial	No
10.2217/fon-2020-0823	study_information	NA	11	Data source name (only if observational study or clinical trial without NCT)	peyrade et al. (2018)
10.2217/fon-2020-0823	study_information	NA	2	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	2	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01198028
10.2217/fon-2020-0823	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2020-0823	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	3	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	3	Clinical Trial	No
10.2217/fon-2020-0823	study_information	NA	3	Data source name (only if observational study or clinical trial without NCT)	jarkowski et al. (2016)
10.2217/fon-2020-0823	study_information	NA	4	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	4	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00240682
10.2217/fon-2020-0823	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/fon-2020-0823	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	5	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	5	Clinical Trial	No
10.2217/fon-2020-0823	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	picard et al. (2017)
10.2217/fon-2020-0823	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/fon-2020-0823	study_information	NA	6	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	6	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	6	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00054691
10.2217/fon-2020-0823	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2020-0823	study_information	NA	6	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	6	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	7	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	7	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	7	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02268747
10.2217/fon-2020-0823	study_information	NA	7	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/fon-2020-0823	study_information	NA	7	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	7	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	8	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	8	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	8	Data source name (only if observational study or clinical trial without NCT)	foote et al. (2014)
10.2217/fon-2020-0823	study_information	NA	8	Country where the clinical trial/observational study was conducted (international if more than one)	australia
10.2217/fon-2020-0823	study_information	NA	8	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	8	Number of treatment arms (clinical trial only)	1
10.2217/fon-2020-0823	study_information	NA	9	Patient-level data used	No
10.2217/fon-2020-0823	study_information	NA	9	Clinical Trial	Yes
10.2217/fon-2020-0823	study_information	NA	9	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02883556
10.2217/fon-2020-0823	study_information	NA	9	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/fon-2020-0823	study_information	NA	9	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2020-0823	study_information	NA	9	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	general_information	NA	NA	Medical Condition of Interest Name	ros1-positive non-small-cell lung cancer
10.2217/fon-2021-1102	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/fon-2021-1102	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/fon-2021-1102	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2021-1102	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/fon-2021-1102	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/fon-2021-1102	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/fon-2021-1102	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 1	crizotinib
10.2217/fon-2021-1102	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2021-1102	methodology	1	NA	Treatment name 2	entrectinib
10.2217/fon-2021-1102	methodology	1	NA	Study 'number(s)' for treatment 2	2;3;4
10.2217/fon-2021-1102	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2021-1102	methodology	1	NA	Anchored comparison?	No
10.2217/fon-2021-1102	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/fon-2021-1102	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2021-1102	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	objective response rate (orr)
10.2217/fon-2021-1102	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.2217/fon-2021-1102	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2021-1102	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/fon-2021-1102	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2021-1102	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 1	crizotinib
10.2217/fon-2021-1102	methodology	2	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2021-1102	methodology	2	NA	Treatment name 2	crizotinib
10.2217/fon-2021-1102	methodology	2	NA	Study 'number(s)' for treatment 2	5
10.2217/fon-2021-1102	methodology	2	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2021-1102	methodology	2	NA	Anchored comparison?	No
10.2217/fon-2021-1102	methodology	2	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2021-1102	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2021-1102	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	progression-free survival
10.2217/fon-2021-1102	methodology	2	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2021-1102	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2021-1102	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/fon-2021-1102	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2021-1102	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 1	crizotinib
10.2217/fon-2021-1102	methodology	3	NA	Study 'number(s)' for treatment 1	1
10.2217/fon-2021-1102	methodology	3	NA	Treatment name 2	crizotinib
10.2217/fon-2021-1102	methodology	3	NA	Study 'number(s)' for treatment 2	6
10.2217/fon-2021-1102	methodology	3	NA	Type of population-adjusted indirect comparisons performed	STC
10.2217/fon-2021-1102	methodology	3	NA	Anchored comparison?	No
10.2217/fon-2021-1102	methodology	3	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2021-1102	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.2217/fon-2021-1102	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/fon-2021-1102	methodology	3	NA	Primary outcome: variable type	Time-to-event
10.2217/fon-2021-1102	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.2217/fon-2021-1102	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/fon-2021-1102	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/fon-2021-1102	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/fon-2021-1102	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	161
10.2217/fon-2021-1102	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	53
10.2217/fon-2021-1102	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53
10.2217/fon-2021-1102	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2021-1102	results	1	NA	Number of covariates adjusted for/matched on	4
10.2217/fon-2021-1102	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/fon-2021-1102	results	1	NA	Primary outcome: treatment effect contrast	RR
10.2217/fon-2021-1102	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	1	NA	Primary outcome: unadjusted treatment effect	1.07
10.2217/fon-2021-1102	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	[0.88;1.31]
10.2217/fon-2021-1102	results	1	NA	Primary outcome: adjusted treatment effect	1.04
10.2217/fon-2021-1102	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.85;1.28]
10.2217/fon-2021-1102	results	1	NA	lb_ci	0.88
10.2217/fon-2021-1102	results	1	NA	ub_ci	1.31
10.2217/fon-2021-1102	results	1	NA	pval	NA
10.2217/fon-2021-1102	results	1	NA	num_pval	NA
10.2217/fon-2021-1102	results	1	NA	ci_cutoff	1
10.2217/fon-2021-1102	results	1	NA	significant	TRUE
10.2217/fon-2021-1102	results	1	NA	lb_ci	0.85
10.2217/fon-2021-1102	results	1	NA	ub_ci	1.28
10.2217/fon-2021-1102	results	1	NA	pval	NA
10.2217/fon-2021-1102	results	1	NA	num_pval	NA
10.2217/fon-2021-1102	results	1	NA	ci_cutoff	1
10.2217/fon-2021-1102	results	1	NA	significant	TRUE
10.2217/fon-2021-1102	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	69
10.2217/fon-2021-1102	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	53
10.2217/fon-2021-1102	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53
10.2217/fon-2021-1102	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2021-1102	results	2	NA	Number of covariates adjusted for/matched on	2
10.2217/fon-2021-1102	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/fon-2021-1102	results	2	NA	Primary outcome: treatment effect contrast	Median difference
10.2217/fon-2021-1102	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	2	NA	Primary outcome: unadjusted treatment effect	10.8
10.2217/fon-2021-1102	results	2	NA	Primary outcome: adjusted treatment effect	8.3
10.2217/fon-2021-1102	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.26;16.94]
10.2217/fon-2021-1102	results	2	NA	geographical region	No
10.2217/fon-2021-1102	results	2	NA	lb_ci	0.26
10.2217/fon-2021-1102	results	2	NA	ub_ci	16.94
10.2217/fon-2021-1102	results	2	NA	pval	NA
10.2217/fon-2021-1102	results	2	NA	num_pval	NA
10.2217/fon-2021-1102	results	2	NA	ci_cutoff	0
10.2217/fon-2021-1102	results	2	NA	significant	FALSE
10.2217/fon-2021-1102	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	38
10.2217/fon-2021-1102	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	53
10.2217/fon-2021-1102	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	53
10.2217/fon-2021-1102	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/fon-2021-1102	results	3	NA	Number of covariates adjusted for/matched on	4
10.2217/fon-2021-1102	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/fon-2021-1102	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	3	NA	Primary outcome: unadjusted treatment effect	15.2
10.2217/fon-2021-1102	results	3	NA	Primary outcome: adjusted treatment effect	-10.5
10.2217/fon-2021-1102	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/fon-2021-1102	results	3	NA	geographical region	No
10.2217/fon-2021-1102	study_information	NA	1	Patient-level data used	Yes
10.2217/fon-2021-1102	study_information	NA	1	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00585195
10.2217/fon-2021-1102	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1102	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	2	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	2	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	2	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2012-000148-88
10.2217/fon-2021-1102	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.2217/fon-2021-1102	study_information	NA	2	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	3	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	3	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02097810
10.2217/fon-2021-1102	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1102	study_information	NA	3	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	4	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	4	Clinical Trial	Yes
10.2217/fon-2021-1102	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02568267
10.2217/fon-2021-1102	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1102	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1102	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1102	study_information	NA	5	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	5	Clinical Trial	No
10.2217/fon-2021-1102	study_information	NA	5	Data source name (only if observational study or clinical trial without NCT)	flatiron health
10.2217/fon-2021-1102	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2021-1102	study_information	NA	6	Patient-level data used	No
10.2217/fon-2021-1102	study_information	NA	6	Clinical Trial	No
10.2217/fon-2021-1102	study_information	NA	6	Data source name (only if observational study or clinical trial without NCT)	ontada (oncology insights & technology)
10.2217/fon-2021-1102	study_information	NA	6	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2021-1509	general_information	NA	NA	Medical Condition of Interest Name	advanced systemic mastocytosis
10.2217/fon-2021-1509	general_information	NA	NA	Countries of first author affiliations	uk
10.2217/fon-2021-1509	general_information	NA	NA	Countries of last author affiliations	switzerland
10.2217/fon-2021-1509	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2021-1509	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/fon-2021-1509	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/fon-2021-1509	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/fon-2021-1509	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/fon-2021-1509	study_information	NA	1	Patient-level data used	Yes
10.2217/fon-2021-1509	study_information	NA	1	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02561988
10.2217/fon-2021-1509	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1509	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	2	Patient-level data used	Yes
10.2217/fon-2021-1509	study_information	NA	2	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT03580655
10.2217/fon-2021-1509	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1509	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1509	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	3	Patient-level data used	No
10.2217/fon-2021-1509	study_information	NA	3	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00782067
10.2217/fon-2021-1509	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/fon-2021-1509	study_information	NA	3	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1509	study_information	NA	3	Number of treatment arms (clinical trial only)	1
10.2217/fon-2021-1509	study_information	NA	4	Patient-level data used	No
10.2217/fon-2021-1509	study_information	NA	4	Clinical Trial	Yes
10.2217/fon-2021-1509	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00233454
10.2217/fon-2021-1509	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.2217/fon-2021-1509	study_information	NA	4	Phase of the clinical trial (clinical trial only)	2
10.2217/fon-2021-1509	study_information	NA	4	Number of treatment arms (clinical trial only)	1
10.2217/imt-2018-0208	general_information	NA	NA	Medical Condition of Interest Name	braf-mutant advanced melanoma
10.2217/imt-2018-0208	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/imt-2018-0208	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/imt-2018-0208	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2018-0208	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/imt-2018-0208	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/imt-2018-0208	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/imt-2018-0208	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.2217/imt-2018-0208	results	2	NA	geographical region	Yes
10.2217/imt-2018-0208	study_information	NA	1	Patient-level data used	Yes
10.2217/imt-2018-0208	study_information	NA	1	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01844505
10.2217/imt-2018-0208	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	2	Patient-level data used	Yes
10.2217/imt-2018-0208	study_information	NA	2	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01927419
10.2217/imt-2018-0208	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.2217/imt-2018-0208	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	3	Patient-level data used	No
10.2217/imt-2018-0208	study_information	NA	3	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01584648
10.2217/imt-2018-0208	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	4	Patient-level data used	No
10.2217/imt-2018-0208	study_information	NA	4	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01597908
10.2217/imt-2018-0208	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2018-0208	study_information	NA	5	Patient-level data used	No
10.2217/imt-2018-0208	study_information	NA	5	Clinical Trial	Yes
10.2217/imt-2018-0208	study_information	NA	5	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01689519
10.2217/imt-2018-0208	study_information	NA	5	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2018-0208	study_information	NA	5	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2018-0208	study_information	NA	5	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	general_information	NA	NA	Medical Condition of Interest Name	multiple myeloma
10.2217/imt-2020-0266	general_information	NA	NA	Countries of first author affiliations	france
10.2217/imt-2020-0266	general_information	NA	NA	Countries of last author affiliations	the netherlands
10.2217/imt-2020-0266	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2020-0266	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/imt-2020-0266	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/imt-2020-0266	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/imt-2020-0266	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/imt-2020-0266	results	3	NA	geographical region	No
10.2217/imt-2020-0266	results	4	NA	geographical region	No
10.2217/imt-2020-0266	results	5	NA	geographical region	No
10.2217/imt-2020-0266	results	6	NA	geographical region	No
10.2217/imt-2020-0266	study_information	NA	1	Patient-level data used	Yes
10.2217/imt-2020-0266	study_information	NA	1	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02541383
10.2217/imt-2020-0266	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2020-0266	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	study_information	NA	2	Patient-level data used	No
10.2217/imt-2020-0266	study_information	NA	2	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01191060
10.2217/imt-2020-0266	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/imt-2020-0266	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	study_information	NA	3	Patient-level data used	No
10.2217/imt-2020-0266	study_information	NA	3	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	3	EudraCT (only for clinical trials registered on clinicaltrialsregister.eu	2010-019173-16
10.2217/imt-2020-0266	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	germany
10.2217/imt-2020-0266	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2020-0266	study_information	NA	4	Patient-level data used	No
10.2217/imt-2020-0266	study_information	NA	4	Clinical Trial	Yes
10.2217/imt-2020-0266	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00200681
10.2217/imt-2020-0266	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.2217/imt-2020-0266	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2020-0266	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2021-0273	general_information	NA	NA	Medical Condition of Interest Name	metastatic non-small-cell lung cancer with pd-l1
10.2217/imt-2021-0273	general_information	NA	NA	Countries of first author affiliations	usa
10.2217/imt-2021-0273	general_information	NA	NA	Countries of last author affiliations	usa
10.2217/imt-2021-0273	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2021-0273	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.2217/imt-2021-0273	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.2217/imt-2021-0273	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.2217/imt-2021-0273	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 1	pembrolizumab
10.2217/imt-2021-0273	methodology	1	NA	Study 'number(s)' for treatment 1	1;2
10.2217/imt-2021-0273	methodology	1	NA	Treatment name 2	nivolumab + ipilimumab
10.2217/imt-2021-0273	methodology	1	NA	Study 'number(s)' for treatment 2	3
10.2217/imt-2021-0273	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.2217/imt-2021-0273	methodology	1	NA	Anchored comparison?	Yes
10.2217/imt-2021-0273	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2021-0273	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2021-0273	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival
10.2217/imt-2021-0273	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.2217/imt-2021-0273	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/imt-2021-0273	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No
10.2217/imt-2021-0273	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.2217/imt-2021-0273	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.2217/imt-2021-0273	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.2217/imt-2021-0273	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	793
10.2217/imt-2021-0273	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	1428
10.2217/imt-2021-0273	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	993
10.2217/imt-2021-0273	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.2217/imt-2021-0273	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.2217/imt-2021-0273	results	1	NA	Number of covariates adjusted for/matched on	8
10.2217/imt-2021-0273	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/imt-2021-0273	results	1	NA	Primary outcome: treatment effect contrast	HR
10.2217/imt-2021-0273	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.2217/imt-2021-0273	results	1	NA	Primary outcome: unadjusted treatment effect	0.98
10.2217/imt-2021-0273	results	1	NA	Primary outcome: adjusted treatment effect	1.07
10.2217/imt-2021-0273	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	[0.82;1.39]
10.2217/imt-2021-0273	results	1	NA	geographical region	Yes
10.2217/imt-2021-0273	results	1	NA	If anchored, total initial sample size IPD	1428
10.2217/imt-2021-0273	results	1	NA	If anchored, total ESS IPD	993
10.2217/imt-2021-0273	results	1	NA	If anchored, total sample size non IPD	793
10.2217/imt-2021-0273	results	1	NA	lb_ci	0.82
10.2217/imt-2021-0273	results	1	NA	ub_ci	1.39
10.2217/imt-2021-0273	results	1	NA	pval	NA
10.2217/imt-2021-0273	results	1	NA	num_pval	NA
10.2217/imt-2021-0273	results	1	NA	ci_cutoff	1
10.2217/imt-2021-0273	results	1	NA	significant	TRUE
10.2217/imt-2021-0273	study_information	NA	1	Patient-level data used	Yes
10.2217/imt-2021-0273	study_information	NA	1	Clinical Trial	Yes
10.2217/imt-2021-0273	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02142738
10.2217/imt-2021-0273	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2021-0273	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2021-0273	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2021-0273	study_information	NA	2	Patient-level data used	Yes
10.2217/imt-2021-0273	study_information	NA	2	Clinical Trial	Yes
10.2217/imt-2021-0273	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02220894
10.2217/imt-2021-0273	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2021-0273	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2021-0273	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.2217/imt-2021-0273	study_information	NA	3	Patient-level data used	No
10.2217/imt-2021-0273	study_information	NA	3	Clinical Trial	Yes
10.2217/imt-2021-0273	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477826
10.2217/imt-2021-0273	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.2217/imt-2021-0273	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.2217/imt-2021-0273	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis
10.3111/13696998.2013.768530	general_information	NA	NA	Countries of first author affiliations	usa
10.3111/13696998.2013.768530	general_information	NA	NA	Countries of last author affiliations	usa
10.3111/13696998.2013.768530	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.3111/13696998.2013.768530	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.3111/13696998.2013.768530	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.3111/13696998.2013.768530	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.3111/13696998.2013.768530	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.3111/13696998.2013.768530	study_information	NA	1	Patient-level data used	Yes
10.3111/13696998.2013.768530	study_information	NA	1	Clinical Trial	Yes
10.3111/13696998.2013.768530	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00195689
10.3111/13696998.2013.768530	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.3111/13696998.2013.768530	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.3111/13696998.2013.768530	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	study_information	NA	2	Patient-level data used	No
10.3111/13696998.2013.768530	study_information	NA	2	Clinical Trial	Yes
10.3111/13696998.2013.768530	study_information	NA	2	Data source name (only if observational study or clinical trial without NCT)	mease et al. (2004)
10.3111/13696998.2013.768530	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.3111/13696998.2013.768530	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.3111/13696998.2013.768530	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	study_information	NA	3	Patient-level data used	No
10.3111/13696998.2013.768530	study_information	NA	3	Clinical Trial	Yes
10.3111/13696998.2013.768530	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.3111/13696998.2013.768530	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.3111/13696998.2013.768530	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.3111/13696998.2013.768530	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00051623
10.3390/biom11060780	general_information	NA	NA	Medical Condition of Interest Name	metastatic pancreatic cancer
10.3390/biom11060780	general_information	NA	NA	Countries of first author affiliations	italy
10.3390/biom11060780	general_information	NA	NA	Countries of last author affiliations	italy
10.3390/biom11060780	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.3390/biom11060780	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.3390/biom11060780	general_information	NA	NA	Mentioned sources of funding	No fundings
10.3390/biom11060780	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	None
10.3390/biom11060780	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.3390/biom11060780	methodology	1	NA	Treatment name 1	gemcitabine + nab-paclitaxel
10.3390/biom11060780	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.3390/biom11060780	methodology	1	NA	Treatment name 2	folfirinox
10.3390/biom11060780	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.3390/biom11060780	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.3390/biom11060780	methodology	1	NA	Anchored comparison?	No
10.3390/biom11060780	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.3390/biom11060780	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3390/biom11060780	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	overall survival (os)
10.3390/biom11060780	methodology	1	NA	Primary outcome: variable type	Time-to-event
10.3390/biom11060780	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Nothing mentioned, not reported
10.3390/biom11060780	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	No discussion (in the main text) of the status of prognostic factors of the variables
10.3390/biom11060780	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3390/biom11060780	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.3390/biom11060780	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.3390/biom11060780	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	171
10.3390/biom11060780	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	268
10.3390/biom11060780	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.3390/biom11060780	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.3390/biom11060780	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.3390/biom11060780	results	1	NA	Primary outcome: treatment effect contrast	HR
10.3390/biom11060780	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Denominator if ratio, or rightside if difference
10.3390/biom11060780	results	1	NA	Primary outcome: adjusted treatment effect	1.1
10.3390/biom11060780	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.527
10.3390/biom11060780	results	1	NA	lb_ci	NA
10.3390/biom11060780	results	1	NA	ub_ci	NA
10.3390/biom11060780	results	1	NA	pval	0.527
10.3390/biom11060780	results	1	NA	num_pval	0.527
10.3390/biom11060780	results	1	NA	ci_cutoff	1
10.3390/biom11060780	results	1	NA	significant	FALSE
10.3390/biom11060780	study_information	NA	1	Patient-level data used	Yes
10.3390/biom11060780	study_information	NA	1	Clinical Trial	No
10.3390/biom11060780	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	local retrospective cohort from ehr
10.3390/biom11060780	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.3390/biom11060780	study_information	NA	2	Patient-level data used	No
10.3390/biom11060780	study_information	NA	2	Clinical Trial	Yes
10.3390/biom11060780	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00112658
10.3390/biom11060780	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	france
10.3390/biom11060780	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.3390/biom11060780	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	general_information	NA	NA	Medical Condition of Interest Name	metastatic non small cell lung cancer
10.3390/cancers12123648	general_information	NA	NA	Countries of first author affiliations	usa
10.3390/cancers12123648	general_information	NA	NA	Countries of last author affiliations	usa
10.3390/cancers12123648	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.3390/cancers12123648	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.3390/cancers12123648	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.3390/cancers12123648	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.3390/cancers12123648	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.3390/cancers12123648	results	1	NA	geographical region	Yes
10.3390/cancers12123648	results	1	NA	If anchored, total initial sample size IPD	816
10.3390/cancers12123648	results	1	NA	If anchored, total ESS IPD	456
10.3390/cancers12123648	results	1	NA	If anchored, total sample size non IPD	793
10.3390/cancers12123648	study_information	NA	1	Patient-level data used	Yes
10.3390/cancers12123648	study_information	NA	1	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02039674
10.3390/cancers12123648	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.3390/cancers12123648	study_information	NA	1	Phase of the clinical trial (clinical trial only)	1, 2
10.3390/cancers12123648	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	study_information	NA	2	Patient-level data used	Yes
10.3390/cancers12123648	study_information	NA	2	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02578680
10.3390/cancers12123648	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.3390/cancers12123648	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.3390/cancers12123648	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	study_information	NA	3	Patient-level data used	Yes
10.3390/cancers12123648	study_information	NA	3	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02775435
10.3390/cancers12123648	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
10.3390/cancers12123648	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.3390/cancers12123648	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers12123648	study_information	NA	4	Patient-level data used	No
10.3390/cancers12123648	study_information	NA	4	Clinical Trial	Yes
10.3390/cancers12123648	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02477826
10.3390/cancers12123648	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.3390/cancers12123648	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.3390/cancers12123648	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.3390/cancers13102406	general_information	NA	NA	Medical Condition of Interest Name	hepatocellular carcinoma
10.3390/cancers13102406	general_information	NA	NA	Countries of first author affiliations	italy
10.3390/cancers13102406	general_information	NA	NA	Countries of last author affiliations	italy
10.3390/cancers13102406	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic
10.3390/cancers13102406	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Not mentioned
10.3390/cancers13102406	general_information	NA	NA	Mentioned sources of funding	No fundings
10.3390/cancers13102406	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	None
10.3390/cancers13102406	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.3390/cancers13102406	study_information	NA	1	Patient-level data used	Yes
10.3390/cancers13102406	study_information	NA	1	Clinical Trial	No
10.3390/cancers13102406	study_information	NA	1	Data source name (only if observational study or clinical trial without NCT)	retrospective cohort of patients affected by hcc who underwent surgical at the hepatobiliary surgery and liver transplantation unit, university of padua.
10.3390/cancers13102406	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.3390/cancers13102406	study_information	NA	2	Patient-level data used	No
10.3390/cancers13102406	study_information	NA	2	Clinical Trial	Yes
10.3390/cancers13102406	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01387503
10.3390/cancers13102406	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	italy
10.3390/cancers13102406	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2, 3
10.3390/cancers13102406	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.36469/jheor.2021.19008	general_information	NA	NA	Medical Condition of Interest Name	steroid-refractory acute graft-versus-host disease
10.36469/jheor.2021.19008	general_information	NA	NA	Countries of first author affiliations	usa
10.36469/jheor.2021.19008	general_information	NA	NA	Countries of last author affiliations	usa
10.36469/jheor.2021.19008	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Pharmaceutical Industry, Private Data Analysis Company
10.36469/jheor.2021.19008	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.36469/jheor.2021.19008	general_information	NA	NA	Mentioned sources of funding	None mentioned
10.36469/jheor.2021.19008	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	No such section presenting competing interest/conflict of interest
10.36469/jheor.2021.19008	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	No
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 1	remestemcel-l-rknd
10.36469/jheor.2021.19008	methodology	1	NA	Study 'number(s)' for treatment 1	1
10.36469/jheor.2021.19008	methodology	1	NA	Treatment name 2	ruxolitinib
10.36469/jheor.2021.19008	methodology	1	NA	Study 'number(s)' for treatment 2	2
10.36469/jheor.2021.19008	methodology	1	NA	Type of population-adjusted indirect comparisons performed	STC
10.36469/jheor.2021.19008	methodology	1	NA	Anchored comparison?	No
10.36469/jheor.2021.19008	methodology	1	NA	Form of the indirect comparison	Simple (ie treatments effects extracted from two studies)
10.36469/jheor.2021.19008	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	Yes
10.36469/jheor.2021.19008	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	day 28 overall response rate (orr)
10.36469/jheor.2021.19008	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.36469/jheor.2021.19008	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.36469/jheor.2021.19008	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.36469/jheor.2021.19008	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.36469/jheor.2021.19008	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.36469/jheor.2021.19008	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.36469/jheor.2021.19008	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	49
10.36469/jheor.2021.19008	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	55
10.36469/jheor.2021.19008	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	55
10.36469/jheor.2021.19008	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.36469/jheor.2021.19008	results	1	NA	Number of covariates adjusted for/matched on	3
10.36469/jheor.2021.19008	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.36469/jheor.2021.19008	results	1	NA	Primary outcome: treatment effect contrast	RR
10.36469/jheor.2021.19008	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.36469/jheor.2021.19008	results	1	NA	Primary outcome: unadjusted treatment effect	1.21
10.36469/jheor.2021.19008	results	1	NA	p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])	0.21
10.36469/jheor.2021.19008	results	1	NA	Primary outcome: adjusted treatment effect	1.13
10.36469/jheor.2021.19008	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.45
10.36469/jheor.2021.19008	results	1	NA	lb_ci	NA
10.36469/jheor.2021.19008	results	1	NA	ub_ci	NA
10.36469/jheor.2021.19008	results	1	NA	pval	0.21
10.36469/jheor.2021.19008	results	1	NA	num_pval	0.21
10.36469/jheor.2021.19008	results	1	NA	ci_cutoff	1
10.36469/jheor.2021.19008	results	1	NA	significant	FALSE
10.36469/jheor.2021.19008	results	1	NA	lb_ci	NA
10.36469/jheor.2021.19008	results	1	NA	ub_ci	NA
10.36469/jheor.2021.19008	results	1	NA	pval	0.45
10.36469/jheor.2021.19008	results	1	NA	num_pval	0.45
10.36469/jheor.2021.19008	results	1	NA	ci_cutoff	1
10.36469/jheor.2021.19008	results	1	NA	significant	FALSE
10.36469/jheor.2021.19008	study_information	NA	1	Patient-level data used	Yes
10.36469/jheor.2021.19008	study_information	NA	1	Clinical Trial	Yes
10.36469/jheor.2021.19008	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02336230
10.36469/jheor.2021.19008	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.36469/jheor.2021.19008	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.36469/jheor.2021.19008	study_information	NA	1	Number of treatment arms (clinical trial only)	1
10.36469/jheor.2021.19008	study_information	NA	2	Patient-level data used	No
10.36469/jheor.2021.19008	study_information	NA	2	Clinical Trial	Yes
10.36469/jheor.2021.19008	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02953678
10.36469/jheor.2021.19008	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.36469/jheor.2021.19008	study_information	NA	2	Phase of the clinical trial (clinical trial only)	2
10.36469/jheor.2021.19008	study_information	NA	2	Number of treatment arms (clinical trial only)	1
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Medical Condition of Interest Name	ankylosing spondylitis
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Countries of first author affiliations	canada
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Countries of last author affiliations	switzerland
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.5152/eurjrheum.2018.18162	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.5152/eurjrheum.2018.18162	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	Patient-level data used	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	Clinical Trial	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01358175
10.5152/eurjrheum.2018.18162	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2018.18162	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2018.18162	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2018.18162	study_information	NA	2	Patient-level data used	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	2	Clinical Trial	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01649375
10.5152/eurjrheum.2018.18162	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2018.18162	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2018.18162	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2018.18162	study_information	NA	3	Patient-level data used	No
10.5152/eurjrheum.2018.18162	study_information	NA	3	Clinical Trial	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00085644
10.5152/eurjrheum.2018.18162	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	usa
10.5152/eurjrheum.2018.18162	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2018.18162	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Medical Condition of Interest Name	psoriatic arthritis
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Countries of first author affiliations	usa
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Countries of last author affiliations	uk
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Positions of study investigators (for any authors of the article, any that applies)	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.5152/eurjrheum.2019.19057	general_information	NA	NA	At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company	Yes
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Mentioned sources of funding	Pharmaceutical Industry
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article	Yes
10.5152/eurjrheum.2019.19057	general_information	NA	NA	Mention of a systematic review to find the studies to compare treatments of interest	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 1	secukinumab 150 mg
10.5152/eurjrheum.2019.19057	methodology	1	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	1	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	1	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	1	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.5152/eurjrheum.2019.19057	methodology	1	NA	Anchored comparison?	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	1	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	1	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 12
10.5152/eurjrheum.2019.19057	methodology	1	NA	Primary outcome: variable type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	1	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	1	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.5152/eurjrheum.2019.19057	methodology	1	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 1	secukinumab 150 mg
10.5152/eurjrheum.2019.19057	methodology	2	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	2	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	2	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	2	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.5152/eurjrheum.2019.19057	methodology	2	NA	Anchored comparison?	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	2	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	2	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 24
10.5152/eurjrheum.2019.19057	methodology	2	NA	Primary outcome: variable type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	2	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	2	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	2	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	2	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 1	secukinumab 300mg
10.5152/eurjrheum.2019.19057	methodology	3	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	3	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	3	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	3	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.5152/eurjrheum.2019.19057	methodology	3	NA	Anchored comparison?	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	3	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	3	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 12
10.5152/eurjrheum.2019.19057	methodology	3	NA	Primary outcome: variable type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	3	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	3	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.5152/eurjrheum.2019.19057	methodology	3	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 1	secukinumab 300mg
10.5152/eurjrheum.2019.19057	methodology	4	NA	Study 'number(s)' for treatment 1	1;2;3
10.5152/eurjrheum.2019.19057	methodology	4	NA	Treatment name 2	etanercept
10.5152/eurjrheum.2019.19057	methodology	4	NA	Study 'number(s)' for treatment 2	4
10.5152/eurjrheum.2019.19057	methodology	4	NA	Type of population-adjusted indirect comparisons performed	MAIC
10.5152/eurjrheum.2019.19057	methodology	4	NA	Anchored comparison?	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	Form of the indirect comparison	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	4	NA	Definition of a single primary outcome for the indirect comparison	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	4	NA	Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined)	acr 20 (american college of rheumatology ) response rates at week 24
10.5152/eurjrheum.2019.19057	methodology	4	NA	Primary outcome: variable type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	4	NA	Justification for selecting variables to be included in the adjustment model (in the main text)	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	4	NA	Inclusion of prognostic factors in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	4	NA	Inclusion of treatment-effect modifiers in the adjustment/matching model	Yes
10.5152/eurjrheum.2019.19057	methodology	4	NA	Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale)	No
10.5152/eurjrheum.2019.19057	results	1	NA	Sample size of the population of interest in the non IPD treatment arm	101
10.5152/eurjrheum.2019.19057	results	1	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	104
10.5152/eurjrheum.2019.19057	results	1	NA	Initial sample size of the population of interest in the IPD treatment arm	458
10.5152/eurjrheum.2019.19057	results	1	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	104
10.5152/eurjrheum.2019.19057	results	1	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	567
10.5152/eurjrheum.2019.19057	results	1	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	159
10.5152/eurjrheum.2019.19057	results	1	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.5152/eurjrheum.2019.19057	results	1	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.5152/eurjrheum.2019.19057	results	1	NA	Number of covariates adjusted for/matched on	11
10.5152/eurjrheum.2019.19057	results	1	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	1	NA	Primary outcome: treatment effect contrast	OR
10.5152/eurjrheum.2019.19057	results	1	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	1	NA	Primary outcome: adjusted treatment effect	0.57
10.5152/eurjrheum.2019.19057	results	1	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	1	NA	lb_ci	NA
10.5152/eurjrheum.2019.19057	results	1	NA	ub_ci	NA
10.5152/eurjrheum.2019.19057	results	1	NA	pval	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	num_pval	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	ci_cutoff	1
10.5152/eurjrheum.2019.19057	results	1	NA	significant	FALSE
10.5152/eurjrheum.2019.19057	results	2	NA	Sample size of the population of interest in the non IPD treatment arm	101
10.5152/eurjrheum.2019.19057	results	2	NA	Initial sample size of the population of interest in the IPD treatment arm	458
10.5152/eurjrheum.2019.19057	results	2	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	104
10.5152/eurjrheum.2019.19057	results	2	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.5152/eurjrheum.2019.19057	results	2	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.5152/eurjrheum.2019.19057	results	2	NA	Number of covariates adjusted for/matched on	11
10.5152/eurjrheum.2019.19057	results	2	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	2	NA	Primary outcome: treatment effect contrast	OR
10.5152/eurjrheum.2019.19057	results	2	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	2	NA	Primary outcome: adjusted treatment effect	1.47
10.5152/eurjrheum.2019.19057	results	2	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA
10.5152/eurjrheum.2019.19057	results	2	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA
10.5152/eurjrheum.2019.19057	results	2	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA
10.5152/eurjrheum.2019.19057	results	2	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	2	NA	lb_ci	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ub_ci	NA
10.5152/eurjrheum.2019.19057	results	2	NA	pval	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	num_pval	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	ci_cutoff	1
10.5152/eurjrheum.2019.19057	results	2	NA	significant	FALSE
10.5152/eurjrheum.2019.19057	results	3	NA	Sample size of the population of interest in the non IPD treatment arm	101
10.5152/eurjrheum.2019.19057	results	3	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	104
10.5152/eurjrheum.2019.19057	results	3	NA	Initial sample size of the population of interest in the IPD treatment arm	461
10.5152/eurjrheum.2019.19057	results	3	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75
10.5152/eurjrheum.2019.19057	results	3	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	567
10.5152/eurjrheum.2019.19057	results	3	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	159
10.5152/eurjrheum.2019.19057	results	3	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.5152/eurjrheum.2019.19057	results	3	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.5152/eurjrheum.2019.19057	results	3	NA	Number of covariates adjusted for/matched on	11
10.5152/eurjrheum.2019.19057	results	3	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	3	NA	Primary outcome: treatment effect contrast	OR
10.5152/eurjrheum.2019.19057	results	3	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	3	NA	Primary outcome: adjusted treatment effect	0.86
10.5152/eurjrheum.2019.19057	results	3	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	3	NA	lb_ci	NA
10.5152/eurjrheum.2019.19057	results	3	NA	ub_ci	NA
10.5152/eurjrheum.2019.19057	results	3	NA	pval	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	num_pval	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	ci_cutoff	1
10.5152/eurjrheum.2019.19057	results	3	NA	significant	FALSE
10.5152/eurjrheum.2019.19057	results	4	NA	Sample size of the population of interest in the non IPD treatment arm	101
10.5152/eurjrheum.2019.19057	results	4	NA	Initial sample size of the population of interest in the IPD treatment arm	461
10.5152/eurjrheum.2019.19057	results	4	NA	Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC	75
10.5152/eurjrheum.2019.19057	results	4	NA	Reporting of a weights' distribution evaluation (MAIC)	Not mentioned
10.5152/eurjrheum.2019.19057	results	4	NA	Reporting of the list of the covariates adjusted for/matched on	Yes
10.5152/eurjrheum.2019.19057	results	4	NA	Number of covariates adjusted for/matched on	11
10.5152/eurjrheum.2019.19057	results	4	NA	Covariates adjusted for/matched on in the indirect comparison	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	4	NA	Primary outcome: treatment effect contrast	OR
10.5152/eurjrheum.2019.19057	results	4	NA	Direction of the treatment effect contrast: IPD treatment is:	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	4	NA	Primary outcome: adjusted treatment effect	3.28
10.5152/eurjrheum.2019.19057	results	4	NA	p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])	<0.001
10.5152/eurjrheum.2019.19057	results	4	NA	If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm	NA
10.5152/eurjrheum.2019.19057	results	4	NA	If anchored comparison, initial sample size of the population of interest in the IPD anchor arm	NA
10.5152/eurjrheum.2019.19057	results	4	NA	If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm	NA
10.5152/eurjrheum.2019.19057	results	4	NA	geographical region	Yes
10.5152/eurjrheum.2019.19057	results	4	NA	lb_ci	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ub_ci	NA
10.5152/eurjrheum.2019.19057	results	4	NA	pval	<0.001
10.5152/eurjrheum.2019.19057	results	4	NA	num_pval	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ci_cutoff	1
10.5152/eurjrheum.2019.19057	results	4	NA	significant	TRUE
10.5152/eurjrheum.2019.19057	study_information	NA	1	Patient-level data used	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	1	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	1	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01752634
10.5152/eurjrheum.2019.19057	study_information	NA	1	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2019.19057	study_information	NA	1	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	1	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	2	Patient-level data used	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	2	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	2	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT01989468
10.5152/eurjrheum.2019.19057	study_information	NA	2	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2019.19057	study_information	NA	2	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	2	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	3	Patient-level data used	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	3	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	3	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT02404350
10.5152/eurjrheum.2019.19057	study_information	NA	3	Country where the clinical trial/observational study was conducted (international if more than one)	international
10.5152/eurjrheum.2019.19057	study_information	NA	3	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	3	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	4	Patient-level data used	No
10.5152/eurjrheum.2019.19057	study_information	NA	4	Clinical Trial	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	4	NCT (only for clinical trial registered on clinicaltrials.gov)	NCT00317499
10.5152/eurjrheum.2019.19057	study_information	NA	4	Phase of the clinical trial (clinical trial only)	3
10.5152/eurjrheum.2019.19057	study_information	NA	4	Number of treatment arms (clinical trial only)	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	4	Country where the clinical trial/observational study was conducted (international if more than one)	unknown
